JP5131783B2 - Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof - Google Patents
Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof Download PDFInfo
- Publication number
- JP5131783B2 JP5131783B2 JP2010098560A JP2010098560A JP5131783B2 JP 5131783 B2 JP5131783 B2 JP 5131783B2 JP 2010098560 A JP2010098560 A JP 2010098560A JP 2010098560 A JP2010098560 A JP 2010098560A JP 5131783 B2 JP5131783 B2 JP 5131783B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- nmr
- dmso
- substituent
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **(N)NC(*)=O Chemical compound **(N)NC(*)=O 0.000 description 32
- FRQQTYAEHIOKDQ-UHFFFAOYSA-O CC(C)(C)S(NC(CC1)CCC1[IH]CO)[OH2+] Chemical compound CC(C)(C)S(NC(CC1)CCC1[IH]CO)[OH2+] FRQQTYAEHIOKDQ-UHFFFAOYSA-O 0.000 description 1
- YVYFOIKCFAKGIU-UHFFFAOYSA-N CC(C)S(C)(NCC1CCC(C)CC1)(O)=O Chemical compound CC(C)S(C)(NCC1CCC(C)CC1)(O)=O YVYFOIKCFAKGIU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明に使用する化合物はNPY Y5受容体拮抗作用を有し、本発明は、食欲抑制剤または抗肥満薬として有用である。 The compound used in the present invention has NPY Y5 receptor antagonistic activity, and the present invention is useful as an appetite suppressant or anti-obesity agent.
肥満は、その原因から、原発性肥満(単純性肥満)と二次性肥満(症候性肥満)とに分類される。原発性肥満の原因としては、エネルギーの過剰摂取(例えば、過食)、エネルギーの利用不足(例えば、運動不足)、及び熱産生低下が考えられる。現在、肥満の90%以上は原発性肥満である。この原発性肥満が発現し、その状態が持続すると、種々の健康障害を引き起こす原因となる。一方、二次性肥満は、何らかの基礎疾患がもとで生じる肥満である。例えば、内分泌性肥満、視床下部性肥満、遺伝性肥満、又は薬剤に基づく肥満などが挙げられる。肥満は成人病の誘因となり、糖尿病、高血圧、高脂血症、冠状動脈硬化症(狭心症、心筋梗塞)、通風、胆石症、脂肪肝、不妊症や変形性関節症などを合併しやすくなる。
肥満治療の基本は食事療法と運動療法の併用であるが、これには限界があり、特に高度肥満症に対しては薬物療法が有効であると期待されている。
ニューロペプチドY(以下、NPYとする)受容体のサブタイプであるY5受容体は少なくとも摂食機能に関与しており、その拮抗剤は抗肥満薬になることが示唆されている(非特許文献1参照)。
Obesity is classified according to its cause into primary obesity (simple obesity) and secondary obesity (symptomatic obesity). Possible causes of primary obesity include excessive intake of energy (for example, overeating), insufficient use of energy (for example, insufficient exercise), and reduced heat production. Currently, over 90% of obesity is primary obesity. If this primary obesity develops and persists, it causes various health problems. On the other hand, secondary obesity is obesity caused by some underlying disease. For example, endocrine obesity, hypothalamic obesity, hereditary obesity, or drug-based obesity. Obesity is an incentive for adult diseases, and it is easy to combine diabetes, hypertension, hyperlipidemia, coronary sclerosis (angina, myocardial infarction), ventilation, cholelithiasis, fatty liver, infertility and osteoarthritis Become.
The basis of obesity treatment is a combination of diet therapy and exercise therapy, but this has limitations, and drug therapy is expected to be effective particularly for severe obesity.
It is suggested that Y5 receptor, which is a subtype of neuropeptide Y (hereinafter referred to as NPY) receptor, is involved in at least the feeding function, and its antagonist becomes an anti-obesity drug (non-patent document). 1).
本発明に係る化合物と類似構造を有し、NPY Y5受容体拮抗作用を有するスルホニル基を有するアミン誘導体が特許文献1、特許文献2、特許文献3、特許文献4、非特許文献1等に記載されている。その他、特許文献5、特許文献8、特許文献9、特許文献10および特許文献11にはスルホニル基を有するアミド誘導体がNPY Y5拮抗活性を有する旨記載されている。特許文献12にも、NPY Y5受容体拮抗作用を有するスルホニル基を有する誘導体が記載されている。特許文献15および特許文献16にも、本発明に係る化合物と類似構造を有し、NPY Y5受容体拮抗作用を有するスルホニル基を有するアミン誘導体が記載されている。これらの化合物は、本発明に使用する化合物とは構造が異なる。 An amine derivative having a sulfonyl group having an NPY Y5 receptor antagonistic activity having a structure similar to that of the compound according to the present invention is described in Patent Document 1, Patent Document 2, Patent Document 3, Patent Document 4, Non-Patent Document 1, and the like. Has been. In addition, Patent Literature 5, Patent Literature 8, Patent Literature 9, Patent Literature 10, and Patent Literature 11 describe that amide derivatives having a sulfonyl group have NPY Y5 antagonistic activity. Patent Document 12 also describes a derivative having a sulfonyl group having an NPY Y5 receptor antagonistic action. Patent Documents 15 and 16 also describe amine derivatives having a sulfonyl group having a similar structure to the compound according to the present invention and having an NPY Y5 receptor antagonistic action. These compounds differ in structure from the compounds used in the present invention.
また、本発明に係る化合物と類似構造を有する化合物が特許文献6、特許文献7、特許文献13、特許文献14等に記載されているが、作用が全く異なるものであり、摂食抑制剤や抗肥満薬として有用である記載はなく、本発明を示唆するものではない。 Moreover, although the compound which has a similar structure with the compound which concerns on this invention is described in patent document 6, patent document 7, patent document 13, patent document 14, etc., an effect | action differs completely, an antifeedant and There is no description useful as an anti-obesity drug, and it does not suggest the present invention.
本発明の目的は、優れた食欲抑制剤または抗肥満薬を提供することにある。 An object of the present invention is to provide an excellent appetite suppressant or anti-obesity agent.
本発明者らは、鋭意研究の結果、以下の優れたNPY Y5受容体拮抗作用を有する新規化合物の合成に成功した。スルホニル基を有するアミド誘導体がNPY Y5受容体拮抗作用を有する化合物として特許文献5で公知となっている。しかし、本発明者らはアミド誘導体をアミン誘導体とした化合物が、置換前の化合物と比較して脳移行性が大きく改善されることを見出した。また、本発明に使用する化合物は、特許文献1、2に記載の化合物と比べ、薬物代謝酵素の誘導を起こしにくい化合物であることを確認した。これらの新規化合物について、摂食抑制作用確認試験、体重抑制作用確認試験等を行い、摂食抑制作用を有すること、体重抑制作用を有することを確認して本発明を完成した。本発明に使用される化合物が、代謝安定性及び水溶性も良いことも見出した。また、本発明に使用される化合物は貧血誘発作用等の毒性が低く、生殖毒性、消化管障害等を起こさない、医薬として使用するために十分安全な化合物であることを見出した。 As a result of intensive studies, the present inventors have succeeded in synthesizing a novel compound having the following excellent NPY Y5 receptor antagonistic activity. An amide derivative having a sulfonyl group is known in Patent Document 5 as a compound having an NPY Y5 receptor antagonistic action. However, the present inventors have found that a compound in which an amide derivative is an amine derivative is greatly improved in brain migration as compared with a compound before substitution. In addition, it was confirmed that the compound used in the present invention is a compound that hardly induces a drug metabolizing enzyme as compared with the compounds described in Patent Documents 1 and 2. About these novel compounds, the feeding suppression effect confirmation test, the body weight suppression effect confirmation test, etc. were performed, and it confirmed having having an eating suppression effect and a body weight suppression effect, and completed this invention. It has also been found that the compounds used in the present invention have good metabolic stability and water solubility. Further, the present inventors have found that the compound used in the present invention is a sufficiently safe compound for use as a medicine, which has low toxicity such as anemia-inducing action and does not cause reproductive toxicity and gastrointestinal tract disorders.
すなわち、本発明は、以下に関する。
(1)式(I):
[式中、R1は置換基を有していてもよい低級アルキルであり、
Yは−S(O)n−(nは1または2である)または−CO−であり、
R2は水素または置換基を有していてもよい低級アルキルであり、
R1およびR2は一緒になって低級アルキレンを形成してもよく、
R7は水素または置換基を有していてもよい低級アルキルであり、
Xは
置換基を有していてもよい低級アルキレン、
置換基を有していてもよい低級アルケニレン、
置換基を有していてもよい−CO−低級アルキレン、
置換基を有していてもよい−CO−低級アルケニレンまたは
(式中、R3、R4、R5およびR6は各々独立して水素または置換基を有していてもよい低級アルキルであり、
は置換基を有していてもよいシクロアルキレン、置換基を有していてもよいシクロアルケニレン、置換基を有していてもよいビシクロアルキレン、置換基を有していてもよいアリーレンまたは置換基を有していてもよいヘテロ環ジイルであり、pおよびqは各々独立して0〜2の整数であり、pおよびqのいずれか一方は0ではない)
であり、
−NR2−X−は
(式中、
はピペリジンジイル、ピペラジンジイル、ピリジンジイル、ピラジンジイル、ピロリジンジイルまたはピロールジイルであり、Uは低級アルキレンまたは低級アルケニレンである)であってもよく、
Zは置換基を有していてもよい低級アルキル、置換基を有していてもよい低級アルケニル、置換基を有していてもよいアミノ、置換基を有していてもよい低級アルコキシ、置換基を有していてもよい炭化水素環式基、置換基を有していてもよいヘテロ環式基である、
(但し、Zは3環の縮合へテロ環式基、置換基を有していてもよいチアゾリルまたは置換基を有していてもよいキナゾリニルではない)]
である化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(2)R1が低級アルキルである、(1)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(3)Yが−S(O)2−である、(1)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(4)Zが置換基を有していてもよい炭化水素環式基または置換基を有していてもよいヘテロ環式基である、(1)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(5)Xが
であり、R1が置換基を有していてもよい炭素数2〜10のアルキルである、(1)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(6)Zが置換基を有していてもよいヘテロ環式基である、(5)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(7)
が置換基を有していてもよいシクロアルキレン、置換基を有していてもよいシクロアルケニレン、置換基を有していてもよいビシクロアルキレンまたは置換基を有していてもよいピペリジニレンである、(5)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(8)
が置換基を有していてもよいシクロへキシレンまたは置換基を有していてもよいピペリジニレンであり、
pおよびqは各々独立して0または1であり、pおよびqのいずれか一方は0ではない、(5)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(9)Zが置換基を有していてもよい低級アルキル、置換基を有していてもよいフェニル、置換基を有していてもよいピリジル、置換基を有していてもよいピラゾリル、置換基を有していてもよいイソオキサゾリル、置換基を有していてもよいオキサジアゾリル、置換基を有していてもよいピリダジニル、置換基を有していてもよいピラジニル、置換基を有していてもよいピリミジニルまたは置換基を有していてもよい2環の縮合へテロ環である、(7)または(8)に記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(10)Xが
であり、p+qが1または2である、(1)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(11)p+qが1である、(10)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(12)式(I):
[式中、R1は置換基を有していてもよい低級アルキルであり、
Yは−S(O)2−であり、
R2は水素または置換基を有していてもよい低級アルキルであり、
R7は水素または置換基を有していてもよい低級アルキルであり、
Xは
(式中、R5およびR6は各々独立して水素であり、
は置換基を有していてもよいシクロアルキレンであり、pは0であり、qは1または2である)であり、
Zは置換基を有していてもよい炭化水素環式基または置換基を有していてもよいヘテロ環式基である]
である化合物(但し、Zが3環の縮合へテロ環式基である化合物を除く)、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(13)Zが置換基を有していてもよいフェニル、置換基を有していてもよいインダニル、置換基を有していてもよいピリジル、置換基を有していてもよいピリダジニル、置換基を有していてもよいピリミジニル、置換基を有していてもよいピラゾリル、置換基を有していてもよいイソオキサゾリル、置換基を有していてもよいオキサジアゾリルまたは置換基を有していてもよい2環の縮合へテロ環である、(12)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(14)Zが置換基を有していてもよいイソキノリル、置換基を有していてもよいベンゾチアゾリル、置換基を有していてもよいベンゾオキサゾリル、置換基を有していてもよいベンゾピリジル、置換基を有していてもよいベンゾピリダジル、置換基を有していてもよいベンゾイミダゾリル、置換基を有していてもよいチアゾロピリジル、置換基を有していてもよいイソキサゾリノニル、置換基を有していてもよいオキサゾリノニル、置換基を有していてもよいベンズオキサジノニルまたは置換基を有していてもよいベンゾキシアゼピノニルである、(12)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(15)式(I):
[式中、R1は置換基を有していてもよい低級アルキルであり、
Yは−S(O)2−であり、
R2は水素または置換基を有していてもよい低級アルキルであり、
R7は水素または置換基を有していてもよい低級アルキルであり、
Xは
(式中、R3およびR4は各々独立して水素であり、
は置換基を有していてもよいシクロアルキレンであり、pは1または2であり、qは0である)であり、
Zは置換基を有していてもよい炭化水素環式基または置換基を有していてもよいヘテロ環式基である]
である化合物(但し、Zが3環の縮合へテロ環式基、置換基を有していてもよいチアゾリルまたは置換基を有していてもよいキナゾリニルである化合物を除く)、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(16)Zが置換基を有していてもよいフェニル、置換基を有していてもよいピリジル、置換基を有していてもよいピリダジニル、置換基を有していてもよいピラジニル、置換基を有していてもよいピリミジニル、置換基を有していてもよいキノリル、置換基を有していてもよいイソキノリル、置換基を有していてもよいベンゾチアゾリル、置換基を有していてもよいベンズイミダゾリル、置換基を有していてもよいベンズオキサゾリル、置換基を有していてもよいチアゾロピリジルまたは置換基を有していてもよいオキサゾロピリジルである、(15)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(17)式(I):
[式中、R1は置換基を有していてもよい低級アルキルであり、
Yは−S(O)2−であり、
R2は水素または置換基を有していてもよい低級アルキルであり、
R7は水素または置換基を有していてもよい低級アルキルであり、
Xは
(式中、R3およびR4は各々独立して水素であり、
は置換基を有していてもよいシクロアルキレンであり、pは1または2であり、qは0である)であり、
Zは置換基を有していてもよいフェニル、置換基を有していてもよいピリジル、置換基を有していてもよいピリダジニル、置換基を有していてもよいピラジニル、置換基を有していてもよいピリミジニル、置換基を有していてもよいキノリル、置換基を有していてもよいイソキノリル、置換基を有していてもよいベンゾチアゾリル、置換基を有していてもよいベンズイミダゾリル、置換基を有していてもよいベンズオキサゾリル、置換基を有していてもよいチアゾロピリジルまたは置換基を有していてもよいオキサゾロピリジルである]である化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(18)式:
で示される化合物、その製薬上許容される塩またはそれらの溶媒和物。
(19)上記(18)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する医薬組成物。
(20)上記(18)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有するNPY Y5受容体拮抗作用を有する医薬組成物。
(21)上記(18)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
(22)上記(18)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を投与する食欲の抑制方法。
(23)上記(18)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を投与する肥満の予防または治療方法。
(24)食欲抑制剤または抗肥満薬を製造するための 上記(18)記載の化合物、その製薬上許容される塩またはそれらの溶媒和物の使用。
That is, the present invention relates to the following.
(1) Formula (I):
[Wherein, R 1 is optionally substituted lower alkyl,
Y is -S (O) n- (n is 1 or 2) or -CO-
R 2 is hydrogen or optionally substituted lower alkyl,
R 1 and R 2 together may form a lower alkylene,
R 7 is hydrogen or optionally substituted lower alkyl,
X is a lower alkylene which may have a substituent,
Lower alkenylene which may have a substituent,
-CO-lower alkylene which may have a substituent,
Optionally substituted -CO-lower alkenylene or
(Wherein R 3 , R 4 , R 5 and R 6 are each independently hydrogen or lower alkyl optionally having substituent (s);
Is an optionally substituted cycloalkylene, an optionally substituted cycloalkenylene, an optionally substituted bicycloalkylene, an optionally substituted arylene or a substituent And p and q are each independently an integer of 0 to 2, and one of p and q is not 0)
And
—NR 2 —X— is
(Where
May be piperidinediyl, piperazinediyl, pyridinediyl, pyrazinediyl, pyrrolidinediyl or pyrrolediyl and U is lower alkylene or lower alkenylene)
Z is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted amino, optionally substituted lower alkoxy, substituted A hydrocarbon cyclic group which may have a group, a heterocyclic group which may have a substituent,
(However, Z is not a tricyclic condensed heterocyclic group, an optionally substituted thiazolyl or an optionally substituted quinazolinyl)]
An appetite suppressant or anti-obesity drug comprising a compound, a pharmaceutically acceptable salt thereof or a solvate thereof.
(2) An appetite suppressant or anti-obesity drug containing the compound according to (1), pharmaceutically acceptable salt or solvate thereof, wherein R 1 is lower alkyl.
(3) An appetite suppressant or anti-obesity drug containing the compound according to (1), pharmaceutically acceptable salt or solvate thereof, wherein Y is —S (O) 2 —.
(4) The compound according to (1), a pharmaceutically acceptable salt thereof, wherein Z is a hydrocarbon cyclic group which may have a substituent or a heterocyclic group which may have a substituent. Or an appetite suppressant or anti-obesity drug containing a solvate thereof.
(5) X is
And R 1 is an optionally substituted alkyl having 2 to 10 carbon atoms, the compound according to (1), a pharmaceutically acceptable salt thereof or a solvate thereof containing an appetite suppressant Agent or anti-obesity agent.
(6) An appetite suppressant or anti-obesity containing the compound according to (5), a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Z is a heterocyclic group which may have a substituent. medicine.
(7)
Is an optionally substituted cycloalkylene, an optionally substituted cycloalkenylene, an optionally substituted bicycloalkylene, or an optionally substituted piperidinylene. (5) An appetite suppressant or anti-obesity drug containing the compound, pharmaceutically acceptable salt or solvate thereof according to (5).
(8)
Is optionally substituted cyclohexylene or optionally substituted piperidinylene,
p and q are each independently 0 or 1, and any one of p and q is not 0. An appetite containing the compound according to (5), a pharmaceutically acceptable salt thereof, or a solvate thereof. Inhibitors or anti-obesity drugs.
(9) Z may have a lower alkyl optionally having a substituent, phenyl optionally having a substituent, pyridyl optionally having a substituent, pyrazolyl optionally having a substituent, Isoxazolyl which may have a substituent, oxadiazolyl which may have a substituent, pyridazinyl which may have a substituent, pyrazinyl which may have a substituent, having a substituent The compound according to (7) or (8), a pharmaceutically acceptable salt thereof, or a solvate thereof, which is an optionally pyrimidinyl group or an optionally substituted bicyclic condensed heterocyclic ring. Contains an appetite suppressant or anti-obesity agent.
(10) X is
And an appetite suppressant or anti-obesity drug containing the compound according to (1), a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein p + q is 1 or 2.
(11) An appetite suppressant or anti-obesity drug containing the compound according to (10), a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein p + q is 1.
(12) Formula (I):
[Wherein, R 1 is optionally substituted lower alkyl,
Y is —S (O) 2 —;
R 2 is hydrogen or optionally substituted lower alkyl,
R 7 is hydrogen or optionally substituted lower alkyl,
X is
Wherein R 5 and R 6 are each independently hydrogen,
Is an optionally substituted cycloalkylene, p is 0, and q is 1 or 2.
Z is a hydrocarbon cyclic group which may have a substituent or a heterocyclic group which may have a substituent]
An appetite suppressant or anti-obesity drug containing a compound wherein Z is a compound in which Z is a three-ring fused heterocyclic group, a pharmaceutically acceptable salt thereof, or a solvate thereof.
(13) Z may be optionally substituted phenyl, optionally substituted indanyl, optionally substituted pyridyl, optionally substituted pyridazinyl, substituted Pyrimidinyl which may have a group, pyrazolyl which may have a substituent, isoxazolyl which may have a substituent, oxadiazolyl which may have a substituent or a substituent An appetite suppressant or anti-obesity drug containing the compound according to (12), a pharmaceutically acceptable salt thereof, or a solvate thereof, which is a fused bicyclic heterocyclic ring.
(14) Z may have an isoquinolyl which may have a substituent, benzothiazolyl which may have a substituent, benzoxazolyl which may have a substituent, or may have a substituent Benzopyridyl, optionally substituted benzopyridyl, optionally substituted benzimidazolyl, optionally substituted thiazolopyridyl, optionally substituted isoxazolyl The compound according to (12), which is nonyl, optionally substituted oxazolinonyl, optionally substituted benzoxazinonyl or optionally substituted benzoxyazepinonyl. , An appetite suppressant or anti-obesity drug containing a pharmaceutically acceptable salt or solvate thereof.
(15) Formula (I):
[Wherein, R 1 is optionally substituted lower alkyl,
Y is —S (O) 2 —;
R 2 is hydrogen or optionally substituted lower alkyl,
R 7 is hydrogen or optionally substituted lower alkyl,
X is
Wherein R 3 and R 4 are each independently hydrogen,
Is an optionally substituted cycloalkylene, p is 1 or 2, and q is 0),
Z is a hydrocarbon cyclic group which may have a substituent or a heterocyclic group which may have a substituent]
A compound wherein Z is a condensed heterocyclic group having 3 rings, thiazolyl optionally having substituent (s) or quinazolinyl optionally having substituent (s), and pharmaceutically acceptable thereof Appetite suppressant or anti-obesity drug containing the salt or solvate thereof.
(16) Z is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, substituted Pyrimidinyl which may have a group, quinolyl which may have a substituent, isoquinolyl which may have a substituent, benzothiazolyl which may have a substituent, Benzimidazolyl which may be substituted, benzoxazolyl which may have a substituent, thiazolopyridyl which may have a substituent or oxazolopyridyl which may have a substituent, (15) Appetite suppressant or anti-obesity agent comprising the described compound, a pharmaceutically acceptable salt thereof or a solvate thereof.
(17) Formula (I):
[Wherein, R 1 is optionally substituted lower alkyl,
Y is —S (O) 2 —;
R 2 is hydrogen or optionally substituted lower alkyl,
R 7 is hydrogen or optionally substituted lower alkyl,
X is
Wherein R 3 and R 4 are each independently hydrogen,
Is an optionally substituted cycloalkylene, p is 1 or 2, and q is 0),
Z is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted pyridazinyl, an optionally substituted pyrazinyl, and an optionally substituted substituent. Pyrimidinyl which may have a substituent, Quinolyl which may have a substituent, Isoquinolyl which may have a substituent, Benzothiazolyl which may have a substituent, Benz which may have a substituent Imidazolyl, optionally substituted benzoxazolyl, optionally substituted thiazolopyridyl or optionally substituted oxazolopyridyl], and its pharmaceutical An appetite suppressant or anti-obesity drug containing a top acceptable salt or a solvate thereof.
(18) Formula:
Or a pharmaceutically acceptable salt or solvate thereof.
(19) A pharmaceutical composition comprising the compound according to (18) above, a pharmaceutically acceptable salt thereof or a solvate thereof.
(20) A pharmaceutical composition having an NPY Y5 receptor antagonistic action, comprising the compound according to (18) above, a pharmaceutically acceptable salt thereof, or a solvate thereof.
(21) An appetite suppressant or anti-obesity drug containing the compound according to (18) above, a pharmaceutically acceptable salt thereof or a solvate thereof.
(22) A method for suppressing appetite, comprising administering the compound according to (18), a pharmaceutically acceptable salt thereof, or a solvate thereof.
(23) A method for preventing or treating obesity, comprising administering the compound according to (18) above, a pharmaceutically acceptable salt thereof, or a solvate thereof.
(24) Use of the compound of the above (18), a pharmaceutically acceptable salt thereof or a solvate thereof for producing an appetite suppressant or anti-obesity agent.
本発明は、具体的には、以下に関する。
(1−1)式:
で示される化合物、その製薬上許容される塩またはそれらの溶媒和物。
(1−2)式:
で示される化合物、その製薬上許容される塩またはそれらの溶媒和物。
(1−3)式:
で示される化合物、その製薬上許容される塩またはそれらの溶媒和物。
(1−4)(1−1)〜(1−3)のいずれかに記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する医薬組成物。
(1−5)NPY Y5受容体拮抗作用を有する(1−4)記載の医薬組成物。
(1−6)(1−1)〜(1−3)のいずれかに記載の化合物、その製薬上許容される塩またはそれらの溶媒和物を含有する食欲抑制剤または抗肥満薬。
Specifically, the present invention relates to the following.
(1-1) Formula:
Or a pharmaceutically acceptable salt or solvate thereof.
(1-2) Formula:
Or a pharmaceutically acceptable salt or solvate thereof.
(1-3) Formula:
Or a pharmaceutically acceptable salt or solvate thereof.
(1-4) A pharmaceutical composition comprising the compound according to any one of (1-1) to (1-3), a pharmaceutically acceptable salt thereof, or a solvate thereof.
(1-5) The pharmaceutical composition according to (1-4), which has an NPY Y5 receptor antagonistic action.
(1-6) An appetite suppressant or anti-obesity drug containing the compound according to any one of (1-1) to (1-3), a pharmaceutically acceptable salt thereof, or a solvate thereof.
本発明に使用する化合物はNPY Y5受容体拮抗作用を示し、本発明は、医薬品、特に、摂食障害、肥満、神経性食欲昂進症の治療および/または予防のための食欲抑制剤または抗肥満薬として非常に有用である。 The compounds used in the present invention exhibit NPY Y5 receptor antagonism, and the present invention relates to pharmaceuticals, in particular, appetite suppressants or anti-obesity for the treatment and / or prevention of eating disorders, obesity, anorexia nervosa Very useful as a medicine.
以下に本明細書中で使用する各用語を説明する。なお、本明細書中、各用語は単独で使用されている場合も、または他の用語と一緒になって使用されている場合も、同一の意義を有する。 The terms used in this specification will be described below. In the present specification, each term has the same meaning whether used alone or in combination with other terms.
「ハロゲン」とは、フッ素、塩素、臭素およびヨウ素を包含する。特にフッ素および塩素が好ましい。 “Halogen” includes fluorine, chlorine, bromine and iodine. In particular, fluorine and chlorine are preferable.
「保護されていてもよいヒドロキシ」、「保護されていてもよいヒドロキシ低級アルキル」の保護基としては、通常用いられるヒドロキシ保護基すべてを包含する。例えばアシル(アセチル、トリクロロアセチル、ベンゾイル等)、低級アルコキシカルボニル(t−ブトキシカルボニル等)、低級アルキルスルホニル(メタンスルホニル等)、低級アルコキシ低級アルキル(メトキシメチル等)、トリアルキルシリル(t−ブチルジメチルシリル等)等が挙げられる。 Protecting groups for “optionally protected hydroxy” and “optionally protected hydroxy lower alkyl” include all commonly used hydroxy protecting groups. For example, acyl (acetyl, trichloroacetyl, benzoyl etc.), lower alkoxycarbonyl (t-butoxycarbonyl etc.), lower alkylsulfonyl (methanesulfonyl etc.), lower alkoxy lower alkyl (methoxymethyl etc.), trialkylsilyl (t-butyldimethyl) Silyl etc.).
「低級アルキル」とは、炭素数1〜10の直鎖または分枝状のアルキルを包含し、例えばメチル、エチル、n−プロピル、イソプロピル、n−ブチル、イソブチル、sec−ブチル、tert−ブチル、n−ペンチル、イソペンチル、ネオペンチル、ヘキシル、イソヘキシル、n−へプチル、イソヘプチル、n−オクチル、イソオクチル、n−ノニルおよびn−デシル等が挙げられる。
R1における「低級アルキル」は好ましくは炭素数2〜10、さらに好ましくは炭素数2〜6、最も好ましくはエチル、イソプロピルまたはt−ブチルである。
“Lower alkyl” includes linear or branched alkyl having 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, Examples include n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl and n-decyl.
“Lower alkyl” in R 1 is preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, and most preferably ethyl, isopropyl or t-butyl.
その他の場合における「低級アルキル」は好ましくは炭素数1〜6、さらに好ましくは炭素数1〜4である。 “Lower alkyl” in other cases preferably has 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms.
Zにおける「置換基を有していてもよい低級アルキル」の置換基としては、例えば、(1)ハロゲン;(2)シアノ;
(3)それぞれ下記に定義する置換基群βから選択される1以上の置換可能な基で置換されていてもよい(i)ヒドロキシ、(ii)低級アルコキシ、(iii)メルカプト、(iv)低級アルキルチオ、(v)アシル、(vi)アシルオキシ、(vii)カルボキシ、(viii)低級アルコキシカルボニル、(ix)イミノ、(x)カルバモイル、(xi)チオカルバモイル、(xii)低級アルキルカルバモイル、(xiii)低級アルキルチオカルバモイル、(xiv)アミノ、(xv)低級アルキルアミノもしくは(xvi)ヘテロ環カルボニル;または
(4)式:
(式中、R10およびR11は各々独立して水素または低級アルキルであり、2以上のR10および/またはR11が存在するとき、各々のR10およびR11は異なっていてもよく、
Wは単結合、O、SまたはNR12であり、
R12は水素、低級アルキルまたはフェニルであり、
はそれぞれ下記に定義する置換基群αから選択される1以上の置換可能な基で置換されていてもよいシクロアルキル、ビシクロアルキル、シクロアルケニル、アリールまたはヘテロ環式基であり、
sは0〜4の整数)
で示される基等が挙げられる。
Examples of the substituent of “lower alkyl optionally having substituent (s)” for Z include (1) halogen; (2) cyano;
(3) (i) hydroxy, (ii) lower alkoxy, (iii) mercapto, (iv) lower, each optionally substituted with one or more substitutable groups selected from the substituent group β defined below Alkylthio, (v) acyl, (vi) acyloxy, (vii) carboxy, (viii) lower alkoxycarbonyl, (ix) imino, (x) carbamoyl, (xi) thiocarbamoyl, (xii) lower alkylcarbamoyl, (xiii) Lower alkylthiocarbamoyl, (xiv) amino, (xv) lower alkylamino or (xvi) heterocyclic carbonyl; or
Equation (4):
Wherein R 10 and R 11 are each independently hydrogen or lower alkyl, and when two or more R 10 and / or R 11 are present, each R 10 and R 11 may be different,
W is a single bond, O, S or NR 12 ,
R 12 is hydrogen, lower alkyl or phenyl;
Are each a cycloalkyl, bicycloalkyl, cycloalkenyl, aryl or heterocyclic group optionally substituted with one or more substitutable groups selected from the substituent group α defined below,
s is an integer of 0 to 4)
Group etc. which are shown by these are mentioned.
ここで置換基群αとは(1)ハロゲン;(2)オキソ;(3)シアノ;(4)ニトロ;(5)低級アルキルもしくはヒドロキシで置換されていてもよいイミノ;
(6)それぞれ置換基群βから選択される1以上の置換可能な基で置換されていてもよい(i)ヒドロキシ、(ii)低級アルキル、(iii)低級アルケニル、(iv)低級アルコキシ、(v)カルボキシ、(vi)低級アルコキシカルボニル、(vii)アシル、(viii)アシルオキシ、(ix)イミノ、(x)メルカプト、(xi)低級アルキルチオ、(xii)カルバモイル、(xiii)低級アルキルカルバモイル、(xiv)シクロアルキルカルバモイル、(xv)チオカルバモイル、(xvi)低級アルキルチオカルバモイル、(xvii)低級アルキルスルフィニル、(xviii)低級アルキルスルホニル、(xix)スルファモイル、(xx)低級アルキルスルファモイルおよび(xxi)シクロアルキルスルファモイル;
(7)それぞれ置換基群β、低級アルキル、低級アルコキシ低級アルキル、保護されていてもよいヒドロキシ低級アルキル、ハロゲノ低級アルキル、低級アルキルスルホニルおよび/またはアリールスルホニルで置換されていてもよい、(i)シクロアルキル、(ii)シクロアルケニル、(iii)シクロアルキルオキシ、(iv)アミノおよび(v)アルキレンジオキシ;並びに
(8)それぞれ置換基群β、低級アルキル、ハロゲノ低級アルキルおよび/またはオキソで置換されていてもよい(i)フェニル、(ii)ナフチル、(iii)フェノキシ、(iv)フェニル低級アルコキシ、(v)フェニルチオ、(vi)フェニル低級アルキルチオ、(vii)フェニルアゾ、(viii)ヘテロ環式基、(ix)ヘテロ環オキシ、(x)ヘテロ環チオ、(xi)ヘテロ環カルボニルおよび(xii)ヘテロ環スルホニルからなる群である。
Here, the substituent group α is (1) halogen; (2) oxo; (3) cyano; (4) nitro; (5) imino optionally substituted with lower alkyl or hydroxy;
(6) (i) hydroxy, (ii) lower alkyl, (iii) lower alkenyl, (iv) lower alkoxy, each optionally substituted with one or more substitutable groups selected from substituent group β v) carboxy, (vi) lower alkoxycarbonyl, (vii) acyl, (viii) acyloxy, (ix) imino, (x) mercapto, (xi) lower alkylthio, (xii) carbamoyl, (xiii) lower alkylcarbamoyl, xiv) cycloalkylcarbamoyl, (xv) thiocarbamoyl, (xvi) lower alkylthiocarbamoyl, (xvii) lower alkylsulfinyl, (xviii) lower alkylsulfonyl, (xix) sulfamoyl, (xx) lower alkylsulfamoyl and (xxi) Cycloalkylsulfamoyl;
(7) Substituent group β, lower alkyl, lower alkoxy lower alkyl, optionally protected hydroxy lower alkyl, halogeno lower alkyl, lower alkylsulfonyl and / or arylsulfonyl, respectively, (i) Cycloalkyl, (ii) cycloalkenyl, (iii) cycloalkyloxy, (iv) amino and (v) alkylenedioxy; and
(8) (i) phenyl, (ii) naphthyl, (iii) phenoxy, (iv) phenyl lower alkoxy, (v) each optionally substituted with substituent group β, lower alkyl, halogeno lower alkyl and / or oxo. ) Phenylthio, (vi) phenyl lower alkylthio, (vii) phenylazo, (viii) heterocyclic group, (ix) heterocyclic oxy, (x) heterocyclic thio, (xi) heterocyclic carbonyl and (xii) heterocyclic sulfonyl A group consisting of
B環における置換基としての置換基群αの好ましい例はハロゲン;ニトロ;ヒドロキシ;
置換基を有していてもよい低級アルキル(ここで置換基とはハロゲン、シアノ、フェニル、カルボキシおよび/または低級アルコキシカルボニル);
低級アルケニル;低級アルコキシカルボニル低級アルケニル;
置換基を有していてもよい低級アルコキシ(ここで置換基とはハロゲン、ヒドロキシ、低級アルコキシ、カルボキシ、低級アルコキシカルボニル、低級アルキルアミノおよび/またはシアノ);
アシル;ヒドロキシイミノ;低級アルキルチオ;低級アルキルスルフィニル;スルファモイル;
置換基を有していてもよいアミノ(ここで置換基とは低級アルキル、保護されていてもよいヒドロキシ低級アルキル、フェニルおよび/またはアシル);
アルキレンジオキシ;シアノフェニル;ヘテロ環置換フェニル;ビフェニルイル;フェノキシ;低級アルキルで置換されていてもよいフェニルアゾ;
置換基を有していてもよいヘテロ環式基(ここで置換基とは保護されていてもよいヒドロキシ;メルカプト;ハロゲン;低級アルキル;シクロアルキル;低級アルコキシカルボニル;アミノ;低級アルコキシカルボニルアミノ;カルバモイル;オキソ;フェニル;低級アルコキシフェニル;またはヘテロ環式基)であり、さらに好ましくはハロゲン;ハロゲンで置換されていてもよい低級アルキル;ハロゲンで置換されていてもよい低級アルコキシである。
Preferred examples of the substituent group α as a substituent in the ring B are halogen; nitro; hydroxy;
Lower alkyl optionally having substituent (wherein the substituent is halogen, cyano, phenyl, carboxy and / or lower alkoxycarbonyl);
Lower alkenyl; lower alkoxycarbonyl lower alkenyl;
Lower alkoxy which may have a substituent (wherein the substituent is halogen, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkylamino and / or cyano);
Hydroxyimino; lower alkylthio; lower alkylsulfinyl; sulfamoyl;
Optionally substituted amino (wherein the substituent is lower alkyl, optionally protected hydroxy lower alkyl, phenyl and / or acyl);
Cyanophenyl; heterocycle-substituted phenyl; biphenylyl; phenoxy; phenylazo optionally substituted with lower alkyl;
Optionally substituted heterocyclic group (wherein the substituent may be protected hydroxy; mercapto; halogen; lower alkyl; cycloalkyl; lower alkoxycarbonyl; amino; lower alkoxycarbonylamino; carbamoyl) Oxo; phenyl; lower alkoxyphenyl; or a heterocyclic group), more preferably halogen; lower alkyl optionally substituted with halogen; lower alkoxy optionally substituted with halogen.
置換基群βとはハロゲン、保護されていてもよいヒドロキシ、メルカプト、低級アルコキシ、低級アルケニル、アミノ、低級アルキルアミノ、低級アルコキシカルボニルアミノ、低級アルキルチオ、アシル、カルボキシ、低級アルコキシカルボニル、カルバモイル、シアノ、シクロアルキル、フェニル、フェノキシ、低級アルキルフェニル、低級アルコキシフェニル、ハロゲノフェニル、ナフチルおよびヘテロ環式基からなる群である。 Substituent group β is halogen, optionally protected hydroxy, mercapto, lower alkoxy, lower alkenyl, amino, lower alkylamino, lower alkoxycarbonylamino, lower alkylthio, acyl, carboxy, lower alkoxycarbonyl, carbamoyl, cyano, A group consisting of cycloalkyl, phenyl, phenoxy, lower alkylphenyl, lower alkoxyphenyl, halogenophenyl, naphthyl and heterocyclic groups.
Z以外における「置換基を有していてもよい低級アルキル」(例えばR1における場合等)の置換基としては、置換基群βから選択される1以上の基が挙げられ、任意の位置がこれらの置換基で置換されていてもよい。 Examples of the substituent of “lower alkyl optionally having a substituent” other than Z (for example, in the case of R 1 ) include one or more groups selected from the substituent group β, and an arbitrary position is It may be substituted with these substituents.
「低級アルコキシ」、「低級アルコキシカルボニル」、「低級アルコキシカルボニル低級アルキル」、「低級アルキルフェニル」、「低級アルコキシフェニル」、「低級アルキルカルバモイル」、「低級アルキルチオカルバモイル」、「低級アルキルアミノ」、「ハロゲノ低級アルキル」、「ヒドロキシ低級アルキル」、「フェニル低級アルコキシ」、「低級アルキルチオ」、「フェニル低級アルキルチオ」、「低級アルコキシカルボニルアミノ」、「低級アルコキシカルボニル低級アルケニル」、「低級アルキルスルフィニル」、「低級アルキルスルホニル」、「アリール低級アルコキシカルボニル」、「低級アルキルベンゾイル」および「低級アルコキシベンゾイル」の低級アルキル部分は上記「低級アルキル」と同様である。 “Lower alkoxy”, “lower alkoxycarbonyl”, “lower alkoxycarbonyl lower alkyl”, “lower alkylphenyl”, “lower alkoxyphenyl”, “lower alkylcarbamoyl”, “lower alkylthiocarbamoyl”, “lower alkylamino”, “ “Halogeno lower alkyl”, “hydroxy lower alkyl”, “phenyl lower alkoxy”, “lower alkylthio”, “phenyl lower alkylthio”, “lower alkoxycarbonylamino”, “lower alkoxycarbonyl lower alkenyl”, “lower alkylsulfinyl”, “ The lower alkyl part of “lower alkylsulfonyl”, “aryl lower alkoxycarbonyl”, “lower alkylbenzoyl” and “lower alkoxybenzoyl” is the same as the above “lower alkyl”.
「置換基を有していてもよい低級アルコキシ」の置換基としては置換基群βから選択される1以上の基が挙げられ、好ましくはフェニル、低級アルキルフェニル、低級アルコキシフェニル、ナフチルまたはヘテロ環式基である。 Examples of the substituent of “lower alkoxy optionally having substituent (s)” include one or more groups selected from substituent group β, preferably phenyl, lower alkylphenyl, lower alkoxyphenyl, naphthyl or heterocyclic ring Formula group.
「シクロアルキル」とは、炭素数3〜8、好ましくは5または6の環状のアルキルを包含する。具体的には、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、シクロへプチルおよびシクロオクチル等が挙げられる。 “Cycloalkyl” includes cyclic alkyl having 3 to 8 carbon atoms, preferably 5 or 6 carbon atoms. Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
「置換基を有していてもよいシクロアルキル」の置換基としては、置換基群αから選択される1以上の基等が挙げられ、任意の位置が置換されていてもよい。 Examples of the substituent of “optionally substituted cycloalkyl” include one or more groups selected from the substituent group α, and any position may be substituted.
「ビシクロアルキル」とは、2つの環が2個またはそれ以上の原子を共有している炭素数5〜8の脂肪族環から水素を1つ除いてできる基を包含する。具体的にはビシクロ[2.1.0]ペンチル、ビシクロ[2.2.1]ヘプチル、ビシクロ[2.2.2]オクチルおよびビシクロ[3.2.1]オクチル等が挙げられる。 “Bicycloalkyl” includes a group formed by removing one hydrogen from an aliphatic ring having 5 to 8 carbon atoms in which two rings share two or more atoms. Specific examples include bicyclo [2.1.0] pentyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl and bicyclo [3.2.1] octyl.
「低級アルケニル」とは、任意の位置に1以上の二重結合を有する炭素数2〜10、好ましくは炭素数2〜8、さらに好ましくは炭素数3〜6の直鎖または分枝状のアルケニルを包含する。具体的にはビニル、プロペニル、イソプロペニル、ブテニル、イソブテニル、プレニル、ブタジエニル、ペンテニル、イソペンテニル、ペンタジエニル、ヘキセニル、イソヘキセニル、ヘキサジエニル、ヘプテニル、オクテニル、ノネニルおよびデセニル等を包含する。 “Lower alkenyl” is a straight or branched alkenyl having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, having one or more double bonds at any position. Is included. Specific examples include vinyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl and decenyl.
「低級アルコキシカルボニル低級アルケニル」における「低級アルケニル」部分は上記「低級アルケニル」と同様である。 The “lower alkenyl” moiety in the “lower alkoxycarbonyl-lower alkenyl” is the same as the above “lower alkenyl”.
「置換基を有していてもよい低級アルケニル」の置換基としては、ハロゲン、低級アルコキシ、低級アルケニル、アミノ、低級アルキルアミノ、低級アルコキシカルボニルアミノ、低級アルキルチオ、アシル、カルボキシ、低級アルコキシカルボニル、カルバモイル、シアノ、シクロアルキル、フェニル、低級アルキルフェニル、低級アルコキシフェニル、ナフチルおよび/またはヘテロ環式基等が挙げられる。 The substituent of “optionally substituted lower alkenyl” includes halogen, lower alkoxy, lower alkenyl, amino, lower alkylamino, lower alkoxycarbonylamino, lower alkylthio, acyl, carboxy, lower alkoxycarbonyl, carbamoyl. , Cyano, cycloalkyl, phenyl, lower alkylphenyl, lower alkoxyphenyl, naphthyl and / or heterocyclic group.
「アシル」とは(1)炭素数1〜10、さらに好ましくは炭素数1〜6、最も好ましくは炭素数1〜4の直鎖もしくは分枝状のアルキルカルボニルもしくはアルケニルカルボニル、(2)炭素数4〜9、好ましくは炭素数4〜7のシクロアルキルカルボニルおよび(3)炭素数7〜11のアリールカルボニルを包含する。具体的には、ホルミル、アセチル、プロピオニル、ブチリル、イソブチリル、バレリル、ピバロイル、ヘキサノイル、アクリロイル、プロピオロイル、メタクリロイル、クロトノイル、シクロプロピルカルボニル、シクロヘキシルカルボニル、シクロオクチルカルボニルおよびベンゾイル等を包含する。 “Acyl” means (1) straight or branched alkylcarbonyl or alkenylcarbonyl having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, most preferably 1 to 4 carbon atoms, and (2) carbon number. It includes 4 to 9, preferably 4 to 7 carbon cycloalkylcarbonyl and (3) aryl carbonyl having 7 to 11 carbon atoms. Specific examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioyl, methacryloyl, crotonoyl, cyclopropylcarbonyl, cyclohexylcarbonyl, cyclooctylcarbonyl and benzoyl.
「アシルオキシ」のアシル部分も上記と同様である。 The acyl part of “acyloxy” is the same as above.
「シクロアルケニル」とは、上記シクロアルキルの環中の任意の位置に1以上の二重結合を有しているものを包含し、具体的にはシクロプロペニル、シクロブテニル、シクロペンテニル、シクロヘキセニルおよびシクロヘキサジエニル等が挙げられる。 “Cycloalkenyl” includes those having one or more double bonds at any position in the ring of the cycloalkyl, specifically, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cyclohexenyl. Sadienyl and the like can be mentioned.
「置換基を有していてもよいシクロアルケニル」の置換基としては置換基群βから選択される1以上の基が挙げられる。 Examples of the substituent of “optionally substituted cycloalkenyl” include one or more groups selected from substituent group β.
「置換基を有していてもよいアミノ」の置換基としては、置換基群β、置換基を有していてもよいベンゾイルおよび/または置換基を有していてもよいヘテロ環カルボニル(ここで置換基とはヒドロキシ、低級アルキル、低級アルコキシおよび/または低級アルキルチオ)が挙げられる。 Examples of the substituent of the “optionally substituted amino” include the substituent group β, the optionally substituted benzoyl and / or the optionally substituted heterocyclic carbonyl (here And the substituent includes hydroxy, lower alkyl, lower alkoxy and / or lower alkylthio).
「アリール」とは、単環または多環の芳香族炭素環式基であり、フェニル、ナフチル、アントリルおよびフェナントリル等を包含する。また、他の非芳香族炭化水素環式基と縮合しているアリールも包含し、具体的にはインダニル、インデニル、ビフェニリル、アセナフチル、テトラヒドロナフチルおよびフルオレニル等が挙げられる。特にフェニルが好ましい。 “Aryl” is a monocyclic or polycyclic aromatic carbocyclic group, and includes phenyl, naphthyl, anthryl, phenanthryl and the like. Also included are aryls fused with other non-aromatic hydrocarbon cyclic groups, and specific examples include indanyl, indenyl, biphenylyl, acenaphthyl, tetrahydronaphthyl and fluorenyl. Particularly preferred is phenyl.
「アリール低級アルコキシカルボニル」のアリール部分も同様である。
Zにおける「置換基を有していてもよいアリール」および「置換基を有していてもよいフェニル」は、置換基群α、置換基群αから選択される置換可能な1以上の基で置換されていてもよい低級アルキル等で置換されていてもよい「アリール」、「フェニル」を包含する。
The same applies to the aryl moiety of “aryl lower alkoxycarbonyl”.
The “optionally substituted aryl” and the “optionally substituted phenyl” in Z are one or more substitutable groups selected from the substituent group α and the substituent group α. It includes “aryl” and “phenyl” which may be substituted with lower alkyl which may be substituted.
Z以外の「置換基を有していてもよいアリール」および「置換基を有していてもよいフェニル」の置換基としては、置換基群βから選択される1以上の基が挙げられる。 Examples of the substituent of “optionally substituted aryl” and “optionally substituted phenyl” other than Z include one or more groups selected from the substituent group β.
「炭化水素環式基」とは、上記「シクロアルキル」、「シクロアルケニル」、「ビシクロアルキル」および「アリール」を包含する。 The “hydrocarbon cyclic group” includes the above “cycloalkyl”, “cycloalkenyl”, “bicycloalkyl” and “aryl”.
「非芳香族炭化水素環式基」とは、上記「シクロアルキル」、「シクロアルケニル」および「ビシクロアルキル」を包含する。 The “non-aromatic hydrocarbon cyclic group” includes the above “cycloalkyl”, “cycloalkenyl” and “bicycloalkyl”.
「置換基を有していてもよい炭化水素環式基」とは、上記「置換基を有していてもよいシクロアルキル」、「置換基を有していてもよいシクロアルケニル」、「置換基を有していてもよいビシクロアルキル」および「置換基を有していてもよいアリール」を包含する。 The “hydrocarbon cyclic group which may have a substituent” means the above “cycloalkyl which may have a substituent”, “cycloalkenyl which may have a substituent”, “substitution” It includes “bicycloalkyl which may have a group” and “aryl which may have a substituent”.
「ヘテロ環式基」とは、O、SおよびNから任意に選択されるヘテロ原子を環内に1以上有するヘテロ環を包含し、具体的にはピロリル、イミダゾリル、ピラゾリル、ピリジル、ピリダジニル、ピリミジニル、ピラジニル、トリアゾリル、トリアジニル、テトラゾリル、イソオキサゾリル、オキサゾリル、オキサジアゾリル、イソチアゾリル、チアゾリル、チアジアゾリル、フリルおよびチエニル等の5〜6員のヘテロアリール;インドリル、イソインドリル、インダゾリル、インドリジニル、インドリニル、イソインドリニル、キノリル、イソキノリル、シンノリニル、フタラジニル、キナゾリニル、ナフチリジニル、キノキサリニル、プリニル、プテリジニル、ベンゾピラニル、ベンズイミダゾリル、ベンズイソオキサゾリル、ベンズオキサゾリル、ベンズオキサジアゾリル、ベンゾイソチアゾリル、ベンゾチアゾリル、ベンゾチアジアゾリル、ベンゾフリル、イソベンゾフリル、ベンゾチエニル、ベンゾトリアゾリル、イミダゾピリジル、トリアゾロピリジル、イミダゾチアゾリル、ピラジノピリダジニル、テトラヒドロキノリル、テトラヒドロベンゾチエニル、オキサゾロピリジル、チアゾロピリジル(例えば、チアゾロ[5,4-b]ピリジン-2-イル、チアゾロ[5,4-c]ピリジン-2-イル、チアゾロ[4,5-b]ピリジン-2-イル、チアゾロ[4,5-c]ピリジン-2-イル等)、ベンズオキサゾリノニル、ベンズイソキサゾリノニル、ベンズオキサジノニル、ベンゾキシアゼピノニル、オキサゾロピリジノニル、ベンゾジオキソリル等の2環の縮合ヘテロ環式基;カルバゾリル、アクリジニル、キサンテニル、フェノチアジニル、フェノキサチイニル、フェノキサジニル、ジベンゾフリル等の3環の縮合ヘテロ環式基;ジオキサニル、チイラニル、オキシラニル、オキサチオラニル、アゼチジニル、チアニル、ピロリジニル、ピロリニル、イミダゾリジニル、イミダゾリニル、ピラゾリジニル、ピラゾリニル、ピペリジル、ピペラジニル、モルホリニル、モルホリノ、チオモルホリニル、チオモルホリノ、ジヒドロピリジル、テトラヒドロフリル、テトラヒドロピラニル、テトラヒドロチアゾリル、テトラヒドロイソチアゾリル等の非芳香族ヘテロ環式基を包含する。 "Heterocyclic group" includes a heterocycle having one or more heteroatoms arbitrarily selected from O, S and N, specifically pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl 5- to 6-membered heteroaryl such as pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl and thienyl; indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, Cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzo Sazolyl, benzoxiadiazolyl, benzoisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazini , Tetrahydroquinolyl, tetrahydrobenzothienyl, oxazolopyridyl, thiazolopyridyl (eg, thiazolo [5,4-b] pyridin-2-yl, thiazolo [5,4-c] pyridin-2-yl, thiazolo [ 4,5-b] pyridin-2-yl, thiazolo [4,5-c] pyridin-2-yl, etc.), benzoxazolinonyl, benzisoxazolinonyl, benzoxazinonyl, benzoxyazepinonyl, Bicyclic fused heterocyclic groups such as oxazolopyridinonyl, benzodioxolyl; carbazolyl, acridinyl, xanthenyl Tricyclic fused heterocyclic groups such as phenothiazinyl, phenoxathinyl, phenoxazinyl, dibenzofuryl; dioxanyl, thiylyl, oxiranyl, oxathiolanyl, azetidinyl, thianyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl , Non-aromatic heterocyclic groups such as morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolyl, tetrahydroisothiazolyl and the like.
ヘテロ環以外の環と縮合している縮合ヘテロ環式基(例えばベンゾチアゾリル等)は、いずれの環に結合手を有していてもよい。 A condensed heterocyclic group condensed with a ring other than a heterocyclic ring (for example, benzothiazolyl) may have a bond on any ring.
「置換基を有していてもよいヘテロ環式基」および「置換基を有していてもよい2環の縮合へテロ環式基」の置換基は上記「置換基を有していてもよいアリール」と同様である。 The substituents of “heterocyclic group which may have a substituent” and “bicyclic fused heterocyclic group which may have a substituent” may be the above-mentioned “having a substituent. Same as “good aryl”.
「ヘテロ環カルボニル」、「ヘテロ環オキシ」、「ヘテロ環チオ」および「ヘテロ環置換フェニル」のヘテロ環式基部分は上記「ヘテロ環式基」と同様である。 The heterocyclic group moiety of “heterocyclic carbonyl”, “heterocyclic oxy”, “heterocyclic thio” and “heterocyclic substituted phenyl” is the same as the above “heterocyclic group”.
「低級アルキレン」とは、メチレンが1〜6個、好ましくは2個〜6個、さらに好ましくは3〜6個連続した2価の基を包含し、具体的にはメチレン、エチレン、トリメチレン、テトラメチレン、ペンタメチレンおよびヘキサメチレン等が挙げられる。特に好ましくはテトラメチレンである。 “Lower alkylene” includes a divalent group in which 1 to 6, preferably 2 to 6, and more preferably 3 to 6 methylenes are continuous. Specifically, methylene, ethylene, trimethylene, tetra Examples include methylene, pentamethylene and hexamethylene. Particularly preferred is tetramethylene.
R1およびR2が一緒になって低級アルキレンを形成する場合とは、
を形成する場合を包含する。好ましくは
である。
When R 1 and R 2 together form a lower alkylene,
The case of forming is included. Preferably
It is.
「低級アルキレンジオキシ」の低級アルキレン部分は上記「低級アルキレン」と同様であり、好ましくはメチレンジオキシまたはエチレンジオキシである。 The lower alkylene part of “lower alkylenedioxy” is the same as the above “lower alkylene”, preferably methylenedioxy or ethylenedioxy.
「低級アルケニレン」とは、メチレンが2〜6個、好ましくは3個〜6個、さらに好ましくは4〜5個連続した2価の基であって、炭素−炭素結合の少なくとも1つが二重結合であるものを包含する。 “Lower alkenylene” is a divalent group in which 2 to 6, preferably 3 to 6, more preferably 4 to 5 methylenes are continuous, and at least one of the carbon-carbon bonds is a double bond. Is included.
「シクロアルキレン」とは、上記「シクロアルキル」から水素原子を1つ除いてできる2価の基である。Xにおける「シクロアルキレン」では1,4−シクロヘキサンジイルが好ましい。 “Cycloalkylene” is a divalent group formed by removing one hydrogen atom from the above “cycloalkyl”. The “cycloalkylene” in X is preferably 1,4-cyclohexanediyl.
「シクロアルケニレン」とは、上記シクロアルキレンの環内に少なくとも1つの二重結合を有する基を包含する。 The “cycloalkenylene” includes a group having at least one double bond in the ring of the cycloalkylene.
「ビシクロアルキレン」とは、上記「ビシクロアルキル」からさらに水素を1つ除いてできる基を包含する。具体的にはビシクロ[2.1.0]ペンチレン、ビシクロ[2.2.1]ヘプタチレン、ビシクロ[2.2.2]オクチレン、ビシクロ[3.2.1]オクチレン等が挙げられる。 “Bicycloalkylene” includes a group formed by removing one hydrogen from the above “bicycloalkyl”. Specific examples include bicyclo [2.1.0] pentylene, bicyclo [2.2.1] heptylene, bicyclo [2.2.2] octylene, bicyclo [3.2.1] octylene.
「ヘテロ環ジイル」とは、上記「ヘテロ環式基」から水素原子を1つ除いてできる2価の基を包含する。好ましくはピペリジンジイル、ピペラジンジイル、ピリジンジイル、ピリミジンジイル、ピラジンジイル、ピロリジンジイルまたはピロールジイルであり、より好ましくはピペリジンジイルである。 The “heterocyclic diyl” includes a divalent group formed by removing one hydrogen atom from the above “heterocyclic group”. Preferred are piperidine diyl, piperazine diyl, pyridine diyl, pyrimidine diyl, pyrazine diyl, pyrrolidine diyl or pyrrole diyl, and more preferred is piperidine diyl.
「アリーレン」とは、上記「アリール」から水素原子を1つ除いてできる2価の基を包含する。好ましくはフェニレンである。 “Arylene” includes a divalent group formed by removing one hydrogen atom from the above “aryl”. Preferable is phenylene.
「ヘテロアリーレン」とは、上記「ヘテロ環ジイル」のうち、芳香属性を有するものを包含する。具体的にはピロールジイル、イミダゾールジイル、ピラゾールジイル、ピリジンジイル、ピリダジンジイル、ピリミジンジイル、ピラジンジイル、トリアゾールジイル、トリアジンジイル、イソオキサゾールジイル、オキサゾールジイル、オキサジアゾールジイル、イソチアゾールジイル、チアゾールジイル、チアジアゾールジイル、フランジイルおよびチオフェンジイル等が挙げられる。 The “heteroarylene” includes those having the aromatic attribute among the above “heterocyclic diyl”. Specifically, pyrrole diyl, imidazole diyl, pyrazole diyl, pyridine diyl, pyridazine diyl, pyrimidine diyl, pyrazine diyl, triazole diyl, triazine diyl, isoxazole diyl, oxazole diyl, oxadiazole diyl, isothiazole diyl, thiazole diyl, thiadiazole diyl , Flangedyl and thiophenediyl.
「置換基を有していてもよい低級アルキレン」、「置換基を有していてもよい低級アルケニレン」、「置換基を有していてもよいシクロアルキレン」、「置換基を有していてもよいシクロへキシレン」、「置換基を有していてもよいビシクロアルキレン」「置換基を有していてもよいシクロアルケニレン」、「置換基を有していてもよいフェニレン」、「置換基を有していてもよいヘテロ環ジイル」および「置換基を有していてもよいピペリジニレン」の置換基としては、置換基群βから選択される1以上の置換可能な基が挙げられ、好ましくはハロゲン、ヒドロキシ、低級アルキル、ハロゲノ低級アルキル、低級アルコキシ、アミノ、低級アルキルアミノ、アシル、カルボキシまたは低級アルコキシカルボニル等である。任意の位置がこれらの基で置換されていてもよい。
−NR2−X−が
である場合、好ましくはUがメチレン、エチレンであり、さらに好ましくは
である。
“Lower alkylene optionally having substituent”, “lower alkenylene optionally having substituent”, “cycloalkylene optionally having substituent”, “having substituent” May be substituted cyclohexylene ”,“ bicycloalkylene optionally having substituent ”,“ cycloalkenylene optionally having substituent ”,“ phenylene optionally having substituent ”,“ substituent ” Examples of the substituent of “optionally substituted heterocyclic diyl” and “optionally substituted piperidinylene” include one or more substitutable groups selected from the substituent group β, Is halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, amino, lower alkylamino, acyl, carboxy, lower alkoxycarbonyl or the like. Any position may be substituted with these groups.
—NR 2 —X— is
And preferably U is methylene or ethylene, more preferably
It is.
本発明に係る化合物としては、以下の化合物が好ましい。
式(I):
[式中、R1は低級アルキルであり、
Yは−S(O)2−であり、
R2は水素であり、
R7は水素であり、
Xは
(式中、R3およびR4は各々独立して水素であり、
はシクロアルキレンであり、pは1であり、qは0である)であり、
Zは置換基を有していてもよいピラゾリル、置換基を有していてもよいベンゾチアゾリルまたは置換基を有していてもよいベンズオキサゾリルである]である化合物。
さらには、以下に記載の化合物が好ましい。
Formula (I):
[Wherein R 1 is lower alkyl,
Y is —S (O) 2 —;
R 2 is hydrogen;
R 7 is hydrogen;
X is
Wherein R 3 and R 4 are each independently hydrogen,
Is cycloalkylene, p is 1 and q is 0),
Z is an optionally substituted pyrazolyl, an optionally substituted benzothiazolyl, or an optionally substituted benzoxazolyl].
Furthermore, the compounds described below are preferred.
上記化合物は、特に、低用量で体重抑制作用を示すという優れた特徴を有している。 The above-mentioned compound has an excellent feature that it exhibits a body weight-suppressing action at a low dose.
本発明に係る化合物には、各々の化合物の生成可能であり、製薬上許容される塩を包含する。「製薬上許容される塩」としては、例えば塩酸、硫酸、硝酸またはリン酸等の無機酸の塩;パラトルエンスルホン酸、メタンスルホン酸、シュウ酸またはクエン酸等の有機酸の塩;アンモニウム、トリメチルアンモニウムまたはトリエチルアンモニウム等の有機塩基の塩;ナトリウムまたはカリウム等のアルカリ金属の塩;およびカルシウムまたはマグネシウム等のアルカリ土類金属の塩等を挙げることができる。 The compound according to the present invention includes a pharmaceutically acceptable salt capable of producing each compound. “Pharmaceutically acceptable salts” include, for example, salts of inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid or phosphoric acid; salts of organic acids such as paratoluenesulfonic acid, methanesulfonic acid, oxalic acid or citric acid; ammonium, Examples include salts of organic bases such as trimethylammonium or triethylammonium; salts of alkali metals such as sodium or potassium; and salts of alkaline earth metals such as calcium or magnesium.
本発明に係る化合物はその溶媒和物を包含し、化合物(I)に対する。好ましくは水和物であり、本発明に係る化合物1分子が任意の数の水分子と配位していてもよい。 The compound according to the present invention includes its solvate and is directed to compound (I). Preferably, it is a hydrate, and one molecule of the compound according to the present invention may be coordinated with an arbitrary number of water molecules.
本発明に係る化合物(I)が不斉炭素原子を有する場合には、ラセミ体、両対掌体および全ての立体異性体(幾何異性体、エピマー、鏡像異性体等)を含む。また、本発明に係る化合物(I)が二重結合を有する場合にE体およびZ体が存在し得るときはそのいずれをも含む。また、Xがシクロアルキレンである場合にはシス体およびトランス体のいずれをも含む。 When the compound (I) according to the present invention has an asymmetric carbon atom, it includes racemates, both enantiomers and all stereoisomers (geometric isomers, epimers, enantiomers, etc.). In addition, when the compound (I) according to the present invention has a double bond, both of the E-form and the Z-form can be present. In addition, when X is cycloalkylene, both cis and trans forms are included.
本発明に係る化合物(I)は、例えば次の方法で合成することができる。以下では、Xを−CH2−G−または−G−CH2−として説明する。 Compound (I) according to the present invention can be synthesized, for example, by the following method. Hereinafter, the X -CH 2 -G-, or -G-CH 2 - is described as.
[Y=S(O)nの場合]
(式中、Halはハロゲンであり、−G−CH2−は式(I)の−X−と同義であり、R13は低級アルキルであり、その他の記号は前記と同義である)
工程A
化合物1と目的化合物に対応する置換基R1を有するスルホニルハライド2と適当な溶媒中、0℃〜50℃で数分〜数時間反応させればnが2である化合物3が得られる。溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジエチルエーテル、ジクロロメタン、トルエン、ベンゼン、キシレン、シクロヘキサン、へキサン、クロロホルム、酢酸エチル、酢酸ブチル、ペンタン、ヘプタン、ジオキサン、アセトン、アセトニトリルおよびそれらの混合溶媒等が使用可能である。
工程B
化合物1と置換基R1を有するスルフィニルハライド4を反応させてn=1である化合物5を得ることもできる。反応条件は上記工程Aと同様である。
工程C
工程Bで得られた化合物5を常法により酸化反応に付せば、n=2である化合物3が得られる。酸化剤としてはm−クロロ過安息香酸、過酢酸、過酸化水素、過トリフルオロ酢酸、過よう素酸ナトリウム、次亜塩素酸ナトリウム、過マンガン酸カリウム等を使用することができ、反応は0℃〜50℃で行えばよい。溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジエチルエーテル、ジクロロメタン、トルエン、ベンゼン、キシレン、シクロヘキサン、へキサン、クロロホルム、酢酸エチル、酢酸ブチル、ペンタン、ヘプタン、ジオキサン、アセトン、アセトニトリル、水、メタノール、エタノール、イソプロパノールおよびそれらの混合溶媒等を用いることができる。
工程D
工程AあるいはCで得た化合物3を適当な溶媒中、塩基で処理し、化合物6を得る。塩基としては水酸化バリウム、水酸化ナトリウム、水酸化カリウム、ヒドラジン、プロパンチオールリチウム塩等を用いることができ、溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジオキサン、アセトン、アセトニトリル、メタノール、エタノール、プロパノール、水およびそれらの混合溶媒等が使用可能である。0℃〜100℃で数分〜数十時間反応させればよい。
工程E
工程Dで得られた化合物6と目的化合物に対応する置換基ZおよびR7を有するアミノ化合物7を適当な溶媒中、0℃〜50℃で数分〜数時間反応させて化合物8を得る。溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジエチルエーテル、ジクロロメタン、トルエン、ベンゼン、キシレン、シクロヘキサン、へキサン、クロロホルム、酢酸エチル、酢酸ブチル、ペンタン、ヘプタン、ジオキサン、アセトン、アセトニトリルおよびそれらの混合溶媒等が使用可能であり、必要であれば塩化チオニル、酸ハロゲン化物、酸無水物、活性化エステル等の活性化剤を用いてもよい。
工程F
得られた化合物8を適当な溶媒中、適当な還元剤で処理し、化合物(I−A)を得る。還元剤としては水素化ホウ素ナトリウム、水素化ホウ素リチウム、水素化リチウムアルミニウム等を用いることができ、溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジオキサン、アセトニトリル、メタノール、エタノール、プロパノール、酢酸およびそれらの混合溶媒等が使用可能である。0℃〜100℃で数分〜数十時間反応させればよい。
工程G
工程Dで得られた化合物6を適当な溶媒中、還元剤で処理し、化合物9を得る。還元剤としては水素化ホウ素ナトリウム、水素化ホウ素リチウム、水素化リチウムアルミニウム、ジボラン等を用いることができ、溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジオキサン、アセトニトリル、メタノール、エタノール、プロパノールおよびそれらの混合溶媒等が使用可能である。0℃〜100℃で数分〜数十時間反応させればよく、必要であれば酸ハロゲン化物、酸無水物、活性化エステル等の中間体を経由してもよい。
工程H
工程Gで得られた化合物9を常法により酸化反応に付せば、化合物10が得られる。酸化剤としてはm−クロロ過安息香酸、過酢酸、過酸化水素、過トリフルオロ酢酸、過よう素酸ナトリウム、次亜塩素酸ナトリウム、過マンガン酸カリウム、デス‐マーチン過よう素酸、ジメチルスルホキシド/オキサリルクロライド(Swern酸化)、ルテニウム触媒等を使用することができ、反応は−80℃〜50℃で行えばよい。溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジエチルエーテル、ジクロロメタン、トルエン、ベンゼン、キシレン、シクロヘキサン、へキサン、クロロホルム、酢酸エチル、酢酸ブチル、ペンタン、ヘプタン、ジオキサン、アセトン、アセトニトリル、水、メタノール、エタノール、イソプロパノールおよびそれらの混合溶媒等を用いることができる。
工程J
得られた化合物10と目的化合物に対応する置換基ZおよびR7を有するアミノ化合物7を常法により還元的アミノ化反応に付せば、化合物(I−A)が得られる。還元剤としては水素化ホウ素ナトリウム、トリアセトキシ水素化ホウ素ナトリウム、シアノ水素化ホウ素ナトリウム等を使用することができ、反応は0℃〜50℃で行えばよい。溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジオキサン、アセトニトリル、メタノール、エタノール、プロパノール、酢酸、塩酸およびそれらの混合溶媒等を用いることができる。
[When Y = S (O) n]
(In the formula, Hal is halogen, -G-CH 2 -has the same meaning as -X- in formula (I), R 13 is lower alkyl, and the other symbols are as defined above).
Process A
When compound 1 and sulfonyl halide 2 having substituent R 1 corresponding to the target compound are reacted in an appropriate solvent at 0 ° C. to 50 ° C. for several minutes to several hours, compound 3 in which n is 2 is obtained. As the solvent, tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile, and mixed solvents thereof can be used. It is.
Process B
Compound 5 in which n = 1 can also be obtained by reacting compound 1 with sulfinyl halide 4 having substituent R 1 . The reaction conditions are the same as in step A above.
Process C
If compound 5 obtained in step B is subjected to an oxidation reaction by a conventional method, compound 3 where n = 2 is obtained. As the oxidizing agent, m-chloroperbenzoic acid, peracetic acid, hydrogen peroxide, pertrifluoroacetic acid, sodium periodate, sodium hypochlorite, potassium permanganate and the like can be used, and the reaction is 0 What is necessary is just to perform at 50 degreeC. Solvents include tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile, water, methanol, ethanol, isopropanol and A mixed solvent thereof or the like can be used.
Process D
Compound 6 obtained in Step A or C is treated with a base in an appropriate solvent to give Compound 6. As the base, barium hydroxide, sodium hydroxide, potassium hydroxide, hydrazine, propanethiol lithium salt and the like can be used, and as the solvent, tetrahydrofuran, dimethylformamide, dioxane, acetone, acetonitrile, methanol, ethanol, propanol, water and A mixed solvent thereof or the like can be used. What is necessary is just to make it react for several minutes-dozens of hours at 0 to 100 degreeC.
Process E
Compound 8 obtained by reacting compound 6 obtained in step D with amino compound 7 having substituents Z and R 7 corresponding to the target compound at 0 ° C. to 50 ° C. for several minutes to several hours in an appropriate solvent is obtained. As the solvent, tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile, and mixed solvents thereof can be used. If necessary, an activating agent such as thionyl chloride, acid halide, acid anhydride, or activated ester may be used.
Process F
The obtained compound 8 is treated with a suitable reducing agent in a suitable solvent to obtain a compound (IA). As the reducing agent, sodium borohydride, lithium borohydride, lithium aluminum hydride and the like can be used, and as the solvent, tetrahydrofuran, dimethylformamide, dioxane, acetonitrile, methanol, ethanol, propanol, acetic acid, and mixed solvents thereof, etc. Can be used. What is necessary is just to make it react for several minutes-dozens of hours at 0 to 100 degreeC.
Process G
Compound 9 obtained in Step D is treated with a reducing agent in a suitable solvent to obtain Compound 9. As the reducing agent, sodium borohydride, lithium borohydride, lithium aluminum hydride, diborane, etc. can be used, and as the solvent, tetrahydrofuran, dimethylformamide, dioxane, acetonitrile, methanol, ethanol, propanol, and mixed solvents thereof, etc. Can be used. The reaction may be carried out at 0 ° C. to 100 ° C. for several minutes to several tens of hours. If necessary, intermediates such as acid halides, acid anhydrides and activated esters may be used.
Process H
Compound 10 is obtained by subjecting compound 9 obtained in step G to an oxidation reaction by a conventional method. As oxidizing agents, m-chloroperbenzoic acid, peracetic acid, hydrogen peroxide, pertrifluoroacetic acid, sodium periodate, sodium hypochlorite, potassium permanganate, Dess-Martin periodate, dimethyl sulfoxide / Oxalyl chloride (Swern oxidation), a ruthenium catalyst, and the like can be used, and the reaction may be performed at -80 ° C to 50 ° C. Solvents include tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile, water, methanol, ethanol, isopropanol and A mixed solvent thereof or the like can be used.
Process J
Compound (IA) is obtained by subjecting the resulting compound 10 and amino compound 7 having substituents Z and R 7 corresponding to the target compound to a reductive amination reaction by a conventional method. As the reducing agent, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride and the like can be used, and the reaction may be performed at 0 ° C to 50 ° C. As the solvent, tetrahydrofuran, dimethylformamide, dioxane, acetonitrile, methanol, ethanol, propanol, acetic acid, hydrochloric acid, a mixed solvent thereof or the like can be used.
[Y=COの場合]
(式中、各記号は前記と同義であり、−G−CH2− は式(I)の −X− と同義である)
工程K
化合物1と目的化合物に対応する置換基R1を有するアシルハライド11と適当な溶媒中、−20℃〜50℃で数分〜数時間反応させれば化合物12が得られる。溶媒としてはテトラヒドロフラン、ジメチルホルムアミド、ジエチルエーテル、ジクロロメタン、トルエン、ベンゼン、キシレン、シクロヘキサン、へキサン、クロロホルム、酢酸エチル、酢酸ブチル、ペンタン、ヘプタン、ジオキサン、アセトン、アセトニトリルおよびそれらの混合溶媒等が使用可能である。
工程D、工程G、工程Hおよび工程J
こうして得られた化合物12を上記工程D、工程G、工程Hおよび工程Jと同様の方法に付せば本発明に係る化合物(I-B)を得ることができる。
[When Y = CO]
(In the formula, each symbol has the same meaning as described above, and -G-CH 2 -has the same meaning as -X- in formula (I)).
Process K
Compound 12 can be obtained by reacting compound 1 with acyl halide 11 having substituent R 1 corresponding to the target compound in an appropriate solvent at −20 ° C. to 50 ° C. for several minutes to several hours. As the solvent, tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane, acetone, acetonitrile, and mixed solvents thereof can be used. It is.
Process D, Process G, Process H and Process J
The compound (IB) according to the present invention can be obtained by subjecting the compound 12 thus obtained to the method similar to the above Step D, Step G, Step H and Step J.
(式中、各記号は前記と同意義であり、−CH2−G−は式(I)の−X−と同義であり、Rはアルキル)
工程L
化合物16に、置換基R7を導入する工程である。例えば、R7X1(X1はハロゲン)を塩基存在下で反応させることにより、化合物17を得ることができる。溶媒としては、テトラヒドロフラン、ジメチルホルムアミドを使用することができる。反応は、室温で行うことができる。塩基としては、トリエチルアミン、ピリジン、ジメチルアミノピリジン等を用いることができる。なお、式(I-C)において、R7が水素である化合物は、本工程を行わない。
工程M
化合物17に置換基Zを導入する工程である。例えば、ZX1(X1はハロゲン)を塩基存在下で反応させることにより、化合物18を得ることができる。溶媒としては、メタノール、エタノール、イソプロパノール、ジメチルホルムアミド等を用いることができる。反応は、室温下または加温下で行うことができる。例えば、封管し、マイクロウェ−ブ反応装置を用いて行うこともできる。塩基としては、N,N-ジイソプロピルエチルアミン等を用いることができる。
工程N
化合物18を還元し、化合物19を得る工程である。還元剤として、水素化リチウムアルミニウムを用いることができる。溶媒としては、テトラヒロドフラン等を用いることができる。反応は、室温で行うことができる。
工程O
化合物19をアジド化して、化合物20に誘導する工程である。例えば、化合物19に、塩基としてトリエチルアミンを用い、メタンスルホニルクロライドを反応させて、化合物19をメシレートに誘導する。メシル化する際の溶媒としては、クロロホルムを用いることができる。得られた化合物に、アジ化ナトリウムを反応させ、ジメチルホルムアミド中等で、室温下または加温下で、アジド化を行い、化合物20を得ることができる。
工程P
化合物20を還元し、化合物21を得る工程である。接触還元で行うことができる。触媒としては、10%パラジウム炭素等を用いることができる。溶媒としては、エタノール等を用いることができる。
工程Q
化合物21に、式:R1−Y−X1(X1はハロゲン等、YはS、SO、SO2またはCOである)で示される化合物を反応させ、化合物22を得る工程である。式:R1−Y−X1で示される化合物として、各種のスルホニルクロライド、スルフィニルクロライド、アシルクロライド等を用いることができる。溶媒としては、テトラヒドロフラン、ジメチルホルムアミド等を用いることができる。反応は、室温下または加温下で行うことができる。塩基の存在下で行うのが好ましく、塩基としては、ピリジン、トリエチルアミン等を用いることができる。なお、式(I−C)において、R2が水素である化合物は、以降の工程Rを行わず、化合物22が最終目的化合物となる。また、Y=SまたはSOである式:R1−Y−X1で示される化合物を用いて反応させ、化合物22を得て、その後に酸化して、YがSO2である化合物に変換し、次の工程に用いても良い。
工程R
化合物22に、置換基R2を導入する工程である。R2X1(X1はハロゲン等)を塩基存在下で化合物22に反応させることにより、化合物(I−C)を得ることができる。塩基としては、水素化ナトリウム等を用いることができる。溶媒としては、ジメチルホルムアミド等を用いることができる。
(In the formula, each symbol is as defined above, —CH 2 —G— is synonymous with —X— in formula (I), and R is alkyl)
Process L
In this step, substituent R 7 is introduced into compound 16. For example, compound 17 can be obtained by reacting R 7 X 1 (X 1 is halogen) in the presence of a base. Tetrahydrofuran and dimethylformamide can be used as the solvent. The reaction can be carried out at room temperature. As the base, triethylamine, pyridine, dimethylaminopyridine and the like can be used. Note that in the formula (IC), this step is not performed for compounds in which R 7 is hydrogen.
Process M
In this step, the substituent Z is introduced into the compound 17. For example, compound 18 can be obtained by reacting ZX 1 (X 1 is halogen) in the presence of a base. As the solvent, methanol, ethanol, isopropanol, dimethylformamide, or the like can be used. The reaction can be carried out at room temperature or under warming. For example, it can be sealed and sealed using a microwave reactor. As the base, N, N-diisopropylethylamine or the like can be used.
Process N
In this step, compound 18 is reduced to obtain compound 19. As a reducing agent, lithium aluminum hydride can be used. Tetrahydrofuran or the like can be used as the solvent. The reaction can be carried out at room temperature.
Process O
In this step, compound 19 is azidated to give compound 20. For example, compound 19 is reacted with methanesulfonyl chloride using triethylamine as a base to induce compound 19 to mesylate. As a solvent for the mesylation, chloroform can be used. The obtained compound is reacted with sodium azide and azidated in dimethylformamide or the like at room temperature or under heating to obtain compound 20.
Process P
In this step, compound 20 is reduced to obtain compound 21. It can be carried out by catalytic reduction. As the catalyst, 10% palladium carbon or the like can be used. As the solvent, ethanol or the like can be used.
Process Q
In this step, compound 21 is reacted with a compound represented by the formula: R 1 —Y—X 1 (X 1 is halogen or the like, Y is S, SO, SO 2 or CO) to obtain compound 22. As the compound represented by the formula: R 1 —Y—X 1 , various sulfonyl chlorides, sulfinyl chlorides, acyl chlorides, and the like can be used. As the solvent, tetrahydrofuran, dimethylformamide, or the like can be used. The reaction can be carried out at room temperature or under warming. The reaction is preferably performed in the presence of a base, and pyridine, triethylamine, or the like can be used as the base. In the formula (IC), the compound in which R 2 is hydrogen does not perform the subsequent step R, and the compound 22 is the final target compound. Alternatively, the compound represented by the formula: R 1 —Y—X 1 in which Y═S or SO is reacted to obtain a compound 22, which is then oxidized to be converted into a compound in which Y is SO 2. You may use for the following process.
Process R
In this step, substituent R 2 is introduced into compound 22. Compound (IC) can be obtained by reacting R 2 X 1 (X 1 is halogen or the like) with compound 22 in the presence of a base. As the base, sodium hydride or the like can be used. As the solvent, dimethylformamide or the like can be used.
上記の工程において、以下の中間体は有用である。
(式中、Rは置換基を有していてもよい低級アルキルであり、R7は水素または置換基を有していてもよい低級アルキルであり、Gは1,4-シクロアルキレンであり、Zは置換基を有していてもよい炭化水素環式基または置換基を有していてもよいヘテロ環式基である)
Rとしては、特に、低級アルキル、さらには、メチル、エチルが好ましい。特にエチルが好ましい。
R7としては、水素が好ましい。
Zとしては、置換基を有していてもよいヘテロ環式基が好ましい。
特に、以下の化合物が好ましい。
式:
(式中、R15はNH2またはOHであり、
Zは置換基を有していてもよいピリジル、置換基を有していてもよいピリダジニル、置換基を有していてもよいピラジニル、置換基を有していてもよいピリミジニル、置換基を有していてもよいキノリル、置換基を有していてもよいイソキノリル、置換基を有していてもよいベンゾチアゾリル、置換基を有していてもよいベンゾオキサゾリル、置換基を有していてもよいベンゾピリジル、置換基を有していてもよいベンゾピリダジル、置換基を有していてもよいベンズイミダゾリル、置換基を有していてもよいベンズオキサゾリル、置換基を有していてもよいチアゾロピリジル置換基を有していてもよいイソキサゾリノニル、置換基を有していてもよいオキサゾリノニル、置換基を有していてもよいベンズオキサジノニルまたは置換基を有していてもよいベンゾキシアゼピノニルである)で示される化合物。
In the above steps, the following intermediates are useful.
Wherein R is optionally substituted lower alkyl, R 7 is hydrogen or optionally substituted lower alkyl, G is 1,4-cycloalkylene, Z is a hydrocarbon cyclic group which may have a substituent or a heterocyclic group which may have a substituent.
R is particularly preferably lower alkyl, more preferably methyl or ethyl. Ethyl is particularly preferable.
R 7 is preferably hydrogen.
Z is preferably a heterocyclic group which may have a substituent.
In particular, the following compounds are preferable.
formula:
Wherein R 15 is NH 2 or OH;
Z is pyridyl which may have a substituent, pyridazinyl which may have a substituent, pyrazinyl which may have a substituent, pyrimidinyl which may have a substituent, and a substituent. Quinolyl which may have a substituent, isoquinolyl which may have a substituent, benzothiazolyl which may have a substituent, benzoxazolyl which may have a substituent, Benzopyridyl which may have a substituent, benzopyridazyl which may have a substituent, benzimidazolyl which may have a substituent, benzoxazolyl which may have a substituent, which may have a substituent Good thiazolopyridyl substituent optionally having isoxazolinonyl, optionally having oxazolinonyl, optionally having benzoxazinonyl or having a substituent Compounds represented by have a good benzoxycarbonyl azelate Pinot sulfonyl be).
(式中、各記号は前記と同意義であり、−CH2−G−は式(I)の−X−と同義であり、Rはアルキル、Proはアミノ保護基である)
工程S
化合物17に、保護基を導入する工程である。保護基としては、広く、Protective Groups in Organic Synthesis(Theodra W. Greene著)等に記載の保護基を用いることができる。酸性条件下で除去することができるアミノ保護基が好ましい。ベンジルオキシカルボニル基、tert-ブチルオキシカルボニル基等があげられる。例えば、ProX1(X1はハロゲン等、Proはベンジルオキシカルボニル基、tert-ブチルオキシカルボニル等)、Pro−O−Pro(Proはベンジルオキシカルボニル基、tert-ブチルオキシカルボニル等)を塩基存在下で反応させることにより、化合物23を得ることができる。溶媒としては、テトラヒドロフラン、ジメチルホルムアミドを使用することができる。反応は、室温で行うことができる。塩基としては、トリエチルアミン、ピリジン、ジメチルアミノピリジン等を用いることができる。なお、R7が水素の化合物でも、同様に反応を行うことができる。
工程T
化合物23を還元し、化合物24を得る工程である。還元剤として、水素化リチウムアルミニウムを用いることができる。溶媒としては、テトラヒロドフラン等を用いることができる。反応は、室温で行うことができる。
工程U
化合物24をアジド化して、化合物25に誘導する工程である。例えば、化合物24に、塩基としてトリエチルアミンを用い、メタンスルホニルクロライドを反応させて、化合物24をメシレートに誘導する。メシル化する際の溶媒としては、クロロホルムを用いることができる。得られた化合物に、アジ化ナトリウムを反応させ、ジメチルホルムアミド中等で、室温下または加温下で、アジド化を行い、化合物25を得ることができる。
工程V
化合物25を還元し、化合物26を得る工程である。化合物25を、トリフェニルホスフィン及び水を用いて、還元することにより、化合物26を得る。反応は、加温下で行うことができる。溶媒としては、テトラヒドロフランを用いることができる。トリフェニルホスフィンを用いた還元法以外にも、接触還元で行うことができる。接触還元の場合は、触媒としては、10%パラジウム炭素などを用いることができる。溶媒としては、エタノールなどを用いることができる。いずれの還元法を用いるかは、使用する保護基により、適宜選択することができる。
工程W
化合物26に、式:R1−Y−X1(X1はハロゲン等、YはS、SO、SO2またはCOである)で示される化合物を反応させ、化合物27を得る工程である。式:R1−Y−X1(X1はハロゲン等)で示される化合物として、各種のスルホニルクロライド、スルフィニルクロライド、アシルクロライド等を用いることができる。溶媒としては、テトラヒドロフラン、ジメチルアミド等を用いることができる。反応は、室温下または加温下で行うことができる。塩基の存在下で行うのが好ましく、塩基としては、ピリジン、トリエチルアミン等を用いることができる。また、Y=SまたはSOである式:R1−Y−X1で示される化合物を用いて反応させ、化合物27を得て、その後に酸化して、YがSO2である化合物に変換し、次の工程に用いても良い。
工程X
化合物27の保護基を除去する工程である。保護基の除去は、保護基によって各種の条件を選択して用いることができる。例えば、tert-ブチルオキシカルボニル基は酸ではずすことができる。ベンジルオキシカルボニル基は、接触還元等ではずすことができる。
工程Y
化合物28に置換基Zを導入する工程である。例えば、ZX1(X1はハロゲン)を塩基存在下で反応させることにより、化合物(I−D)を得ることができる。溶媒としては、メタノール、エタノール、イソプロパノール、ジメチルホルムアミド等を用いることができる。反応は、室温下または加温下で行うことができる。例えば、封管し、マイクロウェ−ブ反応装置を用いて行うこともできる。塩基としては、N,N-ジイソプロピルエチルアミン等を用いることができる。
上記の工程において、以下の中間体は有用である。
(式中、Rは置換基を有していてもよい低級アルキルであり、Proは保護基であり、R7は水素または置換基を有していてもよい低級アルキルであり、Gは1,4-シクロアルキレンであり、YはSO2またはSOであり、R1は置換基を有していてもよい低級アルキルであり、R2は水素または置換基を有していてもよい低級アルキルである)
Rとしては、特に、低級アルキル、さらには、メチル、エチルが好ましい。特にエチルが好ましい。
Proとしては、酸性条件下で除去することができるアミノ保護基が好ましい。例えば、Proとしては、式:−(C=O)-O-R(Rは置換基を有していてもよい低級アルキル、置換基を有していてもよい低級アルケニル)で示される基が好ましい。特に、tert-ブチルオキシカルボニル基が好ましい。
R7としては、水素が好ましい。
Yとしては、SO2が好ましい。
R1としては、特に、低級アルキル、さらには、イソプロピル、エチル、tert-ブチルが好ましい。特にtert-ブチルが好ましい。
R2としては、水素が好ましい。
特に、以下の化合物が好ましい。
式:
(式中、R1はエチルまたはtert-ブチルである)で示される化合物。
式:
(式中、R1はエチル、イソプロピルまたはtert-ブチルである)で示される化合物。
式:
(式中、Zは置換基を有していてもよい炭化水素環式基または置換基を有していてもよいヘテロ環式基である)で示される化合物。
(Wherein each symbol is as defined above, -CH 2 -G- are as defined for formula of (I) -X-, R is alkyl, Pro is an amino protecting group)
Process S
In this step, a protecting group is introduced into compound 17. As the protecting group, a protecting group described in Protective Groups in Organic Synthesis (Theodra W. Greene) and the like can be widely used. Amino protecting groups that can be removed under acidic conditions are preferred. Examples thereof include benzyloxycarbonyl group and tert-butyloxycarbonyl group. For example, ProX 1 (X 1 is halogen, Pro is benzyloxycarbonyl group, tert-butyloxycarbonyl, etc.), Pro-O-Pro (Pro is benzyloxycarbonyl group, tert-butyloxycarbonyl, etc.) in the presence of a base. To give compound 23. Tetrahydrofuran and dimethylformamide can be used as the solvent. The reaction can be carried out at room temperature. As the base, triethylamine, pyridine, dimethylaminopyridine and the like can be used. It is to be noted that the reaction can be similarly performed even when R 7 is a hydrogen compound.
Process T
In this step, compound 23 is reduced to obtain compound 24. As a reducing agent, lithium aluminum hydride can be used. Tetrahydrofuran or the like can be used as the solvent. The reaction can be carried out at room temperature.
Process U
In this step, compound 24 is azidated to give compound 25. For example, compound 24 is reacted with methanesulfonyl chloride using triethylamine as a base to induce compound 24 to mesylate. As a solvent for the mesylation, chloroform can be used. The obtained compound is reacted with sodium azide and azidated in dimethylformamide or the like at room temperature or under heating to obtain compound 25.
Process V
In this step, compound 25 is reduced to obtain compound 26. Compound 26 is obtained by reducing compound 25 with triphenylphosphine and water. The reaction can be carried out under warming. Tetrahydrofuran can be used as the solvent. In addition to the reduction method using triphenylphosphine, it can be carried out by catalytic reduction. In the case of catalytic reduction, 10% palladium carbon or the like can be used as a catalyst. As the solvent, ethanol or the like can be used. Which reduction method is used can be appropriately selected depending on the protecting group to be used.
Process W
In this step, compound 26 is reacted with a compound represented by the formula: R 1 —Y—X 1 (X 1 is halogen or the like, Y is S, SO, SO 2 or CO) to obtain compound 27. As the compound represented by the formula: R 1 —Y—X 1 (X 1 is halogen or the like), various sulfonyl chlorides, sulfinyl chlorides, acyl chlorides and the like can be used. As the solvent, tetrahydrofuran, dimethylamide, or the like can be used. The reaction can be carried out at room temperature or under warming. The reaction is preferably performed in the presence of a base, and pyridine, triethylamine, or the like can be used as the base. Alternatively, the compound represented by the formula: R 1 —Y—X 1 in which Y═S or SO is reacted to obtain a compound 27, which is then oxidized to be converted into a compound in which Y is SO 2. You may use for the following process.
Process X
In this step, the protecting group of compound 27 is removed. The removal of the protecting group can be used by selecting various conditions depending on the protecting group. For example, the tert-butyloxycarbonyl group can be removed with an acid. The benzyloxycarbonyl group can be removed by catalytic reduction or the like.
Process Y
In this step, the substituent Z is introduced into the compound 28. For example, compound (ID) can be obtained by reacting ZX 1 (X 1 is halogen) in the presence of a base. As the solvent, methanol, ethanol, isopropanol, dimethylformamide, or the like can be used. The reaction can be carried out at room temperature or under warming. For example, it can be sealed and sealed using a microwave reactor. As the base, N, N-diisopropylethylamine or the like can be used.
In the above steps, the following intermediates are useful.
(In the formula, R is an optionally substituted lower alkyl, Pro is a protecting group, R 7 is hydrogen or an optionally substituted lower alkyl, and G is 1, 4-cycloalkylene, Y is SO 2 or SO, R 1 is optionally substituted lower alkyl, R 2 is hydrogen or optionally substituted lower alkyl is there)
R is particularly preferably lower alkyl, more preferably methyl or ethyl. Ethyl is particularly preferable.
Pro is preferably an amino protecting group that can be removed under acidic conditions. For example, as Pro, a group represented by the formula: — (C═O) —O—R (R represents a lower alkyl which may have a substituent, a lower alkenyl which may have a substituent) preferable. In particular, a tert-butyloxycarbonyl group is preferable.
R 7 is preferably hydrogen.
Y is preferably SO 2 .
R 1 is particularly preferably lower alkyl, more preferably isopropyl, ethyl or tert-butyl. In particular, tert-butyl is preferred.
R 2 is preferably hydrogen.
In particular, the following compounds are preferable.
formula:
(Wherein R 1 is ethyl or tert-butyl).
formula:
Wherein R 1 is ethyl, isopropyl or tert-butyl.
formula:
(Wherein Z is a hydrocarbon cyclic group which may have a substituent or a heterocyclic group which may have a substituent).
本発明に係る化合物は全てNPY Y5受容体拮抗作用を有しているが、特に好ましい化合物としては、以下の化合物が挙げられる。 Although all the compounds according to the present invention have NPY Y5 receptor antagonistic action, particularly preferred compounds include the following compounds.
式(I)において
R1が置換基を有していてもよい低級アルキルである(以下、R1がR1−1であるとする)化合物、
R1がハロゲンで置換されていてもよい炭素数1〜10のアルキルである(以下、R1がR1−2であるとする)化合物、
R1がイソプロピルまたはt−ブチルである(以下、R1がR1−3であるとする)化合物、
R2が水素または炭素数1〜3のアルキルである(以下、R2がR2−1であるとする)化合物、
R2が水素である(以下、R2がR2−2であるとする)化合物、
Xが置換基を有していてもよい低級アルキレン、置換基を有していてもよい低級アルケニレンまたは
であり、
が置換基を有していてもよいシクロアルキレン、置換基を有していてもよいシクロアルケニレン、置換基を有していてもよいビシクロアルキレン、置換基を有していてもよいフェニレンまたは置換基を有していてもよいヘテロ環ジイルである(以下、XがX−1であるとする)化合物、
Xが炭素数2〜6のアルキレン、炭素数3〜6のアルケニレンまたは
であり、
が置換基を有していてもよいシクロアルキレン、置換基を有していてもよいシクロアルケニレン、置換基を有していてもよいビシクロアルキレン、置換基を有していてもよいフェニレン、置換基を有していてもよいピペリジニレン、置換基を有していてもよいチオフェンジイルまたは置換基を有していてもよいフランジイルである(以下、XがX−2であるとする)化合物、
Xが炭素数2〜6のアルキレンまたは
であり、
が置換基を有していてもよいシクロアルキレン、置換基を有していてもよいフェニレン、置換基を有していてもよいピペリジニレン、置換基を有していてもよいチオフェンジイルまたは置換基を有していてもよいフランジイルである(以下、XがX−3であるとする)化合物、
Xが炭素数2〜6のアルキレンまたはそれぞれハロゲン、ヒドロキシ、低級アルキルもしくはハロゲノ低級アルキルで置換されていてもよいシクロアルキレンもしくはフェニレンである(以下、XがX−4であるとする)化合物、
Xが炭素数2〜6のアルキレンまたは炭素数5〜6のシクロアルキレンである(以下、XがX−5であるとする)化合物、
Xが炭素数3〜6のアルキレンまたは1,4−シクロヘキシレンである(以下、XがX−6であるとする)化合物、
Yが−SO−である(以下、YがY−1であるとする)化合物、
Yが−SO2−である(以下、YがY−2であるとする)化合物、
Yが−CO−である(以下、YがY−3であるとする)化合物、
Zが置換基を有していてもよい低級アルキル、置換基を有していてもよい炭化水素環式基または置換基を有していてもよいヘテロ環式基である(以下、ZがZ−1であるとする)化合物、
Zが−(CR8R9)r−W−(CR10R11)s−V
[式中、R8、R9、R10およびR11は各々独立して水素または低級アルキルであり、2以上のR8、R9、R10および/またはR11が存在するとき、各々のR8、R9、R10およびR11は異なっていてもよく、Wは単結合、O、SまたはNR12であり、R12は水素、低級アルキルまたはフェニルであり、Vは水素、置換基を有していてもよいシクロアルキル、置換基を有していてもよいビシクロアルキル、置換基を有していてもよいアリールまたは置換基を有していてもよいヘテロ環式基であり、rは1〜4の整数であり、sは0〜4の整数である]
である(以下、ZがZ−2であるとする)化合物、
Zが−(CH2)r−W−(CH2)s−V
[式中、Wは単結合、O、SまたはNR12であり、R12は水素または低級アルキルであり、Vはそれぞれ置換基を有していてもよいアリールまたはヘテロ環式基(ここで置換基とはハロゲン、ヒドロキシ、低級アルキル、ハロゲノ低級アルキル、低級アルコキシ、低級アルケニル、アミノ、低級アルキルアミノ、アシル、カルボキシ、低級アルコキシカルボニル、フェニルまたは単環のヘテロアリール)であり、rは1〜4の整数であり、sは0〜4の整数である]
である(以下、ZがZ−3であるとする)化合物、
Zが−(CH2)r−W−(CH2)s−V
[式中、Wは単結合、O、S、NHまたはNMeであり、Vはそれぞれ置換基を有していてもよいフェニルまたはヘテロアリール(ここで置換基とはハロゲン、低級アルキル、ハロゲノ低級アルキル、低級アルコキシ、アミノまたは低級アルキルアミノ)であり、rは1〜3の整数であり、sは0または1である]
である(以下、ZがZ−4であるとする)化合物、
Zが置換基を有していてもよい炭化水素環式基
[ここで置換基とはハロゲン;ヒドロキシ;
置換基を有していてもよい低級アルキル(ここで置換基とはハロゲン、ヒドロキシ、カルボキシ、低級アルコキシカルボニル、シアノおよび/またはフェニル);
低級アルコキシカルボニルで置換されていてもよい低級アルケニル;
置換基を有していてもよい低級アルコキシ(ここで置換基とはハロゲン、ヒドロキシ、低級アルコキシ、カルボキシ、低級アルコキシカルボニル、低級アルキルアミノ、シクロアルキル、シアノおよび/またはヘテロ環式基);
シクロアルキル;シクロアルキルオキシ;アシル;低級アルキルチオ;カルバモイル;低級アルキルカルバモイル;シクロアルキルカルバモイル;ヒドロキシイミノ;
置換基を有していてもよいアミノ(ここで置換基とは低級アルキル、保護されていてもよいヒドロキシ低級アルキル、低級アルコキシ低級アルキル、アシル、低級アルキルスルホニル、アリールスルホニルおよび/またはフェニル);
ハロゲン、シアノ、フェニルおよび/またはヘテロ環式基で置換されていてもよいフェニル;
低級アルキルスルフィニル;低級アルキルスルファモイル;シクロアルキルスルファモイル;
ニトロ;シアノ;アルキレンジオキシ;低級アルキルで置換されていてもよいフェニルアゾ;フェノキシ;オキソ;
置換基を有していてもよいヘテロ環式基(ここで置換基とは保護されていてもよいヒドロキシ;メルカプト;ハロゲン;低級アルキル;シクロアルキル;低級アルコキシカルボニル;アシル;アミノ;低級アルコキシカルボニルアミノ;カルバモイル;オキソ;フェニル;低級アルコキシフェニル;ハロゲノフェニル;ヘテロ環式基および/またはオキソ);
低級アルキルで置換されていてもよいヘテロ環スルホニル;ヘテロ環オキシ;低級アルキルで置換されていてもよいヘテロ環カルボニル]
である(以下、ZがZ−5であるとする)化合物、
Zが置換基を有していてもよいフェニル
(ここで置換基とはハロゲン;ヒドロキシ;ハロゲン、ヒドロキシ、低級アルコキシカルボニル、シアノおよび/またはフェニルで置換されていてもよい低級アルキル;低級アルコキシカルボニル低級アルケニル;ハロゲン、低級アルコキシ、低級アルコキシカルボニル、シクロアルキルおよび/またはヘテロ環式基で置換されていてもよい低級アルコキシ;シクロアルキル;シクロアルキルオキシ;アシル;低級アルキルチオ;カルバモイル;低級アルキルカルバモイル;低級アルキル、ヒドロキシ低級アルキル、アシル、低級アルキルスルホニルおよび/またはフェニルで置換されていてもよいアミノ;ハロゲン、シアノ、フェニルおよび/またはヘテロ環式基で置換されていてもよいフェニル;
低級アルキルスルファモイル;シクロアルキルスルファモイル;ニトロ;アルキレンジオキシ;低級アルキルで置換されていてもよいフェニルアゾ;フェノキシ;オキソ;ヒドロキシ、ハロゲン、低級アルキル、低級アルコキシカルボニル、アミノ、カルバモイル、フェニル、ハロゲノフェニル、ヘテロ環式基および/またはオキソで置換されていてもよいヘテロ環式基;ヘテロ環オキシ;並びに/または低級アルキルで置換されていてもよいヘテロ環スルホニル)である(以下、ZがZ−6であるとする)化合物、
Zが置換基を有していてもよいフェニル
(ここで置換基とはハロゲン;ハロゲン、ヒドロキシ、低級アルコキシカルボニルおよび/またはフェニルで置換されていてもよい低級アルキル;ハロゲンおよび/またはシクロアルキルで置換されていてもよい低級アルコキシ;シクロアルキル;シクロアルキルオキシ;アシル;低級アルキルチオ;低級アルキルカルバモイル;低級アルキル、ヒドロキシ低級アルキル、アシルおよび/またはフェニルで置換されていてもよいアミノ;ピペリジルで置換されていてもよいフェニル;シクロアルキルスルファモイル;アルキレンジオキシ;フェノキシ;
低級アルキルで置換されていてもよいモルホリニルもしくはモルホリノ;ヒドロキシ、低級アルキル、低級アルコキシカルボニル、フェニル、ハロゲノフェニルおよび/またはオキソで置換されていてもよいピペリジル;ヒドロキシ、カルバモイルおよび/またはオキソで置換されていてもよいピロリジニル;フェニルまたはピリミジルで置換されていてもよいピペラジニル;ジヒドロピリジル;ピロリル;ピロリニル;ハロゲンおよび/または低級アルキルで置換されていてもよいイミダゾリル;ピラゾリル;チエニル;チアジアゾリル;フリル;オキサゾリル;イソオキサゾリル;低級アルキルおよび/またはフェニルで置換されていてもよいテトラゾリル;インドリニル;インドリル;テトラヒドロキノリル;低級アルキルで置換されていてもよいベンゾチアゾリル;オキソで置換されていてもよいテトラヒドロイソチアゾリル;オキソで置換されていてもよいベンゾピラニル;テトラヒドロピラニルオキシ;テトラヒドロフリルオキシ;低級アルキルで置換されていてもよいモルホリノスルホニル;および/または低級アルキルで置換されていてもよいピペリジルスルホニル)である(以下、ZがZ−7であるとする)化合物、
Zが置換基を有していてもよいフェニル(ここで置換基とはハロゲン、低級アルキル、ハロゲノ低級アルキル、低級アルコキシ、シクロアルキルオキシ、低級アルキルカルバモイル、フェニル、低級アルキルモルホリノおよび/またはテトラヒドロピラニルオキシ)である(以下、ZがZ−8であるとする)化合物、
Zが置換基を有していてもよいヘテロ環式基(ここで置換基とはハロゲン、ヒドロキシ、低級アルキル、ハロゲノ低級アルキル、低級アルコキシ、メルカプト、低級アルキルチオ、アシル、カルボキシ、低級アルコキシカルボニル、アミノ、低級アルキルアミノ、フェニル、ナフチル、ハロゲンで置換されていてもよいフェニルチオ、ハロゲンで置換されていてもよいフェノキシ、オキソおよび/または低級アルキルで置換されていてもよいヘテロ環式基)である(以下、ZがZ−9であるとする)化合物、
Zがそれぞれ置換基を有していてもよいチエニル、ピラゾリル、チアゾリル、チアジアゾリル、ピリジル、ピリミジニル、ピラジニル、ピリダジニル、トリアジニル、インドリル、イソインドリル、インドリニル、イソインドリニル、インダゾリル、ベンゾピラニル、ベンズオキサゾリル、ベンゾチエニル、ベンゾチアゾリル、ベンゾチアゾリニル、ベンゾチアジアゾリル、ベンズイミダゾリル、キノリル、イソキノリル、ジヒドロベンゾフリル、カルバゾリル、アクリジニル、ジベンゾフリルまたはチアゾロピリジル(ここで置換基とは低級アルキル;ハロゲノ低級アルキル;低級アルコキシ;低級アルコキシカルボニル;アシル;低級アルコキシカルボニル低級アルキル;メルカプト;それぞれハロゲンで置換されていてもよいフェニル、ナフチル、フェニルチオもしくはフェノキシ;フリル;ニトロ;オキソ;および/または低級アルキルで置換されていてもよいモルホリノ)である(以下、ZがZ−10であるとする)化合物、
Zがそれぞれ置換基を有していてもよいチエニル、チアゾリル、チアジアゾリル、ピリジル、ピラジニル、インドリル、イソインドリニル、ベンゾピラニル、キノリル、カルバゾリル、ジベンゾフリル、ベンゾピラニル、ベンゾチエニルまたはベンゾチアゾリル(ここで置換基とは低級アルキル、ハロゲノ低級アルキル、低級アルコキシ、低級アルコキシカルボニル、アシル、フェニル、ナフチル、フェニルチオ、低級アルキルモルホリノおよびオキソからなる群から選択される1以上の基)である(以下、ZがZ−11であるとする)化合物、
R1がR1−2であり、R2がR2−2であり、nが2であり、X、YおよびZの組み合わせ(X,Y,Z)が以下の組み合わせである化合物、
(X,Y,Z)=(X-3,Y-2,Z-1),(X-3,Y-2,Z-2),(X-3,Y-2,Z-3),(X-3,Y-2,Z-4),(X-3,Y-2,Z-5),(X-3,Y-2,Z-6),(X-3,Y-2,Z-7),(X-3,Y-2,Z-8),(X-3,Y-2,Z-9),(X-3,Y-2,Z-10),(X-3,Y-2,Z-11),
(X-3,Y-3,Z-1),(X-3,Y-3,Z-2),(X-3,Y-3,Z-3),(X-3,Y-3,Z-4),(X-3,Y-3,Z-5),(X-3,Y-3,Z-6),(X-3,Y-3,Z-7),(X-3,Y-3,Z-8),(X-3,Y-3,Z-9),(X-3,Y-3,Z-10),(X-3,Y-3,Z-11),
(X-4,Y-2,Z-1),(X-4,Y-2,Z-2),(X-4,Y-2,Z-3),(X-4,Y-2,Z-4),(X-4,Y-2,Z-5),(X-4,Y-2,Z-6),(X-4,Y-2,Z-7),(X-4,Y-2,Z-8),(X-4,Y-2,Z-9),(X-4,Y-2,Z-10),(X-4,Y-2,Z-11),
(X-4,Y-3,Z-1),(X-4,Y-3,Z-2),(X-4,Y-3,Z-3),(X-4,Y-3,Z-4),(X-4,Y-3,Z-5),(X-4,Y-3,Z-6),(X-4,Y-3,Z-7),(X-4,Y-3,Z-8),(X-4,Y-3,Z-9),(X-4,Y-3,Z-10),(X-4,Y-3,Z-11),
(X-5,Y-2,Z-1),(X-5,Y-2,Z-2),(X-5,Y-2,Z-3),(X-5,Y-2,Z-4),(X-5,Y-2,Z-5),(X-5,Y-2,Z-6),(X-5,Y-2,Z-7),(X-5,Y-2,Z-8),(X-5,Y-2,Z-9),(X-5,Y-2,Z-10),(X-5,Y-2,Z-11),
(X-5,Y-3,Z-1),(X-5,Y-3,Z-2),(X-5,Y-3,Z-3),(X-5,Y-3,Z-4),(X-5,Y-3,Z-5),(X-5,Y-3,Z-6),(X-5,Y-3,Z-7),(X-5,Y-3,Z-8),(X-5,Y-3,Z-9),(X-5,Y-3,Z-10)または(X-5,Y-3,Z-11)
もしくはその製薬上許容される塩、またはそれらの溶媒和物が挙げられる。
A compound in which R 1 in formula (I) is optionally substituted lower alkyl (hereinafter referred to as R 1 is R1-1),
R 1 is an alkyl having 1 to 10 carbon atoms which may be substituted with halogen (hereinafter, R 1 is assumed to be R1-2) compound,
A compound in which R 1 is isopropyl or t-butyl (hereinafter, R 1 is R1-3),
A compound in which R 2 is hydrogen or alkyl having 1 to 3 carbon atoms (hereinafter, R 2 is R2-1),
A compound in which R 2 is hydrogen (hereinafter, R 2 is R2-2),
X is an optionally substituted lower alkylene, an optionally substituted lower alkenylene, or
And
Is optionally substituted cycloalkylene, optionally substituted cycloalkenylene, optionally substituted bicycloalkylene, optionally substituted phenylene or substituent A compound that is a heterocyclic diyl (hereinafter, X is X-1),
X is alkylene having 2 to 6 carbons, alkenylene having 3 to 6 carbons, or
And
Is optionally substituted cycloalkylene, optionally substituted cycloalkenylene, optionally substituted bicycloalkylene, optionally substituted phenylene, substituent A piperidinylene optionally having a substituent, a thiophenediyl optionally having a substituent, or a furandyl optionally having a substituent (hereinafter, X is assumed to be X-2),
X is alkylene having 2 to 6 carbon atoms or
And
Is an optionally substituted cycloalkylene, an optionally substituted phenylene, an optionally substituted piperidinylene, an optionally substituted thiophenediyl or a substituent. A compound that is a flangile that may have (hereinafter, X is X-3),
A compound in which X is alkylene having 2 to 6 carbon atoms or cycloalkylene or phenylene each optionally substituted by halogen, hydroxy, lower alkyl or halogeno lower alkyl (hereinafter, X is X-4),
A compound in which X is alkylene having 2 to 6 carbons or cycloalkylene having 5 to 6 carbons (hereinafter, X is X-5),
A compound wherein X is alkylene having 3 to 6 carbon atoms or 1,4-cyclohexylene (hereinafter, X is X-6);
A compound in which Y is -SO- (hereinafter, Y is Y-1);
A compound in which Y is —SO 2 — (hereinafter, Y is Y-2);
A compound in which Y is —CO— (hereinafter, Y is Y-3);
Z is a lower alkyl which may have a substituent, a hydrocarbon cyclic group which may have a substituent or a heterocyclic group which may have a substituent (hereinafter, Z is Z -1) compound,
Z is-(CR < 8 > R < 9 >) r-W- (CR < 10 > R < 11 >) s-V.
[Wherein R 8 , R 9 , R 10 and R 11 are each independently hydrogen or lower alkyl, and when two or more R 8 , R 9 , R 10 and / or R 11 are present, R 8 , R 9 , R 10 and R 11 may be different, W is a single bond, O, S or NR 12 , R 12 is hydrogen, lower alkyl or phenyl, V is hydrogen, substituent Cycloalkyl which may have a substituent, bicycloalkyl which may have a substituent, aryl which may have a substituent, or a heterocyclic group which may have a substituent, r Is an integer from 1 to 4, and s is an integer from 0 to 4.]
(Hereinafter, Z is Z-2),
Z is - (CH 2) r-W- (CH 2) s-V
[Wherein W is a single bond, O, S or NR 12 , R 12 is hydrogen or lower alkyl, and V is an aryl or heterocyclic group optionally substituted (wherein substituted) Group is halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkenyl, amino, lower alkylamino, acyl, carboxy, lower alkoxycarbonyl, phenyl or monocyclic heteroaryl), and r is 1-4. And s is an integer of 0 to 4.]
(Hereinafter, Z is Z-3),
Z is - (CH 2) r-W- (CH 2) s-V
[Wherein W is a single bond, O, S, NH or NMe, and V is phenyl or heteroaryl each optionally having a substituent (wherein the substituents are halogen, lower alkyl, halogeno-lower alkyl) , Lower alkoxy, amino or lower alkylamino), r is an integer of 1 to 3, and s is 0 or 1.]
(Hereinafter, Z is Z-4),
Z is an optionally substituted hydrocarbon cyclic group [wherein the substituent is halogen; hydroxy;
Optionally substituted lower alkyl (wherein the substituent is halogen, hydroxy, carboxy, lower alkoxycarbonyl, cyano and / or phenyl);
Lower alkenyl optionally substituted by lower alkoxycarbonyl;
Lower alkoxy which may have a substituent (wherein the substituent is halogen, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkylamino, cycloalkyl, cyano and / or heterocyclic group);
Cycloalkyl; Cycloalkyloxy; Acyl; Lower alkylthio; Carbamoyl; Lower alkylcarbamoyl; Cycloalkylcarbamoyl; Hydroxyimino;
Optionally substituted amino (wherein the substituent is lower alkyl, optionally protected hydroxy lower alkyl, lower alkoxy lower alkyl, acyl, lower alkylsulfonyl, arylsulfonyl and / or phenyl);
Phenyl optionally substituted by halogen, cyano, phenyl and / or heterocyclic groups;
Lower alkylsulfinyl; lower alkylsulfamoyl; cycloalkylsulfamoyl;
Nitro; cyano; alkylenedioxy; phenylazo optionally substituted with lower alkyl; phenoxy; oxo;
Optionally substituted heterocyclic group (wherein the substituent may be protected hydroxy; mercapto; halogen; lower alkyl; cycloalkyl; lower alkoxycarbonyl; acyl; amino; lower alkoxycarbonylamino) Carbamoyl; oxo; phenyl; lower alkoxyphenyl; halogenophenyl; heterocyclic group and / or oxo);
Heterocyclic sulfonyl optionally substituted with lower alkyl; Heterocyclic oxy; Heterocyclic carbonyl optionally substituted with lower alkyl]
(Hereinafter, Z is Z-5),
Z is optionally substituted phenyl (wherein the substituent is halogen; hydroxy; halogen, hydroxy, lower alkoxycarbonyl, lower alkyl optionally substituted with cyano and / or phenyl; lower alkoxycarbonyl lower Alkenyl; lower alkoxy optionally substituted with halogen, lower alkoxy, lower alkoxycarbonyl, cycloalkyl and / or heterocyclic group; cycloalkyl; cycloalkyloxy; acyl; lower alkylthio; carbamoyl; lower alkylcarbamoyl; Amino optionally substituted with hydroxy, lower alkyl, acyl, lower alkylsulfonyl and / or phenyl; phenyl optionally substituted with halogen, cyano, phenyl and / or heterocyclic group;
Lower alkyl sulfamoyl; cycloalkyl sulfamoyl; nitro; alkylenedioxy; phenylazo optionally substituted with lower alkyl; phenoxy; oxo; hydroxy, halogen, lower alkyl, lower alkoxycarbonyl, amino, carbamoyl, phenyl, Halogenophenyl, heterocyclic group and / or heterocyclic group optionally substituted with oxo; heterocyclic oxy; and / or heterocyclic sulfonyl optionally substituted with lower alkyl) (hereinafter Z is Z-6) compound,
Z is optionally substituted phenyl (wherein the substituent is halogen; halogen, hydroxy, lower alkoxycarbonyl and / or lower alkyl optionally substituted with phenyl; halogen and / or cycloalkyl substituted) Cycloalkyl; cycloalkyloxy; acyl; lower alkylthio; lower alkyl carbamoyl; amino optionally substituted with lower alkyl, hydroxy lower alkyl, acyl and / or phenyl; substituted with piperidyl Optionally phenyl; cycloalkylsulfamoyl; alkylenedioxy; phenoxy;
Morpholinyl or morpholino optionally substituted with lower alkyl; piperidyl optionally substituted with hydroxy, lower alkyl, lower alkoxycarbonyl, phenyl, halogenophenyl and / or oxo; substituted with hydroxy, carbamoyl and / or oxo Pyrrolidinyl optionally substituted with phenyl or pyrimidyl; dihydropyridyl; pyrrolyl; pyrrolyl; pyrrolinyl; imidazolyl optionally substituted with halogen and / or lower alkyl; pyrazolyl; thienyl; thiadiazolyl; furyl; oxazolyl; isoxazolyl Tetrazolyl optionally substituted with lower alkyl and / or phenyl; indolinyl; indolyl; tetrahydroquinolyl; substituted with lower alkyl Optionally benzothiazolyl; tetrahydroisothiazolyl optionally substituted with oxo; benzopyranyl optionally substituted with oxo; tetrahydropyranyloxy; tetrahydrofuryloxy; morpholinosulfonyl optionally substituted with lower alkyl; and (Or piperidylsulfonyl optionally substituted with lower alkyl) (hereinafter, Z is assumed to be Z-7),
Z may optionally have a substituent (wherein the substituent is halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, cycloalkyloxy, lower alkylcarbamoyl, phenyl, lower alkylmorpholino and / or tetrahydropyranyl) Oxy) (hereinafter referred to as Z being Z-8),
Z is an optionally substituted heterocyclic group (wherein the substituents are halogen, hydroxy, lower alkyl, halogeno lower alkyl, lower alkoxy, mercapto, lower alkylthio, acyl, carboxy, lower alkoxycarbonyl, amino , Lower alkylamino, phenyl, naphthyl, phenylthio optionally substituted with halogen, phenoxy optionally substituted with halogen, oxo and / or heterocyclic group optionally substituted with lower alkyl) ( Hereinafter, a compound in which Z is Z-9),
Z may optionally have a substituent, thienyl, pyrazolyl, thiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, indazolyl, benzopyranyl, benzoxazolyl, benzothienyl, Benzothiazolyl, benzothiazolinyl, benzothiadiazolyl, benzimidazolyl, quinolyl, isoquinolyl, dihydrobenzofuryl, carbazolyl, acridinyl, dibenzofuryl or thiazolopyridyl (where the substituent is lower alkyl; halogeno lower alkyl; lower alkoxy; Lower alkoxycarbonyl; acyl; lower alkoxycarbonyl lower alkyl; mercapto; phenyl each optionally substituted by halogen Naphthyl, phenylthio or phenoxy; furyl; nitro; oxo; a and / or lower alkyl optionally substituted morpholino) (hereinafter, Z is assumed to be Z-10) compound,
Each Z may have a substituent such as thienyl, thiazolyl, thiadiazolyl, pyridyl, pyrazinyl, indolyl, isoindolinyl, benzopyranyl, quinolyl, carbazolyl, dibenzofuryl, benzopyranyl, benzothienyl or benzothiazolyl (where the substituent is lower alkyl) , Halogeno lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, phenyl, naphthyl, phenylthio, lower alkylmorpholino and oxo (hereinafter, Z is Z-11). Compound),
A compound in which R 1 is R1-2, R 2 is R2-2, n is 2, and the combination of X, Y and Z (X, Y, Z) is the following combination:
(X, Y, Z) = (X-3, Y-2, Z-1), (X-3, Y-2, Z-2), (X-3, Y-2, Z-3), (X-3, Y-2, Z-4), (X-3, Y-2, Z-5), (X-3, Y-2, Z-6), (X-3, Y-2 , Z-7), (X-3, Y-2, Z-8), (X-3, Y-2, Z-9), (X-3, Y-2, Z-10), (X -3, Y-2, Z-11),
(X-3, Y-3, Z-1), (X-3, Y-3, Z-2), (X-3, Y-3, Z-3), (X-3, Y-3 , Z-4), (X-3, Y-3, Z-5), (X-3, Y-3, Z-6), (X-3, Y-3, Z-7), (X -3, Y-3, Z-8), (X-3, Y-3, Z-9), (X-3, Y-3, Z-10), (X-3, Y-3, Z -11),
(X-4, Y-2, Z-1), (X-4, Y-2, Z-2), (X-4, Y-2, Z-3), (X-4, Y-2 , Z-4), (X-4, Y-2, Z-5), (X-4, Y-2, Z-6), (X-4, Y-2, Z-7), (X -4, Y-2, Z-8), (X-4, Y-2, Z-9), (X-4, Y-2, Z-10), (X-4, Y-2, Z -11),
(X-4, Y-3, Z-1), (X-4, Y-3, Z-2), (X-4, Y-3, Z-3), (X-4, Y-3 , Z-4), (X-4, Y-3, Z-5), (X-4, Y-3, Z-6), (X-4, Y-3, Z-7), (X -4, Y-3, Z-8), (X-4, Y-3, Z-9), (X-4, Y-3, Z-10), (X-4, Y-3, Z -11),
(X-5, Y-2, Z-1), (X-5, Y-2, Z-2), (X-5, Y-2, Z-3), (X-5, Y-2 , Z-4), (X-5, Y-2, Z-5), (X-5, Y-2, Z-6), (X-5, Y-2, Z-7), (X -5, Y-2, Z-8), (X-5, Y-2, Z-9), (X-5, Y-2, Z-10), (X-5, Y-2, Z -11),
(X-5, Y-3, Z-1), (X-5, Y-3, Z-2), (X-5, Y-3, Z-3), (X-5, Y-3 , Z-4), (X-5, Y-3, Z-5), (X-5, Y-3, Z-6), (X-5, Y-3, Z-7), (X -5, Y-3, Z-8), (X-5, Y-3, Z-9), (X-5, Y-3, Z-10) or (X-5, Y-3, Z -11)
Or its pharmaceutically acceptable salt, or those solvates are mentioned.
本発明の食欲抑制剤または抗肥満薬は、肥満の予防および/または治療並びに摂食抑制に有用である。また、肥満がリスクファクターとなる疾患、例えば糖尿病、高血圧、高脂血症、動脈硬化、急性冠症候群等の予防/およびまたは治療に対しても有効である。
さらに、本発明に使用する化合物は、NPY Y5受容体拮抗作用のみならず、医薬としての有用性を備えており、下記いずれか、あるいは全ての優れた特徴を有している。
a)CYP酵素(例えば、CYP1A2、CYP2C9、CYP3A4等)に対する阻害が弱い。
b)薬物代謝酵素の誘導を起こしにくい。
c)高いバイオアベイラビリティー等良好な薬物動態を示す。
d)貧血誘発作用等の毒性が低い。
e)代謝安定性が高い。
f)高いY5受容体選択性を有している。
g)水溶性が高い。
h)脳移行性が高い。
i)生殖毒性(例えば、催奇形性等)を起こさない。
j)消化管障害(例えば、出血性腸炎、消化管潰瘍、消化管出血等)を起こさない。
The appetite suppressant or anti-obesity agent of the present invention is useful for prevention and / or treatment of obesity and suppression of eating. It is also effective for the prevention and / or treatment of diseases in which obesity is a risk factor, such as diabetes, hypertension, hyperlipidemia, arteriosclerosis, and acute coronary syndrome.
Furthermore, the compound used in the present invention has not only NPY Y5 receptor antagonistic activity but also usefulness as a medicament, and has any or all of the following excellent characteristics.
a) Inhibition of CYP enzyme (eg, CYP1A2, CYP2C9, CYP3A4, etc.) is weak.
b) It is difficult to induce drug metabolizing enzymes.
c) Good pharmacokinetics such as high bioavailability.
d) Low toxicity such as anemia-inducing action.
e) High metabolic stability.
f) High Y5 receptor selectivity.
g) High water solubility.
h) High brain transferability.
i) Does not cause reproductive toxicity (eg teratogenicity).
j) Does not cause gastrointestinal disorders (eg, hemorrhagic enteritis, gastrointestinal ulcer, gastrointestinal bleeding, etc.).
さらに、本発明に使用する化合物はNPY Y1およびY2受容体に対する親和性は低く、高いY5受容体選択性を有している。NPYは末梢で持続性の欠陥収縮作用を惹起するが、この作用は主としてY1受容体を介している。Y5受容体はこのような作用に全く関与しないことから、末梢血管収縮に基づく副作用を誘発する可能性は低く、安全な医薬として好適に用いることが可能であると考えられる。 Furthermore, the compounds used in the present invention have low affinity for NPY Y1 and Y2 receptors and high Y5 receptor selectivity. NPY induces persistent defect contraction in the periphery, but this effect is mainly mediated by the Y1 receptor. Since the Y5 receptor is not involved in such an action at all, it is unlikely to induce side effects based on peripheral vasoconstriction, and can be suitably used as a safe pharmaceutical.
本発明に使用する化合物は、摂食を抑制して抗肥満効果を示すものである。そのため、消化吸収を阻害することによって抗肥満効果を示す薬剤に見られるような消化不良等の副作用や、抗肥満効果を示すセロトニントランスポーター阻害剤のような抗鬱作用等の中枢性副作用を発現しないことは本薬剤の特長の一つである。 The compound used in the present invention suppresses food intake and exhibits an anti-obesity effect. Therefore, side effects such as indigestion as seen in drugs that exhibit anti-obesity effects by inhibiting digestion and absorption, and central side effects such as antidepressant effects such as serotonin transporter inhibitors that exhibit anti-obesity effects Not to do is one of the features of this drug.
本発明の食欲抑制剤または抗肥満薬を投与する場合、経口的、非経口的のいずれの方法でも投与することができる。経口投与は常法に従って錠剤、顆粒剤、散剤、カプセル剤、丸剤、液剤、シロップ剤、バッカル剤または舌下剤等の通常用いられる剤型に調製して投与すればよい。非経口投与は、例えば筋肉内投与、静脈内投与等の注射剤、坐剤、経皮吸収剤、吸入剤等、通常用いられるいずれの剤型でも好適に投与することができる。本発明に係る化合物は経口吸収性が高いため、経口剤として好適に使用できる。 When the appetite suppressant or anti-obesity agent of the present invention is administered, it can be administered either orally or parenterally. Oral administration may be prepared and administered in a commonly used dosage form such as tablets, granules, powders, capsules, pills, liquids, syrups, buccals or sublinguals according to conventional methods. For parenteral administration, any commonly used dosage forms such as injections such as intramuscular administration and intravenous administration, suppositories, percutaneous absorption agents, inhalants and the like can be suitably administered. Since the compound according to the present invention has high oral absorbability, it can be suitably used as an oral preparation.
本発明に係る化合物の有効量にその剤型に適した賦形剤、結合剤、湿潤剤、崩壊剤、滑沢剤、希釈剤等の各種医薬用添加剤を必要に応じて混合し医薬製剤とすることができる。注射剤の場合には適当な担体と共に滅菌処理を行なって製剤とすればよい。 Various pharmaceutical additives such as excipients, binders, wetting agents, disintegrants, lubricants, diluents and the like suitable for the dosage form are mixed with an effective amount of the compound according to the present invention as necessary to produce a pharmaceutical preparation It can be. In the case of an injection, it may be sterilized with an appropriate carrier to form a preparation.
具体的には、賦形剤としては乳糖、白糖、ブドウ糖、デンプン、炭酸カルシウムもしくは結晶セルロ−ス等、結合剤としてはメチルセルロ−ス、カルボキシメチルセルロ−ス、ヒドロキシプロピルセルロ−ス、ゼラチンもしくはポリビニルピロリドン等、崩壊剤としてはカルボキシメチルセルロ−ス、カルボキシメチルセルロ−スナトリウム、デンプン、アルギン酸ナトリウム、カンテン末もしくはラウリル硫酸ナトリウム等、滑沢剤としてはタルク、ステアリン酸マグネシウムもしくはマクロゴ−ル等が挙げられる。坐剤の基剤としてはカカオ脂、マクロゴ−ルもしくはメチルセルロ−ス等を用いることができる。また、液剤もしくは乳濁性、懸濁性の注射剤として調製する場合には通常使用されている溶解補助剤、懸濁化剤、乳化剤、安定化剤、保存剤、等張剤等を適宜添加しても良く、経口投与の場合には嬌味剤、芳香剤等を加えても良い。 Specifically, the excipients are lactose, sucrose, glucose, starch, calcium carbonate or crystalline cellulose, and the binders are methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, gelatin or polyvinyl. Examples of disintegrants include pyrrolidone, carboxymethyl cellulose, sodium carboxymethyl cellulose, starch, sodium alginate, agar powder or sodium lauryl sulfate, and lubricants include talc, magnesium stearate, or macrogol. It is done. As a suppository base, cacao butter, macrogol, methyl cellulose, or the like can be used. In addition, when preparing as liquid or emulsion or suspension injections, commonly used solubilizers, suspending agents, emulsifiers, stabilizers, preservatives, isotonic agents, etc. are added as appropriate. In the case of oral administration, a flavoring agent, a fragrance or the like may be added.
本発明の食欲抑制剤または抗肥満薬投与量は、患者の年齢、体重、疾病の種類や程度、投与経路等を考慮した上で設定することが望ましいが、成人に経口投与する場合、通常0.05〜100mg/kg/日であり、好ましくは0.1〜10mg/kg/日の範囲内である。非経口投与の場合には投与経路により大きく異なるが、通常0.005〜10mg/kg/日であり、好ましくは0.01〜1mg/kg/日の範囲内である。これを1日1回〜数回に分けて投与すれば良い。 The dose of the appetite suppressant or anti-obesity agent of the present invention is preferably set in consideration of the age, weight, type and degree of disease, route of administration, etc. of the patient. 0.05 to 100 mg / kg / day, preferably 0.1 to 10 mg / kg / day. In the case of parenteral administration, although it varies greatly depending on the administration route, it is usually 0.005 to 10 mg / kg / day, preferably 0.01 to 1 mg / kg / day. This may be administered once to several times a day.
以下に実施例を示し、本発明をさらに詳しく説明するが、これらは本発明を限定するものではない。
また、本明細書中で用いる略号は以下の意味を表す。
Me:メチル
Et:エチル
i-Pr:イソプロピル
DMSO:ジメチルスルホキシド
Pd−C:パラジウム炭素
THF:テトラヒドロフラン
DMF:N,N−ジメチルホルムアミド
mCPBA:メタクロロ過安息香酸
The present invention will be described in more detail with reference to the following examples, but these are not intended to limit the present invention.
Moreover, the symbol used in this specification represents the following meaning.
Me: methyl Et: ethyl i-Pr: isopropyl DMSO: dimethyl sulfoxide Pd-C: palladium carbon THF: tetrahydrofuran DMF: N, N-dimethylformamide mCPBA: metachloroperbenzoic acid
実施例1 化合物(Ii-1)の合成
第1工程
3−フルオロニトロベンゼン(2.00 g, 14.2 mmol)をジメチルスルホキシド15 mlに溶解させ、3,5−ジメチルピペリジン(3.21 g, 28.4 mmol)と炭酸カリウム(3.92 g, 28.4 mmol)を加え3時間150℃で攪拌した。反応液を水へあけ酢酸エチルで抽出した。有機層を水洗し無水硫酸ナトリウムで乾燥した。溶媒を減圧下留去し、残渣に酢酸エチルおよびヘキサンを加え、析出した結晶を濾取することで目的物の置換ニトロベンゼンが2.05 g、収率62%で得られた。
1H-NMR (CDCl3) δppm: 0.76 (q, 1H, J = 12.0 Hz), 0.96 (d, 6H, J = 6.3 Hz), 1.70-1.91 (m, 3H), 2.32 (t, 2H, J = 12.0 Hz), 3.62-3.72 (m, 2H), 7.17-7.25 (m, 1H), 7.34 (t, 1H, J = 8.1 Hz), 7.59 (d, 1H, J = 8.1 Hz), 7.71 (s, 1H).
第2工程
第1工程で得られた化合物(2.05 g, 8.75 mmol) をエタノール25 mlに溶解させ、10% Pd-C( 0.20g ) を加え水素添加反応を12時間行なった。Pd-Cをセライト濾過により除去し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィにより精製すると目的物のアニリンが1.62 g、収率90%で得られた。
1H-NMR (CDCl3) δppm: 0.69 (q, 1H, J = 12.0 Hz), 0.92 (d, 6H, J = 6.3 Hz), 1.75-1.98 (m, 3H), 2.22 (t, 2H, J = 12.0 Hz), 3.53-3.62 (m, 2H), 6.21 (d, 1H, J = 7.5 Hz), 6.38 (s, 1H), 6.42 (d, 1H, J = 8.1 Hz), 7.04 (t, 1H, J = 8.1 Hz).
第3工程
原料カルボン酸(合成法は国際公開第01/037826号パンフレットに記載)(5.04 g, 19.1 mmol) をテトラヒドロフラン50 mlに懸濁させ、氷冷下水素化リチウムアルミニウム (0.726 g, 19.1 mmol)を加え、室温で1時間攪拌した。反応液を再び氷冷攪拌し、水( 1.5mL )を注意深く滴下した。滴下後、室温で5分間攪拌し、生じた沈殿物を濾過除去し、濾液を減圧下濃縮した。残渣に酢酸エチルおよびヘキサンを加え、析出した結晶を濾取することで目的物のアルコールが3.15 g、収率66%で得られた。
1H-NMR (DMSO-d6) δppm: 0.88 (q, 2H, J = 11.6 Hz), 1.25 (s, 9H), 1.15-1.30 (m, 3H), 1.67-1.76 (m, 2H), 1.83-1.92 (m, 2H), 2.97 (m, 1H), 3.13-3.20 (m, 2H), 4.35 (t, 1H, J = 5.2 Hz), 6.71 (d, 1H, J = 8.8 Hz).
第4工程
第3工程で得た化合物(500 mg, 2.01 mmol) をクロロホルム5 mlに溶解させ、デス‐マーチン過よう素酸(893 mg, 2.11 mmol)を加え室温で1時間攪拌した。沈殿物を濾過除去し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィにより精製すると目的物のアルデヒドが385 mg、収率77%で得られた。
1H-NMR (DMSO-d6) δppm: 1.26 (s, 9H), 1.13-1.38 (m, 4H), 1.85-1.98 (m, 4H), 2.16 (m, 1H), 3.01 (m, 1H), 6.80 (d, 1H, J = 8.0 Hz), 9.54 (s, 1H).
第5工程
第2工程で得たアニリン(107 mg, 0.523 mmol) をテトラヒドロフラン3 mlに溶解させ、第4工程で得たアルデヒド(130 mg, 0.523 mmol)を加え室温で1時間攪拌した。反応液に水素化ホウ素ナトリウム(23.7mg, 0.628 mmol)を加え室温でさらに3時間攪拌した。反応液を水へあけ酢酸エチルで抽出した。有機層を水洗し無水硫酸ナトリウムで乾燥した。溶媒を減圧下留去し、残渣をシリカゲルクロマトグラフィにより精製すると目的物が99.3 mg、収率43%で得られた。
1H-NMR (DMSO-d6) δppm: 0.64 (q, 1H, J = 11.6 Hz), 0.87 (d, 6H, J = 6.0 Hz), 0.92-1.08 (m, 2H), 1.25 (s, 9H), 1.15-1.32 (m, 2H), 1.41 (m, 1H), 1.58-1.95 (m, 7H), 2.08 (t, 2H, J = 11.6 Hz), 2.75-2.82 (m, 2H), 3.00 (m, 1H), 3.48-3.55 (m, 2H), 5.31 (m, 1H), 5.94 (d, 1H, J = 8.5 Hz), 6.08-6.13 (m, 2H), 6.71 (d, 1H, J = 8.5 Hz), 6.85 (t, 1H, J = 8.5 Hz). 融点:161-162℃
Example 1 First Step of Synthesis of Compound (Ii-1)
3-Fluoronitrobenzene (2.00 g, 14.2 mmol) was dissolved in 15 ml of dimethyl sulfoxide, and 3,5-dimethylpiperidine (3.21 g, 28.4 mmol) and potassium carbonate (3.92 g, 28.4 mmol) were added for 3 hours at 150 ° C. Stir. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, ethyl acetate and hexane were added to the residue, and the precipitated crystals were collected by filtration to obtain 2.05 g of the desired substituted nitrobenzene in a yield of 62%.
1 H-NMR (CDCl3) δppm: 0.76 (q, 1H, J = 12.0 Hz), 0.96 (d, 6H, J = 6.3 Hz), 1.70-1.91 (m, 3H), 2.32 (t, 2H, J = 12.0 Hz), 3.62-3.72 (m, 2H), 7.17-7.25 (m, 1H), 7.34 (t, 1H, J = 8.1 Hz), 7.59 (d, 1H, J = 8.1 Hz), 7.71 (s, 1H).
Second step
The compound (2.05 g, 8.75 mmol) obtained in the first step was dissolved in 25 ml of ethanol, 10% Pd—C (0.20 g) was added, and hydrogenation reaction was performed for 12 hours. Pd-C was removed by Celite filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography to obtain 1.62 g of the desired aniline in 90% yield.
1 H-NMR (CDCl3) δppm: 0.69 (q, 1H, J = 12.0 Hz), 0.92 (d, 6H, J = 6.3 Hz), 1.75-1.98 (m, 3H), 2.22 (t, 2H, J = 12.0 Hz), 3.53-3.62 (m, 2H), 6.21 (d, 1H, J = 7.5 Hz), 6.38 (s, 1H), 6.42 (d, 1H, J = 8.1 Hz), 7.04 (t, 1H, J = 8.1 Hz).
Third step
Raw material carboxylic acid (the synthesis method is described in pamphlet of WO 01/037826) (5.04 g, 19.1 mmol) is suspended in 50 ml of tetrahydrofuran, and lithium aluminum hydride (0.726 g, 19.1 mmol) is added under ice cooling. And stirred at room temperature for 1 hour. The reaction mixture was stirred again on ice and water (1.5 mL) was carefully added dropwise. After dropping, the mixture was stirred at room temperature for 5 minutes, the resulting precipitate was removed by filtration, and the filtrate was concentrated under reduced pressure. Ethyl acetate and hexane were added to the residue, and the precipitated crystals were collected by filtration to obtain 3.15 g of the target alcohol in 66% yield.
1 H-NMR (DMSO-d6) δppm: 0.88 (q, 2H, J = 11.6 Hz), 1.25 (s, 9H), 1.15-1.30 (m, 3H), 1.67-1.76 (m, 2H), 1.83- 1.92 (m, 2H), 2.97 (m, 1H), 3.13-3.20 (m, 2H), 4.35 (t, 1H, J = 5.2 Hz), 6.71 (d, 1H, J = 8.8 Hz).
4th process
The compound obtained in the third step (500 mg, 2.01 mmol) was dissolved in 5 ml of chloroform, des-Martin periodic acid (893 mg, 2.11 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The precipitate was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography to obtain the desired aldehyde (385 mg, yield 77%).
1 H-NMR (DMSO-d6) δppm: 1.26 (s, 9H), 1.13-1.38 (m, 4H), 1.85-1.98 (m, 4H), 2.16 (m, 1H), 3.01 (m, 1H), 6.80 (d, 1H, J = 8.0 Hz), 9.54 (s, 1H).
5th process
The aniline (107 mg, 0.523 mmol) obtained in the second step was dissolved in 3 ml of tetrahydrofuran, the aldehyde (130 mg, 0.523 mmol) obtained in the fourth step was added, and the mixture was stirred at room temperature for 1 hour. Sodium borohydride (23.7 mg, 0.628 mmol) was added to the reaction solution, and the mixture was further stirred at room temperature for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography to obtain 99.3 mg of the desired product in 43% yield.
1H-NMR (DMSO-d6) δppm: 0.64 (q, 1H, J = 11.6 Hz), 0.87 (d, 6H, J = 6.0 Hz), 0.92-1.08 (m, 2H), 1.25 (s, 9H), 1.15-1.32 (m, 2H), 1.41 (m, 1H), 1.58-1.95 (m, 7H), 2.08 (t, 2H, J = 11.6 Hz), 2.75-2.82 (m, 2H), 3.00 (m, 1H), 3.48-3.55 (m, 2H), 5.31 (m, 1H), 5.94 (d, 1H, J = 8.5 Hz), 6.08-6.13 (m, 2H), 6.71 (d, 1H, J = 8.5 Hz ), 6.85 (t, 1H, J = 8.5 Hz). Melting point: 161-162 ° C
実施例2 化合物(Ij-1)の合成
第1工程
原料アミン(1.20 g, 3.64 mmol)と2‐クロロ‐5‐トリフルオロメチルピリジン(727 mg, 4.01 mmol)をイソプロパノール4 mlに懸濁させ、N, N-ジイソプロピルエチルアミン(1.87 ml, 10.9 mmol)を加え封管後、マイクロウェーブ反応装置を用いて1時間160℃の条件で反応を行なった。反応液を水へあけ酢酸エチルで抽出した。有機層を水洗し無水硫酸ナトリウムで乾燥した。溶媒を減圧下留去し、残渣をシリカゲルクロマトグラフィにより精製すると目的物のエステルが222 mg、収率20%で得られた。
第2工程
第1工程で得たエステル(207 mg, 0.685 mmol) をテトラヒドロフラン3 mlに溶解させ、氷冷下水素化リチウムアルミニウム (31.1 mg, 0.822 mmol)を加え、室温で0.5時間攪拌した。反応液を氷水へあけ酢酸エチルで抽出した後、有機層を水洗し無水硫酸ナトリウムで乾燥し、溶媒を減圧下留去することでアルコールを得た。得られたアルコールをクロロホルム3mlに溶解し、トリエチルアミン(0.28 ml, 2.04 mmol)を加え、氷冷下メタンスルホニルクロライド (0.12 ml, 1.64 mmol)を滴下し、室温で1時間攪拌した。反応液を水へあけ酢酸エチルで抽出した後、有機層を水洗し無水硫酸ナトリウムで乾燥し、溶媒を減圧下留去することでメシレートを得た。得られたメシレートをジメチルホルムアミド3mlに溶解し、アジ化ナトリウム(221 mg, 3.40 mmol)を加え、3時間100℃で攪拌した。反応液を水へあけ酢酸エチルで抽出した。有機層を水洗し無水硫酸ナトリウムで乾燥した。溶媒を減圧下留去し、残渣をシリカゲルクロマトグラフィにより精製すると目的物のアジドが178 mg、収率87%で得られた。
第3工程
第2工程で得たアジド(178 mg, 0.595 mmol) をエタノール3 mlに溶解させ、10% Pd-C( 30 mg ) を加え水素添加反応を4時間行なった。Pd-Cをセライト濾過により除去し、濾液を減圧下濃縮することでアミンを得た。
得られたアミンをテトラヒドロフラン3mlに溶解し、トリエチルアミン(0.28 ml, 0.714 mmol)を加え、氷冷下イソプロピルスルホニルクロライド (0.10 ml, 1.64 mmol)を滴下し1時間攪拌した。反応液を水へあけ酢酸エチルで抽出した後、有機層を水洗し無水硫酸ナトリウムで乾燥した。溶媒を減圧下留去し、残渣をシリカゲルクロマトグラフィにより精製すると目的物が64.8 mg、収率29%で得られた。
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2 H), 1.10-1.25 (m, 2H,), 1.22 (d, 6H, J = 6.4 Hz), 1.38 (m, 1H), 1.76-1.84 (m, 2H), 1.93-2.02 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.08-3.19 (m, 1H), 3.69 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.95 (t, 1H, J = 5.6 Hz), 7.16 (d, 1H, J = 7.6 Hz), 7.58 (d, 1H, J = 8.8 Hz), 8.26 (s, 1H) 融点:155-156℃
Example 2 First Step of Synthesis of Compound (Ij-1)
The starting amine (1.20 g, 3.64 mmol) and 2-chloro-5-trifluoromethylpyridine (727 mg, 4.01 mmol) were suspended in 4 ml of isopropanol, and N, N-diisopropylethylamine (1.87 ml, 10.9 mmol) was suspended. In addition, after sealing the tube, the reaction was carried out at 160 ° C. for 1 hour using a microwave reactor. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography to obtain 222 mg of the desired ester in a yield of 20%.
Second step
The ester (207 mg, 0.685 mmol) obtained in the first step was dissolved in 3 ml of tetrahydrofuran, lithium aluminum hydride (31.1 mg, 0.822 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 0.5 hour. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain an alcohol. The obtained alcohol was dissolved in 3 ml of chloroform, triethylamine (0.28 ml, 2.04 mmol) was added, methanesulfonyl chloride (0.12 ml, 1.64 mmol) was added dropwise under ice cooling, and the mixture was stirred at room temperature for 1 hour. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain mesylate. The obtained mesylate was dissolved in 3 ml of dimethylformamide, sodium azide (221 mg, 3.40 mmol) was added, and the mixture was stirred at 100 ° C. for 3 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography to obtain 178 mg of the desired product, azide, in a yield of 87%.
Third step
The azide (178 mg, 0.595 mmol) obtained in the second step was dissolved in 3 ml of ethanol, 10% Pd-C (30 mg) was added, and hydrogenation reaction was performed for 4 hours. Pd—C was removed by Celite filtration, and the filtrate was concentrated under reduced pressure to obtain an amine.
The obtained amine was dissolved in 3 ml of tetrahydrofuran, triethylamine (0.28 ml, 0.714 mmol) was added, and isopropylsulfonyl chloride (0.10 ml, 1.64 mmol) was added dropwise under ice cooling, followed by stirring for 1 hour. The reaction solution was poured into water and extracted with ethyl acetate, and then the organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography to obtain 64.8 mg of the desired product in 29% yield.
1 H-NMR (DMSO-d 6 ) δ: 0.92-1.06 (m, 2 H), 1.10-1.25 (m, 2H,), 1.22 (d, 6H, J = 6.4 Hz), 1.38 (m, 1H) , 1.76-1.84 (m, 2H), 1.93-2.02 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.08-3.19 (m, 1H), 3.69 (m, 1H), 6.53 (d , 1H, J = 8.8 Hz), 6.95 (t, 1H, J = 5.6 Hz), 7.16 (d, 1H, J = 7.6 Hz), 7.58 (d, 1H, J = 8.8 Hz), 8.26 (s, 1H ) Melting point: 155-156 ° C
実施例3 化合物(Ij-62)の合成
第1工程
原料アミン(132 g, 401 mmol)を氷冷下ジクロロメタン1000 mlに懸濁させ、トリエチルアミン(123 ml, 882 mmol)、(Boc)2O(101 ml, 440 mmol)を順に加え10分間反応させた。その後さらに室温で2時間反応させ、溶媒を留去した。クエン酸水(クエン酸一水和物50g, 水400 ml)に残渣をあけ、pH4とし、酢酸エチルで抽出した。有機層を水洗し、無水硫酸マグネシウムで乾燥し、溶媒を減圧下留去することで目的物が定量的に得られた。
1H-NMR (DMSO-d6) δppm: 1.06-1.25 (m, 2H), 1.25-1.43 (m, 2H), 1.37 (s, 9H), 1.75-1.94 (m, 4H), 2.19 (tt, 1H, J = 11.7, 3.9 Hz), 3.07-3.24 (m, 1H), 3.58 (s, 3H), 6.74 (d, 1H, J = 6.6 Hz).
第2工程
水素化リチウムアルミニウム (18.3 g, 483 mmol)をテトラヒドロフラン800 mlに懸濁させ、第1工程で得られたエステルのテトラヒドロフラン(300 ml)溶液を氷冷下攪拌しながら1時間かけてゆっくり加えた。氷冷下で10分間反応させた後、さらに室温で2.5時間反応させた。反応液を再び氷冷し、水とテトラヒドロフランの混合液(1:1, 36 ml)、2N水酸化ナトリウム水溶液(18 ml)、水(18 ml)を順に加え20分間攪拌した。その後さらに室温で1.5時間攪拌し、析出物を濾過除去し、濾液を減圧下濃縮した。残渣に酢酸エチルおよびヘキサンを加え、析出した結晶を濾取することで目的物のアルコールが79.5 g、収率87%(第1〜2工程通算)で得られた。
1H-NMR (DMSO-d6) δppm: 0.78-1.00 (m, 2H), 1.00-1.32 (m, 3H), 1.37 (s, 9H), 1.65-1.84 (m, 4H), 3.04-3.24 (m, 3H), 4.32-4.42 (m, 1H), 6.66 (d, 1H, J = 7.8 Hz).
第3工程
原料アルコール (79.5 g, 347 mmol)をテトラヒドロフラン800 mlに溶解させ、トリエチルアミン(72.5 ml, 520 mmol)、メタンスルホニルクロライド(32.2 ml, 416 mmol)を氷冷下攪拌しながら順に加え、1.5時間反応させた。反応液をクエン酸水(クエン酸一水和物30g, 水500 ml)にあけ、pH4とし、酢酸エチルで抽出後、有機層を水洗し無水硫酸マグネシウムで乾燥した。溶媒を減圧下留去する途中に析出した結晶を濾取し、ヘキサンで洗浄することでメシレートを100 g得た。得られたメシレートをジメチルホルムアミド100 mlに溶解させ、アジ化ナトリウム(63.7 g, 980 mmol)を加え、80℃で2時間反応させた。反応液を水にあけ、酢酸エチルで抽出した。有機層を水洗し、無水硫酸マグネシウムで乾燥し、溶媒を減圧下留去することで目的物のアジドが定量的(crude重量85.4 g)に得られた。
1H-NMR (DMSO-d6) δppm: 0.90-1.21 (m, 4H), 1.32-1.50 (m, 1H), 1.37 (s, 9H), 1.65-1.84 (m, 4H), 3.06-3.24 (m, 3H), 6.71 (d, 1H, J = 8.1 Hz).
第4工程
第3工程で得られたアジドを室温でテトラヒドロフラン900 mlに溶解させ、トリフェニルホスフィン(103 g, 392 mmol)、水(90 ml)を順に加え、80℃で1.5時間反応させた。溶媒770 mlを留去し、水300ml、酢酸エチル400 ml、2N塩酸150 mlを順に加え、pH2.5とし、分液抽出を行なった。有機層を2N塩酸で逆抽出した。酢酸エチルで洗浄した後、水層をアルカリ性とし、酢酸エチル及びクロロホルムで何度も抽出を行なった。有機層を合わせ、無水硫酸マグネシウムで乾燥した。溶媒を減圧下留去し、残渣にヘキサンを加え、析出した結晶を濾取し、ヘキサンで洗浄することで目的物のアミンが41.7 g、収率53%(第3〜4工程通算)で得られた。
1H-NMR (DMSO-d6) δppm: 0.77-0.96 (m, 2H), 1.00-1.18 (m, 3H), 1.37 (s, 9H), 1.67-1.82 (m, 4H), 2.30-2.38 (m, 2H), 2.90-3.60 (m, 2H), 3.05-3.22 (m, 1H), 6.66 (d, 1H, J = 7.2 Hz).
第5工程
原料アミン(37.5 g, 164 mmol)をテトラヒドロフラン400 mlに懸濁させ、トリエチルアミン(91.7 ml, 656 mmol)、イソプロピルスルホニルクロライド(32.2 ml, 416 mmol)を順に-55〜-40℃で攪拌しながらゆっくり加え、0℃まで徐々に昇温しながら6時間反応させた。反応液を氷冷の希酸水溶液にあけ、酢酸エチルで抽出した。有機層を水洗し、無水硫酸マグネシウムで乾燥した。溶媒を減圧下留去し、残渣にイソプロピルエーテルを加え、析出した結晶を濾取し、イソプロピルエーテルで洗浄することで目的物のスルホンアミドが43.1 g、収率79%で得られた。
1H-NMR (DMSO-d6) δppm: 0.79-0.98 (m, 2H), 1.00-1.36 (m, 3H), 1.20 (d, 6H, J = 6.6 Hz), 1.37 (s, 9H), 1.70-1.84 (m, 4H), 2.72-2.80 (m, 2H), 3.04-3.22 (m, 2H), 6.68 (d, 1H, J = 8.1 Hz), 6.94 (t, 1H, J = 6.0 Hz).
第6工程
Boc保護された原料アミン(43.0 g, 128 mmol)をメタノール200 mlに懸濁させ、4N 塩酸-ジオキサン溶液(96 ml, 384 mmol) を氷冷下攪拌しながら加え、20分間反応させた後、さらに室温で3時間反応させた。反応液を再び氷冷し、イソプロピルエーテル220 mlを加え、30分間攪拌した後、析出した結晶を濾取し、イソプロピルエーテルで洗浄することで目的物のアミン塩酸塩が30.8 g、収率89%で得られた。
1H-NMR (DMSO-d6) δppm: 0.85-1.02 (m, 2H), 1.20 (d, 6H, J = 6.6 Hz), 1.20-1.40 (m, 3H), 1.75-1.84 (m, 2H), 1.90-2.00 (m, 2H), 2.73-2.82 (m, 2H), 2.83-2.97 (m, 1H), 3.08-3.20 (m, 1H), 7.01 (t, 1H, J = 5.7 Hz), 8.01 (s, 3H).
第7工程
アミン塩酸塩(1.4 g, 5.16 mmol)と2-クロロベンゾチアゾール(2.63 g, 15.5 mmol)をN-メチルピロリドン15 mlに懸濁させ、N,N-ジイソプロピルエチルアミン(4.50 ml, 25.8 mmol)を加え、2本の反応管へ封管後、マイクロウェーブ反応装置を用いて30分間220℃の条件で反応を行なった。2本の反応管から反応液を水へあけ、酢酸エチルで抽出した。有機層を水洗し、無水硫酸ナトリウムで乾燥した。溶媒を減圧下留去し、残渣をシリカゲルクロマトグラフィにより精製すると目的物化合物(Ij-62)が1.5 g、収率79 %で得られた。
Example 3 First Step of Synthesis of Compound (Ij-62)
Raw material amine (132 g, 401 mmol) was suspended in 1000 ml of dichloromethane under ice-cooling, triethylamine (123 ml, 882 mmol) and (Boc) 2 O (101 ml, 440 mmol) were added in this order and reacted for 10 minutes. . Thereafter, the mixture was further reacted at room temperature for 2 hours, and the solvent was distilled off. The residue was poured into citric acid water (citric acid monohydrate 50 g, water 400 ml), adjusted to pH 4, and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain the desired product quantitatively.
1 H-NMR (DMSO-d6) δppm: 1.06-1.25 (m, 2H), 1.25-1.43 (m, 2H), 1.37 (s, 9H), 1.75-1.94 (m, 4H), 2.19 (tt, 1H , J = 11.7, 3.9 Hz), 3.07-3.24 (m, 1H), 3.58 (s, 3H), 6.74 (d, 1H, J = 6.6 Hz).
Second step
Lithium aluminum hydride (18.3 g, 483 mmol) was suspended in 800 ml of tetrahydrofuran, and a solution of the ester obtained in the first step in tetrahydrofuran (300 ml) was slowly added over 1 hour with stirring under ice cooling. After reacting for 10 minutes under ice cooling, the reaction was further allowed to proceed for 2.5 hours at room temperature. The reaction mixture was ice-cooled again, a mixture of water and tetrahydrofuran (1: 1, 36 ml), 2N aqueous sodium hydroxide solution (18 ml) and water (18 ml) were added in this order, and the mixture was stirred for 20 min. Thereafter, the mixture was further stirred at room temperature for 1.5 hours, the precipitate was removed by filtration, and the filtrate was concentrated under reduced pressure. Ethyl acetate and hexane were added to the residue, and the precipitated crystals were collected by filtration to obtain 79.5 g of the target alcohol in a yield of 87% (total of the first and second steps).
1H-NMR (DMSO-d6) δppm: 0.78-1.00 (m, 2H), 1.00-1.32 (m, 3H), 1.37 (s, 9H), 1.65-1.84 (m, 4H), 3.04-3.24 (m, 3H), 4.32-4.42 (m, 1H), 6.66 (d, 1H, J = 7.8 Hz).
Third step
Raw alcohol (79.5 g, 347 mmol) was dissolved in 800 ml of tetrahydrofuran, triethylamine (72.5 ml, 520 mmol) and methanesulfonyl chloride (32.2 ml, 416 mmol) were added in order with stirring under ice-cooling and allowed to react for 1.5 hours. It was. The reaction solution was poured into aqueous citric acid (citric acid monohydrate 30 g, water 500 ml), adjusted to pH 4, extracted with ethyl acetate, the organic layer was washed with water and dried over anhydrous magnesium sulfate. Crystals precipitated while the solvent was distilled off under reduced pressure were collected by filtration and washed with hexane to obtain 100 g of mesylate. The obtained mesylate was dissolved in 100 ml of dimethylformamide, sodium azide (63.7 g, 980 mmol) was added, and the mixture was reacted at 80 ° C. for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to quantitatively obtain the target azide (crude weight 85.4 g).
1 H-NMR (DMSO-d6) δppm: 0.90-1.21 (m, 4H), 1.32-1.50 (m, 1H), 1.37 (s, 9H), 1.65-1.84 (m, 4H), 3.06-3.24 (m , 3H), 6.71 (d, 1H, J = 8.1 Hz).
4th process
The azide obtained in the third step was dissolved in 900 ml of tetrahydrofuran at room temperature, triphenylphosphine (103 g, 392 mmol) and water (90 ml) were sequentially added, and the mixture was reacted at 80 ° C. for 1.5 hours. 770 ml of the solvent was distilled off, and 300 ml of water, 400 ml of ethyl acetate and 150 ml of 2N hydrochloric acid were added in this order to adjust the pH to 2.5, followed by liquid separation extraction. The organic layer was back extracted with 2N hydrochloric acid. After washing with ethyl acetate, the aqueous layer was made alkaline and extracted several times with ethyl acetate and chloroform. The organic layers were combined and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, hexane was added to the residue, the precipitated crystals were collected by filtration, and washed with hexane to obtain 41.7 g of the target amine in a yield of 53% (total 3rd to 4th steps). It was.
1 H-NMR (DMSO-d6) δppm: 0.77-0.96 (m, 2H), 1.00-1.18 (m, 3H), 1.37 (s, 9H), 1.67-1.82 (m, 4H), 2.30-2.38 (m , 2H), 2.90-3.60 (m, 2H), 3.05-3.22 (m, 1H), 6.66 (d, 1H, J = 7.2 Hz).
5th process
The raw material amine (37.5 g, 164 mmol) was suspended in 400 ml of tetrahydrofuran, and triethylamine (91.7 ml, 656 mmol) and isopropylsulfonyl chloride (32.2 ml, 416 mmol) were slowly stirred in this order at -55 to -40 ° C. In addition, the reaction was allowed to proceed for 6 hours while gradually raising the temperature to 0 ° C. The reaction solution was poured into an ice-cooled dilute aqueous acid solution and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, isopropyl ether was added to the residue, and the precipitated crystals were collected by filtration and washed with isopropyl ether to obtain 43.1 g of the desired sulfonamide in a yield of 79%.
1 H-NMR (DMSO-d6) δppm: 0.79-0.98 (m, 2H), 1.00-1.36 (m, 3H), 1.20 (d, 6H, J = 6.6 Hz), 1.37 (s, 9H), 1.70- 1.84 (m, 4H), 2.72-2.80 (m, 2H), 3.04-3.22 (m, 2H), 6.68 (d, 1H, J = 8.1 Hz), 6.94 (t, 1H, J = 6.0 Hz).
6th process
Boc-protected raw amine (43.0 g, 128 mmol) was suspended in 200 ml of methanol, 4N hydrochloric acid-dioxane solution (96 ml, 384 mmol) was added with stirring under ice cooling, and the mixture was reacted for 20 minutes. Furthermore, it was made to react at room temperature for 3 hours. The reaction solution was ice-cooled again, 220 ml of isopropyl ether was added, and the mixture was stirred for 30 minutes.The precipitated crystals were collected by filtration and washed with isopropyl ether to obtain 30.8 g of the target amine hydrochloride, yield 89% Was obtained.
1 H-NMR (DMSO-d6) δppm: 0.85-1.02 (m, 2H), 1.20 (d, 6H, J = 6.6 Hz), 1.20-1.40 (m, 3H), 1.75-1.84 (m, 2H), 1.90-2.00 (m, 2H), 2.73-2.82 (m, 2H), 2.83-2.97 (m, 1H), 3.08-3.20 (m, 1H), 7.01 (t, 1H, J = 5.7 Hz), 8.01 ( s, 3H).
7th process
Amine hydrochloride (1.4 g, 5.16 mmol) and 2-chlorobenzothiazole (2.63 g, 15.5 mmol) are suspended in 15 ml of N-methylpyrrolidone, and N, N-diisopropylethylamine (4.50 ml, 25.8 mmol) is added. After sealing in two reaction tubes, the reaction was carried out at 220 ° C. for 30 minutes using a microwave reactor. The reaction solution was poured into water from two reaction tubes and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel chromatography to obtain 1.5 g of the desired compound (Ij-62) in a yield of 79%.
また、第5工程においてイソプロピルスルホニルクロライドの代わりに、エタンスルホニルクロライドを反応させ、R1がエチル基である以下の化合物が得られた。
1H-NMR (DMSO-d6) δppm: 0.80-0.98 (m, 2H), 1.02-1.18 (m, 2H), 1.17 (t, 3H, J = 7.2 Hz), 1.22-1.34 (m, 1H), 1.37 (s, 9H), 1.68-1.82 (m, 4H), 2.68-2.78 (m, 2H), 2.96 (q, 2H, J = 7.2 Hz), 3.04-3.22 (m, 1H), 6.68 (d, 1H, J = 8.1 Hz), 6.94 (t, 1H, J = 6.0 Hz).
In the fifth step, ethanesulfonyl chloride was reacted instead of isopropylsulfonyl chloride to obtain the following compound in which R 1 is an ethyl group.
1 H-NMR (DMSO-d6) δppm: 0.80-0.98 (m, 2H), 1.02-1.18 (m, 2H), 1.17 (t, 3H, J = 7.2 Hz), 1.22-1.34 (m, 1H), 1.37 (s, 9H), 1.68-1.82 (m, 4H), 2.68-2.78 (m, 2H), 2.96 (q, 2H, J = 7.2 Hz), 3.04-3.22 (m, 1H), 6.68 (d, 1H, J = 8.1 Hz), 6.94 (t, 1H, J = 6.0 Hz).
第5工程においてイソプロピルスルホニルクロライドの代わりに、tert-ブチルスルフィニルクロライドを反応させ、その後mCPBAを用いて酸化し、R1がtert-ブチル基である以下の化合物が得られた(WO2001037826、実施例3参照)。
1H-NMR (DMSO-d6) δppm: 0.79-1.00 (m, 2H), 1.01-1.20 (m, 2H), 1.22-1.34 (m, 1H), 1.25 (s, 9H), 1.37 (s, 9H), 1.70-1.86 (m, 4H), 2.81-2.90 (m, 2H), 3.04-3.22 (m, 1H), 6.68 (d, 1H, J = 8.1 Hz), 6.83 (t, 1H, J = 6.0 Hz).
In the fifth step, tert-butylsulfinyl chloride was reacted instead of isopropylsulfonyl chloride, and then oxidized using mCPBA to obtain the following compound in which R 1 is a tert-butyl group (WO2001037826, Example 3). reference).
1H-NMR (DMSO-d6) δppm: 0.79-1.00 (m, 2H), 1.01-1.20 (m, 2H), 1.22-1.34 (m, 1H), 1.25 (s, 9H), 1.37 (s, 9H) , 1.70-1.86 (m, 4H), 2.81-2.90 (m, 2H), 3.04-3.22 (m, 1H), 6.68 (d, 1H, J = 8.1 Hz), 6.83 (t, 1H, J = 6.0 Hz ).
上記化合物を利用し、第6工程においてR1がエチル基やtert-ブチル基である以下の化合物が得られた。
R1がエチル基の場合
H-NMR (DMSO-d6) δppm: 0.84-1.02 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.20-1.40 (m, 3H), 1.74-1.82 (m, 2H), 1.90-2.00 (m, 2H), 2.72-2.80 (m, 2H), 2.83-2.96 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 7.04 (t, 1H, J = 6.0 Hz), 8.03 (s, 3H).
R1がtert-ブチル基の場合
H-NMR (DMSO-d6) δppm: 0.84-1.04 (m, 2H), 1.16-1.38 (m, 3H), 1.26 (s, 9H), 1.74-1.84 (m, 2H), 1.92-2.02 (m, 2H), 2.82-2.98 (m, 3H), 6.90 (d, 1H, J = 6.0 Hz), 8.01 (s, 3H).
By using the above compound, the following compound in which R 1 is an ethyl group or a tert-butyl group was obtained in the sixth step.
When R 1 is an ethyl group
H-NMR (DMSO-d6) δppm: 0.84-1.02 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.20-1.40 (m, 3H), 1.74-1.82 (m, 2H), 1.90 -2.00 (m, 2H), 2.72-2.80 (m, 2H), 2.83-2.96 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 7.04 (t, 1H, J = 6.0 Hz), 8.03 (s, 3H).
When R 1 is a tert-butyl group
H-NMR (DMSO-d6) δppm: 0.84-1.04 (m, 2H), 1.16-1.38 (m, 3H), 1.26 (s, 9H), 1.74-1.84 (m, 2H), 1.92-2.02 (m, 2H), 2.82-2.98 (m, 3H), 6.90 (d, 1H, J = 6.0 Hz), 8.01 (s, 3H).
同様にして合成される以下の化合物も本発明に含まれる。 The following compounds synthesized in the same manner are also included in the present invention.
化合物I-72
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2 H), 1.05-1.15 (m, 6H), 1.25 (s, 9H,), 1.15-1.32 (m, 3H), 1.41 (m, 1H), 1.75-1.98 (m, 4H), 2.11 (m, 1H), 2.58-3.38 (m, 5H), 3.58-3.76 (m, 2H), 5.17 (m, 1H), 6.25-6.92 (m, 5H) 融点:147-149℃
化合物Ia-140
1H-NMR (CDCl3) δ: 1.02-1.20 (m, 2 H), 1.17-1.32 (m, 2 H), 1.37 (d, 6H, J = 6.9 Hz), 1.46-1.70 (m, 4H), 1.86-1.95 (m, 2H), 2.08-2.18 (m, 2H), 3.01 (d, 2H, J = 6.9 Hz), 3.13 (m, 1H), 3.25 (m, 1H), 3.87 (d, 1H, J = 8.4 Hz) , 6.61(d, 2H, J = 8.7 Hz) , 7.39 (d, 2H, J = 8.7 Hz)
化合物Ia-141
1H-NMR (CDCl3) δ: 1.00-1.30 (m, 4 H), 1.37 (d, 6H, J = 6.9 Hz), 1.59 (m, 1H), 1.87-1.98 (m, 2H), 1.99-2.18 (m, 5H), 2.85 (q, 3H, J = 7.5 Hz), 2.97 (d, 2H, J = 6.9 Hz), 3.12 (m, 1H), 3.23 (m, 1H), 3.88 (d, 1H, J = 8.1 Hz) , 6.53 (d, 1H, J = 7.8 Hz) , 6.63 (brs, 1H), 7.04 (d, 1H, J = 7.8 Hz) Mass: 351[M+H]
化合物Ia-178
1H-NMR (CDCl3) δ: 1.08-1.36 (m, 4 H), 1.39 (s, 9H), 1.59 (m, 1H), 1.90-1.99 (m, 2H), 2.16-2.26 (m, 2H), 3.17-3.34 (m,3H), 3.69 (d, 1H, J = 9.3 Hz), 6.68 (d, 1H, J = 9.3 Hz), 7.77 (dd, 1H, J = 2.1 Hz and 9.3 Hz), 8.49 (brs, 1H) Mass:394[M+H]+
化合物Ib-138
1H-NMR (CDCl3) δ: 1.02-1.34 (m, 4 H), 1.37 (d, 6H, J = 6.6 Hz), 1.57 (m, 1H), 1.87-1.97 (m, 2H), 2.07-2.18 (m, 2H), 2.93 (d, 2H, J = 6.6 Hz), 3.13 (m, 1H), 3.25 (m, 1H), 3.99 (d, 1H, J = 8.4 Hz) , 6.38 (m, 1H) , 6.49 (brs, 1H), 6.97 (q, 1H, J = 9.3 Hz) Mass:347[M+H]
化合物Ii-2
1H-NMR (DMSO-d6) δ: 0.91-1.06 (m, 2H), 1.12-1.28 (m, 11H), 1.31-1.47 (m, 1H), 1.75-1.94 (m, 4H), 2.19 (t, 2H, J = 11.3 Hz), 2.79 (t, 2H, J = 6.0 Hz), 2.93-3.08 (m, 1H), 2.97 (q, 2H, J = 7.42 Hz), 3.46 (m, 2H), 3.57-3.69 (m, 2H), 5.71 (t, 1H, J = 5.2 Hz), 5.77 (d, 1H, J = 11.5 Hz), 5.88-5.96 (m, 2H), 7.01 (d, 1H, J = 7.4 Hz).
化合物Ii-3
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2 H), 1.15-1.21 (m, 1H), 1.27 (s, 9H), 1.40-1.49 (m, 2H), 1.82 (d, 2H, J = 11.6 Hz), 1.92 (d, 2H, J = 11.6 Hz), 2.79-2.84 (m, 2H), 2.97-3.10 (m, 1H), 3.24 (s, 3H), 3.55-3.62 (m, 2H), 3.84-3.91 (m, 2H), 5.50-5.59 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.4 Hz), 6.97 (d, 1H, J = 8.4 Hz). 融点:166-168℃
化合物Ii-4
1H-NMR (DMSO-d6) δ: 0.87 (t, 3H, J = 7.2 Hz), 0.93-1.06 (m, 2H), 1.13-1.21 (m, 1H), 1.26 (s, 9H), 1.37-1.49 (m, 2H), 1.61-1.72 (m, 2H), 1.82 (d, 2H, J = 12.0 Hz), 1.91 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.61-3.71 (m, 2H), 5.52-5.60 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.73 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz). 融点:185-186℃
化合物Ii-5
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2H), 1.26 (s, 9H), 1.28-1.31 (m, 1H), 1.35-1.47 (m, 8H), 1.81 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.77-2.84 (m, 2H), 2.96-3.07 (m, 1H), 4.30-4.42 (m, 1H), 5.51-5.64 (m, 1H), 6.39 (d, 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz), 7.07 (d, 1H, J = 8.8 Hz). 融点:156-157℃
化合物Ii-6
1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.19-1.25 (m, 4H), 1.26 (s, 9H), 1.38-1.49 (m, 2H), 1.82 (d, 2H, J = 8.8 Hz), 1.91 (d, 2H, J = 8.8 Hz), 2.79-2.84 (m, 2H), 2.97-3.07 (m, 1H), 3.69-3.80 (m, 2H), 5.51-5.63 (m, 1H), 6.41 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz). 融点:178-179℃
化合物Ii-7
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.19-1.22 (m, 1H), 1.26 (s, 9H), 1.38-1.48 (m, 2H), 1.82 (d, 2H, J = 11.6 Hz), 1.91 (d, 2H, J = 11.6 Hz), 2.79-2.84 (m, 2H), 2.95-3.09 (m, 1H), 3.25 (s, 3H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.4 Hz), 6.92 (d, 1H, J = 8.4 Hz). 融点:206-207℃
化合物Ii-8
1H-NMR (DMSO-d6) δ: 0.91-1.05 (m, 2H), 1.16-1.24 (m, 1H), 1.26 (s, 9H), 1.37-1.47 (m, 2H), 1.81 (d, 2H, J = 12.8 Hz), 1.90 (d, 2H, J = 12.8 Hz), 2.75-2.81 (m, 2H), 2.96-3.08 (m, 1H), 5.45-5.52 (m, 1H), 6.33 (d, 1H, J = 8.4 Hz), 6.50 (s, 1H), 6.68-6.80 (m, 2H), 11.02 (brs, 1H). 融点:213-214℃
化合物Ii-9
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2 H), 1.17-1.30 (m, 8H), 1.44 (brs, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.89 (d, 2H, J = 12.4 Hz), 2.78-2.82 (m, 2H), 2.97-3.15 (m, 2H), 3.23 (s, 3H), 3.55-3.62 (m, 2H), 3.83-3.90 (m, 2H), 5.52-5.59 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.92 (d, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.4 Hz). 融点:120-121℃
化合物Ii-10
1H-NMR (DMSO-d6) δ: 0.88 (t, 3H, J = 7.2 Hz), 0.93-1.08 (m, 2H), 1.17-1.30 (m, 8H), 1.44 (brs, 1H), 1.52-1.61 (m, 2H), 1.83 (d, 2H, J = 12.0 Hz), 1.90 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.98-3.15 (m, 2H), 3.62-3.71 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 6.92 (d, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.4 Hz). 融点:144-145℃
化合物Ii-11
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.15-1.30 (m, 8H), 1.33-1.50 (m, 7H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.86 (m, 2H), 2.96-3.14 (m, 2H), 4.30-4.45 (m, 1H), 5.50-5.61 (m, 1H), 6.40 (d, 1H, J = 7.6 Hz), 6.55 (s, 1H), 6.92 (d, 1H, J = 7.2 Hz), 7.07 (d, 1H, J = 7.6 Hz). 融点:137-138℃
化合物Ii-12
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.14-1.30 (m, 11H), 1.36-1.50 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.85 (m, 2H), 2.97-3.15 (m, 2H), 3.69-3.79 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.92 (d, 1H, J = 7.2 Hz), 6.98 (d, 1H, J = 8.4 Hz). 融点:158-159℃
化合物Ii-13
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.12-1.30 (m, 8H), 1.34-1.51 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.77-2.83 (m, 2H), 2.95-3.12 (m, 2H), 3.25 (s, 3H), 5.51-5.59 (m, 1H), 6.41 (d, 1H, J = 8.8 Hz), 6.56 (s, 1H), 6.86-6.97 (m, 2H). 融点:157-158℃
化合物Ii-14
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2 H), 1.12-1.30 (m, 5H), 1.38-1.50 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.23 (s, 3H), 3.55-3.61 (m, 2H), 3.84-3.91 (m, 2H), 5.52-5.60 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.55 (s, 1H), 6.89-7.00 (m, 2H). 融点:150-151℃
化合物Ii-15
1H-NMR (DMSO-d6) δ: 0.88 (s, 3H), 0.90 (s, 3H), 0.92-1.08 (m, 2H), 1.12-1.30 (m, 5H), 1.35-1.51 (m, 1H), 1.83 (d, 2H, J = 12.4 Hz), 1.89 (d, 2H, J = 12.4 Hz), 2.00-2.16 (m, 1H), 2.77-2.84 (m, 2H), 2.90-3.10 (m, 3H), 3.42-3.55 (m, 2H), 5.50-5.65 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.88-7.01 (m, 2H) 融点:132-133℃
化合物Ii-16
1H-NMR (DMSO-d6) δ: 0.87 (t, 3H, J = 6.8 Hz), 0.90-1.08 (m, 2H), 1.10-1.28 (m, 5H), 1.35-1.50 (m, 1H), 1.59-1.72 (m, 2H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.61-3.71 (m, 2H), 5.52-5.61 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.97 (d, 2H, J = 8.0 Hz). 融点:136-137℃
化合物Ii-17
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.12-1.28 (m, 5H), 1.33-1.50 (m, 7H), 1.81 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.90-3.08 (m, 3H), 4.28-4.44 (m, 1H), 5.49-5.79 (m, 1H), 6.39 (d, 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.97 (d, 1H, J = 7.6 Hz), 7.07 (d, 1H, J = 8.0 Hz). 融点:124-125℃
化合物Ii-18
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.12-1.29 (m, 8H), 1.36-1.51 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.86 (m, 2H), 2.90-3.09 (m, 3H), 3.68-3.80 (m, 2H), 5.51-5.61 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 6.97 (d, 2H, J = 8.4 Hz). 融点:163-164℃
化合物Ii-19
1H-NMR (DMSO-d6) δ: 0.89-1.08 (m, 2H), 1.11-1.30 (m, 5H), 1.35-1.51 (m, 1H), 1.82 (d, 2H, J = 10.8 Hz), 1.89 (d, 2H, J = 10.8 Hz), 2.75-2.88 (m, 2H), 2.89-3.10 (m, 3H), 3.25 (s, 3H), 5.48-5.60 (m, 1H), 6.42 (d, 1H, J = 7.6 Hz), 6.56 (s, 1H), 6.92 (d, 1H, J = 7.6 Hz), 6.98 (d, 1H, J = 5.6 Hz). 融点:189-190℃
化合物Ii-20
1H-NMR (DMSO-d6) δ: 0.95-1.13 (m, 2H), 1.31-1.59 (m, 10H), 1.73-1.92 (m, 4H), 2.12-2.26 (m, 2H), 2.84 (d, 2H, J = 6.0 Hz), 3.07-3.30 (m, 4H), 4.30-4.46 (m, 1H), 5.64 (brs, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 7.08 (d, 1H, J = 8.4 Hz). 融点:165-166℃
化合物Ii-21
1H-NMR (DMSO-d6) δ: 0.86-1.25 (m, 10H), 1.40 (d, 3H, J = 6.9Hz), 1.52 (m, 1H), 1.82-1.93 (m, 4H), 2.95-3.00 (m, 5H), 3.63-3.91 (m, 2H), 4.61-4.68 (m, 1H), 6.73 (brs, 2H), 7.01 (d, 2H, J = 7.8Hz), 7.11 (d, 1H, J = 8.1Hz,).
化合物Ii-22
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2 H), 1.15-1.34 (m, 5H), 1.36-1.43 (m, 9H), 1.53 (m, 1H), 1.82.1-93 (m, 4H), 2.94-3.01 (m, 6H), 4.52 (m, 1H), 4.63 (m, 1H), 6.73 (brs, 2H), 7.02 (d, 1H, J = 7.5Hz), 7.21-7.25 (m, 1H).
化合物Ii-23
1H-NMR (DMSO-d6) δ: 0.86-1.04 (m, 4 H), 1.25 (s, 10H), 1.30 (s, 6H), 1.38 (s, 3H), 1.40 (s, 3H), 178-1.92 (m 4H), 2.76-2.80 (m, 2H), 3.03 (m, 1H), 4.54-4.63 (m, 1H), 5.57 (m, 1H), 6.16 (s, 1H), 6.22 (d, 1H, J = 8.4Hz), 6.76 (d, 1H, J = 8.4Hz), 6.98 (d, 1H, J = 8.4Hz).
化合物Ii-24
1H-NMR (DMSO-d6) δ: 0.98-1.11 (m, 5 H), 1.15-1.31 (m, 20H), 1.57 (m, 1H), 1.82.1-93 (m, 4H), 2.74-2.81 (m, 1H), 3.01-3.06 (m, 2H), 3.35 (m, 1H), 3.40 (m, 1H), 4.04-4.17 (m, 3H), 6.77 (d, 1H, J = 9.0Hz),
化合物Ii-25
1H-NMR (DMSO-d6) δ: 0.98-1.20 (m, 13 H), 1.30 (d, 3H, J = 3H), 1.59 (m, 1H), 1.81-1.91 (m, 4H), 2.73-2.83 (m, 1H), 2.94-3.04 (m, 4H), 3.35-3.45 (m, 2H), 4.08-4.19 (m, 3H), 6.88 (brs, 3H), 7.03 (d, 1H, J = 8.4Hz).
化合物Ii-26
1H-NMR (DMSO-d6) δ: 1.02-1.10 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H), 1.55 (m, 1H), 1.86-1.93 (m, 4H), 3.01-3.04 (m, 3H), 6.76 (d, 1H, J = 8.7 Hz), 7.03 (m, 1H), 7.37-7.43 (m, 3H), 7.76-7.80 (m, 1H), 8.20-8.23 (m, 1H), 8.34-8.40 (m, 1H), 8.78-8.79 (m, 1H)
化合物Ii-27
1H-NMR (DMSO-d6) δ: 1.03-1.10 (m, 2H), 1.20-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.53 (m, 1H), 1.88 (m, 4H), 2.99-3.15 (m, 3H), 7.33-7.35 (m, 3H), 7.71-7.75 (m, 1H), 8.16-8.18 (m, 1H), 829-8.32 (m, 1H), 8.76-8.78 (m, 1H)
化合物Ii-28
1H-NMR (DMSO-d6) δ: 1.04-1.11 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J =7.2 Hz), 1.59 (m, 1H), 1.87-1.91 (m, 4H), 2.93-3.08 (m, 2H), 2.97 (q, 2H, J =7.2 Hz), 3.06-3.08 (m, 2H), 7.01 (m, 1H), 7.17 (d, 1H, J =7.5Hz), 7.43 (d, 1H, J =7.5Hz), 7.50-7.57 (m, 2H), 7.80-7.84 (m, 1H), 8.25-8.27 (m, 1H), 8.39-8.44 (m, 1H), 8.80-8.82 (m, 1H)
化合物Ii-29
1H-NMR (DMSO-d6) δ: 0.99-1.10 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J =7.5 Hz), 1.52 (m, 1H), 1.84-1.91 (m, 4H), 2.94-3.01 (m, 5H), 6.88 (m, 1H), 7.00 (d, 1H, J =7.8 Hz), 7.26-7.28 (m, 2H), 7.38 (m, 1H), 7.76 (d, 1H, J = 3.3. Hz), 7.90 (d, 1H, J =3.3 Hz)
化合物Ii-30
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2 H), 1.18-1.33 (m, 2H), 1.26 (s, 9H), 1.45 (m, 1H), 1.78-1.97 (m, 4 H), 2.86-2.94 (m, 2H), 2.95-3.10 (m, 1H), 5.91 (m, 1H), 6.55 (d, 1H, J = 7.6 Hz), 6.63-6.71 (m, 2H), 6.73 (d, 1H, J = 8.0 Hz), 7.06 (s, 1H), 7.15 (t, 1H, J = 8.0 Hz), 7.60 (s, 1H), 8.11 (s, 1H), 8.31 (s, 1H)
化合物Ii-31
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2 H), 1.13-1.28 (m, 2H), 1.26 (s, 9H), 1.43 (m, 1H), 1.76-1.97 (m, 4 H), 2.83-3.18 (m, 3H), 5.79 (m, 1H), 6.21 (s, 2H), 6.44 (d, 1H, J = 6.8 Hz), 6.58-6.67 (m, 2H), 6.73 (d, 1H, J = 8.0 Hz), 7.10 (t, 1H, J = 8.0 Hz), 7.21 (s, 2H) 融点:205-206℃
化合物Ii-32
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2 H), 1.05-1.28 (m, 11H), 1.41 (m, 1H), 1.75-1.92 (m, 4 H), 2.11 (t, 2H, J = 10.0 Hz), 2.73-2.82 (m, 2H), 2.91-3.08 (m, 3H), 3.24 (d, 2H, J = 11.2 Hz), 3.62-3.72 (m, 2H), 5.07 (m, 1H), 6.47 (d, 2H, J = 7.2 Hz), 6.72 (d, 2H, J = 7.2 Hz), 6.97 (d, 1H, J = 7.6 Hz) 融点:165-166℃
化合物Ii-33
1H-NMR (DMSO-d6) δ: 0.91-1.06 (m, 2H), 1.15-1.26 (m, 8H), 1.33-1.48 (m, 1H), 1.71-1.93 (m, 4H), 2.88 (d, 2H, J = 6.5 Hz), 2.93-3.15 (m, 2H), 5.70 (brs, 2H), 6.63 (d, 2H, J = 9.1 Hz), 6.93-6.96 (m, 1H), 7.38-7.42 (m, 2H), 7.57 (d, 2H, J = 9.1 Hz), 7.88-7.93 (m, 2H)
化合物Ii-34
1H-NMR (DMSO-d6) δ: 0.98-1.02 (m, 2H), 1.16-1.18 (m, 5H), 1.42 (s, 1H), 1.75-1.91 (m, 4H), 2.88 (d, 2H, J = 6.6 Hz), 2.96 (q, 3H, J = 7.3 Hz), 6.63 (d, 2H, J = 8.9 Hz), 6.99-7.02 (m, 1H), 7.38-7.41 (m, 2H), 7.57 (d, 2H, J = 8.9 Hz), 7.89-7.92 (m, 2H).
化合物Ii-35
1H-NMR (DMSO-d6) δ: 0.90-1.52 (m, 5H), 1.19 (t, 3H, J = 7.2 Hz), 1.75-1.96 (m, 4H), 2.50-3.10 (m, 3H), 2.62 (q, 2H, J = 7.2 Hz), 5.55-5.70 (m, 1H ), 6.57 (d, 2H, J = 8.7 Hz), 6.80-7.04 (m, 4H), 7.01 (d, 1H, J = 7.8 Hz), 7.34 (d, 2H, J = 8.7 Hz)
化合物Ii-36
1H-NMR (DMSO-d6) δ: 0.90-1.50 (m, 5H), 1.19 (t, 3H, J = 7.2 Hz), 1.75-1.95 (m, 4H), 2.70-3.10 (m, 3H), 2.97 (q, 2H, J = 7.2 Hz), 3.70 (s, 3H), 5.40-5.50 (m, 1H ), 6.53 (d, 2H, J = 8.7 Hz), 6.74 (d, 2H, J = 8.7 Hz), 6.78-6.90 (m, 4H), 6.99 (d, 1H, J = 7.8 Hz)
化合物Ii-37
1H-NMR (CDCl3) δ: 1.02-1.32 (m, 4 H), 139 (s, 9H,), 1.58 (m, 1H), 1.86-1.96 (m, 2H), 2.12-2.22 (m, 2H), 3.02 (d, 2H, J = 6.6 Hz), 3.25 (m, 1H), 3.67 (d, 1H, J = 9.3 Hz) , 6.67(d, 2H, J = 8.7 Hz) , 7.41 (d, 2H, J = 8.7 Hz) Mass:393[M+H]
化合物Ii-38
1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.17-1.26 (m, 2H), 1.19 (t, 3H, J = 7.1 Hz), 1.43 (s, 1H), 1.77-1.85 (m, 2H), 1.85-1.94 (m, 2H), 2.82 (t, 1H, J = 5.8 Hz), 2.98 (m, 1H), 2.97 (q, 2H, J = 7.1 Hz), 5.87 (m, 1H), 6.56 (d, 2H, J = 8.6 Hz), 6.98 (d, 1H, J = 7.6 Hz), 7.02 (d, 2H, J = 8.6 Hz).
化合物Ii-39
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.19-1.35 (m, 2H), 1.29 (s, 9H), 1.46 (s, 1H), 1.73-1.98 (m, 4H), 2.93 (m, 1H), 3.04 (m, 1H), 6.60-6.69 (m, 2H), 6.75 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 7.6 Hz), 7.49 (d, 1H, J = 8.8 Hz), 8.05 (s, 1H).
化合物Ii-40
1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.16-1.29 (m, 2H), 1.19 (t, 3H, J = 7.3 Hz), 1.45 (s, 1H), 1.76-1.94 (m, 4H), 1.76 (s, 2H), 2.93 (t, 2H, J = 5.8 Hz), 2.97 (q, 2H, J = 7.3 Hz), 6.66 (s, 1H), 6.94-7.01 (m, 2H), 7.49 (d, 1H, J = 8.6 Hz), 8.04 (s, 1H).
化合物Ii-41
1H-NMR (DMSO-d6) δ: 0.91-1.05 (m, 2H), 1.17-1.33 (m, 2H), 1.26 (s, 9H), 1.35-1.48 (m, 1H), 1.76-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.76-2.82 (m, 1H), 2.96-3.08 (m, 1H), 3.71 (s, 3H), 5.21-5.30 (m, 1H), 6.57 (d, 1H, J = 8.6 Hz), 6.73 (d, 1H, J = 8.6 Hz), 7.02 (dd, 1H, J = 8.6, 2.3 Hz), 7.44 (d, 1H, J = 2.3 Hz).
化合物Ii-42
1H-NMR (DMSO-d6) δ: 0.98-1.01 (m, 2H), 1.18-1.28 (m, 2H), 1.19 (t, 3H, J = 7.1 Hz), 1.42 (s, 1H), 1.76-1.85 (m, 2H), 1.85-1.93 (m, 2H), 2.79 (t, 2H, J = 5.9 Hz), 2.97 (q, 2H, J = 7.1 Hz), 3.02 (m, 1H), 3.71 (s, 3H), 5.26 (m, 1H), 6.58 (d, 1H, J = 8.6 Hz), 6.98 (d, 2H, J = 7.8 Hz), 7.02 (d, 2H, J = 8.6 Hz), 7.44 (br s, 1H).
化合物Ii-43
1H-NMR (DMSO-d6) δ: 0.98-1.06 (m, 2H), 1.16-1.25 (m, 2H), 1.18 (t, 3H, J =7.5 Hz), 1.51 (m, 1H), 1.83-1.91 (m, 4H), 2.85 (t, 2H, J = 6.3 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.04(m, 1H), 3.56 (s, 3H), 5.46 (t, 1H, J = 6.3 Hz), 5.76 (s, 1H), 6.49 (d, 1H, J = 7.8 Hz), 7.21 (t, 1H, J = 7.5Hz), 7.32 (t, 2H, J = 7.5 Hz), 7.68 (d, 2H, J = 7.5 Hz)
化合物Ii-44
1H-NMR (DMSO-d6)δ: 0.96-1.05 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.24 (m, 2H), 1.48 (m, 1H), 1.76-1.91 (m, 4H), 2.91 (d, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.2 Hz), 6.35 (s, 1H), 6.99 (d, 1H, J = 7.8 Hz), 7.46-7.49 (m, 3H), 7.73-7.76 (m, 2H)
化合物Ii-45
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.22 (m, 1H), 1.26 (s, 9H), 1.37-1.51 (m, 2H), 1.81 (d, 2H, J = 11.6 Hz), 1.91 (d, 2H, J = 11.6 Hz), 2.76-2.86 (m, 2H), 2.97-3.08 (m, 1H), 3.35 (s, 3H), 5.82-5.91 (m, 1H), 6.26 (d, 1H, J = 13.6 Hz), 6.39 (s, 1H), 6.73 (brs, 1H). 融点:215-216℃
化合物Ii-46
1H-NMR (CDCl3) δ: 1.02-1.32 (m, 4H), 1.24 (d, 6H, J = 6.0 Hz), 1.39 (s, 9H), 1.54 (m, 1H), 1.84-1.94 (m, 2H), 2.12-2.22 (m, 2H), 2.39 (t, 2H, J = 10.5 Hz), 2.94 (d, 2H, J = 6.9 Hz), 3.24 (m, 1H), 3.38 (d, 1H, J = 9.6 Hz), 3.61 (d, 1H, J = 9.6 Hz), 3.72-4.00 (m, 2H), 5.83-5.94 (m, 1H), 5.96-6.10 (m, 2H).
化合物Ii-47
1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.16-1.34 (m, 11H), 1.40 (m, 1H), 1.79 (d, 2H, J = 12.5 Hz), 1.90 (d, 2H, J = 11.9 Hz), 2.82 (t, 2H, J = 5.5 Hz), 3.01 (m, 1H), 6.12-6.18 (m, 3H), 6.30 (t, 1H, J = 5.5 Hz), 6.76 (d, 1H, J = 8.7 Hz).
化合物Ii-48
1H-NMR (CDCl3) δ: 1.00-1.28 (m, 4H), 1.39 (s, 9H), 1.56 (m, 1H), 1.91 (d, 2H, J = 12.4 Hz), 2.08-2.21 (m, 4H), 2.58 (t, 2H, J = 8.1 Hz), 2.97 (d, 2H, J = 6.0 Hz), 3.23 (m, 1H), 3.70 (d, 1H, J = 9.4 Hz), 3.80 (t, 2H, J = 7.1 Hz), 6.66 (d, 2H, J = 8.7 Hz), 7.36 (d, 2H, J = 8.7 Hz).
化合物Ii-49
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.17-1.33 (m, 11H), 1.41 (m, 1H), 1.80 (d, 2H, J = 12.9 Hz), 1.90 (d, 2H, J = 11.4 Hz), 2.82 (t, 2H, J = 6.1 Hz), 3.01 (m, 1H), 6.07 (t, 1H, J = 5.3 Hz), 6.34-6.43 (m, 2H), 6.51 (dd, 1H, J1 = 8.2 Hz, J2 = 1.8 Hz), 6.75 (d, 1H, J = 8.5 Hz), 7.11 (t, 1H, 8.2 Hz).
化合物Ii-50
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.14-1.31 (m, 8H), 1.43 (m, 1H), 1.76-1.94 (m, 4H), 2.82 (t, 2H, J = 6.0 Hz), 2.95-3.16 (m, 2H), 5.90 (t, 1H, J = 5.5 Hz), 6.56 (d, 2H, J = 8.7 Hz), 6.95 (d, 1H, J = 7.9 Hz), 7.03 (d, 2H, J = 8.6 Hz).
化合物Ii-51
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.13-1.31 (m, 8H), 1.42 (m, 1H), 1.76-1.94 (m, 4H), 2.83 (t, 2H, J = 6.0 Hz), 2.95-3.16 (m, 2H), 6.07 (t, 1H, J = 5.4 Hz), 6.36-6.46 (m, 2H), 6.53 (dd, 1H, J1 = 8.1 Hz, J2 = 1.9 Hz), 6.95 (d, 1H, J = 7.9 Hz), 7.12 (d, 1H, J = 8.1 Hz).
化合物Ii-52
1H-NMR (DMSO-d6) δ: 0.91-1.10 (m, 2H), 1.19-1.37 (m, 11H), 1.45 (m, 1H), 1.78-1.90 (m, 4H), 2.84 (t, 2H, J = 6.0 Hz), 3.04 (m, 1H), 4.64 (q, 2H, J = 9.0 Hz), 5.73 (t, 1H, J = 5.4 Hz), 6.13-6.21 (m, 2H), 6.26 (d, 1H, J = 7.2 Hz), 6.78 (d, 1H, J = 8.4 Hz), 6.99 (t, 1H, 8.0 Hz).
化合物Ii-53
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.13-1.30 (m, 8H), 1.42 (m, 1H), 1.75-1.93 (m, 4H), 2.80 (t, 2H, J = 6.2 Hz), 2.93-3.16 (m, 2H), 5.66 (t, 1H, J = 5.5 Hz), 6.53 (d, 2H, J = 9.1 Hz), 6.89 (d, 2H, J = 8.8 Hz), 6.92 (t, 1H, JH-F = 75 Hz), 6.94 (d, 1H, J = 8.0 Hz).
化合物Ii-54
1H-NMR (DMSO-d6) δ: 0.88-1.05 (m, 2H), 1.14-1.32 (m, 11H), 1.41 (m, 1H), 1.75-1.94 (m, 4H), 2.77 (t, 2H, J = 6.0 Hz), 3.01 (m, 1H), 4.54 (q, 2H, J = 9.0 Hz), 5.33 (t, 1H, J = 5.8 Hz), 6.49 (d, 2H, J = 8.8 Hz), 6.75 (d, 1H, J = 8.8 Hz), 6.80 (d, 2H, J = 8.8 Hz).
化合物Ii-55
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.14-1.31 (m, 8H), 1.40 (m, 1H), 1.74-1.93 (m, 4H), 2.79 (t, 2H, J = 5.9 Hz), 2.94-3.15 (m, 6H), 3.69 (t, 4H, J = 4.8 Hz), 5.70-5.94 (m, 4H), 6.94 (d, 1H, J = 8.0 Hz).
化合物Ii-56
1H-NMR (DMSO-d6) δ: 0.98-1.14 (m, 2H), 1.15-1.32 (m, 5H), 1.54 (m, 1H), 1.83-1.96 (m, 4H), 2.89-3.10 (m, 5H), 6.17 (t, 1H, J = 5.2 Hz), 6.63 (d, 1H, J = 2.2 Hz), 7.02 (d, 1H, J = 7.7 Hz), 7.21 (dd, 1H, J1 = 9.1 Hz, J2 = 2.5 Hz), 7.27 (dd, 1H, J1 = 8.2 Hz, J2 = 4.4 Hz), 7.67 (d, 1H, J = 9.1 Hz), 7.97 (d, 1H, J = 8.2 Hz), 8.45 (dd, 1H, J1 = 4.3 Hz, J2 = 1.5 Hz).
化合物Ii-57
1H-NMR (DMSO-d6) δ: 0.97-1.14 (m, 2H), 1.17-1.34 (m, 8H), 1.54 (m, 1H), 1.83-1.96 (m, 4H), 2.94 (t, 2H, J = 6.0 Hz), 2.99-3.18 (m, 2H), 6.17 (t, 1H, J = 5.4 Hz), 6.63 (d, 1H, J = 2.5 Hz), 6.96 (d, 1H, J = 7.7 Hz), 7.21 (dd, 1H, J1 = 9.1 Hz, J2 = 2.5 Hz), 7.27 (dd, 1H, J1 = 8.2 Hz, J2 = 4.1 Hz), 7.67 (d, 1H, J = 9.1 Hz), 7.97 (d, 1H, J = 8.0 Hz), 8.45 (dd, 1H, J1 = 4.3 Hz, J2 = 1.5 Hz).
化合物Ii-58
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.12-1.29 (m, 5H), 1.40 (m, 1H), 1.74-1.93 (m, 4H), 2.80 (t, 2H, J = 5.9 Hz), 2.92-3.07 (m, 7H), 3.69 (t, 4H, J = 4.8 Hz), 5.69-5.95 (m, 4H), 6.99 (d, 1H, J = 7.7 Hz).
化合物Ii-59
1H-NMR (DMSO-d6) δ: 0.94-1.11 (m, 2H), 1.14-1.30 (m, 5H), 1.47 (m, 1H), 1.78-1.95 (m, 4H), 2.88-3.09 (m, 5H), 3.80 (s, 3H), 6.09 (t, 1H, J = 5.6 Hz), 6.81-6.86 (m, 1H), 6.96 (dd, 1H, J1 = 8.8 Hz, J2 = 2.8 Hz), 7.01 (d, 1H, J = 7.4 Hz), 7.29 (t, 1H, J = 8.0 Hz), 7.45-7.51 (m, 2H), 7.66 (d, 1H, J = 8.5 Hz), 8.04 (d, 1H, J = 2.8 Hz).
化合物Ii-60
1H-NMR (DMSO-d6) δ: 1.03 (m, 2H), 1.19 (t, 2H, J = 7.8 Hz), 1.21 (m, 2H), 1.46 (m, 1H), 1.76-1.95 (m, 4H), 2.90 (t, 2H, J = 5.8 Hz), 2.97 (q, 2H, J = 7.3 Hz), 3.03 (m, 1H), 3.80 (s, 3H), 5.95 (m, 1H), 6.90 (m, 1H), 6.98 (d, 1H, J = 7.8 Hz), 6.98 (dd, 1H, J = 7.8, 7.8 Hz), 7.06 (d, 1H, J = 8.6 Hz), 7.26 (dd, 1H, J = 7.8, 7.8 Hz), 7.61 (d, 1H, J = 8.6 Hz), 7.69 (d, 1H, J = 7.8 Hz), 8.03 (s, 1H).
化合物Ii-61
1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.18-1.29 (m,2H), 1.19 (t, 3H, J = 7.6 Hz), 1.47 (m, 1H), 1.87 (m, 5H), 2.90 (t, 2H, J = 6.3 Hz), 2.97 (q, 2H, J = 7.6 Hz), 3.02 (m, 1H), 5.98 (m, 1H), 6.63 (d, 2H, J = 8.3 Hz), 6.98 (d, 1H, J = 7.3 Hz), 7.14 (m, 1H), 7.73 (s, 2H), 7.83 (d, 2H, J = 8.3 Hz), 8.52 (d, 1H, J = 4.0 Hz).
化合物Ii-62
1H-NMR (DMSO-d6) δ: 0.98-1.01 (m, 2H), 1.20 (s, 9H), 1.20-1.37 (m, 2H), 1.42 (m, 1H), 1.76-1.96 (m, 4H), 2.28-2.37 (m, 2H), 2.75-2.85 (m, 2H), 3.02 (m, 1H), 3.36 (t, 2H, J = 7.8 Hz), 3.57 (t, 2H, J = 6.3 Hz), 5.66 (m, 1H), 6.54 (d, 2H, J = 8.0 Hz), 6.73 (d, 1H, J = 8.6 Hz), 7.00 (d, 1H, J = 8.0 Hz).
化合物Ii-63
1H-NMR (DMSO-d6) δ: 0.96-1.14 (m, 2H), 1.14-1.32 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.50 (m, 1H), 1.76-1.96 (m, 4H), 2.91-3.10 (m, 3H), 2.97 (q, 2H, J = 7.2 Hz), 6.28 (m, 1H), 7.02 (d, 1H, J = 7.8 Hz), 7.32-7.46 (m, 3H), 8.20 (d, 1H, J = 6.9 Hz), 8.22 (s, 2H).
化合物Ii-64
1H-NMR (DMSO-d6) δ: 1.03-1.15 (m, 2H), 1.18-1.29 (m, 2H), 1.24 (d, 6H, J = 6.3 Hz), 1.52 (m, 1H), 1.86-1.94 (m, 2H), 2.10-2.19 (m, 2H), 2.40 (t, 2H, J = 6.0 Hz), 2.95 (d, 2H, J = 6.0 Hz), 3.23 (m, 1H), 3.40 (d, 2H, J = 11.4 Hz), 3.75-3.85 (m, 2H), 3.86 (d, 1H, J = 9.3 Hz), 6.14 (d, 1H, J = 8.5 Hz), 6.15 (s, 1H), 6.29 (d, 1H, J = 8.5 Hz), 7.06 (d, 1H, J = 8.5 Hz).
化合物Ii-65
1H-NMR (CDCl3) δ:1.08-1.16 (m, 2H), 1.14 (d, 6H, J = 6.8 Hz), 1.21-1.30 (m, 2H), 1.29 (s, 9H), 1.78 (t, 2H, J = 10.6 Hz), 1.83-1.92 (m, 2H), 2.11-2.19 (m, 2H), 2.78 (d, 2H, J = 10.6 Hz), 3.06 (s, 2H), 3.23 (m, 1H), 3.38 (s, 2H), 3.70-3.80 (m, 2H), 4.02 (d, 1H, J = 9.9 Hz), 5.37 (s, 1H), 6.30 (s, 1H).
化合物Ii-66
1H-NMR (DMSO-d6) δ: 1.01-1.12 (m, 2H), 1.20-1.34 (m, 2H), 1.27 (s, 9H), 1.54 (m, 1H), 1.82-1.99 (m, 4H), 2.91-2.98 (m, 2H), 3.06 (m ,1H), 6.17 (s, 1H), 6.63 (s, 1H), 6.78 (d, 1H, J = 9.0 Hz), 7.20 (m, 1H), 7.27 (m, 1H), 7.77 (d, 1H, J = 9.0 Hz), 7.98 (d, 1H, J = 9.0 Hz), 8.54 (s, 1H).
化合物Ii-67
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 1.88-1.96 (m, 2H), 2.78-2.86 (m, 2H), 3.02 (m ,1H), 5.89 (s, 1H), 6.56 (d, 1H, J = 8.4 Hz), 6.76 (d, 1H, J = 8.4 Hz), 7.02 (d, 1H, J = 8.4 Hz).
化合物Ii-68
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.19 (s, 9H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.42 (m, 1H), 1.80-1.96 (m, 4H), 2.77 (s, 2H), 3.04 (m, 1H), 5.29 (s, 1H), 6.44 (d, 1H, J = 7.2 Hz), 6.68 (d, 1H, J = 7.2 Hz), 6.75 (d, 1H, J = 8.4 Hz).
化合物Ii-69
1H-NMR (DMSO-d6) δ: 0.95-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.47 (m, 1H), 1.80-1.88 (m, 2H), 1.88-1.95 (m, 2H), 2.88-2.95 (m, 2H), 3.02 (s, 1H), 6.07 (m, 1H), 6.77 (d, 1H, J = 8.4 Hz), 6.97 (d, 1H, J = 7.6 Hz), 7.26 (t, 1H, J = 7.6 Hz), 7.35-7.42 (m, 2H), 7.46 (d, 1H, J = 8.4 Hz), 7.91 (d, 1H, J = 7.6 Hz), 8.04 (s, 1H).
化合物Ii-70
1H-NMR (DMSO-d6) δ: 0.93-1.05 (m, 2H), 1.10-1.32 (m, 2H), 1.26 (s, 9H), 1.42 (m, 1H), 1.78-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.78-2.83 (m, 2H), 3.03 (m, 1H), 4.80 (q, 2H, J = 9.2 Hz), 5.48 (t, 1H, J = 5.6 Hz), 6.69-6.76 (m, 2H), 7.08 (dd, 1H, J = 8.8, 2.4 Hz), 7.45 (d, 1H, J = 2.4 Hz).
化合物Ii-71
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.27 (s, 9H), 1.82-1.88 (m, 2H), 1.88-1.97 (m, 2H), 2.83-2.88 (m, 2H), 3.04 (m, 1H), 5.82 (s, 1H), 6.69 (m, 1H), 6.76 (d, 1H, J = 8.8 Hz), 7.12 (dd, 1H, J = 9.2, 8.8 Hz), 7.37 (m, 1H), 7.87 (d, 1H, J = 2.8 Hz), 7.99 (s, 1H).
化合物Ii-72
化合物Ii-73
化合物Ii-74
化合物Ii-75
化合物Ii-76
化合物Ii-77
化合物Ii-78
化合物Ii-79
化合物Ii-80
化合物Ii-81
化合物Ii-82
化合物Ii-83
化合物Ii-84
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.14-1.30 (t, 3H, J = 7.5 Hz ), 1.41 (m, 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H), 2.85 (t, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.25 (t, 2H, J = 7.5 Hz), 3.53 (t, 2H, J = 6.6 Hz), 6.27 (d, 2H, J = 11.7 Hz), 6.52 (t, 1H, J = 5.1 Hz), 7.00 (d, 1H, J = 7.2 Hz).
化合物Ii-85
化合物Ii-86
化合物Ii-87
化合物Ii-88
化合物Ii-89
化合物Ii-90
化合物Ii-91
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.13 (d, 6H, J = 6.0 Hz), 1.18-1.30 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.40 (m, 1H), 1.76-1.83 (m, 2H), 1.83-1.93 (m, 2H), 2.19 (dd, 1H, J = 11.2, 11.2 Hz), 2.76-2.82 (m, 2H), 3.01 (m, 1H), 3.09 (m, 1H), 3.45 (d, 2H, J = 11.2 Hz), 3.58-3.69 (m, 2H), 5.67 (m, 1H), 5.77 (d, 1H, J = 12.0 Hz), 5.90 (s, 1H), 5.91 (m, 1H), 6.91 (d, 1H, J = 7.6 Hz).
化合物Ii-92
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.14-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.46 (m, 1H), 1.75-1.92 (m, 4H), 2.78-2.83 (m, 2H), 2.95-3.18 (m, 6H), 3.66-3.72 (m, 4H), 5.75 (brs, 1H), 6.00 (s, 1H), 6.04 (s, 1H), 6.11 (s, 1H), 6.95 (d, 1H, J = 9.0 Hz).
化合物Ii-93
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.13-1.27 (m, 5H), 1.42 (m, 1H), 1.74-1.93 (m, 4H), 2.30-2.40 (m, 2H), 2.81 (d, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.49 (t, 2H, J = 7.5 Hz), 3.66 (t, 2H, J = 6.6 Hz), 5.00-5.50 (brs, 2H), 6.07-6.15 (m, 2H), 6.25(s, 1H), 7.00 (d, 1H, J = 6.6Hz).
化合物Ii-94
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.15-1.32 (m, 5H), 1.21 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.74-1.93 (m, 4H), 2.30-2.42 (m, 2H), 2.81 (d, 2H, J = 6.6 Hz), 2.92-3.18 (m, 2H), 3.49 (t, 2H, J = 7.5 Hz), 3.66 (t, 2H, J = 6.6 Hz), 4.70-5.30 (brs, 2H), 6.05-6.16 (m, 2H), 6.25 (s, 1H), 6.95 (d, 1H, J = 8.1Hz).
化合物Ii-95
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.16-1.31 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H), 2.84 (t, 2H, J = 6.0 Hz), 2.94-3.16 (m, 2H), 3.28 (t, 2H, J = 7.5 Hz), 3.53 (t, 2H, J = 6.6 Hz), 6.27 (d, 2H, J = 11.7 Hz), 6.52 (t, 1H, J = 5.4 Hz), 6.94 (d, 1H, J = 7.8 Hz).
化合物Ii-96
1H-NMR (DMSO-d6) δ: 0.91-1.04 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.40 (m, 1H), 1.76-1.95 (m, 4H), 2.77-2.83 (m, 2H), 2.99-3.04 (m, 5H), 3.67-3.72 (m, 4H), 5.71 (m, 1H), 5.79 (d, 1H, J = 11.7 Hz), 5.89 (s, 1H), 5.90 (m, 1H), 6.72 (d, 1H, J = 8.4 Hz).
化合物Ii-97
1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.41 (m, 1H), 1.77-1.93 (m, 4H), 2.78-2.83 (m, 2H), 2.97-3.05 (m, 5H), 3.68-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H, J = 8.0 Hz), 6.10 (s, 1H), 6.11 (d, 1H, J = 8.0 Hz), 6.72 (d, 1H, J = 8.0 Hz), 6.89 (dd, 1H, J = 8.0, 8.0 Hz).
化合物Ii-98
1H-NMR (DMSO-d6) δ: 0.92-1.04 (m, 2H), 1.17-1.29 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.41 (m, 1H), 1.75-1.92 (m, 4H), 2.77-2.83 (m, 2H), 2.95-3.05 (m, 5H), 3.09 (m, 1H), 3.67-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H, J = 8.0 Hz), 6.10 (s, 1H), 6.11 (d, 1H, J = 8.0 Hz), 6.89 (dd, 1H, J = 8.0, 8.0 Hz), 6.92 (d, 1H, J = 8.0 Hz).
化合物Ii-99
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.15-1.31 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.74-1.94 (m, 4H), 2.78 (t, 2H, J = 6.0 Hz), 2.93-3.16 (m, 6H), 5.64-5.76 (m, 2H), 5.83-5.92 (m, 2H), 6.94 (d, 1H, J = 7.8 Hz).
化合物Ii-100
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J = 6.0 Hz), 2.93-3.18 (m, 6H), 5.48-5.67 (m, 4H), 6.94 (d, 1H, J = 8.1 Hz).
化合物Ii-101
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.75-1.94 (m, 4H), 2.79 (t, 2H, J = 6.0 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.03-3.10 (m, 4H), 5.64-5.75 (m, 2H), 5.83-5.91 (m, 2H), 7.00 (d, 1H, J = 7.8 Hz).
化合物Ii-102
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.41 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J = 6.0 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.09-3.19 (m, 4H), 5.46-5.66 (m, 4H), 6.99 (d, 1H, J = 7.2 Hz).
化合物Ii-103
1H-NMR (DMSO-d6) δ: 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.40 (m, 1H), 1.75-1.92 (m, 4H), 2.20 (s, 3H), 2.35-2.43 (m, 4H), 2.75-2.82 (m, 2H), 2.88-3.13 (m, 6H), 5.67 (m, 1H), 5.76 (d, 1H, J = 11.2 Hz), 5.82-5.92 (m, 2H), 6.91 (d, 1H, J = 8.0 Hz).
化合物Ii-104
1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H), 1.39 (m, 1H), 1.75-1.95 (m, 4H), 2.19 (s, 3H), 2.38-2.42 (m, 4H), 2.77-2.83 (m, 5H), 2.98-3.09 (m, 5H), 5.67 (m, 1H), 5.76 (d, 1H, J = 11.2 Hz), 5.88 (m, 1H), 5.88 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz).
化合物Ii-105
1H-NMR (DMSO-d6) δ: 0.95-1.09 (m, 2H), 1.18-1.31 (m, 2H), 1.22 (d, 6H, J = 6.8 Hz), 1.44 (m, 1H), 1.78-1.93 (m, 4H), 2.87-2.92 (m, 2H), 3.03 (m, 1H), 3.10 (m, 1H), 6.13 (m, 1H), 6.21 (m, 1H), 6.22 (s, 2H), 6.51 (s, 1H), 6.52 (d, 1H, J = 8.0 Hz), 6.92 (d, 1H, J = 8.0 Hz), 7.26 (s, 2H).
化合物Ii-106
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.17-1.29 (m, 5H), 1.40-1.68 (m, 3H), 1.80-1.92 (m, 2H), 2.90 (t, 2H, J = 6.0 Hz), 2.94-3.06 (m, 3H), 6.12-6.22 (m, 4H), 6.50-6.54 (m, 2H), 6.94-7.00 (m, 1H), 7.26-7.27 (m, 2H).
化合物Ii-107
1H-NMR (DMSO-d6) δ: 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.40 (m, 1H), 1.74-1.92 (m, 4H), 2.75-2.81 (m, 2H), 2.84 (s, 3H), 3.00 (m, 1H), 3.09 (m, 1H), 3.25 (s, 3H), 3.35-3.47 (m, 4H), 5.59-5.67 (m, 4H), 6.91 (d, 1H, J = 8.0 Hz).
化合物Ii-108
1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.18-1.32 (m, 2H), 1.26 (s, 9H), 1.40 (m, 1H), 1.75-1.94 (m, 4H), 2.75-2.81 (m, 2H), 2.83 (s, 3H), 3.01 (m, 1H), 3.25 (s, 3H), 3.34-3.47 (m, 4H), 5.58-5.70 (m, 4H), 6.72 (d, 1H, J = 8.4 Hz).
化合物Ii-109
1H-NMR (DMSO-d6) δ: 0.90-1.51 (m, 10H), 1.21 (d, 6H, J = 6.9 Hz), 1.56-1.67 (m, 3H), 1.71-1.93 (m, 6H), 2.64 (s, 3H), 2.78 (t, 2H, J = 6.0 Hz), 2.93-3.17 (m, 2H), 3.44 (m, 1H), 5.56-5.77 (m, 4H), 6.94 (d, 1H, J = 7.8 Hz).
化合物Ii-110
1H-NMR (DMSO-d6) δ: 0.83-1.01 (m, 2H), 1.00-1.40 (m, 3H), 1.21 (d, 6H, J = 6.9 Hz), 1.68-1.91 (m, 4H), 2.73 (t, 2H, J = 6.0 Hz), 2.90-3.15 (m, 2H), 2.95 (s, 3H), 4,48 (s, 2H), 5.60-5.72 (m, 4H), 6.94 (d, 1H, J = 7.8 Hz), 7.15-7.35 (m, 5H).
化合物Ii-111
1H-NMR (DMSO-d6) δ: 0.97-1.14 (m, 2H), 1.14-1.33 (m, 5H), 1.45-1.61 (m, 1H), 1.81-1.96 (m, 4H), 2.90-3.10 (m, 5H), 6.34 (t, 1H, J = 5.2 Hz), 6.51 (d, 1H, J = 2.2 Hz), 6.99-7.07 (m, 2H), 7.36 (dd, 1H, J = 8.2, 4.1 Hz), 8.02 (d, 1H, J = 8.5 Hz), 8.48 (dd, 1H, J = 4.1, 1.4 Hz).
化合物Ii-112
1H-NMR (DMSO-d6) δ: 0.97-1.13 (m, 2H), 1.17-1.34 (m, 8H), 1.45-1.59 (m, 1H), 1.81-1.99 (m, 4H), 2.94 (t, 2H, J = 5.9 Hz), 2.99-3.21 (m, 2H), 6.33 (t, 1H, J = 5.4 Hz), 6.51 (d, 1H, J = 2.2 Hz), 6.96 (d, 1H, J = 7.7 Hz), 7.02 (dd, 1H, J = 13.5, 2.2 Hz), 7.36 (dd, 1H, J = 8.2, 4.1 Hz), 8.02 (d, 1H, J = 8.5 Hz), 8.48 (dd, 1H, J = 4.1, 1.4 Hz).
化合物Ii-113
1H-NMR (DMSO-d6) δ: 0.93-1.13 (m, 2H), 1.15-1.34 (m, 8H), 1.39-1.57 (m, 1H), 1.79-1.95 (m, 4H), 2.87 (t, 2H, J = 6.2 Hz), 2.94-3.16 (m, 2H), 3.54 (s, 3H), 5.66 (t, 1H, J = 5.5 Hz), 6.49 (d, 1H, J = 9.6 Hz), 6.73 (d, 1H, J = 2.8 Hz), 6.91-7.02 (m, 2H), 7.29 (d, 1H, J = 9.3 Hz), 7.72 (d, 1H, J = 9.3 Hz).
化合物Ii-114
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.14-1.33 (m, 8H), 1.41-1.56 (m, 1H), 1.79-1.94 (m, 4H), 2.89 (t, 2H, J = 6.0 Hz), 2.95-3.16 (m, 2H), 6.00 (t, 1H, J = 5.4 Hz), 6.84 (dd, 1H, J = 8.8, 2.2 Hz), 6.95 (d, 1H, J = 8.0 Hz), 7.07 (d, 1H, J = 2.2 Hz), 7.72 (d, 1H, J = 8.8 Hz), 8.86 (s, 1H).
化合物Ii-115
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.40-1.51 (m, 1H), 1.84 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.85-2.90 (m, 2H), 2.97-3.06 (m, 1H), 5.93-5.99 (m, 1H), 6.63-6.79 (m, 3H), 7.40 (d, 1H, J = 8.8 Hz), 8.32 (s, 1H).
化合物Ii-116
1H-NMR (DMSO-d6) δ: 0.95-1.07 (m, 4H), 1.26 (s, 9H), 1.39-1.47 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.87-2.93 (m, 2H), 2.98-3.06 (m, 1H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J = 8.8 Hz), 6.73 (d, 1H, J = 8.8 Hz), 6.80 (t, 1H, J = 5.2 Hz), 7.32 (d, 1H, J = 8.8 Hz).
化合物Ii-117
1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H), 1.39-1.51 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.88 (d, 2H, J = 12.4 Hz), 2.87-2.94 (m, 2H), 2.97-3.07 (m, 1H), 3.08-3.14 (m, 1H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J = 8.4 Hz), 6.82 (t, 1H, J = 5.6 Hz), 6.94 (d, 1H, J = 8.0 Hz), 7.32 (d, 1H, J = 8.4 Hz).
化合物Ii-118
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 4H), 1.26 (s, 9H), 1.38-1.50 (m, 1H), 1.83 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.80-2.86 (m, 2H), 2.96-3.06 (m, 1H), 3.26 (s, 3H), 5.58-5.65 (m, 1H), 6.27 (d, 1H, J = 8.4 Hz), 6.38 (s, 1H), 6.75 (d, 1H, J = 8.4 Hz), 6.99 (d, 1H, J = 8.4 Hz).
化合物Ii-119
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.39-1.50 (m, 1H), 1.84 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.81-2.89 (m, 2H), 2.96-3.07 (m, 1H), 3.51 (s, 3H), 5.79-5.84 (m, 1H), 6.60 (s, 1H), 6.75 (d, 1H, J = 8.8 Hz), 7.03 (d, 1H, J = 8.8 Hz), 7.19 (d, 1H, J = 8.8 Hz).
化合物Ii-120
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 4H), 1.26 (s, 9H), 1.37-1.40 (m, 1H), 1.42 (s, 3H), 1.44 (s, 3H), 1.83 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.79-2.96 (m, 2H), 2.97-3.07 (m, 1H), 4.33-4.46 (m, 1H), 5.50-5.59 (m, 1H), 6.25 (d, 1H, J = 8.8 Hz), 6.57 (s, 1H), 6.75 (d, 1H, J = 8.4 Hz), 7.00 (d, 1H, J = 8.4 Hz).
化合物Ii-121
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.36-1.49 (m, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.80-2.87 (m, 2H), 2.95-3.97 (m, 1H), 3.27 (s, 3H), 5.85-5.92 (m, 1H), 6.33 (s, 1H), 6.36 (s, 1H), 6.75 (d, 1H, J = 8.8 Hz).
化合物Ii-122
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 4H), 1.26 (s, 9H), 1.38-1.41 (m, 1H), 1.42 (s, 3H), 1.43 (s, 3H), 1.82 (d, 2H, J = 11.8 Hz), 1.90 (d, 2H, J = 11.8 Hz), 2.83-2.88 (m, 2H), 2.98-3.06 (m, 1H), 4.33-4.47 (m, 1H), 6.35 (s, 1H), 6.54 (s, 1H), 6.76 (d, 1H, J = 8.4 Hz), 8.32 (s, 1H).
化合物Ii-123
1H-NMR (DMSO-d6) δ: 0.93-1.06 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.26 (s, 9H), 1.39-1.50 (m, 1H), 1.81 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.87-2.93 (m, 2H), 2.96-3.07 (m, 1H), 4.39-4.47 (m, 1H), 6.30 (s, 1H), 6.54 (d, 1H, J = 8.8 Hz), 6.77 (d, 1H, J = 8.8 Hz), 6.86 (t, 1H, J = 5.2 Hz), 7.32 (d, 1H, J = 8.4 Hz).
化合物Ii-124
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 4H), 1.26 (s, 9H), 1.36-1.51 (m, 1H), 1.79 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.80-2.86 (m, 2H), 3.01 (s, 3H), 3.02-3.05 (m, 1H), 3.49 (t, 2H, J = 4.8 Hz), 4.26 (t, 2H, J = 4.8 Hz), 6.02 (s, 1H), 6.20 (t, 1H, J = 5.6 Hz), 6.31 (d, 1H, J = 8.8 Hz), 6.74 (d, 1H, J = 8.8 Hz), 7.43 (d, 1H, J = 8.4 Hz).
化合物Ii-125
1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 4H), 1.08 (t, 3H, J = 7.2 Hz), 1.25 (s, 9H), 1.35-1.42 (m, 1H), 1.79 (d, 2H, J = 12.0 Hz), 1.90 (d, 2H, J = 12.0 Hz), 2.80-2.86 (m, 2H), 2.96-3.05 (m, 1H), 3.42-3.51 (m, 4H), 4.20-4.26 (m, 2H), 6.03 (s, 1H), 6.20 (s, 1H), 6.31 (d, 1H, J = 8.8 Hz), 6.75 (d, 1H, J = 8.8 Hz), 7.42 (d, 1H, J = 8.8 Hz).
化合物Ii-126
1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 4H), 1.09 (s, 3H), 1.11 (s, 3H), 1.25 (s, 9H), 1.43−1.55 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.0 Hz), 2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.37 (t, 2H, J = 5.2 Hz), 4.18 (t, 2H, J = 5.2 Hz), 4.71-4.80 (m, 1H), 6.05 (s, 1H), 6.19 (t, 1H, J = 5.2 Hz), 6.32 (d, 1H, J = 8.8 Hz), 6.74 (d, 1H, J = 8.4 Hz), 7.18 (d, 1H, J = 8.4 Hz).
化合物Ii-127
1H-NMR (DMSO-d6) δ: 0.94-1.12 (m, 2H), 1.14-1.39 (m, 5H), 1.34-1.56 (m, 1H), 1.70-1.97 (m, 4H), 2.87-3.10 (m, 5H), 6.17 (t, 1H, J = 5.2 Hz), 6.94-7.06 (m, 2H), 7.35-7.47 (m, 4H), 7.75-7.80 (m, 1H), 8.07 (d, 1H, J = 3.0 Hz).
化合物Ii-128
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.14-1.31 (m, 5H), 1.31-1.55 (m, 1H), 1.70-1.96 (m, 4H), 2.89-3.09 (m, 5H), 6.24 (t, 1H, J = 5.4 Hz), 6.94-7.05 (m, 2H), 7.24 (d, 1H, J = 6.9 Hz), 7.52 (t, 1H, J = 8.0 Hz), 7.75 (d, 1H, J = 8.8 Hz), 7.88-7.97 (m, 2H), 8.07 (d, 1H, J = 2.5 Hz).
化合物Ii-129
1H-NMR (DMSO-d6) δ: 0.98-1.12 (m, 2H), 1.18-1.30 (m, 2H), 1.19 (t, 3H, J = 6.8 Hz), 1.48 (m, 1H), 1.79-1.95 (m, 4H), 2.92-3.09 (m, 3H), 2.97 (q, 2H, J = 6.8 Hz), 6.27 (m, 1H), 7.01 (d, 1H, J = 8.0 Hz), 7.39-7.47 (m, 2H), 7.56 (m, 1H), 8.18-8.25 (m, 2H), 8.23 (s, 2H).
化合物Ii-130
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.45-1.64 (m, 1H), 1.78-1.96 (m, 4H), 2.97 (q, 2H, J = 7.2 Hz), 2.95-3.15 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 6.94-7.02 (m, 2H), 7.38 (t, 1H, J = 6.0 Hz), 7.46 (t, 2H, J = 7.5 Hz), 7.78 (d, 1H, J = 9.0 Hz), 7.96 (d, 2H, J = 9.0 Hz).
化合物Ii-131
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H), 2.98 (q, 2H, J = 7.2 Hz), 2.94-3.10 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.02 (d, 1H, J = 9.0 Hz), 7.10 (t, 1H, J = 5.4 Hz), 7.22 (td, 1H, J = 9.0, 3.0 Hz), 7.47-7.56 (m, 1H), 7.77-7.88 (m, 3H).
化合物Ii-132
1H-NMR (DMSO-d6) δ: 0.96-1.13 (m, 2H), 1.15-1.32 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.48-1.65 (m, 1H), 1.78-1.96 (m, 4H), 2.98 (q, 2H, J = 7.2 Hz), 2.94-3.12 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 6.0 Hz), 7.09 (t, 1H, J = 5.4 Hz), 7.27-7.35 (m, 2H), 7.42-7.50 (m, 1H), 7.57 (dd, 1H, J = 9.0, 3.0 Hz), 7.86 (td, 1H, J = 7.5, 3.0 Hz).
化合物Ii-133
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H), 2.95-3.20 (m, 4H), 4.89-4.98 (m, 2H), 6.65 (brs, 1H), 6.92 (d, 1H, J = 9.0 Hz), 6.91-6.98 (m, 1H), 7.03 (d, 1H, J = 9.0 Hz).
化合物Ii-134
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H), 2.92-3.20 (m, 4H), 6.74 (t, 1H, J = 6.0 Hz), 6.94 (t, 1H, J = 6.0 Hz), 6.97 (s, 1H), 7.08-7.24 (m, 5H).
化合物Ii-135
1H-NMR (DMSO-d6) δ: 0.95-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.48-1.60 (m, 1H), 1.76-1.94 (m, 4H), 2.92-3.10 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.18-3.30 (m, 2H), 6.89 (d, 1H, J = 9.6 Hz), 7.02 (brs, 1H), 7.11 (t, 1H, J = 5.4 Hz), 7.42-7.56 (m, 2H), 7.85 (d, 1H, J = 9.6 Hz), 7.93 (d, 1H, J = 7.5 Hz), 8.03 (s, 1H).
化合物Ii-136
1H-NMR (DMSO-d6) δ: 0.98-1.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H), 2.92-3.12 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.22-3.32 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 7.5 Hz), 7.20 (t, 1H, J = 6.0 Hz), 7.62 (s, 1H), 7.91 (d, 1H, J = 9.0 Hz), 8.02 (s, 2H).
化合物Ii-137
1H-NMR (DMSO-d6) δ: 0.95-1.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.65-1.95 (m, 5H), 2.93-3.12 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.25-3.40 (m, 2H), 5.07-5.16 (m, 2H), 7.01 (d, 1H, J = 7.5 Hz), 7.25 (t, 1H, J = 6.0 Hz), 7.92-8.03 (m, 3H), 8.33 (d, 1H, J = 6.0 Hz).
化合物Ii-138
1H-NMR (DMSO-d6) δ: 0.91-1.26 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.36-1.43 (m, 1H), 1.78-1.90 (m, 4H), 2.90-3.07 (m, 3H), 2.96 (q, 2H, J = 7.5 Hz), 5.69 (t, 1H, J = 5.7 Hz), 5.81 (d, 1H, J = 2.4 Hz), 7.00 (d, 1H, J = 7.8 Hz), 7.16-7.39 (m, 3H), 7.73-7.79 (m, 1H), 7.86-7.88 (m, 1H).
化合物Ii-139
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H), 1.40−1.52 (m, 1H), 1.81 (d, 2H, J = 12.4 Hz), 1.88 (d, 2H, J = 12.4 Hz), 2.90-2.98 (m, 2H), 2.99-3.13 (m, 2H), 5.68 (t, 1H, J = 5.6 Hz), 5.81 (s, 1H), 6.93 (d, 1H, J = 8.8 Hz), 7.16-7.40 (m, 3H), 7.76 (t, 1H, J = 8.0 Hz), 7.87 (s, 1H).
化合物Ii-140
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.40−1.49 (m, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.90-2.99 (m, 2H), 3.01-3.06 (m, 1H), 5.67 (t, 1H, J = 6.0 Hz), 5.81 (s, 1H), 6.74 (d, 1H, J = 8.4 Hz), 7.14-7.40 (m, 3H), 7.76 (t, 1H, J = 8.4 Hz), 7.87 (s, 1H).
化合物Ii-141
1H-NMR (DMSO-d6) δ: 0.97-1.06 (m, 2H), 1.18-1.27 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.45-1.59 (m, 1H), 1.76-1.81 (m, 2H), 1.87-1.91 (m, 2H), 2.97-3.09 (m, 1H), 3.10-3.13 (m, 1H), 3.17-3.22 (m, 2H), 6.94-7.02 (m, 2H), 6.98 (td, 1H, J = 7.8, 1.2 Hz), 7.36 (dd, 1H, J = 7.8, 0.6 Hz), 7.65 (dd, 1H, J = 7.8, 0.6 Hz), 8.00-8.05 (m, 1H).
化合物Ii-142
1H-NMR (DMSO-d6) δ: 0.96-1.04 (m, 2H), 1.18-1.28 (m, 2H), 1.20 (d, 6H, J = 6.9 Hz), 1.43-1.59 (m, 1H), 1.74-1.79 (m, 2H), 1.85-1.90 (m, 2H), 2.92-3.07 (m, 1H), 3.09-3.18 (m, 3H), 6.92-6.99 (m, 2H), 7.10 (td, 1H, J = 7.8, 1.2 Hz), 7.21 (dd, 1H, J = 7.8, 0.6 Hz), 7.31 (dd, 1H, J = 7.8, 0.6 Hz), 7.89-7.97 (m, 1H).
化合物Ii-143
1H-NMR (DMSO-d6)δ: 0.97-1.07 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.42-1.57 (m, 1H), 1.73-1.78 (m, 2H), 1.86-1.90 (m, 2H), 2.93-3.02 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.11 (t, 2H, J = 6.3 Hz), 6.91-7.02 (m, 2H), 7.19 (dd, 1H, J = 8.4, 4.8 Hz), 7.34 (dd, 1H, J = 9.3, 2.4 Hz), 8.00 (t, 1H, J = 6.0 Hz).
化合物Ii-144
1H-NMR (DMSO-d6)δ: 0.97-1.08 (m, 2H), 1.16-1.24 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.42-1.59 (m, 1H), 1.74-1.80 (m, 2H), 1.85-1.90 (m, 2H), 2.92-3.03 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 3.18 (t, 2H, J = 6.3 Hz), 6.99-7.07 (m, 2H), 7.33 (dd, 1H, J = 9.0, 4.8 Hz), 7.58 (dd, 1H, J = 8.7, 2.7 Hz), 8.00 (t, 1H, J = 5.4 Hz).
化合物Ii-145
1H-NMR (DMSO-d6) δ: 0.97-1.09 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.43-1.59 (m, 1H), 1.72-1.81 (m, 2H), 1.85-1.92 (m, 2H), 2.95-3.06 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 3.19 (t, 2H, J = 6.0 Hz), 7.01 (d, 1H, J = 8.1 Hz), 7.20-7.23 (m, 1H), 7.33 (dd, 1H, J = 8.7, 0.6 Hz), 7.58 (dd, 1H, J = 2.1, 0.9 Hz), 8.11-8.18 (m, 1H).
化合物Ii-146
1H-NMR (DMSO-d6) δ: 0.98-1.06 (m, 2H), 1.15-1.21 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.42-1.58 (m, 1H), 1.70-1.81 (m, 2H), 1.82-1.96 (m, 2H), 2.93-3.00 (m, 3H), 3.13-3.19 (m, 2H), 6.98-7.02 (m, 2H), 7.26-7.27 (m, 1H), 7.32-7.35 (m, 1H), 8.18-8.21 (m, 1H).
化合物Ii-147
1H-NMR (DMSO-d6) δ: 0.98-1.04 (m, 2H), 1.16-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.43-1.59 (m, 1H), 1.73-1.78 (m, 2H), 1.86-1.89 (m, 2H), 2.93-3.00 (m, 3H), 3.11-3.15 (m, 2H), 6.72-6.79 (m, 1H), 7.00-7.08 (m, 2H), 7.29-7.34 (m, 1H), 8.13-8.16 (m, 1H).
化合物Ii-148
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.15-1.26 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.45-1.58 (m, 1H), 1.72-1.80 (m, 2H), 1.84-1.92 (m, 2H), 2.96 (q, 2H, J = 7.2 Hz), 2.96-3.05 (m, 1H), 3.09-3.16 (m, 2H), 6.99 (d, 1H, J = 8.0 Hz), 7.13 (dd, 1H, J = 8.0, 2.0 Hz), 7.20 (d, 1H, J = 8.4 Hz), 7.49 (d, 1H, J = 2.0 Hz), 8.11 (t, 1H, J = 6.0 Hz).
化合物Ii-149
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.43-1.59 (m, 1H), 1.74-1.80 (m, 2H), 1.86-1.91 (m, 2H), 2.93-3.01 (m, 3H), 3.17-3.22 (m, 2H), 7.00-7.05 (m, 2H), 7.37-7.39 (m, 1H), 7.65-7.68 (m, 1H), 8.22-8.26 (m, 1H).
化合物Ii-150
1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.29 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.44-1.60 (m, 1H), 1.74-1.80 (m, 2H), 1.86-1.91 (m, 2H), 2.95-3.17 (m, 2H), 3.21-3.27 (m, 2H), 6.95-6.98 (m, 1H), 8.10 (dd, 1H, J = 8.4, 2.7 Hz), 8.19 (dd, 1H, J = 3.0, 1.5 Hz), 8.44-8.47 (m, 1H).
化合物Ii-151
1H-NMR (DMSO-d6) δ: 0.99-1.04 (m, 2H), 1.15-1.23 (m, 2H), 1.21 (d, 6H, J = 6.3 Hz), 1.43-1.59 (m, 1H), 1.73-1.81 (m, 2H), 1.85-1.91 (m, 2H), 2.97-3.18 (m, 2H), 3.21-3.29 (m, 2H), 6.95-6.98 (m, 1H), 8.20-8.23 (m, 2H), 8.58-8.61 (m, 1H).
化合物Ii-152
1H-NMR (DMSO-d6) δ: 0.96-1.04 (m, 2H), 1.15-1.26 (m, 2H), 1.25 (s, 9H), 1.56-1.62 (m, 1H), 1.78-1.83 (m, 2H), 1.87-1.93 (m, 2H), 2.98-3.08 (m, 1H), 3.17 (t, 2H, J = 6.3 Hz), 3.48 (s, 3H), 6.47 (d, 2H, J = 8.7 Hz), 6.89-6.96 (m, 2H), 7.11-7.19 (m, 2H).
化合物Ii-153
1H-NMR (DMSO-d6) δ: 0.95-1.04 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.41 (m, 1H), 1.71-1.94 (m, 4H), 2.80-2.89 (m, 2H), 2.92-3.10 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz), 3.21-3.30 (m, 2H), 6.25-6.35 (m, 2H), 6.39 (dd, 1H, J = 8.4, 2.1 Hz), 7.01 (d, 1H, J = 7.5 Hz), 7.01 (dd, 1H, J = 8.4, 8.4 Hz).
化合物Ii-154
1H-NMR (DMSO-d6) δ: 0.91-1.09 (m, 2H), 1.16-1.28 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.42 (m, 1H), 1.74-1.95 (m, 4H), 2.80-3.16 (m, 9H), 2.97 (q, 2H, J = 7.5 Hz), 6.24-6.36 (m, 2H), 6.30 (dd, 1H, J = 8.4, 2.1 Hz), 7.10 (dd, 1H, J = 8.4, 2.1 Hz), 7.05 (d, 1H, J = 8.4 Hz).
化合物Ii-155
化合物Ii-156
化合物Ii-157
化合物Ii-158
1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.10-1.30 (m, 5H), 1.41 (m, 1H), 1.76-1.94 (m, 4H), 2.74-2.83 (m, 2H), 2.83 (s, 3H), 2.90-3.08 (m, 3H), 2.96 (s, 3H), 5.68 (m, 1H), 6.39 (m, 1H), 6.58 (m, 1H), 6.95 (dd, 1H, J = 8.4, 8.4 Hz), 7.00 (d, 1H, J = 7.8 Hz).
化合物Ii-159
化合物Ii-160
化合物Ii-161
化合物Ii-162
化合物Ii-163
化合物Ii-164
化合物Ii-165
化合物Ii-166
化合物Ii-167
化合物Ii-168
化合物Ii-169
化合物Ii-170
化合物Ii-171
化合物Ii-172
化合物Ii-173
1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz),1.43 (m, 1H), 1.76-1.85 (m, 2H), 1.85-1.93 (m, 2H), 2.76-2.82 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 2.97 (t, 2H, J = 7.2 Hz), 3.00 (m, 1H), 3.64-3.70 (m, 4H), 6.33 (m, 1H), 6.37 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 7.00 (d, 1H, J = 7.8 Hz), 7.28 (d, 1H, J = 8.4 Hz).
化合物Ii-174
化合物Ii-175
化合物Ii-176
化合物Ii-177
化合物Ii-178
化合物Ii-179
化合物Ii-180
化合物Ii-181
化合物Ii-182
化合物Ii-183
化合物Ii-184
化合物Ii-185
化合物Ii-186
化合物Ii-187
化合物Ii-188
化合物Ii-189
化合物Ii-190
化合物Ii-191
化合物Ii-192
化合物Ii-193
化合物Ii-194
化合物Ii-195
化合物Ii-196
化合物Ii-197
化合物Ii-198
化合物Ii-199
化合物Ii-200
化合物Ii-201
化合物Ii-202
化合物Ii-203
化合物Ii-204
化合物Ii-205
化合物Ii-206
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2 H), 1.05-1.15 (m, 6H), 1.25 (s, 9H,), 1.15-1.32 (m, 3H), 1.41 (m, 1H), 1.75-1.98 ( m, 4H), 2.11 (m, 1H), 2.58-3.38 (m, 5H), 3.58-3.76 (m, 2H), 5.17 (m, 1H), 6.25-6.92 (m, 5H) Melting point: 147-149 ℃
Compound Ia-140
1H-NMR (CDClThree) δ: 1.02-1.20 (m, 2 H), 1.17-1.32 (m, 2 H), 1.37 (d, 6H, J = 6.9 Hz), 1.46-1.70 (m, 4H), 1.86-1.95 (m, 2H), 2.08-2.18 (m, 2H), 3.01 (d, 2H, J = 6.9 Hz), 3.13 (m, 1H), 3.25 (m, 1H), 3.87 (d, 1H, J = 8.4 Hz), 6.61 (d, 2H, J = 8.7 Hz), 7.39 (d, 2H, J = 8.7 Hz)
Compound Ia-141
1H-NMR (CDClThree) δ: 1.00-1.30 (m, 4 H), 1.37 (d, 6H, J = 6.9 Hz), 1.59 (m, 1H), 1.87-1.98 (m, 2H), 1.99-2.18 (m, 5H), 2.85 (q, 3H, J = 7.5 Hz), 2.97 (d, 2H, J = 6.9 Hz), 3.12 (m, 1H), 3.23 (m, 1H), 3.88 (d, 1H, J = 8.1 Hz), 6.53 (d, 1H, J = 7.8 Hz), 6.63 (brs, 1H), 7.04 (d, 1H, J = 7.8 Hz) Mass: 351 [M + H]
Compound Ia-178
1H-NMR (CDClThree) δ: 1.08-1.36 (m, 4 H), 1.39 (s, 9H), 1.59 (m, 1H), 1.90-1.99 (m, 2H), 2.16-2.26 (m, 2H), 3.17-3.34 (m , 3H), 3.69 (d, 1H, J = 9.3 Hz), 6.68 (d, 1H, J = 9.3 Hz), 7.77 (dd, 1H, J = 2.1 Hz and 9.3 Hz), 8.49 (brs, 1H) Mass : 394 [M + H]+
Compound Ib-138
1H-NMR (CDClThree) δ: 1.02-1.34 (m, 4 H), 1.37 (d, 6H, J = 6.6 Hz), 1.57 (m, 1H), 1.87-1.97 (m, 2H), 2.07-2.18 (m, 2H), 2.93 (d, 2H, J = 6.6 Hz), 3.13 (m, 1H), 3.25 (m, 1H), 3.99 (d, 1H, J = 8.4 Hz), 6.38 (m, 1H), 6.49 (brs, 1H ), 6.97 (q, 1H, J = 9.3 Hz) Mass: 347 [M + H]
Compound Ii-2
1H-NMR (DMSO-d6) δ: 0.91-1.06 (m, 2H), 1.12-1.28 (m, 11H), 1.31-1.47 (m, 1H), 1.75-1.94 (m, 4H), 2.19 (t, 2H, J = 11.3 Hz) , 2.79 (t, 2H, J = 6.0 Hz), 2.93-3.08 (m, 1H), 2.97 (q, 2H, J = 7.42 Hz), 3.46 (m, 2H), 3.57-3.69 (m, 2H), 5.71 (t, 1H, J = 5.2 Hz), 5.77 (d, 1H, J = 11.5 Hz), 5.88-5.96 (m, 2H), 7.01 (d, 1H, J = 7.4 Hz).
Compound Ii-3
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2 H), 1.15-1.21 (m, 1H), 1.27 (s, 9H), 1.40-1.49 (m, 2H), 1.82 (d, 2H, J = 11.6 Hz), 1.92 (d, 2H, J = 11.6 Hz), 2.79-2.84 (m, 2H), 2.97-3.10 (m, 1H), 3.24 (s, 3H), 3.55-3.62 (m, 2H), 3.84-3.91 ( m, 2H), 5.50-5.59 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.4 Hz), 6.97 (d, 1H , J = 8.4 Hz). Melting point: 166-168 ° C
Compound Ii-4
1H-NMR (DMSO-d6) δ: 0.87 (t, 3H, J = 7.2 Hz), 0.93-1.06 (m, 2H), 1.13-1.21 (m, 1H), 1.26 (s, 9H), 1.37-1.49 (m, 2H), 1.61 -1.72 (m, 2H), 1.82 (d, 2H, J = 12.0 Hz), 1.91 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.61-3.71 (m, 2H), 5.52-5.60 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.73 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz). Melting point: 185-186 ° C
Compound Ii-5
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2H), 1.26 (s, 9H), 1.28-1.31 (m, 1H), 1.35-1.47 (m, 8H), 1.81 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.77-2.84 (m, 2H), 2.96-3.07 (m, 1H), 4.30-4.42 (m, 1H), 5.51-5.64 (m, 1H), 6.39 (d , 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz), 7.07 (d, 1H, J = 8.8 Hz). Melting point: 156-157 ° C
Compound Ii-6
1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.19-1.25 (m, 4H), 1.26 (s, 9H), 1.38-1.49 (m, 2H), 1.82 (d, 2H, J = 8.8 Hz), 1.91 (d, 2H, J = 8.8 Hz), 2.79-2.84 (m, 2H), 2.97-3.07 (m, 1H), 3.69-3.80 (m, 2H), 5.51-5.63 (m, 1H), 6.41 (d , 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 8.8 Hz). Melting point: 178-179 ° C
Compound Ii-7
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.19-1.22 (m, 1H), 1.26 (s, 9H), 1.38-1.48 (m, 2H), 1.82 (d, 2H, J = 11.6 Hz), 1.91 (d, 2H, J = 11.6 Hz), 2.79-2.84 (m, 2H), 2.95-3.09 (m, 1H), 3.25 (s, 3H), 5.52-5.60 (m, 1H), 6.41 (d, 1H , J = 8.4 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J = 8.4 Hz), 6.92 (d, 1H, J = 8.4 Hz). Melting point: 206-207 ° C
Compound Ii-8
1H-NMR (DMSO-d6) δ: 0.91-1.05 (m, 2H), 1.16-1.24 (m, 1H), 1.26 (s, 9H), 1.37-1.47 (m, 2H), 1.81 (d, 2H, J = 12.8 Hz), 1.90 (d, 2H, J = 12.8 Hz), 2.75-2.81 (m, 2H), 2.96-3.08 (m, 1H), 5.45-5.52 (m, 1H), 6.33 (d, 1H, J = 8.4 Hz), 6.50 (s, 1H), 6.68-6.80 (m, 2H), 11.02 (brs, 1H). Melting point: 213-214 ° C
Compound Ii-9
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2 H), 1.17-1.30 (m, 8H), 1.44 (brs, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.89 (d, 2H, J = 12.4 Hz), 2.78-2.82 (m, 2H), 2.97-3.15 (m, 2H), 3.23 (s, 3H), 3.55-3.62 (m, 2H), 3.83-3.90 (m, 2H), 5.52-5.59 ( m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.55 (s, 1H), 6.92 (d, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.4 Hz). Melting points: 120-121 ℃
Compound Ii-10
1H-NMR (DMSO-d6) δ: 0.88 (t, 3H, J = 7.2 Hz), 0.93-1.08 (m, 2H), 1.17-1.30 (m, 8H), 1.44 (brs, 1H), 1.52-1.61 (m, 2H), 1.83 (d, 2H, J = 12.0 Hz), 1.90 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.98-3.15 (m, 2H), 3.62-3.71 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 6.92 (d, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 8.4 Hz) ). Melting point: 144-145 ℃
Compound Ii-11
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.15-1.30 (m, 8H), 1.33-1.50 (m, 7H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.86 (m, 2H), 2.96-3.14 (m, 2H), 4.30-4.45 (m, 1H), 5.50-5.61 (m, 1H), 6.40 (d, 1H, J = 7.6 Hz ), 6.55 (s, 1H), 6.92 (d, 1H, J = 7.2 Hz), 7.07 (d, 1H, J = 7.6 Hz). Melting point: 137-138 ° C
Compound Ii-12
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.14-1.30 (m, 11H), 1.36-1.50 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.85 (m, 2H), 2.97-3.15 (m, 2H), 3.69-3.79 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz ), 6.56 (s, 1H), 6.92 (d, 1H, J = 7.2 Hz), 6.98 (d, 1H, J = 8.4 Hz). Melting point: 158-159 ° C
Compound Ii-13
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.12-1.30 (m, 8H), 1.34-1.51 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.77-2.83 (m, 2H), 2.95-3.12 (m, 2H), 3.25 (s, 3H), 5.51-5.59 (m, 1H), 6.41 (d, 1H, J = 8.8 Hz), 6.56 (s, 1H), 6.86-6.97 (m, 2H). Melting point: 157-158 ° C
Compound Ii-14
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2 H), 1.12-1.30 (m, 5H), 1.38-1.50 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.23 (s, 3H), 3.55-3.61 (m, 2H), 3.84-3.91 (m, 2H), 5.52- 5.60 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.55 (s, 1H), 6.89-7.00 (m, 2H). Melting point: 150-151 ° C
Compound Ii-15
1H-NMR (DMSO-d6) δ: 0.88 (s, 3H), 0.90 (s, 3H), 0.92-1.08 (m, 2H), 1.12-1.30 (m, 5H), 1.35-1.51 (m, 1H), 1.83 (d, 2H, J = 12.4 Hz), 1.89 (d, 2H, J = 12.4 Hz), 2.00-2.16 (m, 1H), 2.77-2.84 (m, 2H), 2.90-3.10 (m, 3H), 3.42-3.55 (m , 2H), 5.50-5.65 (m, 1H), 6.40 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 6.88-7.01 (m, 2H) Melting point: 132-133 ° C
Compound Ii-16
1H-NMR (DMSO-d6) δ: 0.87 (t, 3H, J = 6.8 Hz), 0.90-1.08 (m, 2H), 1.10-1.28 (m, 5H), 1.35-1.50 (m, 1H), 1.59-1.72 (m, 2H) , 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.61-3.71 (m, 2H ), 5.52-5.61 (m, 1H), 6.40 (d, 1H, J = 8.0 Hz), 6.56 (s, 1H), 6.97 (d, 2H, J = 8.0 Hz). Melting point: 136-137 ° C
Compound Ii-17
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.12-1.28 (m, 5H), 1.33-1.50 (m, 7H), 1.81 (d, 2H, J = 12.0 Hz), 1.88 (d, 2H, J = 12.0 Hz), 2.78-2.84 (m, 2H), 2.90-3.08 (m, 3H), 4.28-4.44 (m, 1H), 5.49-5.79 (m, 1H), 6.39 (d, 1H, J = 8.0 Hz ), 6.55 (s, 1H), 6.97 (d, 1H, J = 7.6 Hz), 7.07 (d, 1H, J = 8.0 Hz). Melting point: 124-125 ° C
Compound Ii-18
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.12-1.29 (m, 8H), 1.36-1.51 (m, 1H), 1.82 (d, 2H, J = 12.0 Hz), 1.89 (d, 2H, J = 12.0 Hz), 2.78-2.86 (m, 2H), 2.90-3.09 (m, 3H), 3.68-3.80 (m, 2H), 5.51-5.61 (m, 1H), 6.41 (d, 1H, J = 8.4 Hz ), 6.57 (s, 1H), 6.97 (d, 2H, J = 8.4 Hz). Melting point: 163-164 ° C
Compound Ii-19
1H-NMR (DMSO-d6) δ: 0.89-1.08 (m, 2H), 1.11-1.30 (m, 5H), 1.35-1.51 (m, 1H), 1.82 (d, 2H, J = 10.8 Hz), 1.89 (d, 2H, J = 10.8 Hz), 2.75-2.88 (m, 2H), 2.89-3.10 (m, 3H), 3.25 (s, 3H), 5.48-5.60 (m, 1H), 6.42 (d, 1H, J = 7.6 Hz), 6.56 (s, 1H), 6.92 (d, 1H, J = 7.6 Hz), 6.98 (d, 1H, J = 5.6 Hz). Melting point: 189-190 ° C
Compound Ii-20
1H-NMR (DMSO-d6) δ: 0.95-1.13 (m, 2H), 1.31-1.59 (m, 10H), 1.73-1.92 (m, 4H), 2.12-2.26 (m, 2H), 2.84 (d, 2H, J = 6.0 Hz) , 3.07-3.30 (m, 4H), 4.30-4.46 (m, 1H), 5.64 (brs, 1H), 6.41 (d, 1H, J = 8.4 Hz), 6.57 (s, 1H), 7.08 (d, 1H , J = 8.4 Hz). Melting point: 165-166 ° C
Compound Ii-21
1H-NMR (DMSO-d6) δ: 0.86-1.25 (m, 10H), 1.40 (d, 3H, J = 6.9Hz), 1.52 (m, 1H), 1.82-1.93 (m, 4H), 2.95-3.00 (m, 5H), 3.63 -3.91 (m, 2H), 4.61-4.68 (m, 1H), 6.73 (brs, 2H), 7.01 (d, 2H, J = 7.8Hz), 7.11 (d, 1H, J = 8.1Hz,).
Compound Ii-22
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2 H), 1.15-1.34 (m, 5H), 1.36-1.43 (m, 9H), 1.53 (m, 1H), 1.82.1-93 (m, 4H), 2.94 -3.01 (m, 6H), 4.52 (m, 1H), 4.63 (m, 1H), 6.73 (brs, 2H), 7.02 (d, 1H, J = 7.5Hz), 7.21-7.25 (m, 1H).
Compound Ii-23
1H-NMR (DMSO-d6) δ: 0.86-1.04 (m, 4 H), 1.25 (s, 10H), 1.30 (s, 6H), 1.38 (s, 3H), 1.40 (s, 3H), 178-1.92 (m 4H), 2.76 -2.80 (m, 2H), 3.03 (m, 1H), 4.54-4.63 (m, 1H), 5.57 (m, 1H), 6.16 (s, 1H), 6.22 (d, 1H, J = 8.4Hz), 6.76 (d, 1H, J = 8.4Hz), 6.98 (d, 1H, J = 8.4Hz).
Compound Ii-24
1H-NMR (DMSO-d6) δ: 0.98-1.11 (m, 5 H), 1.15-1.31 (m, 20H), 1.57 (m, 1H), 1.82.1-93 (m, 4H), 2.74-2.81 (m, 1H), 3.01 -3.06 (m, 2H), 3.35 (m, 1H), 3.40 (m, 1H), 4.04-4.17 (m, 3H), 6.77 (d, 1H, J = 9.0Hz),
Compound Ii-25
1H-NMR (DMSO-d6) δ: 0.98-1.20 (m, 13 H), 1.30 (d, 3H, J = 3H), 1.59 (m, 1H), 1.81-1.91 (m, 4H), 2.73-2.83 (m, 1H), 2.94 -3.04 (m, 4H), 3.35-3.45 (m, 2H), 4.08-4.19 (m, 3H), 6.88 (brs, 3H), 7.03 (d, 1H, J = 8.4Hz).
Compound Ii-26
1H-NMR (DMSO-d6) δ: 1.02-1.10 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H), 1.55 (m, 1H), 1.86-1.93 (m, 4H), 3.01-3.04 (m, 3H), 6.76 (d, 1H, J = 8.7 Hz), 7.03 (m, 1H), 7.37-7.43 (m, 3H), 7.76-7.80 (m, 1H), 8.20-8.23 (m, 1H), 8.34 -8.40 (m, 1H), 8.78-8.79 (m, 1H)
Compound Ii-27
1H-NMR (DMSO-d6) δ: 1.03-1.10 (m, 2H), 1.20-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.53 (m, 1H), 1.88 (m, 4H), 2.99-3.15 (m, 3H), 7.33-7.35 (m, 3H), 7.71-7.75 (m, 1H), 8.16-8.18 (m, 1H), 829-8.32 (m, 1H), 8.76-8.78 (m, 1H)
Compound Ii-28
1H-NMR (DMSO-d6) δ: 1.04-1.11 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.59 (m, 1H), 1.87-1.91 (m, 4H), 2.93 -3.08 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.06-3.08 (m, 2H), 7.01 (m, 1H), 7.17 (d, 1H, J = 7.5 Hz), 7.43 ( d, 1H, J = 7.5Hz), 7.50-7.57 (m, 2H), 7.80-7.84 (m, 1H), 8.25-8.27 (m, 1H), 8.39-8.44 (m, 1H), 8.80-8.82 ( m, 1H)
Compound Ii-29
1H-NMR (DMSO-d6) δ: 0.99-1.10 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.52 (m, 1H), 1.84-1.91 (m, 4H), 2.94 -3.01 (m, 5H), 6.88 (m, 1H), 7.00 (d, 1H, J = 7.8 Hz), 7.26-7.28 (m, 2H), 7.38 (m, 1H), 7.76 (d, 1H, J = 3.3.Hz), 7.90 (d, 1H, J = 3.3 Hz)
Compound Ii-30
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2 H), 1.18-1.33 (m, 2H), 1.26 (s, 9H), 1.45 (m, 1H), 1.78-1.97 (m, 4 H), 2.86-2.94 ( m, 2H), 2.95-3.10 (m, 1H), 5.91 (m, 1H), 6.55 (d, 1H, J = 7.6 Hz), 6.63-6.71 (m, 2H), 6.73 (d, 1H, J = 8.0 Hz), 7.06 (s, 1H), 7.15 (t, 1H, J = 8.0 Hz), 7.60 (s, 1H), 8.11 (s, 1H), 8.31 (s, 1H)
Compound Ii-31
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2 H), 1.13-1.28 (m, 2H), 1.26 (s, 9H), 1.43 (m, 1H), 1.76-1.97 (m, 4 H), 2.83-3.18 ( m, 3H), 5.79 (m, 1H), 6.21 (s, 2H), 6.44 (d, 1H, J = 6.8 Hz), 6.58-6.67 (m, 2H), 6.73 (d, 1H, J = 8.0 Hz ), 7.10 (t, 1H, J = 8.0 Hz), 7.21 (s, 2H) Melting point: 205-206 ° C
Compound Ii-32
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2 H), 1.05-1.28 (m, 11H), 1.41 (m, 1H), 1.75-1.92 (m, 4 H), 2.11 (t, 2H, J = 10.0 Hz) , 2.73-2.82 (m, 2H), 2.91-3.08 (m, 3H), 3.24 (d, 2H, J = 11.2 Hz), 3.62-3.72 (m, 2H), 5.07 (m, 1H), 6.47 (d , 2H, J = 7.2 Hz), 6.72 (d, 2H, J = 7.2 Hz), 6.97 (d, 1H, J = 7.6 Hz) Melting point: 165-166 ° C
Compound Ii-33
1H-NMR (DMSO-d6) δ: 0.91-1.06 (m, 2H), 1.15-1.26 (m, 8H), 1.33-1.48 (m, 1H), 1.71-1.93 (m, 4H), 2.88 (d, 2H, J = 6.5 Hz) , 2.93-3.15 (m, 2H), 5.70 (brs, 2H), 6.63 (d, 2H, J = 9.1 Hz), 6.93-6.96 (m, 1H), 7.38-7.42 (m, 2H), 7.57 (d , 2H, J = 9.1 Hz), 7.88-7.93 (m, 2H)
Compound Ii-34
1H-NMR (DMSO-d6) δ: 0.98-1.02 (m, 2H), 1.16-1.18 (m, 5H), 1.42 (s, 1H), 1.75-1.91 (m, 4H), 2.88 (d, 2H, J = 6.6 Hz), 2.96 (q, 3H, J = 7.3 Hz), 6.63 (d, 2H, J = 8.9 Hz), 6.99-7.02 (m, 1H), 7.38-7.41 (m, 2H), 7.57 (d, 2H, J = 8.9 Hz), 7.89-7.92 (m, 2H).
Compound Ii-35
1H-NMR (DMSO-d6) δ: 0.90-1.52 (m, 5H), 1.19 (t, 3H, J = 7.2 Hz), 1.75-1.96 (m, 4H), 2.50-3.10 (m, 3H), 2.62 (q, 2H, J = 7.2 Hz), 5.55-5.70 (m, 1H), 6.57 (d, 2H, J = 8.7 Hz), 6.80-7.04 (m, 4H), 7.01 (d, 1H, J = 7.8 Hz), 7.34 (d, (2H, J = 8.7 Hz)
Compound Ii-36
1H-NMR (DMSO-d6) δ: 0.90-1.50 (m, 5H), 1.19 (t, 3H, J = 7.2 Hz), 1.75-1.95 (m, 4H), 2.70-3.10 (m, 3H), 2.97 (q, 2H, J = 7.2 Hz), 3.70 (s, 3H), 5.40-5.50 (m, 1H), 6.53 (d, 2H, J = 8.7 Hz), 6.74 (d, 2H, J = 8.7 Hz), 6.78-6.90 (m, 4H), 6.99 (d, 1H, J = 7.8 Hz)
Compound Ii-37
1H-NMR (CDClThree) δ: 1.02-1.32 (m, 4 H), 139 (s, 9H,), 1.58 (m, 1H), 1.86-1.96 (m, 2H), 2.12-2.22 (m, 2H), 3.02 (d, 2H, J = 6.6 Hz), 3.25 (m, 1H), 3.67 (d, 1H, J = 9.3 Hz), 6.67 (d, 2H, J = 8.7 Hz), 7.41 (d, 2H, J = 8.7 Hz) Mass: 393 [M + H]
Compound Ii-38
1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.17-1.26 (m, 2H), 1.19 (t, 3H, J = 7.1 Hz), 1.43 (s, 1H), 1.77-1.85 (m, 2H), 1.85 -1.94 (m, 2H), 2.82 (t, 1H, J = 5.8 Hz), 2.98 (m, 1H), 2.97 (q, 2H, J = 7.1 Hz), 5.87 (m, 1H), 6.56 (d, 2H, J = 8.6 Hz), 6.98 (d, 1H, J = 7.6 Hz), 7.02 (d, 2H, J = 8.6 Hz).
Compound Ii-39
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.19-1.35 (m, 2H), 1.29 (s, 9H), 1.46 (s, 1H), 1.73-1.98 (m, 4H), 2.93 (m, 1H) , 3.04 (m, 1H), 6.60-6.69 (m, 2H), 6.75 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 7.6 Hz), 7.49 (d, 1H, J = 8.8 Hz), 8.05 (s, 1H).
Compound Ii-40
1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.16-1.29 (m, 2H), 1.19 (t, 3H, J = 7.3 Hz), 1.45 (s, 1H), 1.76-1.94 (m, 4H), 1.76 (s, 2H), 2.93 (t, 2H, J = 5.8 Hz), 2.97 (q, 2H, J = 7.3 Hz), 6.66 (s, 1H), 6.94-7.01 (m, 2H), 7.49 (d, 1H, J = 8.6 Hz), 8.04 (s, 1H).
Compound Ii-41
1H-NMR (DMSO-d6) δ: 0.91-1.05 (m, 2H), 1.17-1.33 (m, 2H), 1.26 (s, 9H), 1.35-1.48 (m, 1H), 1.76-1.86 (m, 2H), 1.86-1.95 ( m, 2H), 2.76-2.82 (m, 1H), 2.96-3.08 (m, 1H), 3.71 (s, 3H), 5.21-5.30 (m, 1H), 6.57 (d, 1H, J = 8.6 Hz) , 6.73 (d, 1H, J = 8.6 Hz), 7.02 (dd, 1H, J = 8.6, 2.3 Hz), 7.44 (d, 1H, J = 2.3 Hz).
Compound Ii-42
1H-NMR (DMSO-d6) δ: 0.98-1.01 (m, 2H), 1.18-1.28 (m, 2H), 1.19 (t, 3H, J = 7.1 Hz), 1.42 (s, 1H), 1.76-1.85 (m, 2H), 1.85 -1.93 (m, 2H), 2.79 (t, 2H, J = 5.9 Hz), 2.97 (q, 2H, J = 7.1 Hz), 3.02 (m, 1H), 3.71 (s, 3H), 5.26 (m, 1H), 6.58 (d, 1H, J = 8.6 Hz), 6.98 (d, 2H, J = 7.8 Hz), 7.02 (d, 2H, J = 8.6 Hz), 7.44 (br s, 1H).
Compound Ii-43
1H-NMR (DMSO-d6) δ: 0.98-1.06 (m, 2H), 1.16-1.25 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.51 (m, 1H), 1.83-1.91 (m, 4H), 2.85 (t, 2H, J = 6.3 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.04 (m, 1H), 3.56 (s, 3H), 5.46 (t, 1H, J = 6.3 Hz), 5.76 (s, 1H), 6.49 (d, 1H, J = 7.8 Hz), 7.21 (t, 1H, J = 7.5 Hz), 7.32 (t, 2H, J = 7.5 Hz), 7.68 (d, 2H, J = 7.5 Hz)
Compound Ii-44
1H-NMR (DMSO-d6) δ: 0.96-1.05 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.24 (m, 2H), 1.48 (m, 1H), 1.76-1.91 (m, 4H), 2.91 (d , 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.2 Hz), 6.35 (s, 1H), 6.99 (d, 1H, J = 7.8 Hz), 7.46-7.49 (m, 3H), 7.73 -7.76 (m, 2H)
Compound Ii-45
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.22 (m, 1H), 1.26 (s, 9H), 1.37-1.51 (m, 2H), 1.81 (d, 2H, J = 11.6 Hz), 1.91 (d, 2H, J = 11.6 Hz), 2.76-2.86 (m, 2H), 2.97-3.08 (m, 1H), 3.35 (s, 3H), 5.82-5.91 (m, 1H), 6.26 (d, 1H , J = 13.6 Hz), 6.39 (s, 1H), 6.73 (brs, 1H). Melting point: 215-216 ° C
Compound Ii-46
1H-NMR (CDClThree) δ: 1.02-1.32 (m, 4H), 1.24 (d, 6H, J = 6.0 Hz), 1.39 (s, 9H), 1.54 (m, 1H), 1.84-1.94 (m, 2H), 2.12-2.22 (m, 2H), 2.39 (t, 2H, J = 10.5 Hz), 2.94 (d, 2H, J = 6.9 Hz), 3.24 (m, 1H), 3.38 (d, 1H, J = 9.6 Hz), 3.61 (d, 1H, J = 9.6 Hz), 3.72-4.00 (m, 2H), 5.83-5.94 (m, 1H), 5.96-6.10 (m, 2H).
Compound Ii-47
1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.16-1.34 (m, 11H), 1.40 (m, 1H), 1.79 (d, 2H, J = 12.5 Hz), 1.90 (d, 2H, J = 11.9 Hz) ), 2.82 (t, 2H, J = 5.5 Hz), 3.01 (m, 1H), 6.12-6.18 (m, 3H), 6.30 (t, 1H, J = 5.5 Hz), 6.76 (d, 1H, J = 8.7 Hz).
Compound Ii-48
1H-NMR (CDClThree) δ: 1.00-1.28 (m, 4H), 1.39 (s, 9H), 1.56 (m, 1H), 1.91 (d, 2H, J = 12.4 Hz), 2.08-2.21 (m, 4H), 2.58 (t , 2H, J = 8.1 Hz), 2.97 (d, 2H, J = 6.0 Hz), 3.23 (m, 1H), 3.70 (d, 1H, J = 9.4 Hz), 3.80 (t, 2H, J = 7.1 Hz ), 6.66 (d, 2H, J = 8.7 Hz), 7.36 (d, 2H, J = 8.7 Hz).
Compound Ii-49
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.17-1.33 (m, 11H), 1.41 (m, 1H), 1.80 (d, 2H, J = 12.9 Hz), 1.90 (d, 2H, J = 11.4 Hz) ), 2.82 (t, 2H, J = 6.1 Hz), 3.01 (m, 1H), 6.07 (t, 1H, J = 5.3 Hz), 6.34-6.43 (m, 2H), 6.51 (dd, 1H, J1 = 8.2 Hz, J2 = 1.8 Hz), 6.75 (d, 1H, J = 8.5 Hz), 7.11 (t, 1H, 8.2 Hz).
Compound Ii-50
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.14-1.31 (m, 8H), 1.43 (m, 1H), 1.76-1.94 (m, 4H), 2.82 (t, 2H, J = 6.0 Hz), 2.95 -3.16 (m, 2H), 5.90 (t, 1H, J = 5.5 Hz), 6.56 (d, 2H, J = 8.7 Hz), 6.95 (d, 1H, J = 7.9 Hz), 7.03 (d, 2H, J = 8.6 Hz).
Compound Ii-51
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.13-1.31 (m, 8H), 1.42 (m, 1H), 1.76-1.94 (m, 4H), 2.83 (t, 2H, J = 6.0 Hz), 2.95 -3.16 (m, 2H), 6.07 (t, 1H, J = 5.4 Hz), 6.36-6.46 (m, 2H), 6.53 (dd, 1H, J1 = 8.1 Hz, J2 = 1.9 Hz), 6.95 (d, 1H, J = 7.9 Hz), 7.12 (d, 1H, J = 8.1 Hz).
Compound Ii-52
1H-NMR (DMSO-d6) δ: 0.91-1.10 (m, 2H), 1.19-1.37 (m, 11H), 1.45 (m, 1H), 1.78-1.90 (m, 4H), 2.84 (t, 2H, J = 6.0 Hz), 3.04 (m, 1H), 4.64 (q, 2H, J = 9.0 Hz), 5.73 (t, 1H, J = 5.4 Hz), 6.13-6.21 (m, 2H), 6.26 (d, 1H, J = 7.2 Hz) , 6.78 (d, 1H, J = 8.4 Hz), 6.99 (t, 1H, 8.0 Hz).
Compound Ii-53
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.13-1.30 (m, 8H), 1.42 (m, 1H), 1.75-1.93 (m, 4H), 2.80 (t, 2H, J = 6.2 Hz), 2.93 -3.16 (m, 2H), 5.66 (t, 1H, J = 5.5 Hz), 6.53 (d, 2H, J = 9.1 Hz), 6.89 (d, 2H, J = 8.8 Hz), 6.92 (t, 1H, JHF = 75 Hz), 6.94 (d, 1H, J = 8.0 Hz).
Compound Ii-54
1H-NMR (DMSO-d6) δ: 0.88-1.05 (m, 2H), 1.14-1.32 (m, 11H), 1.41 (m, 1H), 1.75-1.94 (m, 4H), 2.77 (t, 2H, J = 6.0 Hz), 3.01 (m, 1H), 4.54 (q, 2H, J = 9.0 Hz), 5.33 (t, 1H, J = 5.8 Hz), 6.49 (d, 2H, J = 8.8 Hz), 6.75 (d, 1H, J = 8.8 Hz), 6.80 (d, 2H, J = 8.8 Hz).
Compound Ii-55
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.14-1.31 (m, 8H), 1.40 (m, 1H), 1.74-1.93 (m, 4H), 2.79 (t, 2H, J = 5.9 Hz), 2.94 -3.15 (m, 6H), 3.69 (t, 4H, J = 4.8 Hz), 5.70-5.94 (m, 4H), 6.94 (d, 1H, J = 8.0 Hz).
Compound Ii-56
1H-NMR (DMSO-d6) δ: 0.98-1.14 (m, 2H), 1.15-1.32 (m, 5H), 1.54 (m, 1H), 1.83-1.96 (m, 4H), 2.89-3.10 (m, 5H), 6.17 (t, 1H, J = 5.2 Hz), 6.63 (d, 1H, J = 2.2 Hz), 7.02 (d, 1H, J = 7.7 Hz), 7.21 (dd, 1H, J1 = 9.1 Hz, J2 = 2.5 Hz), 7.27 (dd, 1H, J1 = 8.2 Hz, J2 = 4.4 Hz), 7.67 (d, 1H, J = 9.1 Hz), 7.97 (d, 1H, J = 8.2 Hz), 8.45 (dd, 1H, J1 = 4.3 Hz , J2 = 1.5 Hz).
Compound Ii-57
1H-NMR (DMSO-d6) δ: 0.97-1.14 (m, 2H), 1.17-1.34 (m, 8H), 1.54 (m, 1H), 1.83-1.96 (m, 4H), 2.94 (t, 2H, J = 6.0 Hz), 2.99 -3.18 (m, 2H), 6.17 (t, 1H, J = 5.4 Hz), 6.63 (d, 1H, J = 2.5 Hz), 6.96 (d, 1H, J = 7.7 Hz), 7.21 (dd, 1H, J1 = 9.1 Hz, J2 = 2.5 Hz), 7.27 (dd, 1H, J1 = 8.2 Hz, J2 = 4.1 Hz), 7.67 (d, 1H, J = 9.1 Hz), 7.97 (d, 1H, J = 8.0 Hz ), 8.45 (dd, 1H, J1 = 4.3 Hz, J2 = 1.5 Hz).
Compound Ii-58
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.12-1.29 (m, 5H), 1.40 (m, 1H), 1.74-1.93 (m, 4H), 2.80 (t, 2H, J = 5.9 Hz), 2.92 -3.07 (m, 7H), 3.69 (t, 4H, J = 4.8 Hz), 5.69-5.95 (m, 4H), 6.99 (d, 1H, J = 7.7 Hz).
Compound Ii-59
1H-NMR (DMSO-d6) δ: 0.94-1.11 (m, 2H), 1.14-1.30 (m, 5H), 1.47 (m, 1H), 1.78-1.95 (m, 4H), 2.88-3.09 (m, 5H), 3.80 (s, 3H), 6.09 (t, 1H, J = 5.6 Hz), 6.81-6.86 (m, 1H), 6.96 (dd, 1H, J1 = 8.8 Hz, J2 = 2.8 Hz), 7.01 (d, 1H, J = 7.4 Hz), 7.29 (t, 1H, J = 8.0 Hz), 7.45-7.51 (m, 2H), 7.66 (d, 1H, J = 8.5 Hz), 8.04 (d, 1H, J = 2.8 Hz).
Compound Ii-60
1H-NMR (DMSO-d6) δ: 1.03 (m, 2H), 1.19 (t, 2H, J = 7.8 Hz), 1.21 (m, 2H), 1.46 (m, 1H), 1.76-1.95 (m, 4H), 2.90 (t, 2H , J = 5.8 Hz), 2.97 (q, 2H, J = 7.3 Hz), 3.03 (m, 1H), 3.80 (s, 3H), 5.95 (m, 1H), 6.90 (m, 1H), 6.98 (d , 1H, J = 7.8 Hz), 6.98 (dd, 1H, J = 7.8, 7.8 Hz), 7.06 (d, 1H, J = 8.6 Hz), 7.26 (dd, 1H, J = 7.8, 7.8 Hz), 7.61 (d, 1H, J = 8.6 Hz), 7.69 (d, 1H, J = 7.8 Hz), 8.03 (s, 1H).
Compound Ii-61
1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.18-1.29 (m, 2H), 1.19 (t, 3H, J = 7.6 Hz), 1.47 (m, 1H), 1.87 (m, 5H), 2.90 (t , 2H, J = 6.3 Hz), 2.97 (q, 2H, J = 7.6 Hz), 3.02 (m, 1H), 5.98 (m, 1H), 6.63 (d, 2H, J = 8.3 Hz), 6.98 (d , 1H, J = 7.3 Hz), 7.14 (m, 1H), 7.73 (s, 2H), 7.83 (d, 2H, J = 8.3 Hz), 8.52 (d, 1H, J = 4.0 Hz).
Compound Ii-62
1H-NMR (DMSO-d6) δ: 0.98-1.01 (m, 2H), 1.20 (s, 9H), 1.20-1.37 (m, 2H), 1.42 (m, 1H), 1.76-1.96 (m, 4H), 2.28-2.37 (m, 2H), 2.75-2.85 (m, 2H), 3.02 (m, 1H), 3.36 (t, 2H, J = 7.8 Hz), 3.57 (t, 2H, J = 6.3 Hz), 5.66 (m, 1H), 6.54 (d, 2H, J = 8.0 Hz), 6.73 (d, 1H, J = 8.6 Hz), 7.00 (d, 1H, J = 8.0 Hz).
Compound Ii-63
1H-NMR (DMSO-d6) δ: 0.96-1.14 (m, 2H), 1.14-1.32 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.50 (m, 1H), 1.76-1.96 (m, 4H), 2.91 -3.10 (m, 3H), 2.97 (q, 2H, J = 7.2 Hz), 6.28 (m, 1H), 7.02 (d, 1H, J = 7.8 Hz), 7.32-7.46 (m, 3H), 8.20 ( d, 1H, J = 6.9 Hz), 8.22 (s, 2H).
Compound Ii-64
1H-NMR (DMSO-d6) δ: 1.03-1.15 (m, 2H), 1.18-1.29 (m, 2H), 1.24 (d, 6H, J = 6.3 Hz), 1.52 (m, 1H), 1.86-1.94 (m, 2H), 2.10 -2.19 (m, 2H), 2.40 (t, 2H, J = 6.0 Hz), 2.95 (d, 2H, J = 6.0 Hz), 3.23 (m, 1H), 3.40 (d, 2H, J = 11.4 Hz) , 3.75-3.85 (m, 2H), 3.86 (d, 1H, J = 9.3 Hz), 6.14 (d, 1H, J = 8.5 Hz), 6.15 (s, 1H), 6.29 (d, 1H, J = 8.5 Hz), 7.06 (d, 1H, J = 8.5 Hz).
Compound Ii-65
1H-NMR (CDClThree) δ: 1.08-1.16 (m, 2H), 1.14 (d, 6H, J = 6.8 Hz), 1.21-1.30 (m, 2H), 1.29 (s, 9H), 1.78 (t, 2H, J = 10.6 Hz ), 1.83-1.92 (m, 2H), 2.11-2.19 (m, 2H), 2.78 (d, 2H, J = 10.6 Hz), 3.06 (s, 2H), 3.23 (m, 1H), 3.38 (s, 2H), 3.70-3.80 (m, 2H), 4.02 (d, 1H, J = 9.9 Hz), 5.37 (s, 1H), 6.30 (s, 1H).
Compound Ii-66
1H-NMR (DMSO-d6) δ: 1.01-1.12 (m, 2H), 1.20-1.34 (m, 2H), 1.27 (s, 9H), 1.54 (m, 1H), 1.82-1.99 (m, 4H), 2.91-2.98 (m, 2H), 3.06 (m, 1H), 6.17 (s, 1H), 6.63 (s, 1H), 6.78 (d, 1H, J = 9.0 Hz), 7.20 (m, 1H), 7.27 (m, 1H), 7.77 (d, 1H, J = 9.0 Hz), 7.98 (d, 1H, J = 9.0 Hz), 8.54 (s, 1H).
Compound Ii-67
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 1.88-1.96 (m, 2H), 2.78-2.86 (m, 2H), 3.02 (m, 1H), 5.89 (s, 1H), 6.56 (d, 1H, J = 8.4 Hz), 6.76 (d, 1H, J = 8.4 Hz), 7.02 (d, 1H, J = 8.4 Hz).
Compound Ii-68
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.19 (s, 9H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.42 (m, 1H), 1.80-1.96 (m, 4H) , 2.77 (s, 2H), 3.04 (m, 1H), 5.29 (s, 1H), 6.44 (d, 1H, J = 7.2 Hz), 6.68 (d, 1H, J = 7.2 Hz), 6.75 (d, 1H, J = 8.4 Hz).
Compound Ii-69
1H-NMR (DMSO-d6) δ: 0.95-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.47 (m, 1H), 1.80-1.88 (m, 2H), 1.88-1.95 (m, 2H), 2.88-2.95 (m, 2H), 3.02 (s, 1H), 6.07 (m, 1H), 6.77 (d, 1H, J = 8.4 Hz), 6.97 (d, 1H, J = 7.6 Hz), 7.26 (t, 1H, J = 7.6 Hz), 7.35-7.42 (m, 2H), 7.46 (d, 1H, J = 8.4 Hz), 7.91 (d, 1H, J = 7.6 Hz), 8.04 (s, 1H ).
Compound Ii-70
1H-NMR (DMSO-d6) δ: 0.93-1.05 (m, 2H), 1.10-1.32 (m, 2H), 1.26 (s, 9H), 1.42 (m, 1H), 1.78-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.78-2.83 (m, 2H), 3.03 (m, 1H), 4.80 (q, 2H, J = 9.2 Hz), 5.48 (t, 1H, J = 5.6 Hz), 6.69-6.76 (m, 2H ), 7.08 (dd, 1H, J = 8.8, 2.4 Hz), 7.45 (d, 1H, J = 2.4 Hz).
Compound Ii-71
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.27 (s, 9H), 1.82-1.88 (m, 2H), 1.88-1.97 (m, 2H), 2.83-2.88 ( m, 2H), 3.04 (m, 1H), 5.82 (s, 1H), 6.69 (m, 1H), 6.76 (d, 1H, J = 8.8 Hz), 7.12 (dd, 1H, J = 9.2, 8.8 Hz ), 7.37 (m, 1H), 7.87 (d, 1H, J = 2.8 Hz), 7.99 (s, 1H).
Compound Ii-72
Compound Ii-73
Compound Ii-74
Compound Ii-75
Compound Ii-76
Compound Ii-77
Compound Ii-78
Compound Ii-79
Compound Ii-80
Compound Ii-81
Compound Ii-82
Compound Ii-83
Compound Ii-84
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.14-1.30 (t, 3H, J = 7.5 Hz), 1.41 (m, 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H) , 2.85 (t, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.25 (t, 2H, J = 7.5 Hz), 3.53 (t, 2H, J = 6.6 Hz), 6.27 (d, 2H, J = 11.7 Hz), 6.52 (t, 1H, J = 5.1 Hz), 7.00 (d, 1H, J = 7.2 Hz).
Compound Ii-85
Compound Ii-86
Compound Ii-87
Compound Ii-88
Compound Ii-89
Compound Ii-90
Compound Ii-91
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.13 (d, 6H, J = 6.0 Hz), 1.18-1.30 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.40 (m, 1H ), 1.76-1.83 (m, 2H), 1.83-1.93 (m, 2H), 2.19 (dd, 1H, J = 11.2, 11.2 Hz), 2.76-2.82 (m, 2H), 3.01 (m, 1H), 3.09 (m, 1H), 3.45 (d, 2H, J = 11.2 Hz), 3.58-3.69 (m, 2H), 5.67 (m, 1H), 5.77 (d, 1H, J = 12.0 Hz), 5.90 (s , 1H), 5.91 (m, 1H), 6.91 (d, 1H, J = 7.6 Hz).
Compound Ii-92
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.14-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.46 (m, 1H), 1.75-1.92 (m, 4H) , 2.78-2.83 (m, 2H), 2.95-3.18 (m, 6H), 3.66-3.72 (m, 4H), 5.75 (brs, 1H), 6.00 (s, 1H), 6.04 (s, 1H), 6.11 (s, 1H), 6.95 (d, 1H, J = 9.0 Hz).
Compound Ii-93
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.13-1.27 (m, 5H), 1.42 (m, 1H), 1.74-1.93 (m, 4H), 2.30-2.40 (m, 2H), 2.81 (d, 2H, J = 6.6 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.49 (t, 2H, J = 7.5 Hz), 3.66 (t, 2H, J = 6.6 Hz) , 5.00-5.50 (brs, 2H), 6.07-6.15 (m, 2H), 6.25 (s, 1H), 7.00 (d, 1H, J = 6.6Hz).
Compound Ii-94
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.15-1.32 (m, 5H), 1.21 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.74-1.93 (m, 4H), 2.30 -2.42 (m, 2H), 2.81 (d, 2H, J = 6.6 Hz), 2.92-3.18 (m, 2H), 3.49 (t, 2H, J = 7.5 Hz), 3.66 (t, 2H, J = 6.6 Hz), 4.70-5.30 (brs, 2H), 6.05-6.16 (m, 2H), 6.25 (s, 1H), 6.95 (d, 1H, J = 8.1 Hz).
Compound Ii-95
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.16-1.31 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H) , 2.84 (t, 2H, J = 6.0 Hz), 2.94-3.16 (m, 2H), 3.28 (t, 2H, J = 7.5 Hz), 3.53 (t, 2H, J = 6.6 Hz), 6.27 (d, 2H, J = 11.7 Hz), 6.52 (t, 1H, J = 5.4 Hz), 6.94 (d, 1H, J = 7.8 Hz).
Compound Ii-96
1H-NMR (DMSO-d6) δ: 0.91-1.04 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.40 (m, 1H), 1.76-1.95 (m, 4H), 2.77-2.83 (m, 2H), 2.99-3.04 (m, 5H), 3.67-3.72 (m, 4H), 5.71 (m, 1H), 5.79 (d, 1H, J = 11.7 Hz), 5.89 (s, 1H), 5.90 (m , 1H), 6.72 (d, 1H, J = 8.4 Hz).
Compound Ii-97
1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H), 1.41 (m, 1H), 1.77-1.93 (m, 4H), 2.78-2.83 (m, 2H), 2.97-3.05 (m, 5H), 3.68-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H, J = 8.0 Hz), 6.10 (s, 1H), 6.11 (d , 1H, J = 8.0 Hz), 6.72 (d, 1H, J = 8.0 Hz), 6.89 (dd, 1H, J = 8.0, 8.0 Hz).
Compound Ii-98
1H-NMR (DMSO-d6) δ: 0.92-1.04 (m, 2H), 1.17-1.29 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.41 (m, 1H), 1.75-1.92 (m, 4H), 2.77 -2.83 (m, 2H), 2.95-3.05 (m, 5H), 3.09 (m, 1H), 3.67-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H, J = 8.0 Hz ), 6.10 (s, 1H), 6.11 (d, 1H, J = 8.0 Hz), 6.89 (dd, 1H, J = 8.0, 8.0 Hz), 6.92 (d, 1H, J = 8.0 Hz).
Compound Ii-99
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.15-1.31 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.74 -1.94 (m, 4H), 2.78 (t, 2H, J = 6.0 Hz), 2.93-3.16 (m, 6H), 5.64-5.76 (m, 2H), 5.83-5.92 (m, 2H), 6.94 (d , 1H, J = 7.8 Hz).
Compound Ii-100
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J = 6.0 Hz), 2.93-3.18 (m, 6H), 5.48-5.67 (m, 4H), 6.94 (d, 1H, J = 8.1 Hz).
Compound Ii-101
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.75 -1.94 (m, 4H), 2.79 (t, 2H, J = 6.0 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.03-3.10 (m, 4H), 5.64-5.75 (m, 2H), 5.83-5.91 (m, 2H), 7.00 (d, 1H, J = 7.8 Hz).
Compound Ii-102
1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.41 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J = 6.0 Hz), 2.97 (q, 2H, J = 7.5 Hz), 3.00 (m, 1H), 3.09-3.19 (m, 4H), 5.46-5.66 (m, 4H), 6.99 ( d, 1H, J = 7.2 Hz).
Compound Ii-103
1H-NMR (DMSO-d6) δ: 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.40 (m, 1H), 1.75-1.92 (m, 4H), 2.20 (s, 3H), 2.35-2.43 (m, 4H), 2.75-2.82 (m, 2H), 2.88-3.13 (m, 6H), 5.67 (m, 1H), 5.76 (d, 1H, J = 11.2 Hz ), 5.82-5.92 (m, 2H), 6.91 (d, 1H, J = 8.0 Hz).
Compound Ii-104
1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H), 1.39 (m, 1H), 1.75-1.95 (m, 4H), 2.19 (s, 3H) , 2.38-2.42 (m, 4H), 2.77-2.83 (m, 5H), 2.98-3.09 (m, 5H), 5.67 (m, 1H), 5.76 (d, 1H, J = 11.2 Hz), 5.88 (m , 1H), 5.88 (s, 1H), 6.72 (d, 1H, J = 8.8 Hz).
Compound Ii-105
1H-NMR (DMSO-d6) δ: 0.95-1.09 (m, 2H), 1.18-1.31 (m, 2H), 1.22 (d, 6H, J = 6.8 Hz), 1.44 (m, 1H), 1.78-1.93 (m, 4H), 2.87 -2.92 (m, 2H), 3.03 (m, 1H), 3.10 (m, 1H), 6.13 (m, 1H), 6.21 (m, 1H), 6.22 (s, 2H), 6.51 (s, 1H), 6.52 (d, 1H, J = 8.0 Hz), 6.92 (d, 1H, J = 8.0 Hz), 7.26 (s, 2H).
Compound Ii-106
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.17-1.29 (m, 5H), 1.40-1.68 (m, 3H), 1.80-1.92 (m, 2H), 2.90 (t, 2H, J = 6.0 Hz) , 2.94-3.06 (m, 3H), 6.12-6.22 (m, 4H), 6.50-6.54 (m, 2H), 6.94-7.00 (m, 1H), 7.26-7.27 (m, 2H).
Compound Ii-107
1H-NMR (DMSO-d6) δ: 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.40 (m, 1H), 1.74-1.92 (m, 4H), 2.75 -2.81 (m, 2H), 2.84 (s, 3H), 3.00 (m, 1H), 3.09 (m, 1H), 3.25 (s, 3H), 3.35-3.47 (m, 4H), 5.59-5.67 (m , 4H), 6.91 (d, 1H, J = 8.0 Hz).
Compound Ii-108
1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.18-1.32 (m, 2H), 1.26 (s, 9H), 1.40 (m, 1H), 1.75-1.94 (m, 4H), 2.75-2.81 (m, 2H), 2.83 (s, 3H), 3.01 (m, 1H), 3.25 (s, 3H), 3.34-3.47 (m, 4H), 5.58-5.70 (m, 4H), 6.72 (d, 1H, J = (8.4 Hz).
Compound Ii-109
1H-NMR (DMSO-d6) δ: 0.90-1.51 (m, 10H), 1.21 (d, 6H, J = 6.9 Hz), 1.56-1.67 (m, 3H), 1.71-1.93 (m, 6H), 2.64 (s, 3H), 2.78 (t, 2H, J = 6.0 Hz), 2.93-3.17 (m, 2H), 3.44 (m, 1H), 5.56-5.77 (m, 4H), 6.94 (d, 1H, J = 7.8 Hz).
Compound Ii-110
1H-NMR (DMSO-d6) δ: 0.83-1.01 (m, 2H), 1.00-1.40 (m, 3H), 1.21 (d, 6H, J = 6.9 Hz), 1.68-1.91 (m, 4H), 2.73 (t, 2H, J = 6.0 Hz), 2.90-3.15 (m, 2H), 2.95 (s, 3H), 4,48 (s, 2H), 5.60-5.72 (m, 4H), 6.94 (d, 1H, J = 7.8 Hz), 7.15-7.35 (m, 5H).
Compound Ii-111
1H-NMR (DMSO-d6) δ: 0.97-1.14 (m, 2H), 1.14-1.33 (m, 5H), 1.45-1.61 (m, 1H), 1.81-1.96 (m, 4H), 2.90-3.10 (m, 5H), 6.34 ( t, 1H, J = 5.2 Hz), 6.51 (d, 1H, J = 2.2 Hz), 6.99-7.07 (m, 2H), 7.36 (dd, 1H, J = 8.2, 4.1 Hz), 8.02 (d, 1H , J = 8.5 Hz), 8.48 (dd, 1H, J = 4.1, 1.4 Hz).
Compound Ii-112
1H-NMR (DMSO-d6) δ: 0.97-1.13 (m, 2H), 1.17-1.34 (m, 8H), 1.45-1.59 (m, 1H), 1.81-1.99 (m, 4H), 2.94 (t, 2H, J = 5.9 Hz) , 2.99-3.21 (m, 2H), 6.33 (t, 1H, J = 5.4 Hz), 6.51 (d, 1H, J = 2.2 Hz), 6.96 (d, 1H, J = 7.7 Hz), 7.02 (dd, 1H, J = 13.5, 2.2 Hz), 7.36 (dd, 1H, J = 8.2, 4.1 Hz), 8.02 (d, 1H, J = 8.5 Hz), 8.48 (dd, 1H, J = 4.1, 1.4 Hz).
Compound Ii-113
1H-NMR (DMSO-d6) δ: 0.93-1.13 (m, 2H), 1.15-1.34 (m, 8H), 1.39-1.57 (m, 1H), 1.79-1.95 (m, 4H), 2.87 (t, 2H, J = 6.2 Hz) , 2.94-3.16 (m, 2H), 3.54 (s, 3H), 5.66 (t, 1H, J = 5.5 Hz), 6.49 (d, 1H, J = 9.6 Hz), 6.73 (d, 1H, J = 2.8 Hz), 6.91-7.02 (m, 2H), 7.29 (d, 1H, J = 9.3 Hz), 7.72 (d, 1H, J = 9.3 Hz).
Compound Ii-114
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.14-1.33 (m, 8H), 1.41-1.56 (m, 1H), 1.79-1.94 (m, 4H), 2.89 (t, 2H, J = 6.0 Hz) , 2.95-3.16 (m, 2H), 6.00 (t, 1H, J = 5.4 Hz), 6.84 (dd, 1H, J = 8.8, 2.2 Hz), 6.95 (d, 1H, J = 8.0 Hz), 7.07 ( d, 1H, J = 2.2 Hz), 7.72 (d, 1H, J = 8.8 Hz), 8.86 (s, 1H).
Compound Ii-115
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.40-1.51 (m, 1H), 1.84 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz) ), 2.85-2.90 (m, 2H), 2.97-3.06 (m, 1H), 5.93-5.99 (m, 1H), 6.63-6.79 (m, 3H), 7.40 (d, 1H, J = 8.8 Hz), 8.32 (s, 1H).
Compound Ii-116
1H-NMR (DMSO-d6) δ: 0.95-1.07 (m, 4H), 1.26 (s, 9H), 1.39-1.47 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz) ), 2.87-2.93 (m, 2H), 2.98-3.06 (m, 1H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J = 8.8 Hz), 6.73 (d, 1H, J = 8.8 Hz), 6.80 (t, 1H, J = 5.2 Hz), 7.32 (d, 1H, J = 8.8 Hz).
Compound Ii-117
1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H), 1.39-1.51 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.88 (d , 2H, J = 12.4 Hz), 2.87-2.94 (m, 2H), 2.97-3.07 (m, 1H), 3.08-3.14 (m, 1H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J = 8.4 Hz), 6.82 (t, 1H, J = 5.6 Hz), 6.94 (d, 1H, J = 8.0 Hz), 7.32 (d, 1H, J = 8.4 Hz).
Compound Ii-118
1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 4H), 1.26 (s, 9H), 1.38-1.50 (m, 1H), 1.83 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz) ), 2.80-2.86 (m, 2H), 2.96-3.06 (m, 1H), 3.26 (s, 3H), 5.58-5.65 (m, 1H), 6.27 (d, 1H, J = 8.4 Hz), 6.38 ( s, 1H), 6.75 (d, 1H, J = 8.4 Hz), 6.99 (d, 1H, J = 8.4 Hz).
Compound Ii-119
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.39-1.50 (m, 1H), 1.84 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz) ), 2.81-2.89 (m, 2H), 2.96-3.07 (m, 1H), 3.51 (s, 3H), 5.79-5.84 (m, 1H), 6.60 (s, 1H), 6.75 (d, 1H, J = 8.8 Hz), 7.03 (d, 1H, J = 8.8 Hz), 7.19 (d, 1H, J = 8.8 Hz).
Compound Ii-120
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 4H), 1.26 (s, 9H), 1.37-1.40 (m, 1H), 1.42 (s, 3H), 1.44 (s, 3H), 1.83 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.79-2.96 (m, 2H), 2.97-3.07 (m, 1H), 4.33-4.46 (m, 1H), 5.50-5.59 (m, 1H ), 6.25 (d, 1H, J = 8.8 Hz), 6.57 (s, 1H), 6.75 (d, 1H, J = 8.4 Hz), 7.00 (d, 1H, J = 8.4 Hz).
Compound Ii-121
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.36-1.49 (m, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz) ), 2.80-2.87 (m, 2H), 2.95-3.97 (m, 1H), 3.27 (s, 3H), 5.85-5.92 (m, 1H), 6.33 (s, 1H), 6.36 (s, 1H), 6.75 (d, 1H, J = 8.8 Hz).
Compound Ii-122
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 4H), 1.26 (s, 9H), 1.38-1.41 (m, 1H), 1.42 (s, 3H), 1.43 (s, 3H), 1.82 (d, 2H, J = 11.8 Hz), 1.90 (d, 2H, J = 11.8 Hz), 2.83-2.88 (m, 2H), 2.98-3.06 (m, 1H), 4.33-4.47 (m, 1H), 6.35 (s, 1H), 6.54 (s, 1H), 6.76 (d, 1H, J = 8.4 Hz), 8.32 (s, 1H).
Compound Ii-123
1H-NMR (DMSO-d6) δ: 0.93-1.06 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.26 (s, 9H), 1.39-1.50 (m, 1H), 1.81 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz), 2.87-2.93 (m, 2H), 2.96-3.07 (m, 1H), 4.39-4.47 (m, 1H), 6.30 (s, 1H), 6.54 (d, 1H, J = 8.8 Hz), 6.77 (d, 1H, J = 8.8 Hz), 6.86 (t, 1H, J = 5.2 Hz), 7.32 (d, 1H, J = 8.4 Hz).
Compound Ii-124
1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 4H), 1.26 (s, 9H), 1.36-1.51 (m, 1H), 1.79 (d, 2H, J = 12.4 Hz), 1.90 (d, 2H, J = 12.4 Hz) ), 2.80-2.86 (m, 2H), 3.01 (s, 3H), 3.02-3.05 (m, 1H), 3.49 (t, 2H, J = 4.8 Hz), 4.26 (t, 2H, J = 4.8 Hz) , 6.02 (s, 1H), 6.20 (t, 1H, J = 5.6 Hz), 6.31 (d, 1H, J = 8.8 Hz), 6.74 (d, 1H, J = 8.8 Hz), 7.43 (d, 1H, J = 8.4 Hz).
Compound Ii-125
1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 4H), 1.08 (t, 3H, J = 7.2 Hz), 1.25 (s, 9H), 1.35-1.42 (m, 1H), 1.79 (d, 2H, J = 12.0 Hz) ), 1.90 (d, 2H, J = 12.0 Hz), 2.80-2.86 (m, 2H), 2.96-3.05 (m, 1H), 3.42-3.51 (m, 4H), 4.20-4.26 (m, 2H), 6.03 (s, 1H), 6.20 (s, 1H), 6.31 (d, 1H, J = 8.8 Hz), 6.75 (d, 1H, J = 8.8 Hz), 7.42 (d, 1H, J = 8.8 Hz).
Compound Ii-126
1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 4H), 1.09 (s, 3H), 1.11 (s, 3H), 1.25 (s, 9H), 1.43-1-1.55 (m, 1H), 1.80 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.0 Hz), 2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.37 (t, 2H, J = 5.2 Hz), 4.18 (t, 2H, J = 5.2 Hz), 4.71-4.80 (m, 1H), 6.05 (s, 1H), 6.19 (t, 1H, J = 5.2 Hz), 6.32 (d, 1H, J = 8.8 Hz), 6.74 (d, 1H, J = 8.4 Hz), 7.18 (d, 1H, J = 8.4 Hz).
Compound Ii-127
1H-NMR (DMSO-d6) δ: 0.94-1.12 (m, 2H), 1.14-1.39 (m, 5H), 1.34-1.56 (m, 1H), 1.70-1.97 (m, 4H), 2.87-3.10 (m, 5H), 6.17 ( t, 1H, J = 5.2 Hz), 6.94-7.06 (m, 2H), 7.35-7.47 (m, 4H), 7.75-7.80 (m, 1H), 8.07 (d, 1H, J = 3.0 Hz).
Compound Ii-128
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.14-1.31 (m, 5H), 1.31-1.55 (m, 1H), 1.70-1.96 (m, 4H), 2.89-3.09 (m, 5H), 6.24 ( t, 1H, J = 5.4 Hz), 6.94-7.05 (m, 2H), 7.24 (d, 1H, J = 6.9 Hz), 7.52 (t, 1H, J = 8.0 Hz), 7.75 (d, 1H, J = 8.8 Hz), 7.88-7.97 (m, 2H), 8.07 (d, 1H, J = 2.5 Hz).
Compound Ii-129
1H-NMR (DMSO-d6) δ: 0.98-1.12 (m, 2H), 1.18-1.30 (m, 2H), 1.19 (t, 3H, J = 6.8 Hz), 1.48 (m, 1H), 1.79-1.95 (m, 4H), 2.92 -3.09 (m, 3H), 2.97 (q, 2H, J = 6.8 Hz), 6.27 (m, 1H), 7.01 (d, 1H, J = 8.0 Hz), 7.39-7.47 (m, 2H), 7.56 ( m, 1H), 8.18-8.25 (m, 2H), 8.23 (s, 2H).
Compound Ii-130
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.45-1.64 (m, 1H), 1.78-1.96 (m, 4H) , 2.97 (q, 2H, J = 7.2 Hz), 2.95-3.15 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 6.94-7.02 (m, 2H ), 7.38 (t, 1H, J = 6.0 Hz), 7.46 (t, 2H, J = 7.5 Hz), 7.78 (d, 1H, J = 9.0 Hz), 7.96 (d, 2H, J = 9.0 Hz).
Compound Ii-131
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H) , 2.98 (q, 2H, J = 7.2 Hz), 2.94-3.10 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.02 (d, 1H, J = 9.0 Hz), 7.10 (t, 1H, J = 5.4 Hz), 7.22 (td, 1H, J = 9.0, 3.0 Hz), 7.47-7.56 (m, 1H), 7.77-7.88 (m, 3H).
Compound Ii-132
1H-NMR (DMSO-d6) δ: 0.96-1.13 (m, 2H), 1.15-1.32 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.48-1.65 (m, 1H), 1.78-1.96 (m, 4H) , 2.98 (q, 2H, J = 7.2 Hz), 2.94-3.12 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 6.0 Hz), 7.09 (t, 1H, J = 5.4 Hz), 7.27-7.35 (m, 2H), 7.42-7.50 (m, 1H), 7.57 (dd, 1H, J = 9.0, 3.0 Hz), 7.86 (td, 1H, J = 7.5, 3.0 Hz).
Compound Ii-133
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H) , 2.95-3.20 (m, 4H), 4.89-4.98 (m, 2H), 6.65 (brs, 1H), 6.92 (d, 1H, J = 9.0 Hz), 6.91-6.98 (m, 1H), 7.03 (d , 1H, J = 9.0 Hz).
Compound Ii-134
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H) , 2.92-3.20 (m, 4H), 6.74 (t, 1H, J = 6.0 Hz), 6.94 (t, 1H, J = 6.0 Hz), 6.97 (s, 1H), 7.08-7.24 (m, 5H).
Compound Ii-135
1H-NMR (DMSO-d6) δ: 0.95-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.48-1.60 (m, 1H), 1.76-1.94 (m, 4H) , 2.92-3.10 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.18-3.30 (m, 2H), 6.89 (d, 1H, J = 9.6 Hz), 7.02 (brs, 1H), 7.11 (t, 1H, J = 5.4 Hz), 7.42-7.56 (m, 2H), 7.85 (d, 1H, J = 9.6 Hz), 7.93 (d, 1H, J = 7.5 Hz), 8.03 (s, 1H ).
Compound Ii-136
1H-NMR (DMSO-d6) δ: 0.98-1.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H) , 2.92-3.12 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.22-3.32 (m, 2H), 6.89 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 7.5 Hz), 7.20 (t, 1H, J = 6.0 Hz), 7.62 (s, 1H), 7.91 (d, 1H, J = 9.0 Hz), 8.02 (s, 2H).
Compound Ii-137
1H-NMR (DMSO-d6) δ: 0.95-1.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.65-1.95 (m, 5H), 2.93-3.12 (m, 1H) , 2.97 (q, 2H, J = 7.2 Hz), 3.25-3.40 (m, 2H), 5.07-5.16 (m, 2H), 7.01 (d, 1H, J = 7.5 Hz), 7.25 (t, 1H, J = 6.0 Hz), 7.92-8.03 (m, 3H), 8.33 (d, 1H, J = 6.0 Hz).
Compound Ii-138
1H-NMR (DMSO-d6) δ: 0.91-1.26 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.36-1.43 (m, 1H), 1.78-1.90 (m, 4H), 2.90-3.07 (m, 3H) , 2.96 (q, 2H, J = 7.5 Hz), 5.69 (t, 1H, J = 5.7 Hz), 5.81 (d, 1H, J = 2.4 Hz), 7.00 (d, 1H, J = 7.8 Hz), 7.16 -7.39 (m, 3H), 7.73-7.79 (m, 1H), 7.86-7.88 (m, 1H).
Compound Ii-139
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H), 1.40−1.52 (m, 1H), 1.81 (d, 2H, J = 12.4 Hz), 1.88 (d , 2H, J = 12.4 Hz), 2.90-2.98 (m, 2H), 2.99-3.13 (m, 2H), 5.68 (t, 1H, J = 5.6 Hz), 5.81 (s, 1H), 6.93 (d, 1H, J = 8.8 Hz), 7.16-7.40 (m, 3H), 7.76 (t, 1H, J = 8.0 Hz), 7.87 (s, 1H).
Compound Ii-140
1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.40−1.49 (m, 1H), 1.82 (d, 2H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz) ), 2.90-2.99 (m, 2H), 3.01-3.06 (m, 1H), 5.67 (t, 1H, J = 6.0 Hz), 5.81 (s, 1H), 6.74 (d, 1H, J = 8.4 Hz) , 7.14-7.40 (m, 3H), 7.76 (t, 1H, J = 8.4 Hz), 7.87 (s, 1H).
Compound Ii-141
1H-NMR (DMSO-d6) δ: 0.97-1.06 (m, 2H), 1.18-1.27 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.45-1.59 (m, 1H), 1.76-1.81 (m, 2H) , 1.87-1.91 (m, 2H), 2.97-3.09 (m, 1H), 3.10-3.13 (m, 1H), 3.17-3.22 (m, 2H), 6.94-7.02 (m, 2H), 6.98 (td, 1H, J = 7.8, 1.2 Hz), 7.36 (dd, 1H, J = 7.8, 0.6 Hz), 7.65 (dd, 1H, J = 7.8, 0.6 Hz), 8.00-8.05 (m, 1H).
Compound Ii-142
1H-NMR (DMSO-d6) δ: 0.96-1.04 (m, 2H), 1.18-1.28 (m, 2H), 1.20 (d, 6H, J = 6.9 Hz), 1.43-1.59 (m, 1H), 1.74-1.79 (m, 2H) , 1.85-1.90 (m, 2H), 2.92-3.07 (m, 1H), 3.09-3.18 (m, 3H), 6.92-6.99 (m, 2H), 7.10 (td, 1H, J = 7.8, 1.2 Hz) , 7.21 (dd, 1H, J = 7.8, 0.6 Hz), 7.31 (dd, 1H, J = 7.8, 0.6 Hz), 7.89-7.97 (m, 1H).
Compound Ii-143
1H-NMR (DMSO-d6) δ: 0.97-1.07 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.42-1.57 (m, 1H), 1.73-1.78 (m, 2H) , 1.86-1.90 (m, 2H), 2.93-3.02 (m, 1H), 2.97 (q, 2H, J = 7.2 Hz), 3.11 (t, 2H, J = 6.3 Hz), 6.91-7.02 (m, 2H ), 7.19 (dd, 1H, J = 8.4, 4.8 Hz), 7.34 (dd, 1H, J = 9.3, 2.4 Hz), 8.00 (t, 1H, J = 6.0 Hz).
Compound Ii-144
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.16-1.24 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.42-1.59 (m, 1H), 1.74-1.80 (m, 2H) , 1.85-1.90 (m, 2H), 2.92-3.03 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 3.18 (t, 2H, J = 6.3 Hz), 6.99-7.07 (m, 2H ), 7.33 (dd, 1H, J = 9.0, 4.8 Hz), 7.58 (dd, 1H, J = 8.7, 2.7 Hz), 8.00 (t, 1H, J = 5.4 Hz).
Compound Ii-145
1H-NMR (DMSO-d6) δ: 0.97-1.09 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.43-1.59 (m, 1H), 1.72-1.81 (m, 2H) , 1.85-1.92 (m, 2H), 2.95-3.06 (m, 1H), 2.97 (q, 2H, J = 7.5 Hz), 3.19 (t, 2H, J = 6.0 Hz), 7.01 (d, 1H, J = 8.1 Hz), 7.20-7.23 (m, 1H), 7.33 (dd, 1H, J = 8.7, 0.6 Hz), 7.58 (dd, 1H, J = 2.1, 0.9 Hz), 8.11-8.18 (m, 1H) .
Compound Ii-146
1H-NMR (DMSO-d6) δ: 0.98-1.06 (m, 2H), 1.15-1.21 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.42-1.58 (m, 1H), 1.70-1.81 (m, 2H) , 1.82-1.96 (m, 2H), 2.93-3.00 (m, 3H), 3.13-3.19 (m, 2H), 6.98-7.02 (m, 2H), 7.26-7.27 (m, 1H), 7.32-7.35 ( m, 1H), 8.18-8.21 (m, 1H).
Compound Ii-147
1H-NMR (DMSO-d6) δ: 0.98-1.04 (m, 2H), 1.16-1.23 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.43-1.59 (m, 1H), 1.73-1.78 (m, 2H) , 1.86-1.89 (m, 2H), 2.93-3.00 (m, 3H), 3.11-3.15 (m, 2H), 6.72-6.79 (m, 1H), 7.00-7.08 (m, 2H), 7.29-7.34 ( m, 1H), 8.13-8.16 (m, 1H).
Compound Ii-148
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.15-1.26 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.45-1.58 (m, 1H), 1.72-1.80 (m, 2H) , 1.84-1.92 (m, 2H), 2.96 (q, 2H, J = 7.2 Hz), 2.96-3.05 (m, 1H), 3.09-3.16 (m, 2H), 6.99 (d, 1H, J = 8.0 Hz ), 7.13 (dd, 1H, J = 8.0, 2.0 Hz), 7.20 (d, 1H, J = 8.4 Hz), 7.49 (d, 1H, J = 2.0 Hz), 8.11 (t, 1H, J = 6.0 Hz) ).
Compound Ii-149
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.43-1.59 (m, 1H), 1.74-1.80 (m, 2H) , 1.86-1.91 (m, 2H), 2.93-3.01 (m, 3H), 3.17-3.22 (m, 2H), 7.00-7.05 (m, 2H), 7.37-7.39 (m, 1H), 7.65-7.68 ( m, 1H), 8.22-8.26 (m, 1H).
Compound Ii-150
1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.29 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.44-1.60 (m, 1H), 1.74-1.80 (m, 2H) , 1.86-1.91 (m, 2H), 2.95-3.17 (m, 2H), 3.21-3.27 (m, 2H), 6.95-6.98 (m, 1H), 8.10 (dd, 1H, J = 8.4, 2.7 Hz) , 8.19 (dd, 1H, J = 3.0, 1.5 Hz), 8.44-8.47 (m, 1H).
Compound Ii-151
1H-NMR (DMSO-d6) δ: 0.99-1.04 (m, 2H), 1.15-1.23 (m, 2H), 1.21 (d, 6H, J = 6.3 Hz), 1.43-1.59 (m, 1H), 1.73-1.81 (m, 2H) , 1.85-1.91 (m, 2H), 2.97-3.18 (m, 2H), 3.21-3.29 (m, 2H), 6.95-6.98 (m, 1H), 8.20-8.23 (m, 2H), 8.58-8.61 ( m, 1H).
Compound Ii-152
1H-NMR (DMSO-d6) δ: 0.96-1.04 (m, 2H), 1.15-1.26 (m, 2H), 1.25 (s, 9H), 1.56-1.62 (m, 1H), 1.78-1.83 (m, 2H), 1.87-1.93 ( m, 2H), 2.98-3.08 (m, 1H), 3.17 (t, 2H, J = 6.3 Hz), 3.48 (s, 3H), 6.47 (d, 2H, J = 8.7 Hz), 6.89-6.96 (m , 2H), 7.11-7.19 (m, 2H).
Compound Ii-153
1H-NMR (DMSO-d6) δ: 0.95-1.04 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.41 (m, 1H), 1.71-1.94 (m, 4H), 2.80 -2.89 (m, 2H), 2.92-3.10 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz), 3.21-3.30 (m, 2H), 6.25-6.35 (m, 2H), 6.39 (dd , 1H, J = 8.4, 2.1 Hz), 7.01 (d, 1H, J = 7.5 Hz), 7.01 (dd, 1H, J = 8.4, 8.4 Hz).
Compound Ii-154
1H-NMR (DMSO-d6) δ: 0.91-1.09 (m, 2H), 1.16-1.28 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.42 (m, 1H), 1.74-1.95 (m, 4H), 2.80 -3.16 (m, 9H), 2.97 (q, 2H, J = 7.5 Hz), 6.24-6.36 (m, 2H), 6.30 (dd, 1H, J = 8.4, 2.1 Hz), 7.10 (dd, 1H, J = 8.4, 2.1 Hz), 7.05 (d, 1H, J = 8.4 Hz).
Compound Ii-155
Compound Ii-156
Compound Ii-157
Compound Ii-158
1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.10-1.30 (m, 5H), 1.41 (m, 1H), 1.76-1.94 (m, 4H), 2.74-2.83 (m, 2H), 2.83 (s, 3H), 2.90-3.08 (m, 3H), 2.96 (s, 3H), 5.68 (m, 1H), 6.39 (m, 1H), 6.58 (m, 1H), 6.95 (dd, 1H, J = 8.4, 8.4 Hz), 7.00 (d, 1H, J = 7.8 Hz).
Compound Ii-159
Compound Ii-160
Compound Ii-161
Compound Ii-162
Compound Ii-163
Compound Ii-164
Compound Ii-165
Compound Ii-166
Compound Ii-167
Compound Ii-168
Compound Ii-169
Compound Ii-170
Compound Ii-171
Compound Ii-172
Compound Ii-173
1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.43 (m, 1H), 1.76-1.85 (m, 2H), 1.85 -1.93 (m, 2H), 2.76-2.82 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 2.97 (t, 2H, J = 7.2 Hz), 3.00 (m, 1H), 3.64- 3.70 (m, 4H), 6.33 (m, 1H), 6.37 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 7.00 (d, 1H, J = 7.8 Hz), 7.28 (d, 1H , J = 8.4 Hz).
Compound Ii-174
Compound Ii-175
Compound Ii-176
Compound Ii-177
Compound Ii-178
Compound Ii-179
Compound Ii-180
Compound Ii-181
Compound Ii-182
Compound Ii-183
Compound Ii-184
Compound Ii-185
Compound Ii-186
Compound Ii-187
Compound Ii-188
Compound Ii-189
Compound Ii-190
Compound Ii-191
Compound Ii-192
Compound Ii-193
Compound Ii-194
Compound Ii-195
Compound Ii-196
Compound Ii-197
Compound Ii-198
Compound Ii-199
Compound Ii-200
Compound Ii-201
Compound Ii-202
Compound Ii-203
Compound Ii-204
Compound Ii-205
Compound Ii-206
化合物Ij-2
1H-NMR (DMSO-d6) δ: 0.98-1.24 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.86 (q, 2H, J = 7.2 Hz), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J = 8.1 Hz), 7.01 (d, 2H, J = 7.2 Hz), 7.32-7.50 (m, 4H), 7.99 (d, 2H, J = 6.9 Hz)
化合物Ij-3
1H-NMR (DMSO-d6) δ: 0.96-1.26 (m, 4H), 1.18 (t, 3H, J = 7.5 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.40-6.50 (m,2H), 6.85-6.92 (m, 1H), 6.97-7.03 (m, 1H), 7.22-7.35 (m, 2H), 7.36-7.46 (m, 2H), 7.88-7.96 (m, 1H)
化合物Ij-4
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (t, 1H, J = 3.9 Hz), 6.53 (s, 1H), 7.00 (t, 1H, J = 5.7 Hz), 7.25 (t, 1H, J = 7.2 Hz), 7.34-7.45 (m, 2H), 7.55 (d, 2H, J = 7.2 Hz), 7.67 (dd, 1H, J = 8.7, 2.7 Hz), 8.29 (d, 1H, J = 2.7 Hz)
化合物Ij-5
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.52 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 7.8 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.20-7.36 (m, 3H), 7.46 (t, 1H, J = 8.1 Hz), 7.55 (d, 1H, J = 8.7 Hz), 8.15 (s, 1H)
化合物Ij-6
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.51 (d, 1H, J = 8.7 Hz), 6.60 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.02-7.12 (m, 1H), 7.36-7.48 (m, 3H), 7.71 (dd, 1H, J = 8.7, 2.1 Hz), 8.33 (d, 1H, J = 2.1 Hz)
化合物Ij-7
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (d, 2H, J = 8.7 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.16-7.26 (m, 2H), 7.52-7.68 (m, 3H), 8.25 (s, 1H)
化合物Ij-8
1H-NMR (CDCl3) δ: 1.15-1.26 (m, 4H), 1.40 (t, 3H, J = 7.5 Hz), 1.55-1.58 (m, 1H), 1.93 (d, 2H, J = 9.7 Hz), 2.23 (d, 2H, J = 9.7 Hz), 3.01-3.11 (m, 4H), 3.56-3.61 (m, 1H), 3.84 (s, 3H), 4.34 (t, 1H, J = 6.1 Hz), 4.83-4.86 (m, 1H), 6.46 (d, 1H, J = 8.6 Hz), 6.99 (d, 1H, J = 8.5 Hz), 7.05 (d, 1H, J = 8.5 Hz), 7.29 (s, 1H), 7.30-7.34 (m, 1H), 7.69 (dd, 1H, J = 8.7, 2.4 Hz), 8.25 (s, 1H).
化合物Ij-9
1H-NMR (CDCl3) δ: 1.16-1.24 (m, 4H), 1.40 (t, 3H, J = 6.2 Hz), 1.55-1.59 (m, 1H), 1.94 (d, 2H, J = 11.8 Hz), 2.23 (d, 2H, J = 11.8 Hz), 3.03-3.09 (m, 4H), 3.58-3.62 (m, 1H), 3.88 (s, 3H), 4.29 (t, 1H, J = 6.4 Hz), 4.85-4.89 (m, 1H), 6.49 (d, 1H, J = 8.7 Hz), 6.88 (dd, 1H, J = 8.7, 2.2 Hz), 7.04-7.06 (m, 1H), 7.10 (d, 1H, J = 8.7 Hz), 7.36 (t, 1H, J = 7.9 Hz), 7.70 (dd, 1H, J = 8.7, 2.2 Hz), 8.32 (s, 1H).
化合物Ij-10
1H-NMR (CDCl3) δ: 1.19-1.30 (m, 4H), 1.41 (t, 3H, J = 6.3 Hz), 1.56-1.59 (m, 1H), 1.94 (d, 2H, J = 11.1 Hz), 2.23 (d, 2H, J = 11.1 Hz), 3.01-3.11 (m, 4H), 3.57-3.61 (m, 1H), 3.87 (s, 3H), 4.27 (t, 1H, J = 6.4 Hz), 4.98 (s, 1H), 6.50 (dd, 1H, J = 8.7, 2.2 Hz), 6.99 (d, 2H, J = 8.9 Hz), 7.43 (d, 2H, J = 8.7 Hz), 7.68 (dd, 1H, J = 8.7, 2.2 Hz), 8.25 (s, 1H).
化合物Ij-11
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H), 1.75-1.86 (m, 2H), 1.95-2.07 (m, 2H), 2.34 (s, 3H), 2.78 (t, 2H, J = 6.2 Hz), 2.98 (q, 2H, J = 7.3 Hz), 3.65 (m, 1H), 6.45-6.53 (m, 2H), 7.01 (t, 1H, J = 5.6 Hz), 7.07 (d, 1H, J = 7.1 Hz), 7.23-7.38 (m, 3H), 7.64 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.26 (d, 1H, J = 2.5 Hz).
化合物Ij-12
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.09-1.27 (m, 11H), 1.39 (m, 1H), 1.76-1.87 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.2 Hz), 2.84-3.03 (m, 3H), 3.66 (m, 1H), 6.45-6.54 (m, 2H), 7.01 (t, 1H, J = 5.8 Hz), 7.13 (d, 1H, J = 6.9 Hz), 7.27-7.41 (m, 3H), 7.66 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.27 (d, 1H, J = 2.2 Hz).
化合物Ij-13
1H-NMR (DMSO-d6) δ: 0.92-1.09 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H), 1.76-1.85 (m, 2H), 1.95-2.06 (m, 2H), 2.78 (t, 2H, J = 6.2 Hz), 2.98 (q, 2H, J = 7.3 Hz), 3.68 (m, 1H), 6.52 (d, 1H, J = 8.8 Hz), 6.66 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 5.5 Hz), 7.23 (d, 1H, J = 8.1 Hz), 7.49-7.55 (m, 2H), 7.62 (d, 1H, J1 = 8.5 Hz), 7.72 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.35 (d, 1H, J = 2.5 Hz).
化合物Ij-14
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.22 (d, 6H, J = 6.4 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.95-2.03 (m, 2H), 2.81 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.60-3.75 (m, 1H), 6.65 (d, 1H, J = 4.8 Hz), 6.70 (s, 1H), 6.88-6.98 (m, 2H), 8.16 (d, 1H, J = 5.2 Hz).
化合物Ij-15
1H-NMR (CDCl3) δ: 1.02-1.28 (m, 4H), 1.38 (d, 6H, J = 6.9 Hz), 1.52 (m, 1H), 1.85-1.94 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J = 6.6 Hz), 3.10-3.25 (m, 1H), 3.38-3.54 (m, 1H), 4.22 (t, 1H, J = 6.3 Hz), 4.58 (d, 1H, J = 7.8 Hz), 6.34 (d, 1H, J = 1.8 Hz), 6.53 (dd, 1H, J = 5.4, 1.8 Hz), 7.93 (d, 1H, J = 5.4 Hz).
化合物Ij-16
1H-NMR (CDCl3) δ: 1.03-1.28 (m, 4H), 1.37 (d, 6H, J = 6.9 Hz), 1.52 (m, 1H), 1.84-1.93 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J = 6.6 Hz), 3.09-3.24 (m, 1H), 3.40-3.54 (m, 1H), 4.26 (t, 1H, J = 6.6 Hz), 4.44 (d, 1H, J = 8.1 Hz), 6.29 (d, 1H, J = 8.7 Hz), 7.33 (dd, 1H, J = 8.7, 2.7 Hz), 7.99 (d, 1H, J = 2.7 Hz).
化合物Ij-17
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.21 (d, 6H, J = 6.8 Hz), 1.36 (m, 1H), 1.76-1.84 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.08-3.18 (m, 1H), 3.45-3.56 (m, 1H), 6.36 (d, 1H, J = 8.4 Hz), 6.43 (d, 1H, J = 7.2 Hz), 6.75 (d, 1H, J = 7.6 Hz), 6.94 (t, 1H, J = 6.0 Hz), 7.33 (t, 1H, J = 7.6 Hz).
化合物Ij-18
1H-NMR (DMSO-d6) δ: 0.98-1.24 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J = 8.4 Hz), 6.95-7.05 (m, 2H), 7.35-7.50 (m, 4H), 7.99 (d, 2H, J = 7.2 Hz)
化合物Ij-19
1H-NMR (CDCl3) δ: 1.22-1.38 (m, 4H), 1.38 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.12-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.16 (t, 1H, J = 6.4 Hz), 4.82-4.92 (m, 1H), 6.46 (d, 1H, J = 8.0 Hz), 7.10-7.20 (m, 2H), 7.23-7.33 (m, 1H), 7.37 (t, 1H, J = 8.0 Hz), 7.65 (d, 1H, J = 8.7 Hz), 8.24 (s, 1H).
化合物Ij-20
1H-NMR (CDCl3) δ: 1.22-1.38 (m, 4H), 1.39 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.12-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.16 (t, 1H, J = 6.4 Hz), 4.78-4.88 (m, 1H), 6.46 (d, 1H, J = 8.0 Hz), 6.98(t, 1H, J = 5.7 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.23-7.29 (m, 1H), 7.33-7.40 (m, 1H), 7.65 (d, 1H, J = 8.7 Hz), 8.29 (s, 1H).
化合物Ij-21
1H-NMR (CDCl3) δ: 1.10-1.30 (m, 4H), 1.38 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.13-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.15 (t, 1H, J = 6.4 Hz), 4.78-4.88 (m, 1H), 6.46 (d, 1H, J = 8.0 Hz), 7.07-7.14 (m, 2H), 7.40-7.46 (m, 2H), 7.62 (d, 1H, J = 8.7 Hz), 8.23 (s, 1H).
化合物Ij-22
1H-NMR (DMSO-d6) δ: 0.95-1.25 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.25-1.50 (br, 1H), 1.81 (d, 2H, J = 11.4 Hz), 2.00 (d, 2H, J = 10.5 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.80 (m, 1H), 3.76 (s, 3H), 6.49 (d, 2H, J = 8.7 Hz), 6.50-6.70 (br, 1H), 6.95-7.10 (m, 3H), 7.20-7.32 (m, 2H), 7.51 (d, 1H, J = 7.2Hz), 8.05 (br, 1H). ESI(positive) 418.3 [M+H]+
化合物Ij-23
1H-NMR (DMSO-d6) δ: 0.95-1.32 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.25-1.55 (br, 1H), 1.82 (d, 2H, J = 11.4 Hz), 2.01 (d, 2H, J = 10.2 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.78 (m, 1H), 3.80 (s, 3H), 6.59 (d, 2H, J = 9.6 Hz), 6.85 (dd, 1H, J = 8.4 Hz, 2.4 Hz), 6.99 (t, 3H, J = 5.7Hz), 7.05-7.18 (m, 2H), 7.32 (d, 1H, J = 7.8Hz), 7.76 (d, 1H, J = 8.4Hz), 8.27 (d, 1H, J = 2.1 Hz). ESI(positive) 418.3 [M+H]+
化合物Ij-24
1H-NMR (DMSO-d6) δ: 0.92-1.25 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.28-1.48 (m, 1H), 1.81 (d, 2H, J = 10.8 Hz), 2.00 (d, 2H, J = 9.6 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.08-3.22 (m, 1H), 3.58-3.74 (m, 1H), 3.77 (s, 3H), 6.51 (d, 2H, J = 8.7 Hz), 6.97 (d, 2H, J = 8.7 Hz), 6.98 (brs, 1H), 7.48 (d, 2H, J = 8.7 Hz), 7.63 (dd, 1H, J = 11.4Hz, 2.4Hz), 8.21 (d, 1H, J = 2.4 Hz). ESI(positive) 418.3[M+H]+
化合物Ij-25
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.95-2.05 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.80 (m, 1H), 6.65 (d, 1H, J = 5.4 Hz), 6.70 (s, 1H), 6.87 (t, 1H, J = 6.0 Hz), 6.94 (d, 1H, J = 7.8 Hz), 8.16 (d, 1H, J = 5.4 Hz)
化合物Ij-26
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.94-2.04 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.80 (m, 1H), 6.53 (d, 1H, J = 8.7 Hz), 6.87 (t, 1H, J = 5.7 Hz), 7.19 (d, 1H, J = 7.5 Hz), 7.59 (dd, 1H, J = 9.0, 2.4 Hz), 8.26 (d, 1H, J = 2.4 Hz)
化合物Ij-27
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.26 (s, 9H), 1.38 (m, 1H), 1.76-1.86 (m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.40-3.60 (m, 1H), 6.36 (d, 1H, J = 8.1 Hz), 6.43 (d, 1H, J = 6.9 Hz), 6.80 (d, 1H, J = 7.5 Hz), 6.86 (t, 1H, J = 5.4 Hz), 7.34 (t, 1H, J = 8.4 Hz)
化合物Ij-28
1H-NMR ((DMSO-d6) δ: 0.93-1.18 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.75-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 3.09-3.27 (m, 2H), 6.19 (d, 1H, J = 8.1 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.33 (d, 2H, J = 8.7 Hz) Mass:379[M+H]+
化合物Ij-29
1H-NMR (DMSO-d6) δ: 0.93-1.18 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.32-1.49 (m, 2H), 1.82 (d, 2H, J = 11.2 Hz), 2.04 (d, 2H, J = 11.2 Hz), 2.75-2.87 (m, 2H), 3.07-3.28 (m, 2H), 6.64 (s, 1H), 6.96 (s, 1H), 7.10-7.22 (m, 2H), 7.25-7.39 (m, 2H), 7.77-7.90 (m, 2H), 8.63 (s, 1H). 融点:161-162℃
化合物Ij-30
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.88 (t, 2H, J = 6.3 Hz), 3.19 (m, 1H), 6.19 (d, 1H, J = 7.5 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.88 (d, 1H, J = 6.0Hz), 7.33 (d, 2H, J = 8.7 Hz) Mass:392M+
化合物Ij-31
1H-NMR (DMSO-d6) δ: 0.92-1.16 (m, 4H), 1.26 (s, 9H), 1,36 (m, 1H), 1.72-1.83 (m, 2H), 1.92-2.02 (m, 2H), 2.87 (t, 2H, J = 6.3 Hz), 3.12 (m, 1H), 6.09-6.23 (m, 4H), 6.87 (t, 1H, J = 6.0 Hz) Mass:361[M+H]+
化合物Ij-32
1H-NMR (CDCl3) δ: 1.00-1.20 (m, 4H), 1.40 (s, 9H), 1.42-1.64 (m, 2H), 1.84-1.95 (m, 2H), 2.09-2.20 (m, 2H), 3.07 (m, 1H), 3.07 (t, 2H, J = 6.3 Hz), 3.90 (m, 1H), 6.10 (dd, 2H, J = 9.6, 5.4 Hz).
化合物Ij-33
1H-NMR (DMSO-d6) δ: 0.93-1.21 (m, 5H), 1.28 (s, 9H), 1.33-1.46 (m, 1H), 1.82 (d, 2H, J = 11.6 Hz), 2.04 (d, 2H, J = 11.6 Hz), 2.86-2.95 (m, 2H), 3.03-3.29 (m, 1H), 6.59-6.71 (m, 1H), 6.80-6.92 (m, 1H), 7.09-7.21 (m, 2H), 7.27-7.37 (m, 2H), 7.77-7.88 (m, 2H), 8.58-8.67 (s, 1H). 融点:172-173℃
化合物Ij-34
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24(m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.38 (m, 1H), 1.76-1.86 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.48-3.60 (m, 1H), 6.95 (t, 1H, J = 5.6 Hz), 7.41 (d, 1H, J = 7.6 Hz), 7.63 (s, 1H), 7.82 (s, 1H).
化合物Ij-35
1H-NMR (DMSO-d6) δ: 0.96-1.26 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.48-3.62 (m, 1H), 6.87 (t, 1H, J = 6.0 Hz), 7.45 (d, 1H, J = 7.5 Hz), 7.63 (s, 1H), 7.82 (s, 1H)
化合物Ij-36
1H-NMR (DMSO-d6) δ: 0.96-1.06 (m, 2H), 1.12-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.39 (m, 1H), 1.78-1.84 (m, 2H), 1.95-1.99 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.10-3.20 (m, 1H), 3.74-3.88 (m, 1H), 6.80 (s, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.93 (d, 2H, J = 7.2 Hz), 8.53 (s, 1H).
化合物Ij-37
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.93 (d, 1H, J = 7.5 Hz), 7.04 (t, 1H, J = 5.7 Hz), 7.26-7.38 (m, 2H), 7.40-7.52 (m, 1H), 7.57 (d, 1H, J = 9.0 Hz), 7.85 (t, 1H, J =7.8 Hz)
化合物Ij-38
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 3.80 (s, 3H), 6.72 (d, 1H, J = 7.8 Hz), 6.77 (d, 1H, J = 9.0 Hz), 6.98-7.10 (m, 2H), 7.12 (d, 1H, J = 8.4 Hz), 7.38 (t, 1H, J = 8.1 Hz), 7.56 (d, 1H, J = 9.3 Hz), 7.61 (d, 1H, J = 7.8 Hz)
化合物Ij-39
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.92 (d, 1H, J = 7.5 Hz), 7.04 (t, 1H, J = 5.7 Hz), 7.21 (t, 1H, J = 8.7 Hz), 7.46-7.56 (m, 1H), 7.75-7.88 (m, 3H)
化合物Ij-40
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.15-1.26 (m, 2H), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.76-3.87 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.91 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.42-7.52 (m, 2H), 7.83 (d, 1H, J = 8.0 Hz), 7.93 (d, 1H, J = 8.0 Hz), 8.02 (s, 1H).
化合物Ij-41
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.20 (t, 3H, J = 7.5 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.76-3.90 (m, 1H), 6.88 (d, 1H, J = 9.3 Hz), 6.97 (d, 1H, J = 7.5 Hz), 7.03 (t, 1H, J = 5.7 Hz), 7.67-7.77 (m, 2H), 7.92 (d, 1H, J = 9.6 Hz), 8.26 (d, 1H, J = 6.9 Hz), 8.33(s, 1H)
化合物Ij-42
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.20 (t, 3H, J= 7.2 Hz), 1.22-1.28 (m, 1H), 1.35-1.50 (m, 2H), 1.84 (d, 2H, J = 12.0 Hz), 2.08 (d, 2H, J = 12.0 Hz), 2.63-2.76 (m, 2H), 2.91-3.03 (m, 2H), 3.75-3.90 (m, 1H), 6.86 (d, 1H, J = 9.2 Hz), 6.93 (d, 1H, J = 7.2 Hz), 6.98-7.07 (m, 1H), 7.36 (d, 1H, J = 7.2 Hz), 7.59 (t, 1H, J = 8.0 Hz), 7.85 (d, 1H, J = 9.2 Hz), 7.91-8.02 (m, 2H). 融点:144-145℃
化合物Ij-43
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.10-1.24 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.98-2.06 (m, 2H), 2.81 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.62-3.74 (m, 1H), 6.84 (d, 1H, J =9.2 Hz), 6.88-6.98 (m, 2H), 7.31 (d, 1H, J = 9.6 Hz).
化合物Ij-44
1H-NMR (DMSO-d6) δ: 0.94-1.26 (m, 4H), 1.20 (d, 6H, J = 6.6 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.06-3.20 (m, 1H), 3.72-3.90 (m, 1H), 6.75-6.88 (m, 2H), 6.97 (t, 1H, J = 6.0 Hz), 7.30-7.48 (m, 3H), 7.76 (d, 1H, J = 9.3 Hz), 7.94 (d, 2H, J =8.4 Hz)
化合物Ij-45
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J = 9.0 Hz), 6.91 (d, 1H, J = 7.5 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.25-7.36 (m, 2H), 7.40-7.50 (m, 1H), 7.57 (d, 1H, J = 6.9 Hz), 7.85 (t, 1H, J =8.1 Hz)
化合物Ij-46
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J = 9.3 Hz), 6.90 (d, 1H, J = 7.5 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.21 (t, 1H, J = 7.8 Hz), 7.46-7.56 (m, 1H), 7.75-7.86 (m, 3H)
化合物Ij-47
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.81 (d, 1H, J = 7.5 Hz), 6.84 (d, 1H, J = 9.3 Hz), 6.98 (t, 1H, J = 6.3 Hz), 7.25-7.35 (m, 2H), 7.77 (d, 1H, J = 9.3 Hz), 7.96-8.06 (m, 2H)
化合物Ij-48
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.71 (d, 1H, J = 7.8 Hz), 6.76 (d, 1H, J = 9.3 Hz), 6.98 (t, 1H, J = 5.7 Hz), 7.05 (d, 1H, J = 7.2 Hz), 7.12 (d, 1H, J = 7.8 Hz), 7.38 (t, 1H, J = 8.4 Hz), 7.56 (d, 1H, J = 9.3 Hz), 7.62 (d, 1H, J = 6.9 Hz)
化合物Ij-49
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.82 (s, 3H), 6.78-6.88 (m, 2H), 6.92-7.04 (m, 2H), 7.37 (t, 1H, J = 7.5 Hz), 7.46-7.58 (m, 2H), 7.79 (d, 1H, J = 9.3 Hz)
化合物Ij-50
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.70 (d, 1H, J = 7.8 Hz), 6.82 (d, 1H, J = 9.3 Hz), 6.95-7.05 (m, 3H), 7.72 (d, 1H, J = 9.3 Hz), 7.90 (d, 2H, J = 9.0 Hz).
化合物Ij-51
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.10 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.57-3.68 (m, 1H), 4.89-4.98 (m, 2H), 6.47 (d, 1H, J = 8.0 Hz), 6.88 (d, 1H, J = 7.5 Hz), 6.96 (t, 1H, J = 6.0 Hz), 7.02 (d, 1H, J = 7.5 Hz).
化合物Ij-52
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.52-1.74 (m, 6H), 1.77-1.85 (m, 2H), 1.87-1.97 (m, 2H), 2.02-2.09 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.55-3.65 (m, 1H), 5.25-5.32 (m, 1H), 6.19 (d, 1H, J = 8.0 Hz), 6.77 (s, 2H), 6.95 (t, 1H, J = 6.0 Hz).
化合物Ij-53
1H-NMR (DMSO-d6) δ: 0.92-1.15 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.88-1.95 (m, 4H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.25-3.35 (m, 4H), 3.55-3.65 (m, 1H), 5.80-5.85 (m, 1H), 6.72 (d, 1H, J = 8.0 Hz), 6.80 (d, 1H, J = 8.0 Hz), 6.96 (t, 1H, J = 6.0 Hz).
化合物Ij-54
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.56 (d, 1H, J = 8.0 Hz), 6.90-6.98 (m, 2H), 7.03-7.10 (m, 3H), 7.15 (t, 1H, J = 8.0 Hz), 6.38 (t, 2H, J = 8.0 Hz).
化合物Ij-55
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.90-6.98 (m, 2H), 7.05-7.15 (m, 3H), 7.21 (t, 2H, J = 8.0 Hz).
化合物Ij-56
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 3.75 (s, 3H), 6.49 (d, 1H, J = 8.0 Hz), 6.87-6.98 (m, 4H), 7.00-7.07 (m, 3H).
化合物Ij-57
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.00-2.10 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.76 (m, 1H), 6.82-6.92 (m, 2H), 6.96 (d, 1H, J = 7.8 Hz), 7.32 (d, 1H, J = 9.6 Hz).
化合物Ij-58
1H-NMR (DMSO-d6) δ: 0.99-1.28 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.78-1.86 (m, 2H), 2.04-2.10 (m, 2H), 2.82 (t, 2H, J = 6.1 Hz), 3.06-3.20 (m, 1H), 3.80-3.96 (m, 1H), 6.71 (d, 1H, J = 9.0 Hz), 6.76-6.86 (m, 1H), 6.90-6.98 (m, 1H), 7.10 (t, 1H, J = 8.1 Hz), 7.39-7.50 (m, 2H), 7.56 (d, 1H, J = 7.5 Hz), 7.78 (d, 1H, J = 7.5 Hz).
化合物Ij-59
1H-NMR (DMSO-d6) δ: 0.99-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H), 1.80-1.85 (m, 2H), 2.04-2.09 (m, 2H), 2.91 (t, 2H, J = 6.1 Hz), 3.80-3.96 (m, 1H), 6.70 (d, 1H, J = 9.0 Hz), 6.81-6.87 (m, 2H), 7.10 (t, 1H, J = 8.1 Hz), 7.39-7.44 (m, 2H), 7.56 (d, 1H, J = 7.5 Hz), 7.79 (d, 1H, J = 7.5 Hz).
化合物Ij-60
1H-NMR (DMSO-d6) δ: 0.97-1.09 (m, 2H), 1.23 (d, 6H, J = 6.9 Hz), 1.31-1.50 (m, 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.11-3.20 (m, 1H), 4.00-4.18 (m, 1H), 6.83 (d, 1H, J = 5.7 Hz), 6.90-7.06 (m, 2H), 7.45 (t, 1H, J = 6.9 Hz), 7.59 (t, 1H, J = 8.1 Hz), 7.67 (d, 1H, J = 8.4 Hz), 7.83 (d, 1H, J = 5.7 Hz), 8.27 (d, 1H, J = 7.5 Hz).
化合物Ij-61
1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.28 (s, 9H), 1.29-1.50 (m, 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.91 (t, 2H, J = 7.8 Hz), 4.00-4.18 (m, 1H), 6.82-6.89 (m, 2H), 6.97 (d, 1H, J = 7.5 Hz ), 7.45 (t, 1H, J = 7.2 Hz), 7.59 (t, 1H, J = 8.1 Hz), 7.67 (d, 1H, J = 7.8 Hz), 7.84 (d, 1H, J = 6.0 Hz), 8.27 (d, 1H, J = 8.4 Hz).
化合物Ij-62
1H-NMR (DMSO-d6) δ: 0.96-1.14 (m, 2H), 1.18-1.30 (m, 2H), 1.22 (d, 6H, J = 6.6 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.58-3.70 (m, 1H), 6.95-7.03 (m, 2H), 7.20 (t, 1H, J = 7.5 Hz ), 7.37 (d, 1H, J = 8.1 Hz), 7.64 (d, 1H, J = 7.5 Hz), 7.92 (d, 1H, J = 7.8 Hz).
化合物Ij-63
1H-NMR (DMSO-d6) δ: 1.00 (dd, 2H, J = 24.8, 10.6 Hz), 1.15-1.22 (m, 2H), 1.18 (t, 3H, J = 7.6 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.81 (d, 2H, J = 11.6 Hz), 2.07 (d, 2H, J = 11.6 Hz), 2.60 (q, 2H, J = 7.6 Hz), 2.89 (t, 2H, J = 6.3 Hz), 3.52-3.63 (m, 1H), 6.87 (t, 1H, J = 5.8 Hz), 7.04 (d, 1H, J = 7.9 Hz), 7.27 (d, 1H, J = 8.2 Hz), 7.47 (s, 1H), 7.80 (d, 1H, J = 7.6 Hz).
化合物Ij-64
1H-NMR (DMSO-d6) δ: 0.92-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.89 (t, 2H, J = 6.0 Hz), 3.50-3.66 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.03 (dd, 1H, J = 8.7, 2.7 Hz), 7.32-7.37 (m, 1H), 7.58 (dd, 1H, J = 8.7, 2.7 Hz), 7.92 (d, 1H, J = 7.2 Hz).
化合物Ij-65
1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J = 24.6, 10.2 Hz), 1.21 (dd, 2H, J = 24.6, 10.2 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.82 (d, 2H, J = 11.2 Hz), 2.08 (d, 2H, J = 11.2 Hz), 2.89 (t, 2H, J = 6.2 Hz), 3.59-3.65 (m, 1H), 6.87 (t, 1H, J = 5.8 Hz), 7.21 (dd, 1H, J = 8.6, 2.4 Hz), 7.34 (d, 1H, J = 8.6 Hz), 7.77 (d, 1H, J = 1.8 Hz), 8.06 (d, 1H, J = 7.6 Hz).
化合物Ij-66
1H-NMR (CDCl3) δ: 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.54 (m, 1H), 1.90-2.00 (m, 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J = 6.6 Hz), 3.46-3.60 (m, 1H), 3.99 (t, 1H, J = 6.6 Hz), 6.58 (brs, 1H), 7.58(s, 2H), 7.85 (s, 1H).
化合物Ij-67
1H-NMR (DMSO-d6) δ: 0.90-1.30 (m, 4H), 1.27 (s, 9H), 1.30-1.48 (m, 1H), 1.82 (d, 2H, J = 11.1 Hz), 2.08 (d, 2H, J = 9.6 Hz), 2.89 (t, 2H, J = 6.3 Hz), 3.55-3.70 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.17 (m, 1H), 7.41 (d, 1H, J = 8.7 Hz), 7.77 (d, 1H, J = 1.5 Hz), 8.10 (d, 1H, J = 7.5 Hz). ESI(positive)m/z 466.2 [M+H]+
化合物Ij-68
1H-NMR (DMSO-d6) δ: 0.90-1.28 (m, 4H), 1.25 (s, 9H), 1.32 (m, 1H), 1.76-1.82 (m, 2H), 2.00-2.10 (m, 2H), 2.87 (t, 2H, J = 6.6 Hz), 3.50-3.62 (m, 1H), 3.71 (s, 3H), 6.77 (dd, 1H, J = 8.7, 2.7 Hz), 6.84 (t, 1H, J = 5.7 Hz), 7.22-7.28 (m, 2H), 7.66 (d, 1H, J = 7.2 Hz).
化合物Ij-69
1H-NMR (DMSO-d6) δ: 0.94-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.90 (t, 2H, J = 6.0 Hz), 3.52-3.68 (m, 1H), 3.84 (s, 3H), 6.82 (d, 1H, J = 8.1 Hz), 6.88 (t, 1H, J = 5.4 Hz), 6.95 (t, 1H, J = 7.8 Hz), 7.23 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz).
化合物Ij-70
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.17-1.32 (m, 2H), 1.40 (m, 1H), 1.76-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.78 (m, 1H), 7.03 (t, 1H, J = 6.3 Hz), 7.45-7.54 (m, 2H), 8.10 (s, 1H), 8.34 (d, 1H, J = 7.2 Hz).
化合物Ij-71
1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J = 26.1, 12.3 Hz), 1.16-1.22 (m, 2H), 1.22 (d, 6H, J = 6.6 Hz), 1.35-1.41 (m, 1H), 1.70-1.77 (m, 1H), 1.82 (d, 2H, J = 11.6 Hz), 2.08 (d, 2H, J = 11.6 Hz), 2.81 (t, 2H, J = 6.3 Hz), 3.66-3.72 (m, 1H), 6.99 (t, 1H, J = 6.3 Hz), 7.23 (dd, 1H, J = 8.1, 4.7 Hz), 7.66 (d, 1H, J = 8.1 Hz), 8.07 (d, 1H, J = 4.7 Hz), 8.26 (d, 1H, J = 6.3 Hz).
化合物Ij-72
1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J = 24.8, 11.3 Hz), 1.18-1.23 (m, 2H), 1.27 (s, 9H), 1.36-1.39 (m, 1H), 1.82 (d, 2H, J = 11.5 Hz), 2.08 (d, 2H, J = 11.5 Hz), 2.89 (t, 2H, J = 6.1 Hz), 3.65-3.73 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.23 (dd, 1H, J = 8.1, 4.8 Hz), 7.66 (d, 1H, J = 7.9 Hz), 8.07 (d, 1H, J = 4.7 Hz), 8.26 (d, 1H, J = 7.6 Hz).
化合物Ij-73
1H-NMR (CDCl3)δ: 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.55 (m, 1H), 1.92-2.02 (m, 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J = 6.3 Hz), 3.58-3.72 (m, 1H), 3.98 (t, 1H, J = 6.0 Hz), 6.30 (brs, 1H), 7.62(d, 1H, J = 8.1 Hz), 7.77 (d, 1H, J = 8.4 Hz).
化合物Ij-74
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.12-1.40 (m, 3H), 1.25 (s, 9H), 1.76-1.86 (m, 2H), 1.98-2.10 (m, 2H), 2.87 (d, 2H, J = 6.3 Hz), 3.40-3.56 (m, 1H), 6.85 (brs, 1H), 6.93 (t, 1H, J = 7.5 Hz), 7.07 (t, 1H, J = 7.5 Hz), 7.20 (d, 1H, J = 7.5 Hz), 7.29 (d, 1H, J = 7.8 Hz), 7.79 (brs, 1H).
化合物Ij-75
1H-NMR (CDCl3) δ: 1.08-1.26 (m, 2H), 1.36-1.60 (m, 3H), 1.40 (s, 9H), 1.92-2.02 (m, 2H), 2.22-2.32 (m, 2H), 3.08 (t, 2H, J = 6.6 Hz), 3.68-3.80 (m, 1H), 4.03 (t, 1H, J = 6.0 Hz), 7.06 (brs, 1H), 7.20-7.36(m, 3H).
化合物Ij-76
1H-NMR (DMSO-d6) δ: 1.02 (dd, 2H, J = 25.2, 12.4 Hz), 1.17 (t, 3H, J = 7.1 Hz), 1.20 (t, 3H, J = 7.3 Hz), 1.26-1.35 (m, 2H), 1.37-1.42 (m, 1H), 1.83 (d, 2H, J = 11.6 Hz), 2.05 (d, 2H, J = 11.6 Hz), 2.80 (t, 2H, J = 6.4 Hz), 2.99 (q, 2H, J = 7.3 Hz), 3.65-3.72 (m, 1H), 4.01 (q, 2H, J = 7.1 Hz), 6.32 (d, 1H, J = 7.9 Hz), 6.86-6.94 (m, 2H), 7.01 (t, 1H, J = 6.0 Hz), 7.12 (d, 1H, J = 6.9 Hz), 7.17 (d, 1H, J = 6.8 Hz).
化合物Ij-77
1H-NMR (DMSO-d6) δ: 1.02 (dd, 2H, J = 24.8, 10.8 Hz), 1.19-1.21 (m, 2H), 1.30 (s, 9H), 1.37-1.41 (m, 1H), 1.84 (d, 2H, J = 10.6 Hz), 2.06 (d, 2H, J = 10.6 Hz), 2.92 (t, 2H, J = 6.3 Hz), 3.50-3.52 (m, 1H), 6.42 (d, 1H, J = 8.1 Hz), 6.83 (d, 1H, J = 7.9 Hz), 6.88-6.92 (m, 2H), 7.11-7.14 (m, 2H), 10.58 (s, 1H).
化合物Ij-78
1H-NMR (DMSO-d6) δ: 0.97-1.05 (m, 2H), 1.20-1.26 (m, 2H), 1.28 (s, 9H), 1.34-1.38 (m, 1H), 1.84 (d, 2H, J = 11.5 Hz), 2.07 (d, 2H, J = 11.5 Hz), 2.90 (t, 2H, J = 6.1 Hz), 3.47 (s, 3H), 3.63-3.69 (m, 1H), 6.34 (d, 1H, J = 7.6 Hz), 6.87-6.93 (m, 3H), 7.11 (d, 1H, J = 8.4 Hz), 7.17 (d, 1H, J = 8.4 Hz).
化合物Ij-79
1H-NMR (DMSO-d6) δ: 1.03 (dd, 2H, J = 23.6, 10.8 Hz), 1.18 (t, 3H, J = 7.5 Hz), 1.25-1.34 (m, 2H), 1.29 (s, 9H), 1.37-1.40 (m, 1H), 1.86 (d, 2H, J = 11.7 Hz), 2.07 (d, 2H, J = 11.7 Hz), 2.92 (t, 2H, J = 6.2 Hz), 3.67-3.73 (m, 1H), 4.03 (q, 2H, J = 7.1 Hz), 6.34 (d, 1H, J = 7.9 Hz), 6.87-6.96 (m, 3H), 7.14 (dd, 1H, J = 8.1, 1.2 Hz), 7.19 (dd, 1H, J = 8.1, 1.2 Hz).
化合物Ij-80
1H-NMR (DMSO-d6) δ: 1.00 (dd, 2H, J = 23.2, 11.9 Hz), 1.19-1.25 (m, 2H), 1.28 (s, 9H), 1.33-1.38 (m, 1H), 1.45 (s, 3H), 1.47 (s, 3H), 1.83 (d, 2H, J = 11.1 Hz), 2.07 (d, 2H, J = 11.1 Hz), 2.90 (t, 2H, J = 6.1 Hz), 3.62-3.70 (m, 1H), 4.57-4.66 (m, 1H), 6.21 (d, 1H, J = 7.9 Hz), 6.82-6.94 (m, 3H), 7.18 (d, 1H, J = 7.6 Hz), 7.31 (d, 1H, J = 7.6 Hz).
化合物Ij-81
化合物Ij-82
1H-NMR (DMSO-d6) δ: 0.90-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.45 (m, 1H), 1.80 (d, 2H, J = 11.2 Hz), 1.98 (d, 2H, J = 11.2 Hz), 2.84-2.93 (m, 2H), 3.26 (s, 3H), 3.40-3.53 (m, 1H), 6.29 (d, 1H, J = 8.0 Hz), 6.38 (d, 1H, J = 7.2 Hz), 6.86 (s, 1H), 7.33 (d, 1H, J = 8.4 Hz).
化合物Ij-83
化合物Ij-84
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.75-1.85 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.78 (m, 1H), 6.38 (d, 1H, J = 8.1 Hz), 6.67 (s, 1H), 6.72 (d, 1H, J = 5.4 Hz), 7.00 (t, 1H, J = 6.0 Hz), 7.36-7.54 (m, 3H), 7.62 (d, 2H, J = 6.9 Hz), 8.00 (d, 1H, J = 5.4 Hz)
化合物Ij-85
1H-NMR (DMSO-d6) δ: 1.00-1.20 (m, 4H), 1.20 (t, 3H, J = 7.2 Hz), 1.43 (m, 1H), 1.80-1.88 (m, 2H), 2.03-2.13 (m, 2H), 2.81 (t, 3H, J = 6.0 Hz), 3.00 (q, 2H, J = 7.2 Hz), 3.26 (m, 1H), 6.17 (d, 1H, J = 7.6 Hz), 6.57 (s, 1H), 6.96-7.07 (m, 2H), 7.35 (dd, 1H, J = 8.4, 4.0 Hz), 8.02 (d, 1H, J = 8.4 Hz), 8.47 (d, 1H, J = 4.0 Hz).
化合物Ij-86
1H-NMR (DMSO-d6) δ: 1.00-1.24 (m, 4H), 1.23 (d, 6H, J = 6.4 Hz), 1.42 (m, 1H), 1.80-1.88 (m, 2H), 2.03-2.12 (m, 2H), 2.79-2.87 (m, 2H), 3.16 (m, 1H), 3.27 (m, 1H), 6.17 (d, 1H, J = 8.0 Hz), 6.57 (s, 1H), 6.99 (d, 1H, J = 8.0 Hz), 7.01 (s, 1H), 7.35 (dd, 1H, J = 8.0, 4.0 Hz), 8.02 (d, 1H, J = 8.0 Hz), 8.47 (d, 1H, J = 2.8 Hz).
化合物Ij-87
1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.11-1.25 (m, 2H), 1.20 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.76-1.86 (m, 2H), 1.97-2.04 (m, 2H), 2.73-2.82 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.70 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.53 (d, 1H, J = 8.8 Hz), 7.01 (t, 1H, J = 6.0 Hz), 7.58 (d, 1H, J = 3.2 Hz), 7.79 (d, 1H, J = 3.2 Hz), 7.86 (d, 1H, J = 8.8 Hz), 8.55 (s, 1H).
化合物Ij-88
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.09-1.20 (m, 2H), 1.19 (t, 6H, J = 7.2 Hz), 1.39 (m, 1H), 1.75-1.83 (m, 2H), 1.95-2.03 (m, 2H), 2.74-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.66 (m, 1H), 6.48 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 7.6 Hz), 7.00 (t, 1H, J = 5.6 Hz), 7.06 (dd, 1H, J = 4.8, 2.4 Hz), 7.25 (d, 1H, J = 2.4 Hz), 7.37 (d, 1H, J = 4.8 Hz), 7.60 (dd, 1H, J = 8.4, 2.0 Hz), 8.26 (s, 1H).
化合物Ij-89
1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.10-1.20 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.39 (m, 1H), 1.76-1.84 (m, 2H), 1.96-2.04 (m, 2H), 2.73-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.65 (m, 1H), 6.41-6.50 (m, 2H), 7.01 (t, 1H, J = 6.0 Hz), 7.44 (d, 1H, J = 4.0 Hz), 7.58 (m, 1H), 7.59 (s, 1H), 7.68 (d, 1H, J = 8.0 Hz), 8.34 (s, 1H).
化合物Ij-90
1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.94-2.03 (m, 2H), 2.75-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.71 (m, 1H), 6.54 (d, 1H, J = 8.8 Hz), 6.98-7.07 (m, 2H), 7.25 (s, 1H), 7.85 (dd, 1H, J = 8.8, 2.0 Hz), 8.07 (s, 1H), 8.56 (d, 1H, J = 2.0 Hz).
化合物Ij-91
1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.11-1.22 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.95-2.03 (m, 2H), 2.77-2.83 (m, 2H), 3.14 (m, 1H), 3.72 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.97 (t, 1H, J = 6.0 Hz), 7.02 (d, 1H, J = 7.6 Hz), 7.25 (s, 1H), 7.84 (dd, 1H, J = 8.8, 2.0 Hz), 8.06 (s, 1H), 8.56 (d, 1H, J = 2.0 Hz).
化合物Ij-92
1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.11-1.23 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.37 (m, 1H), 1.75-1.83 (m, 2H), 1.91-1.99 (m, 2H), 2.36-2.42 (m, 2H), 3.12 (m, 1H), 3.70 (m, 1H), 6.49 (d, 1H, J = 9.2 Hz), 6.97 (t, 1H, J = 6.0 Hz), 7.47 (d, 1H, J = 8.0 Hz), 7.62 (d, 1H, J = 8.0 Hz), 8.36 (s, 1H).
化合物Ij-93
1H-NMR (DMSO-d6) δ: 0.95-1.13 (m, 4H), 1.23 (d, 6H, J = 6.9 Hz), 1.31-1.44 (m, 1H), 1.78-1.82 (m, 2H), 2.03-2.06 (m, 2H), 2.76-2.82 (m, 2H), 3.10-3.19 (m, 1H), 3.20-3.25 (m, 4H), 3.58-3.65 (m, 1H), 3.69-3.74 (m, 4H), 6.04 (d, 1H, J = 7.5 Hz), 6.72 (d, 1H, J = 9.6 Hz), 6.95-6.99 (m, 1H), 7.10 (d, 1H, J = 9.6 Hz).
化合物Ij-94
1H-NMR (DMSO-d6) δ: 0.96-1.42 (m, 5H), 1.22 (d, 6H, J = 6.9 Hz), 1.79-1.83 (m, 2H), 2.03-2.07 (m, 2H), 2.80 (d, 2H, J = 6.3 Hz), 3.10-3.19 (m, 1H), 3.54-3.70 (m, 1H), 3.74 (s, 3H), 6.57-6.64 (m, 3H), 6.72-6.75 (m, 1H), 6.90-7.09 (m, 3H), 7.24-7.30 (m, 1H).
化合物Ij-95
1H-NMR (DMSO-d6) δ: 0.93-1.04 (m, 2H), 1.10-1.18 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.34-1.44 (m, 1H), 1.78-1.87 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.52-3.70 (m, 1H), 6.64 (d, 1H, J = 8.0 Hz), 6.88-7.06 (m, 5H), 7.12 (d, 1H, J = 8.0 Hz), 7.37-7.46 (m, 1H).
化合物Ij-96
1H-NMR (DMSO-d6) δ: 0.90-1.04 (m, 2H), 1.05-1.18 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.84 (m, 2H), 1.98-2.08 (m, 2H), 2.76-2.84 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.64 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.91-7.00 (m, 2H), 7.15-7.38 (m, 5H).
化合物Ij-97
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.35-1.47 (m, 1H), 1.78-1.87 (m, 2H), 2.02-2.10 (m, 2H), 2.78-2.83 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.70-3.82 (m, 1H), 6.82 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 7.01 (t, 1H, J = 4.5 Hz), 7.13 (d, 1H, J = 4.0 Hz), 7.43 (d, 1H, J = 4.0 Hz), 7.76 (d, 1H, J = 8.0 Hz).
化合物Ij-98
1H-NMR (DMSO-d6) δ: 0.97-1.10 (m, 2H), 1.17-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.37-1.49 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.12 (m, 2H), 2.77-2.83 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.88 (m, 1H), 6.85 (d, 1H, J = 8.0 Hz), 6.99-7.05 (m, 2H), 7.61 (s, 1H), 7.90 (d, 1H, J = 8.0 Hz), 8.02 (s, 2H).
化合物Ij-99
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.13 (m, 2H), 2.77-2.83 (m, 2H), 2.96 (s, 6H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.86 (m, 1H), 6.72-6.78 (m, 2H), 6.82 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 4.5 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.26 (t, 1H, J = 8.0 Hz), 7.34 (s, 1H), 7.74 (d, 1H, J = 8.0 Hz).
化合物Ij-100
1H-NMR (DMSO-d6)δ: 0.98-1.10 (m, 2H), 1.16-1.27 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.13 (m, 2H), 2.77-2.83 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.86 (m, 1H), 6.83 (d, 1H, J = 8.0 Hz), 6.89 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 4.5 Hz), 7.42-7.50 (m, 3H), 7.53-7.59 (m, 2H).
化合物Ij-101
1H-NMR (DMSO-d6)δ: 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.09 (m, 2H), 2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.56-3.68 (m, 1H), 6.62 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 6.98 (t, 1H, J = 4.5 Hz), 7.10-7.15 (m, 3H), 7.43 (d, 2H, J = 8.0 Hz).
化合物Ij-102
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.09 (m, 2H), 2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.68 (m, 1H), 6.65 (d, 1H, J = 8.0 Hz), 6.94 (d, 1H, J = 8.0 Hz), 6.97 (t, 1H, J = 4.5 Hz), 7.06 (d, 1H, J = 8.0 Hz), 7.13 (d, 1H, J = 8.0 Hz), 7.18-7.26 (m, 2H), 7.41 (t, 1H, J = 8.0 Hz).
化合物Ij-103
1H-NMR (DMSO-d6) δ: 0.88-1.04 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.77-1.82 (m, 2H), 2.00-2.07 (m, 2H), 2.76-2.82 (m, 2H), 3.08-3.20 (m, 1H), 3.52-3.64 (m, 1H), 6.57 (d, 1H, J = 8.0 Hz), 6.92-7.00 (m, 2H), 7.17 (d, 1H, J = 8.0 Hz), 7.23-7.28 (m, 2H), 7.38 (t, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz).
化合物Ij-104
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.19 (t, 3H, J = 7.6 Hz), 1.35-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.04-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.6 Hz), 3.67-3.78 (m, 1H), 6.27 (s, 2H), 6.71 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 7.02 (brs, 1H), 7.52 (s, 2H), 7.67 (d, 1H, J = 8.0 Hz).
化合物Ij-105
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.13-1.25 (m, 2H), 1.19 (t, 3H, J = 7.6 Hz), 1.35-1.46 (m, 1H), 1.78-1.87 (m, 2H), 2.04-2.12 (m, 2H), 2.76-2.83 (m, 2H), 2.99 (q, 2H, J = 7.6 Hz), 3.72-3.82 (m, 1H), 6.82 (d, 1H, J = 8.0 Hz), 6.85 (d, 1H, J = 8.0 Hz), 7.03 (t, 1H, J = 4.5 Hz), 7.12 (t, 1H, J = 4.0 Hz), 7.51 (d, 1H, J = 4.0 Hz), 7.56 (d, 1H, J = 4.0 Hz), 7.76 (d, 1H, J = 8.0 Hz).
化合物Ij-106
1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.45 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.08 (m, 2H), 2.76-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.67 (m, 1H), 6.63 (d, 1H, J = 8.0 Hz), 6.92-7.00 (m, 3H), 7.13 (d, 1H, J = 8.0 Hz), 7.29-7.36 (m, 1H), 7.42-7.50 (m, 1H).
化合物Ij-107
1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H), 1.98-2.06 (m, 2H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.63 (m, 1H), 6.57 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 6.97 (t, 1H, J = 4.5 Hz), 7.12 (t, 1H, J = 4.0 Hz), 7.19 (d, 1H, J = 8.0 Hz), 7.33-7.47 (m, 2H).
化合物Ij-108
1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H), 1.98-2.07 (m, 2H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.54-3.63 (m, 1H), 6.63 (d, 1H, J = 8.0 Hz), 6.93-7.00 (m, 2H), 7.14 (t, 1H, J = 8.0 Hz), 7.20-7.37 (m, 3H).
化合物Ij-109
1H-NMR (DMSO-d6) δ: 0.82-1.05 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.43 (m, 1H), 1.76-1.83 (m, 2H), 2.00-2.08 (m, 2H), 2.29 (s, 3H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.56-3.66 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.90 (d, 1H, J = 8.0 Hz), 6.93-7.00 (m, 3H), 7.05 (d, 1H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.0 Hz).
化合物Ij-110
1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.43 (m, 1H), 1.80 (d, 2H, J = 12.0 Hz), 2.07 (d, 2H, J = 12.0 Hz), 2.88 (t, 2H, J = 6.4 Hz), 3.16-3.27 (m, 1H), 5.47 (d, 1H, J = 7.6 Hz), 5.80 (s, 1H), 6.83 (d, 1H, J = 6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (t, 1H, J = 8.4 Hz), 7.86 (s, 1H).
化合物Ij-111
1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.32-1.43 (m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.83 (m, 2H), 3.08-3.27 (m, 2H), 5.48 (d, 1H, J = 8.1 Hz), 5.80 (d, 1H, J = 2.7 Hz), 6.95 (t, 1H, J = 6.0 Hz), 7.15-7.39 (m, 3H), 7.75 (td, 1H, J = 8.4, 1.8 Hz), 7.86 (t, 1H, J = 2.7 Hz).
化合物Ij-112
1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.30-1.45 (m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.83 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz) 3.10-3.30 (m, 1H), 5.48 (d, 1H, J = 7.8 Hz), 5.80 (d, 1H, J = 2.7 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (td, 1H, J = 8.4, 1.8 Hz), 7.86 (t, 1H, J = 2.7 Hz).
化合物Ij-113
化合物Ij-114
化合物Ij-115
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.30-1.45 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.74-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz) 3.15-3.30 (m, 1H), 5.53 (d, 1H, J = 8.1 Hz), 5.80 (d, 1H, J = 2.4 Hz), 6.92 (t, 1H, J = 8.4 Hz), 7.01 (t, 1H, J = 6.0 Hz), 7.37-7.43 (m, 3H), 8.21 (d, 1H, J = 2.4 Hz).
化合物Ij-116
化合物Ij-117
化合物Ij-118
1H-NMR (DMSO-d6)δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 1H), 1.75-1.86 (m, 2H), 2.02-2.12 (m, 2H), 2.74-2.83 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz) 3.13-3.30 (m, 1H), 5.38 (d, 1H, J = 8.4 Hz), 5.75 (d, 1H, J = 2.7 Hz), 6.99 (t, 1H, J = 6.3 Hz), 7.18-7.28 (m, 2H), 7.63-7.70 (m, 2H), 8.11 (d, 1H, J = 2.7 Hz).
化合物Ij-119
1H-NMR (DMSO-d6) δ: 0.88-1.19 (m, 4H), 1.18 (t, 3H, J = 7.5 Hz), 1.28-1.45 (m, 1H), 1.73-1.83 (m, 2H), 2.02-2.13 (m, 2H), 2.73-2.81 (m, 2H), 2.95 (q, 2H, J = 7.5 Hz) 3.12-3.30 (m, 1H), 5.36 (d, 1H, J = 7.5 Hz), 5.76 (d, 1H, J = 2.4 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.30 (td, 1H, J = 7.5, 1.8 Hz), 7.42 (td, 1H, J = 7.8, 1.5 Hz), 7.53-7.60 (m, 2H), 7.84 (d, 1H, J = 2.7 Hz).
化合物Ij-120
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 1H), 1.74-1.84 (m, 2H), 2.02-2.10 (m, 2H), 2.75-2.82 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz) 3.20-3.30 (m, 1H), 5.52 (d, 1H, J = 7.8 Hz), 5.80 (d, 1H, J = 2.4 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.13 (d, 1H, J = 8.1 Hz), 7.40 (t, 1H, J = 8.1 Hz), 7.62 (d, 1H, J = 8.4 Hz), 7.72 (s, 1H), 8.22 (d, 1H, J = 2.4 Hz).
化合物Ij-121
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 1H), 1.74-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.75-2.82 (m, 2H), 2.98 (q, 2H, J = 7.5 Hz) 3.15-3.30 (m, 1H), 5.47 (d, 1H, J = 8.1 Hz), 5.78 (d, 1H, J = 2.4 Hz), 7.00 (t, 1H, J = 6.0 Hz), 7.43 (d, 2H, J = 7.8 Hz), 7.67 (d, 2H, J = 9.0 Hz), 8.17 (d, 1H, J = 2.4 Hz).
化合物Ij-122
1H-NMR (DMSO-d6) δ: 0.94-1.07 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.81-1.84 (m, 2H), 1.99-2.07 (m, 2H), 2.77-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.77 (m, 1H), 7.01-7.05 (m, 1H), 7.22-7.40 (m, 4H), 7.81-7.87 (m, 1H), 8.02 (s, 1H), 8.36 (s, 1H).
化合物Ij-123
1H-NMR (DMSO-d6) δ: 0.95-1.12 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.77-1.81 (m, 2H), 1.96-1.99 (m, 2H), 2.74-2.78 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.54-3.70 (m, 1H), 4.81 (q, 2H, J = 9.0 Hz), 6.50-6.53 (m, 1H), 6.99-7.03 (m, 1H), 7.50 (d, 1H, J =0.9 Hz) 7.83 (d, 1H, J = 0.9 Hz).
化合物Ij-124
1H-NMR (DMSO-d6) δ: 0.95-1.23 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.77-1.81 (m, 2H), 2.03-2.07 (m, 2H), 2.74-2.80 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.61-3.73 (m, 1H), 7.00-7.04 (m, 1H), 7.09-7.12 (m, 1H), 7.29-7.37 (m, 2H), 7.45-7.52 (m, 1H), 7.88-7.94 (m, 2H), 8.04-8.05 (m, 1H).
化合物Ij-125
1H-NMR (DMSO-d6) δ: 0.94-1.14 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.79-1.83 (m, 2H), 1.97-2.03 (m, 2H), 2.76-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.50-3.63 (m, 1H), 4.43 (q, 2H, J = 9.0 Hz), 7.00-7.04 (m, 1H), 7.13-7.15 (m, 1H), 7.35 (s, 1H) 7.55 (s, 1H).
化合物Ij-126
1H-NMR (DMSO-d6) δ: 1.02-1.08 (m, 2H), 1.17-1.29 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.36-1.43 (m, 1H), 1.79-1.85 (m, 2H), 2.05-2.11 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.53-3.62 (m, 1H), 6.98 (t, 1H, J = 7.8 Hz), 7.03 (t, 1H, J = 6.3 Hz), 7.28 (dd, 1H, J = 7.5, 1.2 Hz), 7.63 (dd, 1H, J = 7.5, 1.2 Hz), 8.28 (d, 1H, J = 7.5 Hz).
化合物Ij-127
1H-NMR (DMSO-d6) δ: 0.97-1.05 (m, 2H), 1.18-1.24 (m, 2H), 1.16 (t, 3H, J = 7.5 Hz), 1.34-1.41 (m, 1H), 1.77-1.81 (m, 2H), 2.02-2.08 (m, 2H), 2.76 (t, 2H, J = 6.0 Hz), 2.96 (q, 2H, J = 7.5 Hz), 3.55-3.64 (m, 1H), 7.00 (t, 1H, J = 7.8 Hz), 7.18 (dd, 1H, J = 8.4, 1.8 Hz), 7.32 (dd, 1H, J = 8.4, 0.6 Hz), 7.74 (d, 1H, J = 1.8 Hz), 8.04 (d, 1H, J = 7.8 Hz).
化合物Ij-128
1H-NMR (DMSO-d6) δ: 0.98-1.07 (m, 2H), 1.15-1.26 (m, 8H), 1.32-1.43 (m, 1H), 1.78-1.84 (m, 2H), 1.98-2.09 (m, 2H), 2.60 (q, 2H, J = 7.5 Hz), 2.78 (t, 2H, J = 6.3 Hz), 2.96 (q, 2H, J = 7.5 Hz), 3.55-3.64 (m, 1H), 6.98-7.05 (m, 2H), 7.27 (dd, 1H, J = 7.8, 1.8 Hz), 7.47 (m, 1H), 7.84 (d, 1H, J =7.5 Hz).
化合物Ij-129
1H-NMR (DMSO-d6) δ: 0.92-1.15 (m, 2H), 1.15-1.35 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.48 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.78-2.84 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.62-3.80 (m, 1H), 7.02 (t, 1H, J = 6.0 Hz), 7.45 (d, 1H, J = 9.0 Hz), 8.09 (dd, 1H, J = 9.0, 2.4 Hz), 8.68 (d, 1H, J = 2.4 Hz), 8.70 (brs, 1H).
化合物Ij-130
1H-NMR (DMSO-d6) δ: 0.88-1.10 (m, 2H), 1.15-1.46 (m, 3H), 1.21 (d, 6H, J = 6.6 Hz), 1.78-1.88 (m, 2H), 1.98-2.08 (m, 2H), 2.76-2.86 (m, 2H), 3.10-3.20 (m, 1H), 3.46-3.62 (m, 1H), 6.91-6.96 (m, 1H), 7.01 (brs, 1H), 7.64 (d, 1H, J = 7.8 Hz), 8.07 (d, 1H, J = 5.1 Hz), 8.35 (d, 1H, J = 7.8 Hz).
化合物Ij-131
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.15-1.30 (m, 2H), 1.27 (s, 9H), 1.30-1.43 (m, 1H), 1.77-1.86 (m, 2H), 1.98-2.08 (m, 2H), 2.86-2.92 (m, 2H), 3.35-3.50 (m, 1H), 3.73 (s, 3H), 6.69 (dd, 1H, J = 8.4, 2.0 Hz), 6.86 (t, 1H, J = 6.0 Hz), 7.01 (d, 1H, J = 2.0 Hz), 7.10 (d, 1H, J = 8.4 Hz), 7.62 (d, 1H, J = 7.6 Hz).
化合物Ij-132
1H-NMR (DMSO-d6)δ: 0.92-1.08 (m, 2H), 1.15-1.33 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.42 (m, 1H), 1.76-1.86 (m, 2H), 1.98-2.08 (m, 2H), 2.76-2.82 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.40-3.58 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz), 7.13 (d, 1H, J = 8.4 Hz), 7.20 (d, 1H, J = 8.4 Hz), 7.49 (s, 1H), 8.01 (d, 1H, J = 7.6 Hz).
化合物Ij-133
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.16-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.46 (m, 1H), 1.78-1.85 (m, 2H), 2.04-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.55-3.70 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz), 7.12 (t, 1H, J = 9.6 Hz), 7.48 (d, 1H, J = 7.6 Hz), 8.13 (d, 1H, J = 7.6 Hz).
化合物Ij-134
1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.26 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.33-1.42 (m, 1H), 1.39-1.84 (m, 2H), 2.05-2.09 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.61-3.75 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.45 (dd, 1H, J = 7.5, 0.6 Hz), 7.60 (dd, 1H, J = 8.4, 1.5 Hz), 8.17 (d, 1H, J = 1.5 Hz), 8.50 (d, 1H, J = 7.5 Hz).
化合物Ij-135
1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.25 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.35-1.44 (m, 1H), 1.80-1.84 (m, 2H), 2.05-2.08 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.19 (m, 1H), 3.62-3.78 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.79 (d, 1H, J = 2.1 Hz), 8.10 (d, 1H, J = 2.1, 1.5 Hz), 8.52 (d, 1H, J = 6.9 Hz).
化合物Ij-136
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.17-1.24 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.33-1.41 (m, 1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78 (t, 2H, J = 6.3 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.56-3.67 (m, 1H), 7.00-7.04 (m, 2H), 7.39 (d, 1H, J = 2.1 Hz), 7.66 (dd, 1H, J = 8.4, 1.8 Hz), 8.14 (d, 1H, J = 7.5 Hz).
化合物Ij-137
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.12-1.28 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.31 (t, 3H, J = 6.9 Hz), 1.33-1.46 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.22 (m, 1H), 3.50-3.64 (m, 1H), 3.98 (q, 2H, J = 6.9 Hz), 6.78 (dd, 1H, J = 8.7, 2.7 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.23-7.27 (m, 2H), 7.68 (d, 1H, J = 7.2 Hz).
化合物Ij-138
1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H), 2.03-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.52-3.68 (m, 1H), 6.97-7.06 (m, 2H), 7.34 (dd, 1H, J = 8.4, 4.8 Hz), 7.56 (dd, 1H, J = 8.4, 2.4 Hz), 7.91 (d, 1H, J = 7.6 Hz).
化合物Ij-139
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.16-1.32 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.21 (m, 1H), 3.58-3.76 (m, 1H), 7.00 (t, 1H, J = 6.0 Hz), 8.19-8.23 (m, 2H), 8.52 (d, 1H, J = 6.9 Hz).
化合物Ij-140
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.12-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.58-3.78 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz), 8.08 (dd, 1H, J = 8.4, 2.7 Hz), 8.19 (d, 1H, J = 2.7 Hz), 8.38 (d, 1H, J = 7.2 Hz).
化合物Ij-141
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.15-1.22 (m, 5H), 1.34-1.42 (m, 1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.53-3.62 (m, 1H), 3.81 (s, 1H), 7.02 (t, 1H, J = 6.3 Hz), 7.41 (s, 1H), 7.53 (s, 1H), 7.88 (d, 1H, J = 7.5 Hz).
化合物Ij-142
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.17-1.30 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.32-1.41 (m, 1H), 1.79-1.84 (m, 2H), 2.01-2.05 (m, 2H), 2.77 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.41-3.58 (m, 1H), 6.97 (dd, 1H, J = 8.4, 2.4 Hz), 6.99-7.03 (m, 1H), 7.27 (d, 1H, J = 2.4 Hz), 7.34 (dd, 1H, J = 8.4, 0.3 Hz), 8.07-8.14 (m, 1H).
化合物Ij-143
1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 2H), 1.16-1.33 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H), 2.00-2.08 (m, 2H), 2.74-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.38-3.54 (m, 1H), 6.90-7.00 (m, 1H), 7.02 (t, 1H, J = 4.5 Hz), 7.19 (dd, 1H, J = 8.4, 5.1 Hz), 7.33 (dd, 1H, J = 8.4, 2.7 Hz), 7.88 (d, 1H, J = 7.8 Hz).
化合物Ij-144
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.19-1.29 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.31-1.41 (m, 1H), 1.79-1.84 (m, 2H), 2.01-2.05 (m, 2H), 2.77 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 6.9 Hz), 3.41-3.57 (m, 1H), 6.71-6.79 (m, 1H), 7.06-7.08 (m, 2H), 7.31 (dd, 1H, J = 8.7, 4.8 Hz), 8.03 (d, 1H, J = 7.8 Hz).
化合物Ij-145
1H-NMR (DMSO-d6) δ: 0.95-1.16 (m, 2H), 1.18-1.44 (m, 3H), 1.21 (d, 6H, J = 6.6 Hz), 1.78-1.86 (m, 2H), 2.02-2.12 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.40-3.58 (m, 1H), 6.95 (t, 1H, J = 7.8 Hz), 7.01 (brs, 1H), 7.09 (t, 1H, J = 6.9 Hz), 7.22 (d, 1H, J = 6.6 Hz), 7.31 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz).
化合物Ij-146
化合物Ij-147
化合物Ij-148
化合物Ij-149
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.13-1.30 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.39 (m, 1H), 1.76-1.87 (m, 2H), 2.02-2.14 (m, 2H), 2.79 (t, 2H, J = 6.3 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.56-3.70 (m, 1H), 6.95-7.05 (m, 2H), 7.20 (t, 1H, J = 7.8 Hz ), 7.37 (d, 1H, J = 7.8 Hz), 7.64 (d, 1H, J = 7.5 Hz), 7.92 (d, 1H, J = 7.5 Hz). 融点:168-169℃ Anal. Calcd for C16H23N3O2S2: C,54.36; H,6.56; N,11.89; S,18.14. Found: C,54.33; H,6.55; N,11.89; S,18.05.
化合物Ij-150
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.39 (m, 1H), 1.77-1.87 (m, 2H), 1.99-2.12 (m, 2H), 2.78 (t, 2H, J = 6.6 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.40-3.58 (m, 1H), 6.95 (t, 1H, J = 7.8 Hz), 7.02 (t, 1H, J = 6.0 Hz), 7.09 (t, 1H, J = 7.8 Hz), 7.22 (d, 1H, J = 7.5 Hz), 7.31 (d, 1H, J = 8.1 Hz), 7.83 (d, 1H, J = 7.8 Hz). 融点:170-171℃ Anal. Calcd for C16H23N3O3S: C,56.95; H,6.87; N,12.45; S,9.50. Found: C,56.91; H,6.91; N,12.43; S,9.51.
化合物Ij-151
1H-NMR (DMSO-d6) δ: 0.92-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.76-1.87 (m, 2H), 2.02-2.14 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.08-3.22 (m, 1H), 3.54-3.70 (m, 1H), 6.83 (t, 1H, J = 10.5 Hz), 6.99 (t, 1H, J = 5.4 Hz), 7.17 (dd, 1H, J = 10.5, 2.1 Hz), 7.63 (dd, 1H, J = 8.4, 5.7 Hz), 8.10 (d, 1H, J = 7.5 Hz). 融点:165-166℃ Anal. Calcd for C17H24FN3O2S2: C,52.96; H,6.27; F,4.93; N,10.90; S,16.63. Found: C,52.99; H,6.31; F,5.00; N,10.91; S,16.84.
化合物Ij-152
1H-NMR (DMSO-d6) δ: 0.92-1.09 (m, 2H), 1.11-1.28 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.75-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.52-3.67 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.03 (td, 1H, J = 9.6, 2.7 Hz), 7.34 (dd, 1H, J = 9.0, 5.1 Hz), 7.57 (dd, 1H, J = 9.0, 2.7 Hz), 7.91 (d, 1H, J = 7.2 Hz). 融点:151-152℃ Anal. Calcd for C17H24FN3O2S2: C,52.96; H,6.27; F,4.93; N,10.90; S,16.63. Found: C,52.97; H,6.28; F,4.90; N,10.87; S,16.71.
化合物Ij-153
1H-NMR (DMSO-d6) δ: 0.94-1.12 (m, 2H), 1.14-1.31 (m, 2H), 1.22 (d, 6H, J = 6.6 Hz), 1.39 (m, 1H), 1.76-1.87 (m, 2H), 2.02-2.15 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.55-3.70 (m, 1H), 6.84-6.94 (m, 1H), 6.99 (t, 1H, J = 6.0 Hz), 7.18-7.28 (m, 2H), 8.21 (d, 1H, J = 7.2 Hz).
化合物Ij-154
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.13-1.30 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.76-1.87 (m, 2H), 2.02-2.14 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.08-3.22 (m, 1H), 3.54-3.70 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.02 (dd, 1H, J = 8.1, 2.1 Hz), 7.39 (d, 1H, J = 2.1 Hz), 7.66 (d, 1H, J = 8.1 Hz), 8.15 (d, 1H, J = 7.5 Hz). 融点:166-167℃ Anal. Calcd for C17H24ClN3O2S2: C,50.79; H,6.02; Cl,8.82; N,10.45; S,15.95. Found: C,50.84; H,6.04; Cl,8.80; N,10.44; S,16.00.
化合物Ij-155
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.20-1.34 (m, 2H), 1.22 (d, 6H, J = 6.8 Hz), 1.38 (m, 1H), 1.78-1.86 (m, 2H), 1.99-2.14 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.42-3.54 (m, 1H), 6.74 (td, 1H, J = 8.8, 2.8 Hz), 6.98 (t, 1H, J = 5.6 Hz), 7.06 (dd, 1H, J = 9.6, 2.8 Hz), 7.30 (dd, 1H, J = 8.0, 4.4 Hz), 8.02 (d, 1H, J = 8.0 Hz). Anal. Calcd for C17H24FN3O3S: C,55.27; H,6.55; F,5.14; N,11.37; S,8.68. Found: C,55.16; H,6.50; F,5.16; N,11.30; S,8.42.
化合物Ij-156
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.20-1.34 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.78-1.86 (m, 2H), 2.00-2.14 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.21 (m, 1H), 3.38-3.54 (m, 1H), 6.90-7.00 (m, 2H), 7.19 (dd, 1H, J = 8.4, 4.8 Hz), 7.33 (dd, 1H, J = 8.4, 2.4 Hz), 7.86 (d, 1H, J = 7.8 Hz). 融点:170-171℃ Anal. Calcd for C17H24FN3O3S: C,55.27; H,6.55; F,5.14; N,11.37; S,8.68. Found: C,55.31; H,6.59; F,5.13; N,11.46; S,8.59.
化合物Ij-157
1H-NMR (DMSO-d6) δ: 0.88-1.20 (m, 4H), 1.20 (d, 6H, J = 6.9 Hz), 1.36 (m, 1H), 1.75-1.83 (m, 2H), 2.02-2.13 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 3.05-3.25 (m, 2H), 5.36 (d, 1H, J = 7.8 Hz), 5.76 (d, 1H, J = 2.4 Hz), 6.95(t, 1H, J = 6.9 Hz), 7.30 (td, 1H, J = 7.5, 1.8 Hz), 7.42 (td, 1H, J = 7.8, 1.5 Hz), 7.53-7.60 (m, 2H), 7.84 (d, 1H, J = 2.7 Hz). 融点:142-143℃
化合物Ij-158
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.19-1.34 (m, 2H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.86 (m, 2H), 1.99-2.14 (m, 2H), 2.88 (t, 2H, J = 6.3 Hz), 3.40-3.56 (m, 1H), 6.75 (td, 1H, J = 8.7, 2.7 Hz), 6.87 (t, 1H, J = 6.0 Hz), 7.06 (dd, 1H, J = 9.3, 2.7 Hz), 7.31 (dd, 1H, J = 8.7, 4.5 Hz), 8.02 (d, 1H, J = 7.8 Hz). 融点:220-221℃ Anal. Calcd for C18H26FN3O3S: C,56.38; H,6.83; F,4.95; N,10.96; S,8.36. Found: C,56.41; H,6.90; F,4.96; N,11.07; S,8.36.
化合物Ij-159
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.16-1.46 (m, 3H), 1.27 (s, 9H), 1.77-1.87 (m, 2H), 1.98-2.10 (m, 2H), 2.89 (t, 2H, J = 6.0 Hz), 3.38-3.54 (m, 1H), 6.88 (t, 1H, J = 5.7 Hz), 6.90-7.00 (m, 1H), 7.19 (dd, 1H, J = 8.7, 5.1 Hz), 7.34 (dd, 1H, J = 8.7, 2.7 Hz), 7.88 (d, 1H, J = 7.5 Hz). Anal. Calcd for C18H26FN3O3S: C,56.38; H,6.83; F,4.95; N,10.96; S,8.36. Found: C,56.39; H,6.93; F,4.98; N,11.09; S,8.29.
化合物Ij-160
1H-NMR (DMSO-d6) δ: 0.95 (t, 3H, J = 7.8 Hz), 0.92-1.07 (m, 2H), 1.21 (d, 3H, J = 6.9 Hz), 1.20-1.47 (m, 4H), 1.77-1.96 (m, 3H), 1.98-2.08 (m, 2H), 2.79 (t, 2H, J = 6.3 Hz), 2.85-2.98 (m, 1H), 3.42-3.57 (m, 1H), 6.71-6.80 (m, 1H), 7.00 (t, 1H, J = 5.7 Hz), 7.06 (dd, 1H, J = 9.3, 2.7 Hz), 7.31 (dd, 1H, J = 8.7, 4.5 Hz), 8.02 (d, 1H, J = 7.8 Hz). 融点:172-173℃ Anal. Calcd for C18H26FN3O3S: C,56.38; H,6.83; F,4.95; N,10.96; S,8.36. Found: C,56.37; H,6.84; F,5.04; N,11.12; S,8.14.
化合物Ij-161
1H-NMR (DMSO-d6) δ: 0.95 (t, 3H, J = 7.5 Hz), 0.92-1.08 (m, 2H), 1.21 (d, 3H, J = 6.9 Hz), 1.20-1.47 (m, 4H), 1.77-1.96 (m, 3H), 1.98-2.08 (m, 2H), 2.79 (t, 2H, J = 6.3 Hz), 2.85-2.98 (m, 1H), 3.38-3.56 (m, 1H), 6.90-6.98 (m, 1H), 7.00 (t, 1H, J = 6.0 Hz), 7.19 (dd, 1H, J = 8.7, 5.1 Hz), 7.33 (dd, 1H, J = 8.7, 2.7 Hz), 7.88 (d, 1H, J = 7.8 Hz). 融点:173-174℃ Anal. Calcd for C18H26FN3O3S: C,56.38; H,6.83; F,4.95; N,10.96; S,8.36. Found: C,56.45; H,6.80; F,4.93; N,11.02; S,8.54.
Compound Ij-2
1H-NMR (DMSO-d6) δ: 0.98-1.24 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.86 (q, 2H, J = 7.2 Hz), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J = 8.1 Hz), 7.01 (d, 2H, J = 7.2 Hz), 7.32-7.50 (m, 4H), 7.99 (d, 2H, J = 6.9 Hz)
Compound Ij-3
1H-NMR (DMSO-d6) δ: 0.96-1.26 (m, 4H), 1.18 (t, 3H, J = 7.5 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.40-6.50 (m, 2H), 6.85-6.92 (m, 1H), 6.97-7.03 (m, 1H), 7.22-7.35 (m, 2H), 7.36-7.46 (m, 2H), 7.88-7.96 (m, 1H)
Compound Ij-4
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (t, 1H, J = 3.9 Hz), 6.53 (s, 1H) , 7.00 (t, 1H, J = 5.7 Hz), 7.25 (t, 1H, J = 7.2 Hz), 7.34-7.45 (m, 2H), 7.55 (d, 2H, J = 7.2 Hz), 7.67 (dd, 1H, J = 8.7, 2.7 Hz), 8.29 (d, 1H, J = 2.7 Hz)
Compound Ij-5
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.52 (d, 1H, J = 8.4 Hz), 6.60 (d, 1H, J = 7.8 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.20-7.36 (m, 3H), 7.46 (t, 1H, J = 8.1 Hz), 7.55 (d, 1H, J = 8.7 Hz) , 8.15 (s, 1H)
Compound Ij-6
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.51 (d, 1H, J = 8.7 Hz), 6.60 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.02-7.12 (m, 1H), 7.36-7.48 (m, 3H), 7.71 (dd, 1H, J = 8.7, 2.1 Hz), 8.33 (d, 1H, J = 2.1 Hz)
Compound Ij-7
1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (d, 2H, J = 8.7 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.16-7.26 (m, 2H), 7.52-7.68 (m, 3H), 8.25 (s, 1H)
Compound Ij-8
1H-NMR (CDClThree) δ: 1.15-1.26 (m, 4H), 1.40 (t, 3H, J = 7.5 Hz), 1.55-1.58 (m, 1H), 1.93 (d, 2H, J = 9.7 Hz), 2.23 (d, 2H , J = 9.7 Hz), 3.01-3.11 (m, 4H), 3.56-3.61 (m, 1H), 3.84 (s, 3H), 4.34 (t, 1H, J = 6.1 Hz), 4.83-4.86 (m, 1H), 6.46 (d, 1H, J = 8.6 Hz), 6.99 (d, 1H, J = 8.5 Hz), 7.05 (d, 1H, J = 8.5 Hz), 7.29 (s, 1H), 7.30-7.34 ( m, 1H), 7.69 (dd, 1H, J = 8.7, 2.4 Hz), 8.25 (s, 1H).
Compound Ij-9
1H-NMR (CDClThree) δ: 1.16-1.24 (m, 4H), 1.40 (t, 3H, J = 6.2 Hz), 1.55-1.59 (m, 1H), 1.94 (d, 2H, J = 11.8 Hz), 2.23 (d, 2H , J = 11.8 Hz), 3.03-3.09 (m, 4H), 3.58-3.62 (m, 1H), 3.88 (s, 3H), 4.29 (t, 1H, J = 6.4 Hz), 4.85-4.89 (m, 1H), 6.49 (d, 1H, J = 8.7 Hz), 6.88 (dd, 1H, J = 8.7, 2.2 Hz), 7.04-7.06 (m, 1H), 7.10 (d, 1H, J = 8.7 Hz), 7.36 (t, 1H, J = 7.9 Hz), 7.70 (dd, 1H, J = 8.7, 2.2 Hz), 8.32 (s, 1H).
Compound Ij-10
1H-NMR (CDClThree) δ: 1.19-1.30 (m, 4H), 1.41 (t, 3H, J = 6.3 Hz), 1.56-1.59 (m, 1H), 1.94 (d, 2H, J = 11.1 Hz), 2.23 (d, 2H , J = 11.1 Hz), 3.01-3.11 (m, 4H), 3.57-3.61 (m, 1H), 3.87 (s, 3H), 4.27 (t, 1H, J = 6.4 Hz), 4.98 (s, 1H) , 6.50 (dd, 1H, J = 8.7, 2.2 Hz), 6.99 (d, 2H, J = 8.9 Hz), 7.43 (d, 2H, J = 8.7 Hz), 7.68 (dd, 1H, J = 8.7, 2.2 Hz), 8.25 (s, 1H).
Compound Ij-11
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H), 1.75-1.86 (m, 2H), 1.95-2.07 (m, 2H), 2.34 (s, 3H), 2.78 (t, 2H, J = 6.2 Hz), 2.98 (q, 2H, J = 7.3 Hz), 3.65 (m, 1H), 6.45-6.53 (m, 2H), 7.01 (t, 1H, J = 5.6 Hz), 7.07 (d, 1H, J = 7.1 Hz), 7.23-7.38 (m, 3H), 7.64 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.26 (d, 1H, J = 2.5 Hz).
Compound Ij-12
1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.09-1.27 (m, 11H), 1.39 (m, 1H), 1.76-1.87 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.2 Hz), 2.84-3.03 (m, 3H), 3.66 (m, 1H), 6.45-6.54 (m, 2H), 7.01 (t, 1H, J = 5.8 Hz), 7.13 (d, 1H , J = 6.9 Hz), 7.27-7.41 (m, 3H), 7.66 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.27 (d, 1H, J = 2.2 Hz).
Compound Ij-13
1H-NMR (DMSO-d6) δ: 0.92-1.09 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H), 1.76-1.85 (m, 2H), 1.95-2.06 (m, 2H), 2.78 (t, 2H, J = 6.2 Hz), 2.98 (q, 2H, J = 7.3 Hz), 3.68 (m, 1H), 6.52 (d, 1H, J = 8.8 Hz), 6.66 (d, 1H, J = 8.0 Hz) , 7.02 (t, 1H, J = 5.5 Hz), 7.23 (d, 1H, J = 8.1 Hz), 7.49-7.55 (m, 2H), 7.62 (d, 1H, J1 = 8.5 Hz), 7.72 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz), 8.35 (d, 1H, J = 2.5 Hz).
Compound Ij-14
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.22 (d, 6H, J = 6.4 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.95-2.03 (m, 2H), 2.81 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.60-3.75 (m, 1H), 6.65 (d, 1H, J = 4.8 Hz), 6.70 (s, 1H), 6.88- 6.98 (m, 2H), 8.16 (d, 1H, J = 5.2 Hz).
Compound Ij-15
1H-NMR (CDClThree) δ: 1.02-1.28 (m, 4H), 1.38 (d, 6H, J = 6.9 Hz), 1.52 (m, 1H), 1.85-1.94 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J = 6.6 Hz), 3.10-3.25 (m, 1H), 3.38-3.54 (m, 1H), 4.22 (t, 1H, J = 6.3 Hz), 4.58 (d, 1H, J = 7.8 Hz), 6.34 (d, 1H, J = 1.8 Hz), 6.53 (dd, 1H, J = 5.4, 1.8 Hz), 7.93 (d, 1H, J = 5.4 Hz).
Compound Ij-16
1H-NMR (CDClThree) δ: 1.03-1.28 (m, 4H), 1.37 (d, 6H, J = 6.9 Hz), 1.52 (m, 1H), 1.84-1.93 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J = 6.6 Hz), 3.09-3.24 (m, 1H), 3.40-3.54 (m, 1H), 4.26 (t, 1H, J = 6.6 Hz), 4.44 (d, 1H, J = 8.1 Hz), 6.29 (d, 1H, J = 8.7 Hz), 7.33 (dd, 1H, J = 8.7, 2.7 Hz), 7.99 (d, 1H, J = 2.7 Hz).
Compound Ij-17
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.21 (d, 6H, J = 6.8 Hz), 1.36 (m, 1H), 1.76-1.84 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.08-3.18 (m, 1H), 3.45-3.56 (m, 1H), 6.36 (d, 1H, J = 8.4 Hz), 6.43 (d, 1H, J = 7.2 Hz), 6.75 (d, 1H, J = 7.6 Hz), 6.94 (t, 1H, J = 6.0 Hz), 7.33 (t, 1H, J = 7.6 Hz).
Compound Ij-18
1H-NMR (DMSO-d6) δ: 0.98-1.24 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J = 8.4 Hz), 6.95-7.05 (m, 2H), 7.35-7.50 (m, 4H), 7.99 (d, 2H, J = 7.2 Hz)
Compound Ij-19
1H-NMR (CDClThree) δ: 1.22-1.38 (m, 4H), 1.38 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.12-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.16 (t, 1H, J = 6.4 Hz), 4.82-4.92 (m, 1H), 6.46 (d, 1H, J = 8.0 Hz), 7.10-7.20 (m, 2H), 7.23-7.33 (m, 1H), 7.37 (t, 1H, J = 8.0 Hz), 7.65 (d, 1H, J = 8.7 Hz), 8.24 (s, 1H).
Compound Ij-20
1H-NMR (CDClThree) δ: 1.22-1.38 (m, 4H), 1.39 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.12-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.16 (t, 1H, J = 6.4 Hz), 4.78-4.88 (m, 1H), 6.46 (d, 1H, J = 8.0 Hz), 6.98 (t, 1H, J = 5.7 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.23-7.29 (m, 1H), 7.33-7.40 (m , 1H), 7.65 (d, 1H, J = 8.7 Hz), 8.29 (s, 1H).
Compound Ij-21
1H-NMR (CDClThree) δ: 1.10-1.30 (m, 4H), 1.38 (d, 6H, J = 8.0 Hz), 1.54 (m, 1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J = 6.0 Hz), 3.13-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.15 (t, 1H, J = 6.4 Hz), 4.78-4.88 (m, 1H), 6.46 (d, 1H, J = 8.0 Hz), 7.07-7.14 (m, 2H), 7.40-7.46 (m, 2H), 7.62 (d, 1H, J = 8.7 Hz), 8.23 (s, 1H).
Compound Ij-22
1H-NMR (DMSO-d6) δ: 0.95-1.25 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.25-1.50 (br, 1H), 1.81 (d, 2H, J = 11.4 Hz), 2.00 (d, 2H , J = 10.5 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.80 (m, 1H), 3.76 (s, 3H), 6.49 (d, 2H, J = 8.7 Hz), 6.50-6.70 (br, 1H), 6.95-7.10 (m, 3H), 7.20-7.32 (m, 2H), 7.51 (d, 1H, J = 7.2Hz), 8.05 (br, 1H ). ESI (positive) 418.3 [M + H] +
Compound Ij-23
1H-NMR (DMSO-d6) δ: 0.95-1.32 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.25-1.55 (br, 1H), 1.82 (d, 2H, J = 11.4 Hz), 2.01 (d, 2H , J = 10.2 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.78 (m, 1H), 3.80 (s, 3H), 6.59 (d, 2H, J = 9.6 Hz), 6.85 (dd, 1H, J = 8.4 Hz, 2.4 Hz), 6.99 (t, 3H, J = 5.7 Hz), 7.05-7.18 (m, 2H), 7.32 (d, 1H, J = 7.8Hz), 7.76 (d, 1H, J = 8.4Hz), 8.27 (d, 1H, J = 2.1 Hz). ESI (positive) 418.3 [M + H] +
Compound Ij-24
1H-NMR (DMSO-d6) δ: 0.92-1.25 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.28-1.48 (m, 1H), 1.81 (d, 2H, J = 10.8 Hz), 2.00 (d, 2H , J = 9.6 Hz), 2.81 (t, 2H, J = 6.6 Hz), 3.08-3.22 (m, 1H), 3.58-3.74 (m, 1H), 3.77 (s, 3H), 6.51 (d, 2H, J = 8.7 Hz), 6.97 (d, 2H, J = 8.7 Hz), 6.98 (brs, 1H), 7.48 (d, 2H, J = 8.7 Hz), 7.63 (dd, 1H, J = 11.4Hz, 2.4Hz ), 8.21 (d, 1H, J = 2.4 Hz). ESI (positive) 418.3 [M + H] +
Compound Ij-25
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.95-2.05 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.80 (m, 1H), 6.65 (d, 1H, J = 5.4 Hz), 6.70 (s, 1H), 6.87 (t, 1H, J = 6.0 Hz), 6.94 (d, 1H, J = 7.8 Hz), 8.16 (d, 1H, J = 5.4 Hz)
Compound Ij-26
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.94-2.04 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.80 (m, 1H), 6.53 (d, 1H, J = 8.7 Hz), 6.87 (t, 1H, J = 5.7 Hz), 7.19 (d, 1H, J = 7.5 Hz) , 7.59 (dd, 1H, J = 9.0, 2.4 Hz), 8.26 (d, 1H, J = 2.4 Hz)
Compound Ij-27
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.26 (s, 9H), 1.38 (m, 1H), 1.76-1.86 (m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.40-3.60 (m, 1H), 6.36 (d, 1H, J = 8.1 Hz), 6.43 (d, 1H, J = 6.9 Hz), 6.80 (d, 1H, J = 7.5 Hz) , 6.86 (t, 1H, J = 5.4 Hz), 7.34 (t, 1H, J = 8.4 Hz)
Compound Ij-28
1H-NMR ((DMSO-d6) δ: 0.93-1.18 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.75-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 3.09-3.27 (m, 2H), 6.19 (d, 1H, J = 8.1 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.33 (d, 2H, J = 8.7 Hz) Mass: 379 [M + H]+
Compound Ij-29
1H-NMR (DMSO-d6) δ: 0.93-1.18 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.32-1.49 (m, 2H), 1.82 (d, 2H, J = 11.2 Hz), 2.04 (d , 2H, J = 11.2 Hz), 2.75-2.87 (m, 2H), 3.07-3.28 (m, 2H), 6.64 (s, 1H), 6.96 (s, 1H), 7.10-7.22 (m, 2H), 7.25-7.39 (m, 2H), 7.77-7.90 (m, 2H), 8.63 (s, 1H). Melting point: 161-162 ° C
Compound Ij-30
1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.88 (t, 2H, J = 6.3 Hz), 3.19 (m, 1H), 6.19 (d, 1H, J = 7.5 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.88 (d, 1H, J = 6.0 Hz), 7.33 (d, 2H, J = 8.7 Hz) Mass: 392M +
Compound Ij-31
1H-NMR (DMSO-d6) δ: 0.92-1.16 (m, 4H), 1.26 (s, 9H), 1,36 (m, 1H), 1.72-1.83 (m, 2H), 1.92-2.02 (m, 2H), 2.87 (t, 2H, J = 6.3 Hz), 3.12 (m, 1H), 6.09-6.23 (m, 4H), 6.87 (t, 1H, J = 6.0 Hz) Mass: 361 [M + H]+
Compound Ij-32
1H-NMR (CDClThree) δ: 1.00-1.20 (m, 4H), 1.40 (s, 9H), 1.42-1.64 (m, 2H), 1.84-1.95 (m, 2H), 2.09-2.20 (m, 2H), 3.07 (m, 1H), 3.07 (t, 2H, J = 6.3 Hz), 3.90 (m, 1H), 6.10 (dd, 2H, J = 9.6, 5.4 Hz).
Compound Ij-33
1H-NMR (DMSO-d6) δ: 0.93-1.21 (m, 5H), 1.28 (s, 9H), 1.33-1.46 (m, 1H), 1.82 (d, 2H, J = 11.6 Hz), 2.04 (d, 2H, J = 11.6 Hz) ), 2.86-2.95 (m, 2H), 3.03-3.29 (m, 1H), 6.59-6.71 (m, 1H), 6.80-6.92 (m, 1H), 7.09-7.21 (m, 2H), 7.27-7.37 (m, 2H), 7.77-7.88 (m, 2H), 8.58-8.67 (s, 1H). Melting point: 172-273 ° C
Compound Ij-34
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.21 (d, 6H, J = 6.4 Hz), 1.38 (m, 1H), 1.76-1.86 (m, 2H), 1.92 -2.00 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.48-3.60 (m, 1H), 6.95 (t, 1H, J = 5.6 Hz), 7.41 (d, 1H, J = 7.6 Hz), 7.63 (s, 1H), 7.82 (s, 1H).
Compound Ij-35
1H-NMR (DMSO-d6) δ: 0.96-1.26 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.88 (m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.48-3.62 (m, 1H), 6.87 (t, 1H, J = 6.0 Hz), 7.45 (d, 1H, J = 7.5 Hz), 7.63 (s, 1H), 7.82 (s, 1H)
Compound Ij-36
1H-NMR (DMSO-d6) δ: 0.96-1.06 (m, 2H), 1.12-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.39 (m, 1H), 1.78-1.84 (m, 2H), 1.95 -1.99 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.10-3.20 (m, 1H), 3.74-3.88 (m, 1H), 6.80 (s, 1H), 6.98 (t, 1H , J = 6.0 Hz), 7.93 (d, 2H, J = 7.2 Hz), 8.53 (s, 1H).
Compound Ij-37
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.93 (d, 1H, J = 7.5 Hz), 7.04 (t, 1H, J = 5.7 Hz), 7.26-7.38 (m, 2H), 7.40-7.52 (m, 1H), 7.57 (d, 1H, J = 9.0 Hz), 7.85 ( (t, 1H, J = 7.8 Hz)
Compound Ij-38
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 3.80 (s, 3H), 6.72 (d, 1H, J = 7.8 Hz) , 6.77 (d, 1H, J = 9.0 Hz), 6.98-7.10 (m, 2H), 7.12 (d, 1H, J = 8.4 Hz), 7.38 (t, 1H, J = 8.1 Hz), 7.56 (d, 1H, J = 9.3 Hz), 7.61 (d, 1H, J = 7.8 Hz)
Compound Ij-39
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.92 (d, 1H, J = 7.5 Hz), 7.04 (t, 1H, J = 5.7 Hz), 7.21 (t, 1H, J = 8.7 Hz), 7.46-7.56 (m, 1H), 7.75-7.88 (m, 3H)
Compound Ij-40
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.15-1.26 (m, 2H), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04 -2.14 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.76-3.87 (m, 1H), 6.85 (d, 1H, J = 9.6 Hz), 6.91 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 5.7 Hz), 7.42-7.52 (m, 2H), 7.83 (d, 1H, J = 8.0 Hz), 7.93 ( d, 1H, J = 8.0 Hz), 8.02 (s, 1H).
Compound Ij-41
1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.20 (t, 3H, J = 7.5 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.76-3.90 (m, 1H), 6.88 (d, 1H, J = 9.3 Hz), 6.97 (d, 1H, J = 7.5 Hz), 7.03 (t, 1H, J = 5.7 Hz), 7.67-7.77 (m, 2H), 7.92 (d, 1H, J = 9.6 Hz), 8.26 (d, 1H, J = 6.9 Hz) , 8.33 (s, 1H)
Compound Ij-42
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.20 (t, 3H, J = 7.2 Hz), 1.22-1.28 (m, 1H), 1.35-1.50 (m, 2H), 1.84 (d, 2H, J = 12.0 Hz), 2.08 (d, 2H, J = 12.0 Hz), 2.63-2.76 (m, 2H), 2.91-3.03 (m, 2H), 3.75-3.90 (m, 1H), 6.86 (d, 1H, J = 9.2 Hz), 6.93 (d, 1H, J = 7.2 Hz), 6.98-7.07 (m, 1H), 7.36 (d, 1H, J = 7.2 Hz), 7.59 (t, 1H, J = 8.0 Hz), 7.85 (d, 1H, J = 9.2 Hz), 7.91-8.02 (m, 2H). Melting point: 144-145 ° C
Compound Ij-43
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.10-1.24 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.98 -2.06 (m, 2H), 2.81 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.62-3.74 (m, 1H), 6.84 (d, 1H, J = 9.2 Hz), 6.88-6.98 (m, 2H), 7.31 (d, 1H, J = 9.6 Hz).
Compound Ij-44
1H-NMR (DMSO-d6) δ: 0.94-1.26 (m, 4H), 1.20 (d, 6H, J = 6.6 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.06-3.20 (m, 1H), 3.72-3.90 (m, 1H), 6.75-6.88 (m, 2H), 6.97 (t, 1H, J = 6.0 Hz), 7.30-7.48 (m, 3H), 7.76 (d, 1H, J = 9.3 Hz), 7.94 (d, 2H, J = 8.4 Hz)
Compound Ij-45
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J = 9.0 Hz), 6.91 (d, 1H, J = 7.5 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.25-7.36 (m, 2H), 7.40-7.50 (m, 1H), 7.57 (d, 1H, J = 6.9 Hz), 7.85 (t, 1H , J = 8.1 Hz)
Compound Ij-46
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J = 9.3 Hz), 6.90 (d, 1H, J = 7.5 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.21 (t, 1H, J = 7.8 Hz), 7.46-7.56 (m, 1H), 7.75-7.86 (m, 3H)
Compound Ij-47
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.81 (d, 1H, J = 7.5 Hz), 6.84 (d, 1H, J = 9.3 Hz), 6.98 (t, 1H, J = 6.3 Hz), 7.25-7.35 (m, 2H), 7.77 (d, 1H, J = 9.3 Hz), 7.96-8.06 (m, 2H)
Compound Ij-48
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.71 (d, 1H, J = 7.8 Hz), 6.76 ( d, 1H, J = 9.3 Hz), 6.98 (t, 1H, J = 5.7 Hz), 7.05 (d, 1H, J = 7.2 Hz), 7.12 (d, 1H, J = 7.8 Hz), 7.38 (t, 1H, J = 8.4 Hz), 7.56 (d, 1H, J = 9.3 Hz), 7.62 (d, 1H, J = 6.9 Hz)
Compound Ij-49
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.6 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.82 (s, 3H), 6.78-6.88 (m, 2H), 6.92-7.04 (m , 2H), 7.37 (t, 1H, J = 7.5 Hz), 7.46-7.58 (m, 2H), 7.79 (d, 1H, J = 9.3 Hz)
Compound Ij-50
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J = 6.9 Hz), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J = 6.0 Hz), 3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.70 (d, 1H, J = 7.8 Hz), 6.82 ( d, 1H, J = 9.3 Hz), 6.95-7.05 (m, 3H), 7.72 (d, 1H, J = 9.3 Hz), 7.90 (d, 2H, J = 9.0 Hz).
Compound Ij-51
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.76-1.85 (m, 2H), 2.02 -2.10 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.57-3.68 (m, 1H), 4.89-4.98 (m, 2H), 6.47 (d , 1H, J = 8.0 Hz), 6.88 (d, 1H, J = 7.5 Hz), 6.96 (t, 1H, J = 6.0 Hz), 7.02 (d, 1H, J = 7.5 Hz).
Compound Ij-52
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.52-1.74 (m, 6H), 1.77 -1.85 (m, 2H), 1.87-1.97 (m, 2H), 2.02-2.09 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.55-3.65 (m, 1H), 5.25-5.32 (m, 1H), 6.19 (d, 1H, J = 8.0 Hz), 6.77 (s, 2H), 6.95 (t, 1H, J = 6.0 Hz).
Compound Ij-53
1H-NMR (DMSO-d6) δ: 0.92-1.15 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.88-1.95 (m, 4H), 2.02 -2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.25-3.35 (m, 4H), 3.55-3.65 (m, 1H), 5.80-5.85 (m, 1H), 6.72 (d, 1H, J = 8.0 Hz), 6.80 (d, 1H, J = 8.0 Hz), 6.96 (t, 1H, J = 6.0 Hz).
Compound Ij-54
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.56 (d, 1H, J = 8.0 Hz), 6.90-6.98 (m, 2H), 7.03-7.10 (m, 3H), 7.15 (t, 1H, J = 8.0 Hz), 6.38 (t, 2H, J = 8.0 Hz).
Compound Ij-55
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.90-6.98 (m, 2H), 7.05-7.15 (m, 3H), 7.21 (t, 2H, J = 8.0 Hz).
Compound Ij-56
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J = 6.3 Hz), 3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 3.75 (s, 3H), 6.49 (d, 1H, J = 8.0 Hz), 6.87- 6.98 (m, 4H), 7.00-7.07 (m, 3H).
Compound Ij-57
1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.00-2.10 (m, 2H), 2.88 (t, 2H, J = 6.0 Hz), 3.60-3.76 (m, 1H), 6.82-6.92 (m, 2H), 6.96 (d, 1H, J = 7.8 Hz), 7.32 (d, 1H, J = 9.6 Hz).
Compound Ij-58
1H-NMR (DMSO-d6) δ: 0.99-1.28 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.39 (m, 1H), 1.78-1.86 (m, 2H), 2.04-2.10 (m, 2H), 2.82 (t, 2H, J = 6.1 Hz), 3.06-3.20 (m, 1H), 3.80-3.96 (m, 1H), 6.71 (d, 1H, J = 9.0 Hz), 6.76-6.86 (m, 1H), 6.90-6.98 (m, 1H), 7.10 (t, 1H, J = 8.1 Hz), 7.39-7.50 (m, 2H), 7.56 (d, 1H, J = 7.5 Hz), 7.78 (d, 1H, J = 7.5 Hz).
Compound Ij-59
1H-NMR (DMSO-d6) δ: 0.99-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H), 1.80-1.85 (m, 2H), 2.04-2.09 (m, 2H), 2.91 (t, 2H, J = 6.1 Hz), 3.80-3.96 (m, 1H), 6.70 (d, 1H, J = 9.0 Hz), 6.81-6.87 (m, 2H), 7.10 (t, 1H, J = 8.1 Hz), 7.39- 7.44 (m, 2H), 7.56 (d, 1H, J = 7.5 Hz), 7.79 (d, 1H, J = 7.5 Hz).
Compound Ij-60
1H-NMR (DMSO-d6) δ: 0.97-1.09 (m, 2H), 1.23 (d, 6H, J = 6.9 Hz), 1.31-1.50 (m, 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H) , 2.83 (t, 2H, J = 6.0 Hz), 3.11-3.20 (m, 1H), 4.00-4.18 (m, 1H), 6.83 (d, 1H, J = 5.7 Hz), 6.90-7.06 (m, 2H ), 7.45 (t, 1H, J = 6.9 Hz), 7.59 (t, 1H, J = 8.1 Hz), 7.67 (d, 1H, J = 8.4 Hz), 7.83 (d, 1H, J = 5.7 Hz), 8.27 (d, 1H, J = 7.5 Hz).
Compound Ij-61
1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.28 (s, 9H), 1.29-1.50 (m, 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.91 (t, 2H, J = 7.8 Hz), 4.00-4.18 (m, 1H), 6.82-6.89 (m, 2H), 6.97 (d, 1H, J = 7.5 Hz), 7.45 (t, 1H, J = 7.2 Hz), 7.59 (t, 1H, J = 8.1 Hz), 7.67 (d, 1H, J = 7.8 Hz), 7.84 (d, 1H, J = 6.0 Hz), 8.27 (d, 1H, J = 8.4 Hz).
Compound Ij-62
1H-NMR (DMSO-d6) δ: 0.96-1.14 (m, 2H), 1.18-1.30 (m, 2H), 1.22 (d, 6H, J = 6.6 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04 -2.14 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.58-3.70 (m, 1H), 6.95-7.03 (m, 2H), 7.20 (t , 1H, J = 7.5 Hz), 7.37 (d, 1H, J = 8.1 Hz), 7.64 (d, 1H, J = 7.5 Hz), 7.92 (d, 1H, J = 7.8 Hz).
Compound Ij-63
1H-NMR (DMSO-d6) δ: 1.00 (dd, 2H, J = 24.8, 10.6 Hz), 1.15-1.22 (m, 2H), 1.18 (t, 3H, J = 7.6 Hz), 1.27 (s, 9H), 1.34-1.40 (m , 1H), 1.81 (d, 2H, J = 11.6 Hz), 2.07 (d, 2H, J = 11.6 Hz), 2.60 (q, 2H, J = 7.6 Hz), 2.89 (t, 2H, J = 6.3 Hz ), 3.52-3.63 (m, 1H), 6.87 (t, 1H, J = 5.8 Hz), 7.04 (d, 1H, J = 7.9 Hz), 7.27 (d, 1H, J = 8.2 Hz), 7.47 (s , 1H), 7.80 (d, 1H, J = 7.6 Hz).
Compound Ij-64
1H-NMR (DMSO-d6) δ: 0.92-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.89 (t, 2H, J = 6.0 Hz), 3.50-3.66 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.03 (dd, 1H, J = 8.7, 2.7 Hz), 7.32-7.37 (m, 1H), 7.58 (dd, 1H, J = 8.7, 2.7 Hz), 7.92 (d, 1H, J = 7.2 Hz).
Compound Ij-65
1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J = 24.6, 10.2 Hz), 1.21 (dd, 2H, J = 24.6, 10.2 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.82 (d , 2H, J = 11.2 Hz), 2.08 (d, 2H, J = 11.2 Hz), 2.89 (t, 2H, J = 6.2 Hz), 3.59-3.65 (m, 1H), 6.87 (t, 1H, J = 5.8 Hz), 7.21 (dd, 1H, J = 8.6, 2.4 Hz), 7.34 (d, 1H, J = 8.6 Hz), 7.77 (d, 1H, J = 1.8 Hz), 8.06 (d, 1H, J = (7.6 Hz).
Compound Ij-66
1H-NMR (CDClThree) δ: 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.54 (m, 1H), 1.90-2.00 (m, 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J = 6.6 Hz), 3.46-3.60 (m, 1H), 3.99 (t, 1H, J = 6.6 Hz), 6.58 (brs, 1H), 7.58 (s, 2H), 7.85 (s, 1H).
Compound Ij-67
1H-NMR (DMSO-d6) δ: 0.90-1.30 (m, 4H), 1.27 (s, 9H), 1.30-1.48 (m, 1H), 1.82 (d, 2H, J = 11.1 Hz), 2.08 (d, 2H, J = 9.6 Hz) ), 2.89 (t, 2H, J = 6.3 Hz), 3.55-3.70 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.17 (m, 1H), 7.41 (d, 1H, J = 8.7 Hz), 7.77 (d, 1H, J = 1.5 Hz), 8.10 (d, 1H, J = 7.5 Hz). ESI (positive) m / z 466.2 [M + H] +
Compound Ij-68
1H-NMR (DMSO-d6) δ: 0.90-1.28 (m, 4H), 1.25 (s, 9H), 1.32 (m, 1H), 1.76-1.82 (m, 2H), 2.00-2.10 (m, 2H), 2.87 (t, 2H, J = 6.6 Hz), 3.50-3.62 (m, 1H), 3.71 (s, 3H), 6.77 (dd, 1H, J = 8.7, 2.7 Hz), 6.84 (t, 1H, J = 5.7 Hz), 7.22- 7.28 (m, 2H), 7.66 (d, 1H, J = 7.2 Hz).
Compound Ij-69
1H-NMR (DMSO-d6) δ: 0.94-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H), 1.37 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.90 (t, 2H, J = 6.0 Hz), 3.52-3.68 (m, 1H), 3.84 (s, 3H), 6.82 (d, 1H, J = 8.1 Hz), 6.88 (t, 1H, J = 5.4 Hz), 6.95 (t, 1H, J = 7.8 Hz), 7.23 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz).
Compound Ij-70
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.17-1.32 (m, 2H), 1.40 (m, 1H), 1.76-1.88 (m, 2H), 2.04 -2.14 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.78 (m, 1H), 7.03 (t, 1H, J = 6.3 Hz), 7.45-7.54 (m, 2H), 8.10 (s, 1H), 8.34 (d, 1H, J = 7.2 Hz).
Compound Ij-71
1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J = 26.1, 12.3 Hz), 1.16-1.22 (m, 2H), 1.22 (d, 6H, J = 6.6 Hz), 1.35-1.41 (m, 1H), 1.70-1.77 (m, 1H), 1.82 (d, 2H, J = 11.6 Hz), 2.08 (d, 2H, J = 11.6 Hz), 2.81 (t, 2H, J = 6.3 Hz), 3.66-3.72 (m, 1H) , 6.99 (t, 1H, J = 6.3 Hz), 7.23 (dd, 1H, J = 8.1, 4.7 Hz), 7.66 (d, 1H, J = 8.1 Hz), 8.07 (d, 1H, J = 4.7 Hz) , 8.26 (d, 1H, J = 6.3 Hz).
Compound Ij-72
1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J = 24.8, 11.3 Hz), 1.18-1.23 (m, 2H), 1.27 (s, 9H), 1.36-1.39 (m, 1H), 1.82 (d, 2H, J = 11.5 Hz), 2.08 (d, 2H, J = 11.5 Hz), 2.89 (t, 2H, J = 6.1 Hz), 3.65-3.73 (m, 1H), 6.87 (t, 1H, J = 5.7 Hz), 7.23 (dd, 1H, J = 8.1, 4.8 Hz), 7.66 (d, 1H, J = 7.9 Hz), 8.07 (d, 1H, J = 4.7 Hz), 8.26 (d, 1H, J = 7.6 Hz).
Compound Ij-73
1H-NMR (CDClThree) δ: 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.55 (m, 1H), 1.92-2.02 (m, 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J = 6.3 Hz), 3.58-3.72 (m, 1H), 3.98 (t, 1H, J = 6.0 Hz), 6.30 (brs, 1H), 7.62 (d, 1H, J = 8.1 Hz), 7.77 (d, 1H, J = 8.4 Hz).
Compound Ij-74
1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.12-1.40 (m, 3H), 1.25 (s, 9H), 1.76-1.86 (m, 2H), 1.98-2.10 (m, 2H), 2.87 (d, 2H, J = 6.3 Hz), 3.40-3.56 (m, 1H), 6.85 (brs, 1H), 6.93 (t, 1H, J = 7.5 Hz), 7.07 (t, 1H, J = 7.5 Hz), 7.20 ( d, 1H, J = 7.5 Hz), 7.29 (d, 1H, J = 7.8 Hz), 7.79 (brs, 1H).
Compound Ij-75
1H-NMR (CDClThree) δ: 1.08-1.26 (m, 2H), 1.36-1.60 (m, 3H), 1.40 (s, 9H), 1.92-2.02 (m, 2H), 2.22-2.32 (m, 2H), 3.08 (t, 2H, J = 6.6 Hz), 3.68-3.80 (m, 1H), 4.03 (t, 1H, J = 6.0 Hz), 7.06 (brs, 1H), 7.20-7.36 (m, 3H).
Compound Ij-76
1H-NMR (DMSO-d6) δ: 1.02 (dd, 2H, J = 25.2, 12.4 Hz), 1.17 (t, 3H, J = 7.1 Hz), 1.20 (t, 3H, J = 7.3 Hz), 1.26-1.35 (m, 2H), 1.37-1.42 (m, 1H), 1.83 (d, 2H, J = 11.6 Hz), 2.05 (d, 2H, J = 11.6 Hz), 2.80 (t, 2H, J = 6.4 Hz), 2.99 (q, 2H , J = 7.3 Hz), 3.65-3.72 (m, 1H), 4.01 (q, 2H, J = 7.1 Hz), 6.32 (d, 1H, J = 7.9 Hz), 6.86-6.94 (m, 2H), 7.01 (t, 1H, J = 6.0 Hz), 7.12 (d, 1H, J = 6.9 Hz), 7.17 (d, 1H, J = 6.8 Hz).
Compound Ij-77
1H-NMR (DMSO-d6) δ: 1.02 (dd, 2H, J = 24.8, 10.8 Hz), 1.19-1.21 (m, 2H), 1.30 (s, 9H), 1.37-1.41 (m, 1H), 1.84 (d, 2H, J = 10.6 Hz), 2.06 (d, 2H, J = 10.6 Hz), 2.92 (t, 2H, J = 6.3 Hz), 3.50-3.52 (m, 1H), 6.42 (d, 1H, J = 8.1 Hz), 6.83 (d, 1H, J = 7.9 Hz), 6.88-6.92 (m, 2H), 7.11-7.14 (m, 2H), 10.58 (s, 1H).
Compound Ij-78
1H-NMR (DMSO-d6) δ: 0.97-1.05 (m, 2H), 1.20-1.26 (m, 2H), 1.28 (s, 9H), 1.34-1.38 (m, 1H), 1.84 (d, 2H, J = 11.5 Hz), 2.07 (d, 2H, J = 11.5 Hz), 2.90 (t, 2H, J = 6.1 Hz), 3.47 (s, 3H), 3.63-3.69 (m, 1H), 6.34 (d, 1H, J = 7.6 Hz) , 6.87-6.93 (m, 3H), 7.11 (d, 1H, J = 8.4 Hz), 7.17 (d, 1H, J = 8.4 Hz).
Compound Ij-79
1H-NMR (DMSO-d6) δ: 1.03 (dd, 2H, J = 23.6, 10.8 Hz), 1.18 (t, 3H, J = 7.5 Hz), 1.25-1.34 (m, 2H), 1.29 (s, 9H), 1.37-1.40 (m , 1H), 1.86 (d, 2H, J = 11.7 Hz), 2.07 (d, 2H, J = 11.7 Hz), 2.92 (t, 2H, J = 6.2 Hz), 3.67-3.73 (m, 1H), 4.03 (q, 2H, J = 7.1 Hz), 6.34 (d, 1H, J = 7.9 Hz), 6.87-6.96 (m, 3H), 7.14 (dd, 1H, J = 8.1, 1.2 Hz), 7.19 (dd, 1H, J = 8.1, 1.2 Hz).
Compound Ij-80
1H-NMR (DMSO-d6) δ: 1.00 (dd, 2H, J = 23.2, 11.9 Hz), 1.19-1.25 (m, 2H), 1.28 (s, 9H), 1.33-1.38 (m, 1H), 1.45 (s, 3H), 1.47 (s, 3H), 1.83 (d, 2H, J = 11.1 Hz), 2.07 (d, 2H, J = 11.1 Hz), 2.90 (t, 2H, J = 6.1 Hz), 3.62-3.70 (m, 1H) , 4.57-4.66 (m, 1H), 6.21 (d, 1H, J = 7.9 Hz), 6.82-6.94 (m, 3H), 7.18 (d, 1H, J = 7.6 Hz), 7.31 (d, 1H, J = 7.6 Hz).
Compound Ij-81
Compound Ij-82
1H-NMR (DMSO-d6) δ: 0.90-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.45 (m, 1H), 1.80 (d, 2H, J = 11.2 Hz), 1.98 (d, 2H, J = 11.2 Hz) ), 2.84-2.93 (m, 2H), 3.26 (s, 3H), 3.40-3.53 (m, 1H), 6.29 (d, 1H, J = 8.0 Hz), 6.38 (d, 1H, J = 7.2 Hz) , 6.86 (s, 1H), 7.33 (d, 1H, J = 8.4 Hz).
Compound Ij-83
Compound Ij-84
1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.75-1.85 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.78 (m, 1H), 6.38 (d, 1H, J = 8.1 Hz), 6.67 (s, 1H) , 6.72 (d, 1H, J = 5.4 Hz), 7.00 (t, 1H, J = 6.0 Hz), 7.36-7.54 (m, 3H), 7.62 (d, 2H, J = 6.9 Hz), 8.00 (d, (1H, J = 5.4 Hz)
Compound Ij-85
1H-NMR (DMSO-d6) δ: 1.00-1.20 (m, 4H), 1.20 (t, 3H, J = 7.2 Hz), 1.43 (m, 1H), 1.80-1.88 (m, 2H), 2.03-2.13 (m, 2H), 2.81 (t, 3H, J = 6.0 Hz), 3.00 (q, 2H, J = 7.2 Hz), 3.26 (m, 1H), 6.17 (d, 1H, J = 7.6 Hz), 6.57 (s, 1H), 6.96 -7.07 (m, 2H), 7.35 (dd, 1H, J = 8.4, 4.0 Hz), 8.02 (d, 1H, J = 8.4 Hz), 8.47 (d, 1H, J = 4.0 Hz).
Compound Ij-86
1H-NMR (DMSO-d6) δ: 1.00-1.24 (m, 4H), 1.23 (d, 6H, J = 6.4 Hz), 1.42 (m, 1H), 1.80-1.88 (m, 2H), 2.03-2.12 (m, 2H), 2.79 -2.87 (m, 2H), 3.16 (m, 1H), 3.27 (m, 1H), 6.17 (d, 1H, J = 8.0 Hz), 6.57 (s, 1H), 6.99 (d, 1H, J = 8.0 Hz), 7.01 (s, 1H), 7.35 (dd, 1H, J = 8.0, 4.0 Hz), 8.02 (d, 1H, J = 8.0 Hz), 8.47 (d, 1H, J = 2.8 Hz).
Compound Ij-87
1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.11-1.25 (m, 2H), 1.20 (t, 3H, J = 7.2 Hz), 1.40 (m, 1H), 1.76-1.86 (m, 2H), 1.97 -2.04 (m, 2H), 2.73-2.82 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.70 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.53 ( d, 1H, J = 8.8 Hz), 7.01 (t, 1H, J = 6.0 Hz), 7.58 (d, 1H, J = 3.2 Hz), 7.79 (d, 1H, J = 3.2 Hz), 7.86 (d, 1H, J = 8.8 Hz), 8.55 (s, 1H).
Compound Ij-88
1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.09-1.20 (m, 2H), 1.19 (t, 6H, J = 7.2 Hz), 1.39 (m, 1H), 1.75-1.83 (m, 2H), 1.95 -2.03 (m, 2H), 2.74-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.66 (m, 1H), 6.48 (d, 1H, J = 8.4 Hz), 6.60 ( d, 1H, J = 7.6 Hz), 7.00 (t, 1H, J = 5.6 Hz), 7.06 (dd, 1H, J = 4.8, 2.4 Hz), 7.25 (d, 1H, J = 2.4 Hz), 7.37 ( d, 1H, J = 4.8 Hz), 7.60 (dd, 1H, J = 8.4, 2.0 Hz), 8.26 (s, 1H).
Compound Ij-89
1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.10-1.20 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.39 (m, 1H), 1.76-1.84 (m, 2H), 1.96 -2.04 (m, 2H), 2.73-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.65 (m, 1H), 6.41-6.50 (m, 2H), 7.01 (t, 1H , J = 6.0 Hz), 7.44 (d, 1H, J = 4.0 Hz), 7.58 (m, 1H), 7.59 (s, 1H), 7.68 (d, 1H, J = 8.0 Hz), 8.34 (s, 1H ).
Compound Ij-90
1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.94 -2.03 (m, 2H), 2.75-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.71 (m, 1H), 6.54 (d, 1H, J = 8.8 Hz), 6.98- 7.07 (m, 2H), 7.25 (s, 1H), 7.85 (dd, 1H, J = 8.8, 2.0 Hz), 8.07 (s, 1H), 8.56 (d, 1H, J = 2.0 Hz).
Compound Ij-91
1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.11-1.22 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.95 -2.03 (m, 2H), 2.77-2.83 (m, 2H), 3.14 (m, 1H), 3.72 (m, 1H), 6.53 (d, 1H, J = 8.8 Hz), 6.97 (t, 1H, J = 6.0 Hz), 7.02 (d, 1H, J = 7.6 Hz), 7.25 (s, 1H), 7.84 (dd, 1H, J = 8.8, 2.0 Hz), 8.06 (s, 1H), 8.56 (d, 1H , J = 2.0 Hz).
Compound Ij-92
1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.11-1.23 (m, 2H), 1.21 (d, 6H, J = 6.8 Hz), 1.37 (m, 1H), 1.75-1.83 (m, 2H), 1.91 -1.99 (m, 2H), 2.36-2.42 (m, 2H), 3.12 (m, 1H), 3.70 (m, 1H), 6.49 (d, 1H, J = 9.2 Hz), 6.97 (t, 1H, J = 6.0 Hz), 7.47 (d, 1H, J = 8.0 Hz), 7.62 (d, 1H, J = 8.0 Hz), 8.36 (s, 1H).
Compound Ij-93
1H-NMR (DMSO-d6) δ: 0.95-1.13 (m, 4H), 1.23 (d, 6H, J = 6.9 Hz), 1.31-1.44 (m, 1H), 1.78-1.82 (m, 2H), 2.03-2.06 (m, 2H) , 2.76-2.82 (m, 2H), 3.10-3.19 (m, 1H), 3.20-3.25 (m, 4H), 3.58-3.65 (m, 1H), 3.69-3.74 (m, 4H), 6.04 (d, 1H, J = 7.5 Hz), 6.72 (d, 1H, J = 9.6 Hz), 6.95-6.99 (m, 1H), 7.10 (d, 1H, J = 9.6 Hz).
Compound Ij-94
1H-NMR (DMSO-d6) δ: 0.96-1.42 (m, 5H), 1.22 (d, 6H, J = 6.9 Hz), 1.79-1.83 (m, 2H), 2.03-2.07 (m, 2H), 2.80 (d, 2H, J = 6.3 Hz), 3.10-3.19 (m, 1H), 3.54-3.70 (m, 1H), 3.74 (s, 3H), 6.57-6.64 (m, 3H), 6.72-6.75 (m, 1H), 6.90-7.09 (m, 3H), 7.24-7.30 (m, 1H).
Compound Ij-95
1H-NMR (DMSO-d6) δ: 0.93-1.04 (m, 2H), 1.10-1.18 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.34-1.44 (m, 1H), 1.78-1.87 (m, 2H) , 2.02-2.12 (m, 2H), 2.77-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.52-3.70 (m, 1H), 6.64 (d, 1H, J = 8.0 Hz), 6.88 -7.06 (m, 5H), 7.12 (d, 1H, J = 8.0 Hz), 7.37-7.46 (m, 1H).
Compound Ij-96
1H-NMR (DMSO-d6) δ: 0.90-1.04 (m, 2H), 1.05-1.18 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.84 (m, 2H) , 1.98-2.08 (m, 2H), 2.76-2.84 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.64 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.91 -7.00 (m, 2H), 7.15-7.38 (m, 5H).
Compound Ij-97
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.35-1.47 (m, 1H), 1.78-1.87 (m, 2H) , 2.02-2.10 (m, 2H), 2.78-2.83 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.70-3.82 (m, 1H), 6.82 (d, 1H, J = 8.0 Hz ), 6.93 (d, 1H, J = 8.0 Hz), 7.01 (t, 1H, J = 4.5 Hz), 7.13 (d, 1H, J = 4.0 Hz), 7.43 (d, 1H, J = 4.0 Hz), 7.76 (d, 1H, J = 8.0 Hz).
Compound Ij-98
1H-NMR (DMSO-d6) δ: 0.97-1.10 (m, 2H), 1.17-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.37-1.49 (m, 1H), 1.80-1.88 (m, 2H) , 2.04-2.12 (m, 2H), 2.77-2.83 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.88 (m, 1H), 6.85 (d, 1H, J = 8.0 Hz ), 6.99-7.05 (m, 2H), 7.61 (s, 1H), 7.90 (d, 1H, J = 8.0 Hz), 8.02 (s, 2H).
Compound Ij-99
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H) , 2.04-2.13 (m, 2H), 2.77-2.83 (m, 2H), 2.96 (s, 6H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.86 (m, 1H), 6.72-6.78 (m, 2H), 6.82 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 4.5 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.26 (t, 1H, J = 8.0 Hz), 7.34 (s, 1H), 7.74 (d, 1H, J = 8.0 Hz).
Compound Ij-100
1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.16-1.27 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H) , 2.04-2.13 (m, 2H), 2.77-2.83 (m, 2H), 2.99 (q, 2H, J = 7.2 Hz), 3.76-3.86 (m, 1H), 6.83 (d, 1H, J = 8.0 Hz ), 6.89 (d, 1H, J = 8.0 Hz), 7.02 (t, 1H, J = 4.5 Hz), 7.42-7.50 (m, 3H), 7.53-7.59 (m, 2H).
Compound Ij-101
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H) , 2.02-2.09 (m, 2H), 2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.56-3.68 (m, 1H), 6.62 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 6.98 (t, 1H, J = 4.5 Hz), 7.10-7.15 (m, 3H), 7.43 (d, 2H, J = 8.0 Hz).
Compound Ij-102
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H) , 2.02-2.09 (m, 2H), 2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.68 (m, 1H), 6.65 (d, 1H, J = 8.0 Hz), 6.94 (d, 1H, J = 8.0 Hz), 6.97 (t, 1H, J = 4.5 Hz), 7.06 (d, 1H, J = 8.0 Hz), 7.13 (d, 1H, J = 8.0 Hz), 7.18-7.26 (m, 2H), 7.41 (t, 1H, J = 8.0 Hz).
Compound Ij-103
1H-NMR (DMSO-d6) δ: 0.88-1.04 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.77-1.82 (m, 2H) , 2.00-2.07 (m, 2H), 2.76-2.82 (m, 2H), 3.08-3.20 (m, 1H), 3.52-3.64 (m, 1H), 6.57 (d, 1H, J = 8.0 Hz), 6.92 -7.00 (m, 2H), 7.17 (d, 1H, J = 8.0 Hz), 7.23-7.28 (m, 2H), 7.38 (t, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz).
Compound Ij-104
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.19 (t, 3H, J = 7.6 Hz), 1.35-1.46 (m, 1H), 1.78-1.86 (m, 2H) , 2.04-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.6 Hz), 3.67-3.78 (m, 1H), 6.27 (s, 2H), 6.71 (d , 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 7.02 (brs, 1H), 7.52 (s, 2H), 7.67 (d, 1H, J = 8.0 Hz).
Compound Ij-105
1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.13-1.25 (m, 2H), 1.19 (t, 3H, J = 7.6 Hz), 1.35-1.46 (m, 1H), 1.78-1.87 (m, 2H) , 2.04-2.12 (m, 2H), 2.76-2.83 (m, 2H), 2.99 (q, 2H, J = 7.6 Hz), 3.72-3.82 (m, 1H), 6.82 (d, 1H, J = 8.0 Hz ), 6.85 (d, 1H, J = 8.0 Hz), 7.03 (t, 1H, J = 4.5 Hz), 7.12 (t, 1H, J = 4.0 Hz), 7.51 (d, 1H, J = 4.0 Hz), 7.56 (d, 1H, J = 4.0 Hz), 7.76 (d, 1H, J = 8.0 Hz).
Compound Ij-106
1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.45 (m, 1H), 1.76-1.85 (m, 2H) , 2.02-2.08 (m, 2H), 2.76-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.67 (m, 1H), 6.63 (d, 1H, J = 8.0 Hz), 6.92 -7.00 (m, 3H), 7.13 (d, 1H, J = 8.0 Hz), 7.29-7.36 (m, 1H), 7.42-7.50 (m, 1H).
Compound Ij-107
1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H) , 1.98-2.06 (m, 2H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.63 (m, 1H), 6.57 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 8.0 Hz), 6.97 (t, 1H, J = 4.5 Hz), 7.12 (t, 1H, J = 4.0 Hz), 7.19 (d, 1H, J = 8.0 Hz), 7.33-7.47 (m, 2H).
Compound Ij-108
1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H) , 1.98-2.07 (m, 2H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.54-3.63 (m, 1H), 6.63 (d, 1H, J = 8.0 Hz), 6.93 -7.00 (m, 2H), 7.14 (t, 1H, J = 8.0 Hz), 7.20-7.37 (m, 3H).
Compound Ij-109
1H-NMR (DMSO-d6) δ: 0.82-1.05 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.43 (m, 1H), 1.76-1.83 (m, 2H) , 2.00-2.08 (m, 2H), 2.29 (s, 3H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.56-3.66 (m, 1H), 6.55 (d, 1H, J = 8.0 Hz), 6.90 (d, 1H, J = 8.0 Hz), 6.93-7.00 (m, 3H), 7.05 (d, 1H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.0 Hz) .
Compound Ij-110
1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.43 (m, 1H), 1.80 (d, 2H, J = 12.0 Hz), 2.07 (d, 2H, J = 12.0 Hz) ), 2.88 (t, 2H, J = 6.4 Hz), 3.16-3.27 (m, 1H), 5.47 (d, 1H, J = 7.6 Hz), 5.80 (s, 1H), 6.83 (d, 1H, J = 6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (t, 1H, J = 8.4 Hz), 7.86 (s, 1H).
Compound Ij-111
1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.21 (d, 6H, J = 6.9 Hz), 1.32-1.43 (m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H) , 2.77-2.83 (m, 2H), 3.08-3.27 (m, 2H), 5.48 (d, 1H, J = 8.1 Hz), 5.80 (d, 1H, J = 2.7 Hz), 6.95 (t, 1H, J = 6.0 Hz), 7.15-7.39 (m, 3H), 7.75 (td, 1H, J = 8.4, 1.8 Hz), 7.86 (t, 1H, J = 2.7 Hz).
Compound Ij-112
1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.30-1.45 (m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H) , 2.77-2.83 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz) 3.10-3.30 (m, 1H), 5.48 (d, 1H, J = 7.8 Hz), 5.80 (d, 1H, J = 2.7 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (td, 1H, J = 8.4, 1.8 Hz), 7.86 (t, 1H, J = 2.7 Hz) .
Compound Ij-113
Compound Ij-114
Compound Ij-115
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.30-1.45 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H) , 2.74-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz) 3.15-3.30 (m, 1H), 5.53 (d, 1H, J = 8.1 Hz), 5.80 (d, 1H, J = 2.4 Hz), 6.92 (t, 1H, J = 8.4 Hz), 7.01 (t, 1H, J = 6.0 Hz), 7.37-7.43 (m, 3H), 8.21 (d, 1H, J = 2.4 Hz).
Compound Ij-116
Compound Ij-117
Compound Ij-118
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 1H), 1.75-1.86 (m, 2H), 2.02-2.12 (m, 2H) , 2.74-2.83 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz) 3.13-3.30 (m, 1H), 5.38 (d, 1H, J = 8.4 Hz), 5.75 (d, 1H, J = 2.7 Hz), 6.99 (t, 1H, J = 6.3 Hz), 7.18-7.28 (m, 2H), 7.63-7.70 (m, 2H), 8.11 (d, 1H, J = 2.7 Hz).
Compound Ij-119
1H-NMR (DMSO-d6) δ: 0.88-1.19 (m, 4H), 1.18 (t, 3H, J = 7.5 Hz), 1.28-1.45 (m, 1H), 1.73-1.83 (m, 2H), 2.02-2.13 (m, 2H) , 2.73-2.81 (m, 2H), 2.95 (q, 2H, J = 7.5 Hz) 3.12-3.30 (m, 1H), 5.36 (d, 1H, J = 7.5 Hz), 5.76 (d, 1H, J = 2.4 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.30 (td, 1H, J = 7.5, 1.8 Hz), 7.42 (td, 1H, J = 7.8, 1.5 Hz), 7.53-7.60 (m, 2H), 7.84 (d, 1H, J = 2.7 Hz).
Compound Ij-120
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 1H), 1.74-1.84 (m, 2H), 2.02-2.10 (m, 2H) , 2.75-2.82 (m, 2H), 2.97 (q, 2H, J = 7.5 Hz) 3.20-3.30 (m, 1H), 5.52 (d, 1H, J = 7.8 Hz), 5.80 (d, 1H, J = 2.4 Hz), 6.99 (t, 1H, J = 6.0 Hz), 7.13 (d, 1H, J = 8.1 Hz), 7.40 (t, 1H, J = 8.1 Hz), 7.62 (d, 1H, J = 8.4 Hz) ), 7.72 (s, 1H), 8.22 (d, 1H, J = 2.4 Hz).
Compound Ij-121
1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J = 7.5 Hz), 1.30-1.45 (m, 1H), 1.74-1.84 (m, 2H), 2.02-2.12 (m, 2H) , 2.75-2.82 (m, 2H), 2.98 (q, 2H, J = 7.5 Hz) 3.15-3.30 (m, 1H), 5.47 (d, 1H, J = 8.1 Hz), 5.78 (d, 1H, J = 2.4 Hz), 7.00 (t, 1H, J = 6.0 Hz), 7.43 (d, 2H, J = 7.8 Hz), 7.67 (d, 2H, J = 9.0 Hz), 8.17 (d, 1H, J = 2.4 Hz ).
Compound Ij-122
1H-NMR (DMSO-d6) δ: 0.94-1.07 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.81-1.84 (m, 2H), 1.99-2.07 (m, 2H) , 2.77-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.60-3.77 (m, 1H), 7.01-7.05 (m, 1H), 7.22-7.40 (m, 4H), 7.81 -7.87 (m, 1H), 8.02 (s, 1H), 8.36 (s, 1H).
Compound Ij-123
1H-NMR (DMSO-d6) δ: 0.95-1.12 (m, 4H), 1.18 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.77-1.81 (m, 2H), 1.96-1.99 (m, 2H) , 2.74-2.78 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.54-3.70 (m, 1H), 4.81 (q, 2H, J = 9.0 Hz), 6.50-6.53 (m, 1H ), 6.99-7.03 (m, 1H), 7.50 (d, 1H, J = 0.9 Hz) 7.83 (d, 1H, J = 0.9 Hz).
Compound Ij-124
1H-NMR (DMSO-d6) δ: 0.95-1.23 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.77-1.81 (m, 2H), 2.03-2.07 (m, 2H) , 2.74-2.80 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.61-3.73 (m, 1H), 7.00-7.04 (m, 1H), 7.09-7.12 (m, 1H), 7.29 -7.37 (m, 2H), 7.45-7.52 (m, 1H), 7.88-7.94 (m, 2H), 8.04-8.05 (m, 1H).
Compound Ij-125
1H-NMR (DMSO-d6) δ: 0.94-1.14 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz), 1.32-1.50 (m, 1H), 1.79-1.83 (m, 2H), 1.97-2.03 (m, 2H) , 2.76-2.81 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.50-3.63 (m, 1H), 4.43 (q, 2H, J = 9.0 Hz), 7.00-7.04 (m, 1H ), 7.13-7.15 (m, 1H), 7.35 (s, 1H) 7.55 (s, 1H).
Compound Ij-126
1H-NMR (DMSO-d6) δ: 1.02-1.08 (m, 2H), 1.17-1.29 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.36-1.43 (m, 1H), 1.79-1.85 (m, 2H) , 2.05-2.11 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 2.99 (q, 2H, J = 7.5 Hz), 3.53-3.62 (m, 1H), 6.98 (t, 1H, J = 7.8 Hz), 7.03 (t, 1H, J = 6.3 Hz), 7.28 (dd, 1H, J = 7.5, 1.2 Hz), 7.63 (dd, 1H, J = 7.5, 1.2 Hz), 8.28 (d, 1H , J = 7.5 Hz).
Compound Ij-127
1H-NMR (DMSO-d6) δ: 0.97-1.05 (m, 2H), 1.18-1.24 (m, 2H), 1.16 (t, 3H, J = 7.5 Hz), 1.34-1.41 (m, 1H), 1.77-1.81 (m, 2H) , 2.02-2.08 (m, 2H), 2.76 (t, 2H, J = 6.0 Hz), 2.96 (q, 2H, J = 7.5 Hz), 3.55-3.64 (m, 1H), 7.00 (t, 1H, J = 7.8 Hz), 7.18 (dd, 1H, J = 8.4, 1.8 Hz), 7.32 (dd, 1H, J = 8.4, 0.6 Hz), 7.74 (d, 1H, J = 1.8 Hz), 8.04 (d, 1H , J = 7.8 Hz).
Compound Ij-128
1H-NMR (DMSO-d6) δ: 0.98-1.07 (m, 2H), 1.15-1.26 (m, 8H), 1.32-1.43 (m, 1H), 1.78-1.84 (m, 2H), 1.98-2.09 (m, 2H), 2.60 ( q, 2H, J = 7.5 Hz), 2.78 (t, 2H, J = 6.3 Hz), 2.96 (q, 2H, J = 7.5 Hz), 3.55-3.64 (m, 1H), 6.98-7.05 (m, 2H ), 7.27 (dd, 1H, J = 7.8, 1.8 Hz), 7.47 (m, 1H), 7.84 (d, 1H, J = 7.5 Hz).
Compound Ij-129
1H-NMR (DMSO-d6) δ: 0.92-1.15 (m, 2H), 1.15-1.35 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.48 (m, 1H), 1.78-1.88 (m, 2H) , 2.04-2.16 (m, 2H), 2.78-2.84 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.62-3.80 (m, 1H), 7.02 (t, 1H, J = 6.0 Hz ), 7.45 (d, 1H, J = 9.0 Hz), 8.09 (dd, 1H, J = 9.0, 2.4 Hz), 8.68 (d, 1H, J = 2.4 Hz), 8.70 (brs, 1H).
Compound Ij-130
1H-NMR (DMSO-d6) δ: 0.88-1.10 (m, 2H), 1.15-1.46 (m, 3H), 1.21 (d, 6H, J = 6.6 Hz), 1.78-1.88 (m, 2H), 1.98-2.08 (m, 2H) , 2.76-2.86 (m, 2H), 3.10-3.20 (m, 1H), 3.46-3.62 (m, 1H), 6.91-6.96 (m, 1H), 7.01 (brs, 1H), 7.64 (d, 1H, J = 7.8 Hz), 8.07 (d, 1H, J = 5.1 Hz), 8.35 (d, 1H, J = 7.8 Hz).
Compound Ij-131
1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.15-1.30 (m, 2H), 1.27 (s, 9H), 1.30-1.43 (m, 1H), 1.77-1.86 (m, 2H), 1.98-2.08 ( m, 2H), 2.86-2.92 (m, 2H), 3.35-3.50 (m, 1H), 3.73 (s, 3H), 6.69 (dd, 1H, J = 8.4, 2.0 Hz), 6.86 (t, 1H, J = 6.0 Hz), 7.01 (d, 1H, J = 2.0 Hz), 7.10 (d, 1H, J = 8.4 Hz), 7.62 (d, 1H, J = 7.6 Hz).
Compound Ij-132
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.33 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.42 (m, 1H), 1.76-1.86 (m, 2H) , 1.98-2.08 (m, 2H), 2.76-2.82 (m, 2H), 2.97 (q, 2H, J = 7.2 Hz), 3.40-3.58 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz ), 7.13 (d, 1H, J = 8.4 Hz), 7.20 (d, 1H, J = 8.4 Hz), 7.49 (s, 1H), 8.01 (d, 1H, J = 7.6 Hz).
Compound Ij-133
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.16-1.28 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.46 (m, 1H), 1.78-1.85 (m, 2H) , 2.04-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.55-3.70 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz ), 7.12 (t, 1H, J = 9.6 Hz), 7.48 (d, 1H, J = 7.6 Hz), 8.13 (d, 1H, J = 7.6 Hz).
Compound Ij-134
1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.26 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.33-1.42 (m, 1H), 1.39-1.84 (m, 2H) , 2.05-2.09 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.61-3.75 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz ), 7.45 (dd, 1H, J = 7.5, 0.6 Hz), 7.60 (dd, 1H, J = 8.4, 1.5 Hz), 8.17 (d, 1H, J = 1.5 Hz), 8.50 (d, 1H, J = 7.5 Hz).
Compound Ij-135
1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.25 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.35-1.44 (m, 1H), 1.80-1.84 (m, 2H) , 2.05-2.08 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.19 (m, 1H), 3.62-3.78 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz ), 7.79 (d, 1H, J = 2.1 Hz), 8.10 (d, 1H, J = 2.1, 1.5 Hz), 8.52 (d, 1H, J = 6.9 Hz).
Compound Ij-136
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.17-1.24 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.33-1.41 (m, 1H), 1.78-1.83 (m, 2H) , 2.04-2.08 (m, 2H), 2.78 (t, 2H, J = 6.3 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.56-3.67 (m, 1H), 7.00-7.04 (m, 2H ), 7.39 (d, 1H, J = 2.1 Hz), 7.66 (dd, 1H, J = 8.4, 1.8 Hz), 8.14 (d, 1H, J = 7.5 Hz).
Compound Ij-137
1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.12-1.28 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.31 (t, 3H, J = 6.9 Hz), 1.33-1.46 (m , 1H), 1.76-1.85 (m, 2H), 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.22 (m, 1H), 3.50-3.64 (m, 1H), 3.98 (q, 2H, J = 6.9 Hz), 6.78 (dd, 1H, J = 8.7, 2.7 Hz), 6.98 (t, 1H, J = 6.0 Hz), 7.23-7.27 (m, 2H), 7.68 (d, 1H, J = 7.2 Hz).
Compound Ij-138
1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H) , 2.03-2.12 (m, 2H), 2.76-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.52-3.68 (m, 1H), 6.97-7.06 (m, 2H), 7.34 (dd, 1H, J = 8.4, 4.8 Hz), 7.56 (dd, 1H, J = 8.4, 2.4 Hz), 7.91 (d, 1H, J = 7.6 Hz).
Compound Ij-139
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.16-1.32 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H) , 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.21 (m, 1H), 3.58-3.76 (m, 1H), 7.00 (t, 1H, J = 6.0 Hz), 8.19 -8.23 (m, 2H), 8.52 (d, 1H, J = 6.9 Hz).
Compound Ij-140
1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.12-1.30 (m, 2H), 1.21 (d, 6H, J = 6.6 Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H) , 2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.58-3.78 (m, 1H), 7.01 (t, 1H, J = 6.0 Hz), 8.08 (dd, 1H, J = 8.4, 2.7 Hz), 8.19 (d, 1H, J = 2.7 Hz), 8.38 (d, 1H, J = 7.2 Hz).
Compound Ij-141
1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.15-1.22 (m, 5H), 1.34-1.42 (m, 1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78 ( t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.53-3.62 (m, 1H), 3.81 (s, 1H), 7.02 (t, 1H, J = 6.3 Hz), 7.41 (s, 1H), 7.53 (s, 1H), 7.88 (d, 1H, J = 7.5 Hz).
Compound Ij-142
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.17-1.30 (m, 2H), 1.18 (t, 3H, J = 7.5 Hz), 1.32-1.41 (m, 1H), 1.79-1.84 (m, 2H) , 2.01-2.05 (m, 2H), 2.77 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.41-3.58 (m, 1H), 6.97 (dd, 1H, J = 8.4, 2.4 Hz), 6.99-7.03 (m, 1H), 7.27 (d, 1H, J = 2.4 Hz), 7.34 (dd, 1H, J = 8.4, 0.3 Hz), 8.07-8.14 (m, 1H) .
Compound Ij-143
1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 2H), 1.16-1.33 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H) , 2.00-2.08 (m, 2H), 2.74-2.82 (m, 2H), 2.98 (q, 2H, J = 7.2 Hz), 3.38-3.54 (m, 1H), 6.90-7.00 (m, 1H), 7.02 (t, 1H, J = 4.5 Hz), 7.19 (dd, 1H, J = 8.4, 5.1 Hz), 7.33 (dd, 1H, J = 8.4, 2.7 Hz), 7.88 (d, 1H, J = 7.8 Hz) .
Compound Ij-144
1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.19-1.29 (m, 2H), 1.18 (t, 3H, J = 7.2 Hz), 1.31-1.41 (m, 1H), 1.79-1.84 (m, 2H) , 2.01-2.05 (m, 2H), 2.77 (t, 2H, J = 6.0 Hz), 2.98 (q, 2H, J = 6.9 Hz), 3.41-3.57 (m, 1H), 6.71-6.79 (m, 1H ), 7.06-7.08 (m, 2H), 7.31 (dd, 1H, J = 8.7, 4.8 Hz), 8.03 (d, 1H, J = 7.8 Hz).
Compound Ij-145
1H-NMR (DMSO-d6) δ: 0.95-1.16 (m, 2H), 1.18-1.44 (m, 3H), 1.21 (d, 6H, J = 6.6 Hz), 1.78-1.86 (m, 2H), 2.02-2.12 (m, 2H) , 2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.40-3.58 (m, 1H), 6.95 (t, 1H, J = 7.8 Hz), 7.01 (brs, 1H), 7.09 (t , 1H, J = 6.9 Hz), 7.22 (d, 1H, J = 6.6 Hz), 7.31 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz).
Compound Ij-146
Compound Ij-147
Compound Ij-148
Compound Ij-149
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.13-1.30 (m, 2H), 1.19 (t, 3H, J = 7.5 Hz), 1.39 (m, 1H), 1.76-1.87 (m, 2H), 2.02 -2.14 (m, 2H), 2.79 (t, 2H, J = 6.3 Hz), 2.98 (q, 2H, J = 7.5 Hz), 3.56-3.70 (m, 1H), 6.95-7.05 (m, 2H), 7.20 (t, 1H, J = 7.8 Hz), 7.37 (d, 1H, J = 7.8 Hz), 7.64 (d, 1H, J = 7.5 Hz), 7.92 (d, 1H, J = 7.5 Hz). Melting points: 168-169 ℃ Anal. Calcd for C16Htwenty threeNThreeO2S2: C, 54.36; H, 6.56; N, 11.89; S, 18.14.Found: C, 54.33; H, 6.55; N, 11.89; S, 18.05.
Compound Ij-150
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.19 (t, 3H, J = 7.2 Hz), 1.39 (m, 1H), 1.77-1.87 (m, 2H), 1.99 -2.12 (m, 2H), 2.78 (t, 2H, J = 6.6 Hz), 2.98 (q, 2H, J = 7.2 Hz), 3.40-3.58 (m, 1H), 6.95 (t, 1H, J = 7.8 Hz), 7.02 (t, 1H, J = 6.0 Hz), 7.09 (t, 1H, J = 7.8 Hz), 7.22 (d, 1H, J = 7.5 Hz), 7.31 (d, 1H, J = 8.1 Hz) , 7.83 (d, 1H, J = 7.8 Hz). Melting point: 170-171 ° C Anal. Calcd for C16Htwenty threeNThreeOThreeS: C, 56.95; H, 6.87; N, 12.45; S, 9.50. Found: C, 56.91; H, 6.91; N, 12.43; S, 9.51.
Compound Ij-151
1H-NMR (DMSO-d6) δ: 0.92-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.21 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.76-1.87 (m, 2H), 2.02 -2.14 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.08-3.22 (m, 1H), 3.54-3.70 (m, 1H), 6.83 (t, 1H, J = 10.5 Hz), 6.99 (t, 1H, J = 5.4 Hz), 7.17 (dd, 1H, J = 10.5, 2.1 Hz), 7.63 (dd, 1H, J = 8.4, 5.7 Hz), 8.10 (d, 1H, J = 7.5 Hz ). Melting point: 165-166 ° C Anal. Calcd for C17Htwenty fourFNThreeO2S2: C, 52.96; H, 6.27; F, 4.93; N, 10.90; S, 16.63. Found: C, 52.99; H, 6.31; F, 5.00; N, 10.91; S, 16.84.
Compound Ij-152
1H-NMR (DMSO-d6) δ: 0.92-1.09 (m, 2H), 1.11-1.28 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.75-1.82 (m, 2H), 2.02 -2.12 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.20 (m, 1H), 3.52-3.67 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.03 (td, 1H, J = 9.6, 2.7 Hz), 7.34 (dd, 1H, J = 9.0, 5.1 Hz), 7.57 (dd, 1H, J = 9.0, 2.7 Hz), 7.91 (d, 1H, J = 7.2 Hz). Melting point: 151-152 ° C Anal. Calcd for C17Htwenty fourFNThreeO2S2: C, 52.96; H, 6.27; F, 4.93; N, 10.90; S, 16.63.Found: C, 52.97; H, 6.28; F, 4.90; N, 10.87; S, 16.71.
Compound Ij-153
1H-NMR (DMSO-d6) δ: 0.94-1.12 (m, 2H), 1.14-1.31 (m, 2H), 1.22 (d, 6H, J = 6.6 Hz), 1.39 (m, 1H), 1.76-1.87 (m, 2H), 2.02 -2.15 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.22 (m, 1H), 3.55-3.70 (m, 1H), 6.84-6.94 (m, 1H), 6.99 (t , 1H, J = 6.0 Hz), 7.18-7.28 (m, 2H), 8.21 (d, 1H, J = 7.2 Hz).
Compound Ij-154
1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.13-1.30 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.76-1.87 (m, 2H), 2.02 -2.14 (m, 2H), 2.81 (t, 2H, J = 6.0 Hz), 3.08-3.22 (m, 1H), 3.54-3.70 (m, 1H), 6.98 (t, 1H, J = 6.0 Hz), 7.02 (dd, 1H, J = 8.1, 2.1 Hz), 7.39 (d, 1H, J = 2.1 Hz), 7.66 (d, 1H, J = 8.1 Hz), 8.15 (d, 1H, J = 7.5 Hz). Melting point: 166-167 ℃ Anal. Calcd for C17Htwenty fourClNThreeO2S2: C, 50.79; H, 6.02; Cl, 8.82; N, 10.45; S, 15.95.Found: C, 50.84; H, 6.04; Cl, 8.80; N, 10.44; S, 16.00.
Compound Ij-155
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.20-1.34 (m, 2H), 1.22 (d, 6H, J = 6.8 Hz), 1.38 (m, 1H), 1.78-1.86 (m, 2H), 1.99 -2.14 (m, 2H), 2.80 (t, 2H, J = 6.4 Hz), 3.10-3.20 (m, 1H), 3.42-3.54 (m, 1H), 6.74 (td, 1H, J = 8.8, 2.8 Hz ), 6.98 (t, 1H, J = 5.6 Hz), 7.06 (dd, 1H, J = 9.6, 2.8 Hz), 7.30 (dd, 1H, J = 8.0, 4.4 Hz), 8.02 (d, 1H, J = 8.0 Hz). Anal. Calcd for C17Htwenty fourFNThreeOThreeS: C, 55.27; H, 6.55; F, 5.14; N, 11.37; S, 8.68. Found: C, 55.16; H, 6.50; F, 5.16; N, 11.30; S, 8.42.
Compound Ij-156
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.20-1.34 (m, 2H), 1.22 (d, 6H, J = 6.9 Hz), 1.38 (m, 1H), 1.78-1.86 (m, 2H), 2.00 -2.14 (m, 2H), 2.81 (t, 2H, J = 6.3 Hz), 3.10-3.21 (m, 1H), 3.38-3.54 (m, 1H), 6.90-7.00 (m, 2H), 7.19 (dd , 1H, J = 8.4, 4.8 Hz), 7.33 (dd, 1H, J = 8.4, 2.4 Hz), 7.86 (d, 1H, J = 7.8 Hz). Melting point: 170-171 ° C Anal. Calcd for C17Htwenty fourFNThreeOThreeS: C, 55.27; H, 6.55; F, 5.14; N, 11.37; S, 8.68. Found: C, 55.31; H, 6.59; F, 5.13; N, 11.46; S, 8.59.
Compound Ij-157
1H-NMR (DMSO-d6) δ: 0.88-1.20 (m, 4H), 1.20 (d, 6H, J = 6.9 Hz), 1.36 (m, 1H), 1.75-1.83 (m, 2H), 2.02-2.13 (m, 2H), 2.79 (t, 2H, J = 6.0 Hz), 3.05-3.25 (m, 2H), 5.36 (d, 1H, J = 7.8 Hz), 5.76 (d, 1H, J = 2.4 Hz), 6.95 (t, 1H, J = 6.9 Hz), 7.30 (td, 1H, J = 7.5, 1.8 Hz), 7.42 (td, 1H, J = 7.8, 1.5 Hz), 7.53-7.60 (m, 2H), 7.84 (d, 1H, J = 2.7 Hz). Melting point: 142-143 ° C
Compound Ij-158
1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.19-1.34 (m, 2H), 1.27 (s, 9H), 1.38 (m, 1H), 1.78-1.86 (m, 2H), 1.99-2.14 (m, 2H), 2.88 (t, 2H, J = 6.3 Hz), 3.40-3.56 (m, 1H), 6.75 (td, 1H, J = 8.7, 2.7 Hz), 6.87 (t, 1H, J = 6.0 Hz), 7.06 (dd, 1H, J = 9.3, 2.7 Hz), 7.31 (dd, 1H, J = 8.7, 4.5 Hz), 8.02 (d, 1H, J = 7.8 Hz). Melting point: 220-221 ° C Anal. Calcd for C18H26FNThreeOThreeS: C, 56.38; H, 6.83; F, 4.95; N, 10.96; S, 8.36. Found: C, 56.41; H, 6.90; F, 4.96; N, 11.07; S, 8.36.
Compound Ij-159
1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.16-1.46 (m, 3H), 1.27 (s, 9H), 1.77-1.87 (m, 2H), 1.98-2.10 (m, 2H), 2.89 (t, 2H, J = 6.0 Hz), 3.38-3.54 (m, 1H), 6.88 (t, 1H, J = 5.7 Hz), 6.90-7.00 (m, 1H), 7.19 (dd, 1H, J = 8.7, 5.1 Hz ), 7.34 (dd, 1H, J = 8.7, 2.7 Hz), 7.88 (d, 1H, J = 7.5 Hz). Anal. Calcd for C18H26FNThreeOThreeS: C, 56.38; H, 6.83; F, 4.95; N, 10.96; S, 8.36. Found: C, 56.39; H, 6.93; F, 4.98; N, 11.09; S, 8.29.
Compound Ij-160
1H-NMR (DMSO-d6) δ: 0.95 (t, 3H, J = 7.8 Hz), 0.92-1.07 (m, 2H), 1.21 (d, 3H, J = 6.9 Hz), 1.20-1.47 (m, 4H), 1.77-1.96 (m , 3H), 1.98-2.08 (m, 2H), 2.79 (t, 2H, J = 6.3 Hz), 2.85-2.98 (m, 1H), 3.42-3.57 (m, 1H), 6.71-6.80 (m, 1H ), 7.00 (t, 1H, J = 5.7 Hz), 7.06 (dd, 1H, J = 9.3, 2.7 Hz), 7.31 (dd, 1H, J = 8.7, 4.5 Hz), 8.02 (d, 1H, J = 7.8 Hz). Melting point: 172-173 ° C Anal. Calcd for C18H26FNThreeOThreeS: C, 56.38; H, 6.83; F, 4.95; N, 10.96; S, 8.36. Found: C, 56.37; H, 6.84; F, 5.04; N, 11.12; S, 8.14.
Compound Ij-161
1H-NMR (DMSO-d6) δ: 0.95 (t, 3H, J = 7.5 Hz), 0.92-1.08 (m, 2H), 1.21 (d, 3H, J = 6.9 Hz), 1.20-1.47 (m, 4H), 1.77-1.96 (m , 3H), 1.98-2.08 (m, 2H), 2.79 (t, 2H, J = 6.3 Hz), 2.85-2.98 (m, 1H), 3.38-3.56 (m, 1H), 6.90-6.98 (m, 1H ), 7.00 (t, 1H, J = 6.0 Hz), 7.19 (dd, 1H, J = 8.7, 5.1 Hz), 7.33 (dd, 1H, J = 8.7, 2.7 Hz), 7.88 (d, 1H, J = 7.8 Hz). Melting point: 173-174 ° C Anal. Calcd for C18H26FNThreeOThreeS: C, 56.38; H, 6.83; F, 4.95; N, 10.96; S, 8.36. Found: C, 56.45; H, 6.80; F, 4.93; N, 11.02; S, 8.54.
試験例1 脳移行性とP-gp を介した薬物間相互作用
脳移行性(脳/血漿分配係数;Kp)について、マウス(Jcl;C57BL/6J mouse, ♂, 7 weeks)静脈内投与(0.5 mg/2 mL/kg)後の血漿および脳内濃度から評価した。その結果、化合物(I-72)の脳 Kp 値(Kp Cont.)は1.29であり、高い脳移行性を示した。
P-gp を介した薬物間相互作用を in vivo で検討するため、P-gp 阻害剤であるシクロスポリンA 20 mg/kg 共存下での脳Kp値(Kp CSA)を測定し、コントロール群(Kp Cont.)と比較した。化合物(I-72)の Kp CSA は1.14であり、Kp Cont. とのKp ratio(Kp CSA / Kp Cont.)は 0.9と、P-gp を介した薬物間相互作用は認められなかった。
Test example 1 Brain transportability and drug-drug interaction via P-gp For brain transportability (brain / plasma partition coefficient; Kp), mice (Jcl; C57BL / 6J mouse, ♂, 7 weeks) were administered intravenously (0.5 (mg / 2 mL / kg) and evaluated from plasma and brain concentrations. As a result, the brain Kp value (Kp Cont. ) Of compound (I-72) was 1.29, indicating high brain migration.
In order to examine the interaction between drugs via P-gp in vivo, the brain Kp value (Kp CSA ) in the presence of cyclosporin A 20 mg / kg, a P-gp inhibitor, was measured and the control group (Kp Cont. ). Compound (I-72) had a Kp CSA of 1.14, a Kp ratio with Kp Cont. (Kp CSA / Kp Cont. ) Of 0.9, and no drug-drug interaction via P-gp was observed.
比較参考のため、類似構造を有するアミド化合物 B について同様の評価系で試験を行なった結果、Kp Cont., Kp CSA はそれぞれ 0.04, 0.84 と Kp ratio は20.5であり、P-gp を介して脳から強い汲み出しを受けているとともに、薬物間相互作用が認められた。
試験例2−1 マウスNPY Y5受容体に対する親和性
マウスNPY Y5受容体をコードするcDNA配列(Biochim. Biophys. Acta 1328:83-89, 1997参照)を、発現ベクター pME18S(Takebe et al. Mol. Cell. Biol. 8, 466-472)にクローニングした。得られた発現ベクターを、LipofectAMINE試薬(商標、Gibco BRL社)を用いて、宿主細胞CHOに、使用説明書にしたがってトランスフェクションし、NPY Y5受容体安定発現細胞を得た。
マウスNPY Y5受容体を発現させたCHO細胞から調製した膜標品を、本発明に係る化合物および30,000 cpmの[125I]ペプタイドYY(終濃度60 pM:アマーシャム社製)とともに、アッセイ緩衝液(0.1% 牛血清アルブミンを含む20 mM HEPES-Hanks緩衝液、pH 7.4)中で、25℃、2時間インキュベーションした後、1% ポリエチレンイミン処理したグラスフィルターGF/Cにて濾過した。50 mM Tris-HCl緩衝液、pH 7.4にて洗浄後、ガンマカウンターにてグラスフィルター上の放射活性を求めた。非特異的結合は200 nMペプタイドYY存在下で測定し、特異的ペプタイドYY結合に対する被検化合物の50%阻害濃度(IC50値)を求めた[Inui, A. et al. Endocrinology 131, 2090-2096 (1992) 参照]。結果を表1に示す。
本発明に係る化合物は、マウスNPY Y5受容体に対するペプタイドYY(NPYと同属物質)の結合を阻害した。即ち、本化合物はマウスNPY Y5受容体に対して親和性を示した。
試験例2−2 ヒトNPY Y5受容体に対する親和性
ヒトNPY Y5受容体をコードするcDNA配列(WO96/16542号参照)を、発現ベクター pME18S(Takebe et al. Mol. Cell. Biol. 8, 466-472)にクローニングした。得られた発現ベクターを、LipofectAMINE試薬(商標、Gibco BRL社)を用いて、宿主細胞CHOに、使用説明書にしたがってトランスフェクションし、NPY Y5受容体安定発現細胞を得た。
NPY Y5受容体を発現させたCHO細胞から調製した膜標品を、本発明に係る化合物および30,000 cpmの[125I]ペプタイドYY(終濃度60 pM:アマーシャム社製)とともに、アッセイ緩衝液(0.1% 牛血清アルブミンを含む20 mM HEPES-Hanks緩衝液、pH 7.4)中で、25℃、2時間インキュベーションした後、1% ポリエチレンイミン処理したグラスフィルターGF/Cにて濾過した。50 mM Tris-HCl緩衝液、pH 7.4にて洗浄後、ガンマカウンターにてグラスフィルター上の放射活性を求めた。非特異的結合は200 nMペプタイドYY存在下で測定し、特異的ペプタイドYY結合に対する被検化合物の50%阻害濃度(IC50値)を求めた[Inui, A. et al. Endocrinology 131, 2090-2096 (1992) 参照]。
本発明に係る化合物は、ヒトNPY Y5受容体に対するペプタイドYY(NPYと同属物質)の結合を阻害した。即ち、本化合物はヒトNPY Y5受容体に対して親和性を示した。
Test Example 2-1 Affinity for mouse NPY Y5 receptor cDNA sequence encoding mouse NPY Y5 receptor (see Biochim. Biophys. Acta 1328: 83-89, 1997) was expressed in expression vector pME18S (Takebe et al. Mol. Cell. Biol. 8, 466-472). The obtained expression vector was transfected into host cell CHO using LipofectAMINE reagent (trademark, Gibco BRL) according to the instruction manual to obtain NPY Y5 receptor stably expressing cells.
Membrane preparations prepared from CHO cells expressing mouse NPY Y5 receptor were combined with the compounds of the present invention and 30,000 cpm [ 125 I] peptide YY (final concentration 60 pM, manufactured by Amersham) with assay buffer ( After incubating in 20 mM HEPES-Hanks buffer solution (pH 7.4) containing 0.1% bovine serum albumin at 25 ° C. for 2 hours, it was filtered through a glass filter GF / C treated with 1% polyethyleneimine. After washing with 50 mM Tris-HCl buffer, pH 7.4, the radioactivity on the glass filter was determined with a gamma counter. Nonspecific binding was measured in the presence of 200 nM peptide YY, and the 50% inhibitory concentration (IC 50 value) of the test compound for specific peptide YY binding was determined [Inui, A. et al. Endocrinology 131, 2090- 2096 (1992)]. The results are shown in Table 1.
The compound according to the present invention inhibited the binding of peptide YY (similar substance to NPY) to mouse NPY Y5 receptor. That is, this compound showed affinity for the mouse NPY Y5 receptor.
Test Example 2-2 Affinity for human NPY Y5 receptor cDNA sequence encoding human NPY Y5 receptor (see WO96 / 16542) was expressed in expression vector pME18S (Takebe et al. Mol. Cell. Biol. 8, 466- 472). The obtained expression vector was transfected into host cell CHO using LipofectAMINE reagent (trademark, Gibco BRL) according to the instruction manual to obtain NPY Y5 receptor stably expressing cells.
Membrane preparations prepared from CHO cells expressing the NPY Y5 receptor were combined with the compounds of the present invention and 30,000 cpm [ 125 I] peptide YY (final concentration 60 pM, manufactured by Amersham) with an assay buffer (0.1 After incubating in 20 mM HEPES-Hanks buffer solution (pH 7.4) containing 2% bovine serum albumin at 25 ° C. for 2 hours, the solution was filtered through a glass filter GF / C treated with 1% polyethyleneimine. After washing with 50 mM Tris-HCl buffer, pH 7.4, the radioactivity on the glass filter was determined with a gamma counter. Nonspecific binding was measured in the presence of 200 nM peptide YY, and the 50% inhibitory concentration (IC 50 value) of the test compound for specific peptide YY binding was determined [Inui, A. et al. Endocrinology 131, 2090- 2096 (1992)].
The compound according to the present invention inhibited the binding of peptide YY (NPY and related substances) to the human NPY Y5 receptor. That is, this compound showed affinity for the human NPY Y5 receptor.
試験例3 CHO細胞におけるcAMP生成抑制作用
ヒトNPY Y5受容体を発現させたCHO細胞を、0.1mMイソブチルメチルキサンチン(SIGMA社)、0.2mM RO-201724(Calbiochem社)存在下で37℃、20分間インキュベーションした後、本発明に係る化合物を添加し10分間インキュベーションし、その後50 nMNPYおよび10 μMフォルスコリン(Sigma社)を加えて30分間インキュベーションした。1N HClを添加して反応を停止した後、上清中のcAMP量をEIA kit(Amersham LIFE SIENCE社製)を用いて測定した。フォルスコリン刺激によるcAMP生成に対するNPYの抑制作用を100%とし、このNPY作用に対する本発明に係る化合物の50%阻害濃度(IC50値)を求めた。
Test Example 3 Inhibition of cAMP production in CHO cells CHO cells expressing human NPY Y5 receptor were cultured at 37 ° C. for 20 minutes in the presence of 0.1 mM isobutylmethylxanthine (SIGMA) and 0.2 mM RO-201724 (Calbiochem). After incubation, the compound according to the present invention was added and incubated for 10 minutes, and then 50 nM NPY and 10 μM forskolin (Sigma) were added and incubated for 30 minutes. After stopping the reaction by adding 1N HCl, the amount of cAMP in the supernatant was measured using an EIA kit (manufactured by Amersham LIFE SIENCE). The inhibitory action of NPY on cAMP production by forskolin stimulation was taken as 100%, and the 50% inhibitory concentration (IC 50 value) of the compound according to the present invention for this NPY action was determined.
試験例4
Y1発現細胞(human neuroblastoma, SK-N-MC)膜標品およびY2発現細胞(human neuroblastoma, SMS-KAN)膜標品を使用して試験例2−2と同様の方法で試験を行い、本発明に係る化合物のNPY Y1受容体およびNPY Y2受容体に対する親和性を測定した。その結果により、本発明に係る化合物がNPY Y5受容体選択性を有していることを確認することができた。
Test example 4
Using a Y1-expressing cell (human neuroblastoma, SK-N-MC) membrane sample and a Y2-expressing cell (human neuroblastoma, SMS-KAN) membrane sample, the test was performed in the same manner as in Test Example 2-2. The affinity of the compounds of the invention for the NPY Y1 receptor and NPY Y2 receptor was measured. From the result, it was confirmed that the compound according to the present invention has NPY Y5 receptor selectivity.
試験例5
エーテル麻酔下、雄性C57BL/6Jマウス(12-14 週齢、25-30g)の外後頭稜から鼻背部まで正中に沿って皮膚を切開し、頭蓋骨上部を露出させた。露出部bregma よりlambdaに向かって約 1 mm後方、正中線から左側に約1mmの位置に電気ドリルを用いて直径約1mmの穴を開けた。麻酔から覚醒後のマウスに0.5%ヒドロキシプロピルメチルセルロース(信越化学株式会社製)水溶液(Vehicle)あるいはこの水溶液に懸濁した被検物質を強制経口投与し、投与1時間後、生理食塩水1.5μLあるいは、NPY Y5受容体特異的アゴニスト([ cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide:Tocris社製)0.1nmolを先に設けた頭部開口部よりカニューレを用いて注入した。注入2時間後および4時間後にマウスの摂食量を測定し、以下の式により摂食抑制率を算出した。摂食抑制率(%)=[1-(被検物質経口投与・Y5アゴニスト注入群の摂餌量−Vehicle経口投与・Saline注入群の摂餌量)/ Vehicle経口投与・Y5注入群の摂餌量-Vehicle経口投与・Saline注入群の摂餌量)]×100。その結果、本発明に使用する化合物を1.5mg/kgまたは6mg/kgの用量で投与した場合、0.5%ヒドロキシプロピルメチルセルロースを投与した場合と比較して摂食量が有意に抑制された。4時間での摂食抑制率の結果を表2に示す。
Test Example 5
Under ether anesthesia, male C57BL / 6J mice (12-14 weeks old, 25-30 g) were incised through the midline from the outer occipital crest to the back of the nose to expose the upper skull. A hole with a diameter of about 1 mm was drilled with an electric drill at a position about 1 mm backward from the exposed part bregma toward the lambda and about 1 mm on the left side from the midline. A 0.5% hydroxypropylmethylcellulose (manufactured by Shin-Etsu Chemical Co., Ltd.) aqueous solution (Vehicle) or a test substance suspended in this aqueous solution is forcibly administered orally to mice after waking up from anesthesia. NPY Y5 receptor specific agonist ([cPP 1-7 , NPY 19-23 , Ala 31 , Aib 32 , Gln 34 ] -hPancreatic Polypeptide: manufactured by Tocris) 0.1 nmol was previously cannulated from the head opening Was injected. The amount of food intake of the mice was measured 2 hours and 4 hours after the injection, and the feeding suppression rate was calculated by the following formula. Feeding inhibition rate (%) = [1- (test substance oral administration / feeding amount of Y5 agonist injection group−feeding amount of vehicle oral administration / saline injection group) / vehicle oral administration / feeding of Y5 injection group Amount-Vehicle oral administration / Saline injection group food intake)] × 100. As a result, when the compound used in the present invention was administered at a dose of 1.5 mg / kg or 6 mg / kg, the amount of food intake was significantly suppressed as compared with the case where 0.5% hydroxypropylmethylcellulose was administered. Table 2 shows the results of the feeding suppression rate at 4 hours.
試験例6
高脂肪食の給餌により体重の増加した雄性C57BL/6Jマウス(13-14 週齢、体重28-33g)に0.5%ヒドロキシプロピルメチルセルロース(信越化学株式会社製)水溶液あるいはこの水溶液に懸濁した被検物質を1日2回、3週間毎日強制経口投与し、0.5%ヒドロキシメチルセルロース溶液(Vehicle)投与群と被検物質投与群それぞれの体重変化を毎日調査した。なお化合物投与期間中も高脂肪食の給餌を継続した。その結果、本発明に使用する化合物を6.25mg/kgの用量で1日2回投与した場合、0.5%ヒドロキシプロピルメチルセルロースを投与した場合と比較して体重増加が有意に抑制された。
Test Example 6
Tests suspended in 0.5% hydroxypropylmethylcellulose (manufactured by Shin-Etsu Chemical Co., Ltd.) aqueous solution or in male C57BL / 6J mice (13-14 weeks old, body weight 28-33 g) whose body weight was increased by feeding high fat diet The substance was orally administered by gavage twice a day for 3 weeks every day, and daily changes in body weight of the 0.5% hydroxymethylcellulose solution (Vehicle) administration group and the test substance administration group were investigated. During the compound administration period, feeding with a high fat diet was continued. As a result, when the compound used in the present invention was administered twice daily at a dose of 6.25 mg / kg, body weight gain was significantly suppressed as compared with the case where 0.5% hydroxypropylmethylcellulose was administered.
製剤例
以下に示す製剤例は例示にすぎないものであり、発明の範囲を何ら限定することを意図するものではない。
製剤例1 錠剤
化合物(I−1) 15mg
デンプン 15mg
乳糖 15mg
結晶性セルロース 19mg
ポリビニルアルコール 3mg
蒸留水 30ml
ステアリン酸カルシウム 3mg
ステアリン酸カルシウム以外の成分を均一に混合し、破砕造粒して乾燥し、適当な大きさの顆粒剤とする。次にステアリン酸カルシウムを添加して圧縮成形して錠剤とする。
Formulation Examples Formulation examples shown below are merely illustrative and are not intended to limit the scope of the invention.
Formulation Example 1 Tablet Compound (I-1) 15 mg
Starch 15mg
Lactose 15mg
Crystalline cellulose 19mg
Polyvinyl alcohol 3mg
30ml distilled water
Calcium stearate 3mg
Ingredients other than calcium stearate are uniformly mixed, crushed and granulated, and dried to obtain granules of an appropriate size. Next, calcium stearate is added and compressed to form tablets.
製剤例2 カプセル剤
化合物(I−2) 10mg
ステアリン酸マグネシウム 10mg
乳糖 80mg
を均一に混合して粉末または細粒状として散剤をつくる。それをカプセル容器に充填してカプセル剤とする。
Formulation Example 2 Capsule Compound (I-2) 10 mg
Magnesium stearate 10mg
Lactose 80mg
Are mixed uniformly to make a powder as a fine powder or powder. It is filled into a capsule container to form a capsule.
製剤例3 顆粒剤
化合物(I−3) 30g
乳糖 265g
ステアリン酸マグネシウム 5g
よく混合し、圧縮成型した後、粉砕、整粒し、篩別して適当な大きさの顆粒剤とする。
Formulation Example 3 Granules Compound (I-3) 30 g
Lactose 265g
Magnesium stearate 5g
After mixing well, compression molding, pulverizing, sizing, and sieving to make granules of appropriate size.
以上の試験例から明らかなように、本発明に係る化合物はNPY Y5受容体拮抗作用、摂食抑制作用および体重抑制作用を示す。従って、本発明は食欲抑制剤または抗肥満薬として非常に有用である。 As is clear from the above test examples, the compound according to the present invention exhibits NPY Y5 receptor antagonistic action, feeding inhibitory action, and body weight inhibitory action. Therefore, the present invention is very useful as an appetite suppressant or anti-obesity agent.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010098560A JP5131783B2 (en) | 2009-04-23 | 2010-04-22 | Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009104755 | 2009-04-23 | ||
JP2009104755 | 2009-04-23 | ||
JP2010098560A JP5131783B2 (en) | 2009-04-23 | 2010-04-22 | Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010270114A JP2010270114A (en) | 2010-12-02 |
JP5131783B2 true JP5131783B2 (en) | 2013-01-30 |
Family
ID=43418445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010098560A Expired - Fee Related JP5131783B2 (en) | 2009-04-23 | 2010-04-22 | Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5131783B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2505584A1 (en) * | 2009-11-25 | 2012-10-03 | Shionogi&Co., Ltd. | Method for producing cyclohexane derivative |
ES2639940T3 (en) | 2011-04-27 | 2017-10-30 | Shionogi & Co., Ltd. | 5-membered aromatic heterocyclic ring derivative that has NPY Y5 receptor antagonist activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101441146B1 (en) * | 2006-04-28 | 2014-09-17 | 시오노기세야쿠 가부시키가이샤 | Amine derivative having npy y5 receptor antagonist activity |
WO2008134228A1 (en) * | 2007-04-30 | 2008-11-06 | H. Lundbeck A/S | Benzoxazole compounds |
-
2010
- 2010-04-22 JP JP2010098560A patent/JP5131783B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2010270114A (en) | 2010-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4528901B2 (en) | Amine derivatives having NPYY5 receptor antagonistic activity | |
JP4375683B2 (en) | Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof | |
EP3290424B1 (en) | Substituted polycyclic pyridone derivatives and prodrug thereof | |
CN114502543A (en) | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | |
US11649236B2 (en) | Polycyclic carbamoylpyridone derivative | |
US8227618B2 (en) | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof | |
EP4424314A2 (en) | Substituted polycyclic pyridone derivative and prodrug thereof | |
JP5131783B2 (en) | Amine derivatives having NPYY5 receptor antagonistic activity and uses thereof | |
CN113677659B (en) | Substituted amide compounds useful as farnesoid X receptor modulators | |
CN117616011A (en) | Inhibitors of transglutaminase | |
KR20240028466A (en) | transglutaminase inhibitor | |
AU2012211458A1 (en) | Amine derivative having NPY Y5 receptor antagonist activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120717 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121030 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121031 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |